{"PMC7337672": [["Materials and MethodsDatabases including PubMed, medRxiv, and bioRxiv were searched for published and preprint papers on COVID-19 and coronavirus serology.", [["coronavirus", "ORGANISM", 134, 145], ["MethodsDatabases", "TREATMENT", 14, 30], ["medRxiv", "TREATMENT", 49, 56], ["bioRxiv", "TREATMENT", 62, 69], ["COVID", "TEST", 121, 126], ["coronavirus serology", "TEST", 134, 154]]], ["Search terminology included COVID-19 terms (COVID-19, SARS-CoV-2, novel corona, 2019-ncov) and serology, antibody, neutralizing antibody, seroconversion, rapid testing, IgG, IgM, IgA, LFD, ELISA, PRNT, chemiluminescence, and immunochromatography.Materials and MethodsAs of June 2, 2020, a total of 55 papers with performance data of serologic techniques were examined.", [["IgM", "GENE_OR_GENE_PRODUCT", 174, 177], ["IgA", "GENE_OR_GENE_PRODUCT", 179, 182], ["LFD", "SIMPLE_CHEMICAL", 184, 187], ["neutralizing antibody", "PROTEIN", 115, 136], ["IgG", "PROTEIN", 169, 172], ["IgM", "PROTEIN", 174, 177], ["IgA", "PROTEIN", 179, 182], ["COVID", "TEST", 28, 33], ["COVID", "TEST", 44, 49], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["novel corona", "TEST", 66, 78], ["serology", "TEST", 95, 103], ["antibody", "TEST", 105, 113], ["neutralizing antibody", "TEST", 115, 136], ["seroconversion", "TEST", 138, 152], ["rapid testing", "TEST", 154, 167], ["IgG", "TEST", 169, 172], ["IgM", "TEST", 174, 177], ["IgA", "TEST", 179, 182], ["LFD", "TEST", 184, 187], ["ELISA", "TEST", 189, 194], ["PRNT", "TEST", 196, 200], ["chemiluminescence", "TEST", 202, 219], ["immunochromatography", "TEST", 225, 245], ["serologic techniques", "TEST", 333, 353]]], ["The assays utilized in these studies included the neutralizing antibody assay, enzyme-linked immunosorbent assay (ELISA), automated chemiluminescence immunoassay (CLIA), and lateral flow immunoassay (LFIA).", [["The assays", "TEST", 0, 10], ["these studies", "TEST", 23, 36], ["the neutralizing antibody assay", "TEST", 46, 77], ["enzyme", "TEST", 79, 85], ["immunosorbent assay", "TEST", 93, 112], ["ELISA", "TEST", 114, 119], ["automated chemiluminescence immunoassay", "TEST", 122, 161], ["CLIA", "TEST", 163, 167], ["lateral flow immunoassay", "TEST", 174, 198]]], ["Thirty-two papers were peer-reviewed publications and 23 preprints were not peer-reviewed (medRxiv, 22; bioRxiv, 1).Materials and MethodsThe compiled information included the assay method with a focus on the detection of particular isotype(s) of antibody and selection of targeted antigen(s).", [["antigen", "GENE_OR_GENE_PRODUCT", 281, 288], ["targeted antigen", "PROTEIN", 272, 288], ["Methods", "TREATMENT", 130, 137], ["the assay method", "TEST", 171, 187], ["antibody", "TEST", 246, 254]]], ["In addition, the composition of cohorts of samples used in the validation studies was examined with focus on control groups.", [["samples", "ANATOMY", 43, 50], ["the validation studies", "TEST", 59, 81]]], ["Details regarding the time of sample acquisition and characteristics of the clinical disease of confirmed SARS-CoV-2 patients were also recorded when available.", [["sample", "ANATOMY", 30, 36], ["SARS", "DISEASE", 106, 110], ["SARS-CoV", "ORGANISM", 106, 114], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 106, 114], ["sample acquisition", "TEST", 30, 48], ["the clinical disease", "PROBLEM", 72, 92], ["SARS", "PROBLEM", 106, 110]]], ["Lastly, calculated test accuracy and information regarding comparison to other immunoassays and RT-PCR testing was noted.", [["calculated test accuracy", "TEST", 8, 32], ["other immunoassays", "TEST", 73, 91], ["RT-PCR testing", "TEST", 96, 110]]], ["Two independent reviewers from the Department of Pathology and Laboratory Medicine and Department of Hematology at the University of Miami and Jackson Health System extracted the information.Lateral Flow Immunoassay (LFIA) ::: Overview of Immunoassays ::: ResultsThe variable sensitivity and specificity of LFIA have been the focus of the media and numerous studies due to the growing number of commercially available devices.6,17 Several investigations reported high sensitivity and specificity of these assays although many lacked information regarding the target antigens and well-defined negative control groups (ie, human coronavirus controls).", [["human", "ORGANISM", 621, 626], ["coronavirus", "ORGANISM", 627, 638], ["human", "SPECIES", 621, 626], ["human coronavirus", "SPECIES", 621, 638], ["Lateral Flow Immunoassay", "TEST", 191, 215], ["The variable sensitivity", "TEST", 263, 287], ["numerous studies", "TEST", 349, 365], ["Several investigations", "TEST", 431, 453], ["these assays", "TEST", 499, 511]]], ["Table 1 summarizes the review of studies using LFIA methods.6,7,18-29Lateral Flow Immunoassay (LFIA) ::: Overview of Immunoassays ::: ResultsThe experimental design and data of 7 studies were judged to provide insight into LFIA method applications.", [["6,7,18-29Lateral", "CHEMICAL", 60, 76], ["6,7,18-29Lateral", "SIMPLE_CHEMICAL", 60, 76], ["LFIA methods", "TREATMENT", 47, 59], ["7 studies", "TEST", 177, 186]]], ["Li et al7 evaluated a combined IgM/IgG LFIA using the RBD antigen in a sample set obtained from 397 positive patients defined by positive RT-PCR and COVID-19 symptoms and 128 negative patients.", [["sample", "ANATOMY", 71, 77], ["IgM", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 54, 65], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 184, 192], ["IgM", "PROTEIN", 31, 34], ["IgG LFIA", "PROTEIN", 35, 43], ["RBD antigen", "PROTEIN", 54, 65], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 184, 192], ["a combined IgM/IgG LFIA", "TEST", 20, 43], ["the RBD antigen", "TEST", 50, 65], ["a sample set", "TEST", 69, 81], ["PCR", "TEST", 141, 144], ["COVID", "TEST", 149, 154], ["symptoms", "TEST", 158, 166]]], ["The assay sensitivity was 89% and the specificity was 91%.", [["The assay sensitivity", "TEST", 0, 21], ["the specificity", "TEST", 34, 49]]], ["Notably, 64% of the samples from the positive patient group demonstrated both IgM and IgG reactivity.", [["samples", "ANATOMY", 20, 27], ["samples", "CANCER", 20, 27], ["patient", "ORGANISM", 46, 53], ["IgM", "GENE_OR_GENE_PRODUCT", 78, 81], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgM", "PROTEIN", 78, 81], ["IgG", "PROTEIN", 86, 89], ["patient", "SPECIES", 46, 53], ["the samples", "TEST", 16, 27], ["IgM", "TEST", 78, 81], ["IgM", "OBSERVATION", 78, 81], ["IgG reactivity", "OBSERVATION", 86, 100]]], ["Lou et al22 reported the use of 3 different LFIA: IgM and total antibody using RBD antigen and IgG detection using NP antigen.", [["LFIA", "GENE_OR_GENE_PRODUCT", 44, 48], ["IgM", "GENE_OR_GENE_PRODUCT", 50, 53], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 79, 90], ["IgG", "GENE_OR_GENE_PRODUCT", 95, 98], ["NP antigen", "GENE_OR_GENE_PRODUCT", 115, 125], ["LFIA", "PROTEIN", 44, 48], ["IgM", "PROTEIN", 50, 53], ["total antibody", "PROTEIN", 58, 72], ["RBD antigen", "PROTEIN", 79, 90], ["IgG", "PROTEIN", 95, 98], ["NP antigen", "PROTEIN", 115, 125], ["IgM", "TEST", 50, 53], ["total antibody", "TEST", 58, 72], ["RBD antigen", "TEST", 79, 90], ["IgG detection", "TEST", 95, 108], ["NP antigen", "TEST", 115, 125]]], ["Using a large group of COVID-19\u2013negative patient samples (n = 209) but not a control group of samples from patients with other viral infections or diseases, an excellent specificity ranging from 95% to 100% was reported for all 3 devices.", [["samples", "ANATOMY", 49, 56], ["samples", "ANATOMY", 94, 101], ["viral infections", "DISEASE", 127, 143], ["patient", "ORGANISM", 41, 48], ["samples", "CANCER", 94, 101], ["patients", "ORGANISM", 107, 115], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 107, 115], ["other viral infections", "PROBLEM", 121, 143], ["diseases", "PROBLEM", 147, 155], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infections", "OBSERVATION", 133, 143], ["excellent", "OBSERVATION_MODIFIER", 160, 169]]], ["Notably, the sensitivity of the total antibody LFIA had the highest performance at 98%.", [["total antibody LFIA", "PROTEIN", 32, 51], ["the sensitivity", "TEST", 9, 24], ["the total antibody LFIA", "TEST", 28, 51]]], ["Also, the performance of all the assays compared well with similarly constructed and validated ELISA in the same study.", [["all the assays", "TEST", 25, 39], ["validated ELISA", "TEST", 85, 100], ["the same study", "TEST", 104, 118]]], ["Using 147 control samples from patients with various viral infections and 93 samples from COVID-19 patients, Geurtsvankessel et al26 reviewed 3 LFIA including the Cellex.", [["samples", "ANATOMY", 18, 25], ["samples", "ANATOMY", 77, 84], ["viral infections", "DISEASE", 53, 69], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 99, 107], ["various viral infections", "PROBLEM", 45, 69], ["COVID", "TEST", 90, 95], ["the Cellex", "TREATMENT", 159, 169]]], ["This device uses a combination of SP and NP antigens.", [["SP", "SIMPLE_CHEMICAL", 34, 36], ["NP antigens", "GENE_OR_GENE_PRODUCT", 41, 52], ["SP", "PROTEIN", 34, 36], ["NP antigens", "PROTEIN", 41, 52], ["This device", "TREATMENT", 0, 11], ["SP and NP antigens", "TREATMENT", 34, 52]]], ["The sensitivity and specificity were calculated as 87% and 81% for IgM detection and 84% and 85% for IgG detection, respectively.", [["IgM", "PROTEIN", 67, 70], ["IgG", "PROTEIN", 101, 104], ["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 20, 31], ["IgM detection", "TEST", 67, 80], ["IgG detection", "TEST", 101, 114]]], ["Interestingly, the Orient LFIA, also constructed with the same 2 antigens, showed a sensitivity of 89% for IgM detection and 92% for IgG detection.", [["IgG", "GENE_OR_GENE_PRODUCT", 133, 136], ["Orient LFIA", "PROTEIN", 19, 30], ["IgM", "PROTEIN", 107, 110], ["IgG", "PROTEIN", 133, 136], ["the Orient LFIA", "TEST", 15, 30], ["a sensitivity", "TEST", 82, 95], ["IgM detection", "TEST", 107, 120], ["IgG detection", "TEST", 133, 146]]], ["The assay specificity for each isotype was 100%, but it should be noted that the latter study tested a very small sample set of negative controls.", [["The assay specificity", "TEST", 0, 21], ["each isotype", "TEST", 26, 38], ["the latter study", "TEST", 77, 93]]], ["Another study utilized samples from both negative patients and patients with other viral infections and examined 6 LFIA devices.18 Although no target antigen information was presented, the patient sample sets were robust.", [["samples", "ANATOMY", 23, 30], ["viral infections", "DISEASE", 83, 99], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 63, 71], ["patient", "ORGANISM", 189, 196], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 63, 71], ["patient", "SPECIES", 189, 196], ["Another study", "TEST", 0, 13], ["samples", "TEST", 23, 30], ["other viral infections", "PROBLEM", 77, 99], ["6 LFIA devices", "TREATMENT", 113, 127], ["the patient sample sets", "TEST", 185, 208], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infections", "OBSERVATION", 89, 99], ["no", "UNCERTAINTY", 140, 142]]], ["While evaluation of 2 of the LFIA demonstrated a poor performance, the remaining devices demonstrated 83% to 93% sensitivity and 100% specificity values.", [["evaluation", "TEST", 6, 16], ["the remaining devices", "TEST", 67, 88], ["sensitivity", "TEST", 113, 124]]], ["Lastly, Traugott et al28 presented data regarding 2 LFIA with specificity ranging from 98% 100%, but sensitivity was reported as poor at less than 5 days post onset of symptoms (13%-20%), poor to moderate at days 6 to 10 (20%-80%), and excellent at or after day 11 (100%).Lateral Flow Immunoassay (LFIA) ::: Overview of Immunoassays ::: ResultsOne study examined the accuracy of 10 different LFIA and 2 ELISA immunoassays using samples obtained from COVID-19 patients at different time points of disease.6 Specificity was assessed using 108 samples from healthy subjects and 52 samples from patients with other respiratory illnesses (not specified).", [["samples", "ANATOMY", 428, 435], ["samples", "ANATOMY", 541, 548], ["samples", "ANATOMY", 578, 585], ["respiratory", "ANATOMY", 611, 622], ["respiratory illnesses", "DISEASE", 611, 632], ["patients", "ORGANISM", 459, 467], ["patients", "ORGANISM", 591, 599], ["patients", "SPECIES", 459, 467], ["patients", "SPECIES", 591, 599], ["specificity", "TEST", 62, 73], ["sensitivity", "TEST", 101, 112], ["symptoms", "PROBLEM", 168, 176], ["Lateral Flow Immunoassay", "TEST", 272, 296], ["One study", "TEST", 344, 353], ["the accuracy", "TEST", 363, 375], ["2 ELISA immunoassays", "TEST", 401, 421], ["samples", "TEST", 428, 435], ["COVID", "TEST", 450, 455], ["disease", "PROBLEM", 496, 503], ["other respiratory illnesses", "PROBLEM", 605, 632], ["moderate", "OBSERVATION_MODIFIER", 196, 204], ["disease", "OBSERVATION", 496, 503]]], ["The highest detection rate observed using LFIA devices was obtained with combined IgM and IgG detection.", [["IgM", "GENE_OR_GENE_PRODUCT", 82, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgM", "PROTEIN", 82, 85], ["IgG", "PROTEIN", 90, 93], ["The highest detection rate", "TEST", 0, 26], ["LFIA devices", "TREATMENT", 42, 54], ["combined IgM", "TEST", 73, 85], ["IgG detection", "TEST", 90, 103]]], ["Accuracy peaked at days 16 to 20 post onset of symptoms with sensitivity results greater than 80% and specificity results greater than 95%.", [["Accuracy", "TEST", 0, 8], ["symptoms", "PROBLEM", 47, 55], ["sensitivity", "TEST", 61, 72], ["specificity", "TEST", 102, 113]]], ["Notably, this study reported several false-positive results obtained from banked specimens collected before the pandemic.", [["specimens", "ANATOMY", 81, 90], ["this study", "TEST", 9, 19], ["banked specimens", "TEST", 74, 90]]], ["These false-positive results suggest nonspecific binding by plasma proteins or cross-reactivity with antibodies produced during other viral infections.", [["plasma", "ANATOMY", 60, 66], ["viral infections", "DISEASE", 134, 150], ["plasma", "ORGANISM_SUBSTANCE", 60, 66], ["plasma proteins", "PROTEIN", 60, 75], ["antibodies", "PROTEIN", 101, 111], ["These false", "TEST", 0, 11], ["nonspecific binding", "PROBLEM", 37, 56], ["plasma proteins", "TEST", 60, 75], ["antibodies", "PROBLEM", 101, 111], ["other viral infections", "PROBLEM", 128, 150], ["false", "OBSERVATION", 6, 11], ["nonspecific", "OBSERVATION_MODIFIER", 37, 48], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["infections", "OBSERVATION", 140, 150]]], ["In a separate study of 7 LFIA devices, Van Elslande et al29 also used a secondary set of 103 control samples to assess assay performance and reported a range of 97% to 100% specificity with the combination of positive IgM and IgG results but an 85% to 98% range of specificity when only IgM or IgG positive results were used.", [["samples", "ANATOMY", 101, 108], ["IgM", "GENE_OR_GENE_PRODUCT", 218, 221], ["IgG", "GENE_OR_GENE_PRODUCT", 226, 229], ["IgM", "GENE_OR_GENE_PRODUCT", 287, 290], ["IgG", "GENE_OR_GENE_PRODUCT", 294, 297], ["IgM", "PROTEIN", 218, 221], ["IgG", "PROTEIN", 226, 229], ["IgM", "PROTEIN", 287, 290], ["IgG", "PROTEIN", 294, 297], ["a separate study", "TEST", 3, 19], ["7 LFIA devices", "TREATMENT", 23, 37], ["assay performance", "TEST", 119, 136], ["positive IgM", "PROBLEM", 209, 221], ["IgG", "TEST", 226, 229], ["IgM", "TEST", 287, 290], ["IgG", "TEST", 294, 297]]], ["In their study, sensitivity was also reported to vary with the timing of sample acquisition post onset of symptoms.Lateral Flow Immunoassay (LFIA) ::: Overview of Immunoassays ::: ResultsLFIA is an appealing platform for SARS-CoV-2 testing with a relatively low cost per test and the advantage of potential use for point-of-care testing.30 LFIA described in the literature thus far provided results for both IgM and IgG.", [["sample", "ANATOMY", 73, 79], ["IgM", "GENE_OR_GENE_PRODUCT", 408, 411], ["IgG", "GENE_OR_GENE_PRODUCT", 416, 419], ["IgM", "PROTEIN", 408, 411], ["IgG", "PROTEIN", 416, 419], ["their study", "TEST", 3, 14], ["sample acquisition", "TEST", 73, 91], ["symptoms", "PROBLEM", 106, 114], ["Lateral Flow Immunoassay", "TEST", 115, 139], ["SARS", "TEST", 221, 225], ["CoV-2 testing", "TEST", 226, 239], ["care testing", "TEST", 324, 336], ["both IgM", "TEST", 403, 411]]], ["The majority of the reports demonstrated a higher sensitivity and specificity with the detection of both isotypes, and a higher specificity was observed with the detection of the IgG isotype over the detection of the IgM isotype alone.", [["IgG", "GENE_OR_GENE_PRODUCT", 179, 182], ["IgM", "GENE_OR_GENE_PRODUCT", 217, 220], ["IgG isotype", "PROTEIN", 179, 190], ["IgM isotype", "PROTEIN", 217, 228], ["a higher sensitivity", "PROBLEM", 41, 61], ["both isotypes", "PROBLEM", 100, 113], ["the IgG isotype", "PROBLEM", 175, 190], ["the IgM isotype", "TREATMENT", 213, 228], ["both", "OBSERVATION_MODIFIER", 100, 104], ["isotypes", "OBSERVATION", 105, 113], ["IgM isotype", "OBSERVATION", 217, 228]]], ["Antigens frequently used in LFIA include NP, RBD, and combined use of NP and SP.", [["RBD", "DISEASE", 45, 48], ["LFIA", "SIMPLE_CHEMICAL", 28, 32], ["SP", "PROTEIN", 77, 79], ["NP", "TREATMENT", 41, 43], ["RBD", "PROBLEM", 45, 48], ["NP", "TREATMENT", 70, 72], ["RBD", "OBSERVATION", 45, 48]]], ["A superior test accuracy based on the use of specific target antigen(s) was not evident at this time.", [["antigen", "GENE_OR_GENE_PRODUCT", 61, 68], ["A superior test accuracy", "TEST", 0, 24]]], ["Studies utilizing samples obtained at various time points demonstrated the accuracy of LFIA was optimal at approximately 2 weeks post onset of symptoms.", [["samples", "ANATOMY", 18, 25], ["samples", "TEST", 18, 25], ["LFIA", "TEST", 87, 91], ["symptoms", "PROBLEM", 143, 151]]], ["Overall, the understanding of the limitations or advantages for the implementation of LFIA-based assays is severely impacted by the presence of only a few properly designed studies in the current literature (Table 1).Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsPublications that described ELISA method validation often sought to address which antigens and antibody isotypes provided the best sensitivity and specificity Table 2.6,18,19,22,26-28,31-40 In many of these studies, these calculations were reported solely to compare the performance of different antigens or the detection of different isotypes and not necessarily to propose the use of the assay for clinical implementation.", [["LFIA", "SIMPLE_CHEMICAL", 86, 90], ["LFIA", "DNA", 86, 90], ["antigens", "PROTEIN", 381, 389], ["antibody isotypes", "PROTEIN", 394, 411], ["antigens", "PROTEIN", 595, 603], ["the implementation of LFIA-based assays", "TEST", 64, 103], ["severely impacted", "PROBLEM", 107, 124], ["Enzyme", "TEST", 217, 223], ["ELISA method validation", "TEST", 327, 350], ["antibody isotypes", "TEST", 394, 411], ["these studies", "TEST", 500, 513], ["these calculations", "TEST", 515, 533], ["different isotypes", "PROBLEM", 624, 642], ["the assay", "TEST", 685, 694], ["clinical implementation", "TREATMENT", 699, 722]]], ["Additionally, as noted in Table 2, many investigations utilized the ELISA method to study the timeline of antibody expression in SARS-CoV-2 patients.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsTo date, few investigations have focused on immunoassays utilizing the full SP antigen.31,34 The SP antigen includes the RBD antigen as well as other essential peptides that may be the target of the humoral immune response.", [["SARS", "DISEASE", 129, 133], ["SARS-CoV-2", "ORGANISM", 129, 139], ["patients", "ORGANISM", 140, 148], ["SP antigen", "GENE_OR_GENE_PRODUCT", 307, 317], ["SP antigen", "GENE_OR_GENE_PRODUCT", 328, 338], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 352, 363], ["SP antigen", "PROTEIN", 307, 317], ["SP antigen", "PROTEIN", 328, 338], ["RBD antigen", "PROTEIN", 352, 363], ["patients", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 129, 137], ["Enzyme", "TEST", 149, 155], ["few investigations", "TEST", 240, 258], ["immunoassays", "TEST", 275, 287], ["The SP antigen", "TEST", 324, 338], ["the RBD antigen", "TEST", 348, 363], ["peptides", "OBSERVATION", 391, 399], ["humoral immune response", "OBSERVATION", 430, 453]]], ["Amanat et al31 generated 2 different versions of the SARS-CoV-2 spike protein.", [["SARS", "DISEASE", 53, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["SARS-CoV-2 spike protein", "PROTEIN", 53, 77], ["SARS-CoV", "SPECIES", 53, 61], ["the SARS", "TEST", 49, 57], ["CoV", "TEST", 58, 61]]], ["One construct expressed the full length of SP and a second construct presented only the RBD.", [["RBD", "DISEASE", 88, 91], ["SP", "PROTEIN", 43, 45], ["RBD", "PROTEIN", 88, 91], ["full length", "OBSERVATION_MODIFIER", 28, 39], ["RBD", "OBSERVATION", 88, 91]]], ["Evaluating a small number of samples from RT-PCR\u2013positive patients, reactivity to both antigens was excellent as demonstrated by optical density values.", [["samples", "ANATOMY", 29, 36], ["samples", "CANCER", 29, 36], ["patients", "ORGANISM", 58, 66], ["antigens", "PROTEIN", 87, 95], ["patients", "SPECIES", 58, 66], ["RT", "TEST", 42, 44], ["small", "OBSERVATION_MODIFIER", 13, 18], ["optical density", "OBSERVATION", 129, 144]]], ["However, SP reactivity was significantly higher than that observed for RBD.", [["RBD", "DISEASE", 71, 74], ["SP", "PROTEIN", 9, 11], ["RBD", "PROTEIN", 71, 74], ["SP reactivity", "TEST", 9, 22], ["RBD", "PROBLEM", 71, 74], ["significantly", "OBSERVATION_MODIFIER", 27, 40], ["higher", "OBSERVATION_MODIFIER", 41, 47]]], ["IgG3, IgM, and IgA were the dominant isotypes observed in these patient samples.", [["samples", "ANATOMY", 72, 79], ["IgG3", "GENE_OR_GENE_PRODUCT", 0, 4], ["IgM", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgA", "GENE_OR_GENE_PRODUCT", 15, 18], ["patient", "ORGANISM", 64, 71], ["IgG3", "PROTEIN", 0, 4], ["IgM", "PROTEIN", 6, 9], ["IgA", "PROTEIN", 15, 18], ["patient", "SPECIES", 64, 71], ["IgG3", "TEST", 0, 4], ["IgM", "TEST", 6, 9], ["IgA", "TEST", 15, 18], ["the dominant isotypes", "PROBLEM", 24, 45], ["IgA", "ANATOMY", 15, 18], ["dominant", "OBSERVATION_MODIFIER", 28, 36], ["isotypes", "OBSERVATION", 37, 45]]], ["The investigators further reported that reactivity to a sample bank of sera obtained from patients with other human coronavirus infections was negligible.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsOkba et al34 produced an array of different ELISA to examine antibody reactivity to SP, S1, NP, and RBD antigens.", [["sera", "ANATOMY", 71, 75], ["coronavirus infections", "DISEASE", 116, 138], ["sera", "ORGANISM_SUBSTANCE", 71, 75], ["patients", "ORGANISM", 90, 98], ["human", "ORGANISM", 110, 115], ["coronavirus", "ORGANISM", 116, 127], ["S1", "GENE_OR_GENE_PRODUCT", 324, 326], ["NP", "GENE_OR_GENE_PRODUCT", 328, 330], ["RBD antigens", "GENE_OR_GENE_PRODUCT", 336, 348], ["SP", "PROTEIN", 320, 322], ["S1", "PROTEIN", 324, 326], ["NP", "PROTEIN", 328, 330], ["RBD antigens", "PROTEIN", 336, 348], ["patients", "SPECIES", 90, 98], ["human", "SPECIES", 110, 115], ["human coronavirus", "SPECIES", 110, 127], ["a sample bank of sera", "TEST", 54, 75], ["other human coronavirus infections", "PROBLEM", 104, 138], ["Enzyme", "TEST", 154, 160], ["Immunosorbent Assay", "TEST", 168, 187], ["different ELISA", "TEST", 270, 285], ["antibody reactivity", "TEST", 297, 316], ["SP", "TEST", 320, 322], ["coronavirus", "OBSERVATION_MODIFIER", 116, 127], ["infections", "OBSERVATION", 128, 138], ["S1", "ANATOMY", 324, 326]]], ["A large cohort of samples was obtained from patients with other viral respiratory infections and was inclusive of 116 banked samples from patients infected with various human coronaviruses.", [["samples", "ANATOMY", 18, 25], ["respiratory", "ANATOMY", 70, 81], ["samples", "ANATOMY", 125, 132], ["viral respiratory infections", "DISEASE", 64, 92], ["samples", "CANCER", 18, 25], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 138, 146], ["human", "ORGANISM", 169, 174], ["coronaviruses", "ORGANISM", 175, 188], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 138, 146], ["human", "SPECIES", 169, 174], ["human coronaviruses", "SPECIES", 169, 188], ["A large cohort of samples", "PROBLEM", 0, 25], ["other viral respiratory infections", "PROBLEM", 58, 92], ["banked samples", "TEST", 118, 132], ["various human coronaviruses", "PROBLEM", 161, 188], ["large", "OBSERVATION_MODIFIER", 2, 7], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["respiratory", "ANATOMY", 70, 81], ["infections", "OBSERVATION", 82, 92], ["human coronaviruses", "OBSERVATION", 169, 188]]], ["Only samples from some SARS-CoV and MERS-CoV patients cross-reacted with the SARS-CoV-2 antigens.", [["samples", "ANATOMY", 5, 12], ["SARS", "DISEASE", 23, 27], ["samples", "CANCER", 5, 12], ["SARS-CoV", "ORGANISM", 23, 31], ["MERS-CoV", "ORGANISM", 36, 44], ["patients", "ORGANISM", 45, 53], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 77, 96], ["SARS-CoV-2 antigens", "PROTEIN", 77, 96], ["MERS-CoV", "SPECIES", 36, 44], ["patients", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 23, 31], ["MERS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 77, 85], ["samples", "TEST", 5, 12], ["some SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["MERS", "TEST", 36, 40], ["the SARS", "TEST", 73, 81], ["some", "OBSERVATION_MODIFIER", 18, 22], ["SARS", "OBSERVATION", 23, 27]]], ["The RBD and NP ELISA were the most effective in the detection of antibodies in patients with mild infection.", [["infection", "DISEASE", 98, 107], ["patients", "ORGANISM", 79, 87], ["RBD", "PROTEIN", 4, 7], ["antibodies", "PROTEIN", 65, 75], ["patients", "SPECIES", 79, 87], ["The RBD and NP ELISA", "TEST", 0, 20], ["antibodies", "PROBLEM", 65, 75], ["mild infection", "PROBLEM", 93, 107], ["RBD", "OBSERVATION", 4, 7], ["NP", "ANATOMY", 12, 14], ["ELISA", "OBSERVATION", 15, 20], ["most effective", "OBSERVATION_MODIFIER", 30, 44], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["infection", "OBSERVATION", 98, 107]]], ["These 2 antigens were examined in a second study using samples obtained from a cohort of 16 patients obtained 14 days or longer after symptom onset.38 The RBD ELISA showed higher sensitivity (100% for IgG and 94% for IgM) compared to the NP ELISA (94% for IgG and 88% for IgM).Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsOkba et al34 also examined commercial ELISA using the S1 antigen for the detection of IgA and IgG antibodies.", [["samples", "ANATOMY", 55, 62], ["patients", "ORGANISM", 92, 100], ["IgM", "GENE_OR_GENE_PRODUCT", 217, 220], ["IgG", "GENE_OR_GENE_PRODUCT", 256, 259], ["IgM", "GENE_OR_GENE_PRODUCT", 272, 275], ["S1 antigen", "GENE_OR_GENE_PRODUCT", 413, 423], ["IgA", "GENE_OR_GENE_PRODUCT", 445, 448], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 453, 467], ["RBD", "PROTEIN", 155, 158], ["IgG", "PROTEIN", 201, 204], ["IgM", "PROTEIN", 217, 220], ["IgG", "PROTEIN", 256, 259], ["IgM", "PROTEIN", 272, 275], ["S1 antigen", "PROTEIN", 413, 423], ["IgA", "PROTEIN", 445, 448], ["IgG antibodies", "PROTEIN", 453, 467], ["patients", "SPECIES", 92, 100], ["a second study", "TEST", 34, 48], ["The RBD ELISA", "TEST", 151, 164], ["higher sensitivity", "PROBLEM", 172, 190], ["IgG", "TEST", 201, 204], ["IgM", "TEST", 217, 220], ["the NP ELISA", "TEST", 234, 246], ["IgG", "TEST", 256, 259], ["IgM", "TEST", 272, 275], ["Enzyme", "TEST", 277, 283], ["the detection", "TEST", 428, 441], ["IgA", "TEST", 445, 448], ["IgG antibodies", "PROBLEM", 453, 467], ["higher", "OBSERVATION_MODIFIER", 172, 178]]], ["Both ELISA showed some cross-reactivity with samples obtained from other human coronavirus positive patients.", [["samples", "ANATOMY", 45, 52], ["human", "ORGANISM", 73, 78], ["coronavirus", "ORGANISM", 79, 90], ["patients", "ORGANISM", 100, 108], ["human", "SPECIES", 73, 78], ["patients", "SPECIES", 100, 108], ["human coronavirus", "SPECIES", 73, 90], ["Both ELISA", "TEST", 0, 10], ["some cross-reactivity", "PROBLEM", 18, 39], ["samples", "TEST", 45, 52]]], ["Overall, the IgA ELISA displayed a higher sensitivity and the IgG ELISA displayed a higher specificity.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsLassauni\u00e8re et al18 evaluated ELISA constructed with RBD and S1 antigens using a control group of samples from patients with other non\u2013SARS-CoV-2 viral infections.", [["samples", "ANATOMY", 283, 290], ["SARS", "DISEASE", 320, 324], ["viral infections", "DISEASE", 331, 347], ["IgA", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 62, 65], ["patients", "ORGANISM", 296, 304], ["SARS-CoV-2 viral", "ORGANISM", 320, 336], ["IgA", "PROTEIN", 13, 16], ["IgG", "PROTEIN", 62, 65], ["RBD", "PROTEIN", 238, 241], ["S1 antigens", "PROTEIN", 246, 257], ["patients", "SPECIES", 296, 304], ["the IgA ELISA", "TEST", 9, 22], ["the IgG ELISA", "TEST", 58, 71], ["Enzyme", "TEST", 103, 109], ["ELISA", "TEST", 215, 220], ["RBD", "PROBLEM", 238, 241], ["S1 antigens", "TREATMENT", 246, 257], ["SARS", "PROBLEM", 320, 324], ["2 viral infections", "PROBLEM", 329, 347], ["viral infections", "OBSERVATION", 331, 347]]], ["The performance of a sandwich ELISA for the detection of total antibody reactivity to RBD was superior to that observed for the commercial IgG and IgA ELISA using the S1 antigen.", [["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["IgA", "GENE_OR_GENE_PRODUCT", 147, 150], ["S1 antigen", "GENE_OR_GENE_PRODUCT", 167, 177], ["RBD", "PROTEIN", 86, 89], ["IgG", "PROTEIN", 139, 142], ["IgA", "PROTEIN", 147, 150], ["S1 antigen", "PROTEIN", 167, 177], ["a sandwich ELISA", "TEST", 19, 35], ["total antibody reactivity to RBD", "PROBLEM", 57, 89], ["the commercial IgG", "TEST", 124, 142], ["IgA ELISA", "TEST", 147, 156]]], ["The ELISA for total antibody detection provided the highest sensitivity and specificity of 93% and 100%, respectively.", [["The ELISA", "TEST", 0, 9], ["total antibody detection", "TEST", 14, 38], ["specificity", "TEST", 76, 87]]], ["The specificity of the IgG and IgA assays were similar, but the IgA ELISA had a superior sensitivity of 93% vs 67% for IgG.", [["IgG", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgA", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgA", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgG", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgG", "PROTEIN", 23, 26], ["IgA", "PROTEIN", 31, 34], ["IgA", "PROTEIN", 64, 67], ["IgG", "PROTEIN", 119, 122], ["the IgG", "TEST", 19, 26], ["IgA assays", "TEST", 31, 41], ["the IgA ELISA", "TEST", 60, 73], ["a superior sensitivity", "TEST", 78, 100], ["IgG", "TEST", 119, 122]]], ["The authors reported a similar cross-reactivity of the commercial S1 ELISA to other human coronaviruses as observed by Okba et al.34Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsZhao et al33 also utilized a sandwich ELISA to measure total antibody reactivity to RBD antigen as well as a RBD targeted ELISA to measure IgM reactivity alone and a NP targeted ELISA to detect IgG reactivity.", [["human", "ORGANISM", 84, 89], ["coronaviruses", "ORGANISM", 90, 103], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 298, 309], ["IgM", "GENE_OR_GENE_PRODUCT", 353, 356], ["IgG", "GENE_OR_GENE_PRODUCT", 408, 411], ["RBD antigen", "PROTEIN", 298, 309], ["RBD", "PROTEIN", 323, 326], ["IgM", "PROTEIN", 353, 356], ["IgG", "PROTEIN", 408, 411], ["human", "SPECIES", 84, 89], ["human coronaviruses", "SPECIES", 84, 103], ["34Enzyme", "TEST", 130, 138], ["a sandwich ELISA", "TEST", 241, 257], ["total antibody reactivity", "TEST", 269, 294], ["RBD antigen", "TEST", 298, 309], ["a RBD targeted ELISA", "TEST", 321, 341], ["IgM reactivity", "TEST", 353, 367], ["a NP targeted ELISA", "TEST", 378, 397]]], ["Examining a cohort of over 300 patient samples, the total antibody assay had superior performance vs the other assays with a sensitivity and specificity of 93% and 99%, respectively.", [["samples", "ANATOMY", 39, 46], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["the total antibody assay", "TEST", 48, 72], ["a sensitivity", "TEST", 123, 136], ["specificity", "TEST", 141, 152]]], ["While the specificity of the IgM and IgG ELISA was 99%, the sensitivity of the IgG ELISA (NP) was 65% compared to the IgM ELISA (RBD) at 83%.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsWhitman et al6 evaluated 2 different ELISA and 10 different LFIA.", [["IgM", "GENE_OR_GENE_PRODUCT", 29, 32], ["IgG", "GENE_OR_GENE_PRODUCT", 37, 40], ["IgG", "GENE_OR_GENE_PRODUCT", 79, 82], ["IgM", "PROTEIN", 29, 32], ["IgG", "PROTEIN", 37, 40], ["IgM", "PROTEIN", 118, 121], ["RBD", "PROTEIN", 129, 132], ["the IgM", "TEST", 25, 32], ["IgG ELISA", "TEST", 37, 46], ["the sensitivity", "TEST", 56, 71], ["the IgG ELISA", "TEST", 75, 88], ["NP", "TEST", 90, 92], ["the IgM ELISA", "TEST", 114, 127], ["Enzyme", "TEST", 141, 147], ["different ELISA", "TEST", 250, 265]]], ["In their study, the sensitivity for the ELISA assays using samples obtained after day 16 post onset of symptoms was greater than 80% and the specificity was greater than 95%.", [["samples", "ANATOMY", 59, 66], ["their study", "TEST", 3, 14], ["the sensitivity", "TEST", 16, 31], ["the ELISA assays", "TEST", 36, 52], ["samples", "TEST", 59, 66], ["symptoms", "PROBLEM", 103, 111], ["the specificity", "TEST", 137, 152], ["greater", "OBSERVATION_MODIFIER", 157, 164]]], ["The agreement of the ELISA with different LFIA ranged from 75 to 95%.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Overview of Immunoassays ::: ResultsOverall, ELISA assays with RBD and NP antigens were the most frequently used in these early studies.", [["NP antigens", "GENE_OR_GENE_PRODUCT", 186, 197], ["RBD", "PROTEIN", 178, 181], ["NP antigens", "PROTEIN", 186, 197], ["the ELISA", "TEST", 17, 26], ["different LFIA", "TEST", 32, 46], ["Enzyme", "TEST", 69, 75], ["ELISA assays", "TEST", 160, 172], ["RBD", "PROBLEM", 178, 181], ["NP antigens", "TREATMENT", 186, 197], ["these early studies", "TEST", 231, 250]]], ["Although the sensitivity of the assays was affected by the timing of sample acquisition, a higher overall sensitivity was consistently observed with the use of total antibody detection.", [["sample", "ANATOMY", 69, 75], ["the assays", "TEST", 28, 38], ["sample acquisition", "TEST", 69, 87], ["a higher overall sensitivity", "PROBLEM", 89, 117], ["total antibody detection", "TEST", 160, 184]]], ["The ELISA technique is labor intensive and unsuitable for point-of-care testing; however, it may offer the advantage of determining antibody titers and selective isotype detection.", [["labor", "PROBLEM", 23, 28], ["care testing", "TEST", 67, 79], ["determining antibody titers", "TEST", 120, 147], ["selective isotype detection", "TEST", 152, 179]]], ["The importance of these options as clinical applications is unknown at this time.", [["these options", "TREATMENT", 18, 31], ["clinical applications", "TREATMENT", 35, 56]]], ["Overall, while several ELISA-based studies were robust in experimental design, many reports did not include examination of important control samples to best evaluate method specificity (Table 2).Direct Chemiluminescence Immunoassay (CLIA) ::: Overview of Immunoassays ::: ResultsThe use of CLIA in the detection of SARS-CoV-2 antibody is of particular interest, as this method has excellent sensitivity with a high signal-to-noise ratio in the detection of other viral infections.", [["SARS", "DISEASE", 315, 319], ["viral infections", "DISEASE", 463, 479], ["SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 315, 334], ["SARS-CoV-2 antibody", "PROTEIN", 315, 334], ["SARS-CoV", "SPECIES", 315, 323], ["several ELISA-based studies", "TEST", 15, 42], ["examination", "TEST", 108, 119], ["Direct Chemiluminescence Immunoassay", "TEST", 195, 231], ["CLIA", "TEST", 290, 294], ["SARS", "PROBLEM", 315, 319], ["CoV", "TEST", 320, 323], ["other viral infections", "PROBLEM", 457, 479], ["viral", "OBSERVATION_MODIFIER", 463, 468], ["infections", "OBSERVATION", 469, 479]]], ["CLIA uses recombinant antigen coated magnetic beads and a lumigen substrate with analysis on automated platforms.", [["recombinant antigen", "PROTEIN", 10, 29], ["recombinant antigen coated magnetic beads", "TREATMENT", 10, 51]]], ["In current reports, NP, combined NP and SP, and RBD antigens were most commonly used Table 3.8,22,26,27,41-46Direct Chemiluminescence Immunoassay (CLIA) ::: Overview of Immunoassays ::: ResultsMany studies utilized CLIA to address differences in patient populations and time of onset of symptoms vs serologic results.", [["SP", "SIMPLE_CHEMICAL", 40, 42], ["RBD antigens", "GENE_OR_GENE_PRODUCT", 48, 60], ["patient", "ORGANISM", 246, 253], ["SP", "PROTEIN", 40, 42], ["RBD antigens", "PROTEIN", 48, 60], ["patient", "SPECIES", 246, 253], ["combined NP and SP, and RBD antigens", "TEST", 24, 60], ["Chemiluminescence Immunoassay", "TEST", 116, 145], ["Many studies", "TEST", 193, 205], ["symptoms", "PROBLEM", 287, 295], ["serologic results", "TEST", 299, 316]]], ["Long et al42 reported the use of the NP and SP antigen combination in a study of 363 samples from confirmed and suspect COVID-19 patients.", [["samples", "ANATOMY", 85, 92], ["SP antigen", "GENE_OR_GENE_PRODUCT", 44, 54], ["patients", "ORGANISM", 129, 137], ["SP antigen combination", "PROTEIN", 44, 66], ["patients", "SPECIES", 129, 137], ["the NP", "TREATMENT", 33, 39], ["a study", "TEST", 70, 77]]], ["In their report, IgG-positive serostatus approached 100% at 20 days after onset of symptoms, and the median seroconversion for IgM and IgG was 13 days.", [["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgM", "GENE_OR_GENE_PRODUCT", 127, 130], ["IgG", "GENE_OR_GENE_PRODUCT", 135, 138], ["IgG", "PROTEIN", 17, 20], ["IgM", "PROTEIN", 127, 130], ["IgG", "PROTEIN", 135, 138], ["IgG", "TEST", 17, 20], ["symptoms", "PROBLEM", 83, 91], ["the median seroconversion", "TEST", 97, 122], ["IgM", "TEST", 127, 130], ["IgG", "TEST", 135, 138]]], ["Using a similar NP and SP assay but a smaller cohort of positive and negative patients, Jin et al8 reported a 48% sensitivity and 100% specificity for IgM detection.", [["patients", "ORGANISM", 78, 86], ["SP", "PROTEIN", 23, 25], ["IgM", "PROTEIN", 151, 154], ["patients", "SPECIES", 78, 86], ["a similar NP and SP assay", "TEST", 6, 31], ["IgM detection", "TEST", 151, 164]]], ["However, for IgG, the reported sensitivity was 89% and specificity was 91%.", [["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "PROTEIN", 13, 16], ["IgG", "TEST", 13, 16], ["sensitivity", "TEST", 31, 42], ["specificity", "TEST", 55, 66]]], ["Accuracy was higher for combined IgM and IgG testing with a posterior probability of greater than 99%; this was followed by IgG alone (90%) and IgM alone (86%) and was corroborated in a separate study.47Direct Chemiluminescence Immunoassay (CLIA) ::: Overview of Immunoassays ::: ResultsFive studies warranted a closer examination, as each included control samples from patients with non-SARS-CoV-2 infections.", [["samples", "ANATOMY", 357, 364], ["infections", "DISEASE", 399, 409], ["IgM", "GENE_OR_GENE_PRODUCT", 33, 36], ["IgG", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 124, 127], ["IgM", "GENE_OR_GENE_PRODUCT", 144, 147], ["patients", "ORGANISM", 370, 378], ["non-SARS-CoV-2", "ORGANISM", 384, 398], ["IgM", "PROTEIN", 33, 36], ["IgG", "PROTEIN", 41, 44], ["IgG", "PROTEIN", 124, 127], ["IgM", "PROTEIN", 144, 147], ["patients", "SPECIES", 370, 378], ["Accuracy", "TEST", 0, 8], ["combined IgM", "TEST", 24, 36], ["IgG testing", "TEST", 41, 52], ["a posterior probability", "TEST", 58, 81], ["IgG", "TEST", 124, 127], ["IgM", "TEST", 144, 147], ["a separate study", "TEST", 184, 200], ["Chemiluminescence Immunoassay", "TEST", 210, 239], ["Five studies", "TEST", 287, 299], ["a closer examination", "TEST", 310, 330], ["non-SARS", "TEST", 384, 392], ["CoV-2 infections", "PROBLEM", 393, 409], ["posterior", "ANATOMY_MODIFIER", 60, 69], ["greater", "OBSERVATION_MODIFIER", 85, 92], ["infections", "OBSERVATION", 399, 409]]], ["Lin et al43 used NP antigen to detect IgM and IgG reactivity.", [["NP antigen", "GENE_OR_GENE_PRODUCT", 17, 27], ["IgM", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "GENE_OR_GENE_PRODUCT", 46, 49], ["Lin et al43 used NP antigen", "PROTEIN", 0, 27], ["IgM", "PROTEIN", 38, 41], ["IgG", "PROTEIN", 46, 49], ["NP antigen", "TEST", 17, 27], ["IgM", "TEST", 38, 41], ["IgG reactivity", "OBSERVATION", 46, 60]]], ["Sensitivity for both IgM and IgG assays was reported as 82%, and the specificity was 81% for IgM detection and 98% for IgG detection.", [["IgM", "GENE_OR_GENE_PRODUCT", 21, 24], ["IgG", "GENE_OR_GENE_PRODUCT", 29, 32], ["IgG", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgM", "PROTEIN", 21, 24], ["IgG", "PROTEIN", 29, 32], ["IgM", "PROTEIN", 93, 96], ["IgG", "PROTEIN", 119, 122], ["Sensitivity", "TEST", 0, 11], ["both IgM", "TEST", 16, 24], ["IgG assays", "TEST", 29, 39], ["the specificity", "TEST", 65, 80], ["IgM detection", "TEST", 93, 106], ["IgG detection", "TEST", 119, 132]]], ["Ma et al44 compared RBD and NP antigen targeted CLIA and reported a higher sensitivity and specificity when using the RBD antigen.", [["NP antigen", "GENE_OR_GENE_PRODUCT", 28, 38], ["RBD antigen", "GENE_OR_GENE_PRODUCT", 118, 129], ["RBD", "PROTEIN", 20, 23], ["RBD antigen", "PROTEIN", 118, 129], ["RBD", "TEST", 20, 23], ["NP antigen", "TEST", 28, 38], ["a higher sensitivity", "PROBLEM", 66, 86], ["the RBD antigen", "TEST", 114, 129]]], ["A superior sensitivity and specificity were also demonstrated with the detection of IgA over IgM or IgG detection alone.", [["IgA", "GENE_OR_GENE_PRODUCT", 84, 87], ["IgM", "GENE_OR_GENE_PRODUCT", 93, 96], ["IgG", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgA", "PROTEIN", 84, 87], ["IgM", "PROTEIN", 93, 96], ["IgG", "PROTEIN", 100, 103], ["A superior sensitivity", "TEST", 0, 22], ["IgA over IgM", "TEST", 84, 96], ["IgG detection", "TEST", 100, 113]]], ["In addition, the use of IgA in tandem with the detection of either IgM or IgG increased assay sensitivity and specificity.", [["IgA", "GENE_OR_GENE_PRODUCT", 24, 27], ["IgM", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 74, 77], ["IgA", "PROTEIN", 24, 27], ["IgM", "PROTEIN", 67, 70], ["IgG", "PROTEIN", 74, 77], ["the detection", "TEST", 43, 56], ["IgM", "TEST", 67, 70], ["IgG increased assay sensitivity", "PROBLEM", 74, 105]]], ["Geurtsvankessel et al26 examined a total antibody assay for S1/S2 reactivity and reported a sensitivity of 73% and a specificity of 98%.", [["S1", "PROTEIN", 60, 62], ["S2", "PROTEIN", 63, 65], ["a total antibody assay", "TEST", 33, 55], ["S1/S2 reactivity", "PROBLEM", 60, 76], ["a sensitivity", "TEST", 90, 103], ["a specificity", "TEST", 115, 128]]], ["Bryan et al46 validated an IgG antibody assay using NP antigen with a specificity of 100% based on the analysis of banked samples originally submitted for HSV testing.", [["samples", "ANATOMY", 122, 129], ["NP antigen", "GENE_OR_GENE_PRODUCT", 52, 62], ["HSV", "ORGANISM", 155, 158], ["IgG antibody", "PROTEIN", 27, 39], ["NP antigen", "PROTEIN", 52, 62], ["HSV", "SPECIES", 155, 158], ["an IgG antibody assay", "TEST", 24, 45], ["NP antigen", "TEST", 52, 62], ["the analysis", "TEST", 99, 111], ["banked samples", "TEST", 115, 129], ["HSV testing", "TEST", 155, 166]]], ["This study also included 689 samples from confirmed COVID-19 patients.", [["samples", "ANATOMY", 29, 36], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["This study", "TEST", 0, 10], ["samples", "TEST", 29, 36], ["COVID", "TEST", 52, 57]]], ["The assay sensitivity increased from 53% at day 7 to 100% at day 17.", [["The assay sensitivity", "TEST", 0, 21], ["increased", "OBSERVATION_MODIFIER", 22, 31]]], ["Lastly, Zhang et al41 used a large cohort of samples and showed an area under the curve of 0.99 and 1.00 for IgM and IgG, respectively, using a combined NP and SP CLIA.Direct Chemiluminescence Immunoassay (CLIA) ::: Overview of Immunoassays ::: ResultsThe CLIA assay is traditionally considered a very sensitive method with the capability to detect low levels of antibodies.", [["samples", "ANATOMY", 45, 52], ["samples", "CANCER", 45, 52], ["IgM", "GENE_OR_GENE_PRODUCT", 109, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 117, 120], ["IgM", "PROTEIN", 109, 112], ["IgG", "PROTEIN", 117, 120], ["antibodies", "PROTEIN", 363, 373], ["the curve", "TEST", 78, 87], ["IgM", "TEST", 109, 112], ["IgG", "TEST", 117, 120], ["a combined NP", "TREATMENT", 142, 155], ["Direct Chemiluminescence Immunoassay", "TEST", 168, 204], ["The CLIA assay", "TEST", 252, 266], ["low levels of antibodies", "PROBLEM", 349, 373], ["SP CLIA", "OBSERVATION", 160, 167]]], ["CLIA assays are automated and allow for a high throughput of samples.", [["samples", "ANATOMY", 61, 68], ["CLIA assays", "TEST", 0, 11]]], ["In the current literature review, RBD and NP were the most commonly targeted antigens, and the studies detected IgM and IgG isotypes as well as total antibody reactivity.", [["IgM", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgG", "GENE_OR_GENE_PRODUCT", 120, 123], ["RBD", "PROTEIN", 34, 37], ["IgM", "PROTEIN", 112, 115], ["IgG isotypes", "PROTEIN", 120, 132], ["RBD and NP", "PROBLEM", 34, 44], ["the studies", "TEST", 91, 102], ["IgM", "TEST", 112, 115], ["IgG isotypes", "TEST", 120, 132], ["total antibody reactivity", "TEST", 144, 169], ["IgG isotypes", "OBSERVATION", 120, 132], ["antibody reactivity", "OBSERVATION", 150, 169]]], ["The use of RBD antigen and IgG detection produced the highest accuracy data among studies.", [["RBD antigen", "GENE_OR_GENE_PRODUCT", 11, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["RBD antigen", "PROTEIN", 11, 22], ["IgG", "PROTEIN", 27, 30], ["RBD antigen", "TEST", 11, 22], ["IgG detection", "TEST", 27, 40]]], ["It is important to consider that the variation in performance among different platforms may have been related to sample acquisition timing, which was not consistently reported in the studies.Diagnosis in Symptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsRT-PCR testing for viral detection is a frontline tool to detect patients with suspected SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 375, 395], ["Patients", "ORGANISM", 216, 224], ["patients", "ORGANISM", 351, 359], ["SARS-CoV-2", "ORGANISM", 375, 385], ["Patients", "SPECIES", 216, 224], ["patients", "SPECIES", 351, 359], ["SARS-CoV-2", "SPECIES", 375, 385], ["sample acquisition timing", "TEST", 113, 138], ["the studies", "TEST", 179, 190], ["Serologic Testing", "TEST", 257, 274], ["ResultsRT", "TEST", 279, 288], ["PCR testing", "TEST", 289, 300], ["viral detection", "TEST", 305, 320], ["SARS", "PROBLEM", 375, 379], ["CoV", "PROBLEM", 380, 383], ["2 infection", "PROBLEM", 384, 395], ["Symptomatic", "OBSERVATION_MODIFIER", 204, 215], ["infection", "OBSERVATION", 386, 395]]], ["However, several studies showed that the sensitivity of RT-PCR testing decreased over time post onset of symptoms and that this change was observed to be concurrent with the increasing sensitivity of antibody detection methods.Diagnosis in Symptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsGuo et al32 evaluated the use of a NP targeted ELISA using IgM, IgA, and IgG detection in a sample set of 82 RT-PCR confirmed cases and 58 suspected cases with negative RT-PCR.", [["Patients", "ORGANISM", 252, 260], ["IgM", "GENE_OR_GENE_PRODUCT", 381, 384], ["IgA", "GENE_OR_GENE_PRODUCT", 386, 389], ["IgG", "GENE_OR_GENE_PRODUCT", 395, 398], ["IgM", "PROTEIN", 381, 384], ["IgA", "PROTEIN", 386, 389], ["IgG", "PROTEIN", 395, 398], ["Patients", "SPECIES", 252, 260], ["several studies", "TEST", 9, 24], ["RT-PCR testing", "TEST", 56, 70], ["symptoms", "PROBLEM", 105, 113], ["antibody detection methods", "TREATMENT", 200, 226], ["Serologic Testing", "TEST", 293, 310], ["a NP targeted ELISA", "TEST", 355, 374], ["IgM", "TEST", 381, 384], ["IgA", "TEST", 386, 389], ["IgG detection", "TEST", 395, 408], ["a sample set", "TEST", 412, 424], ["RT-PCR", "TEST", 431, 437], ["cases", "TEST", 448, 453]]], ["Early in disease (5 days post onset of symptoms), IgM detection was positive in 93% of suspected cases with negative RT-PCR results and 76% of the RT-PCR confirmed cases.", [["IgM", "PROTEIN", 50, 53], ["Early in disease", "PROBLEM", 0, 16], ["symptoms", "PROBLEM", 39, 47], ["IgM detection", "TEST", 50, 63], ["the RT-PCR", "TEST", 143, 153], ["disease", "OBSERVATION", 9, 16]]], ["Overall, the sensitivity of RT-PCR testing alone was 52%; however, when using RT-PCR in combination with the ELISA, the total sensitivity increased to 99%.", [["RT-PCR testing", "TEST", 28, 42], ["RT-PCR", "TREATMENT", 78, 84], ["the ELISA", "TEST", 105, 114], ["the total sensitivity", "TEST", 116, 137]]], ["Similar results were observed in another study where combined detection of IgG and IgM identified over 70% of suspected cases that were negative by RT-PCR testing.38Diagnosis in Symptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsAs the course of the disease progresses, the utility of serology increases as well.", [["IgG", "GENE_OR_GENE_PRODUCT", 75, 78], ["IgM", "GENE_OR_GENE_PRODUCT", 83, 86], ["Patients", "ORGANISM", 190, 198], ["IgG", "PROTEIN", 75, 78], ["IgM", "PROTEIN", 83, 86], ["Patients", "SPECIES", 190, 198], ["another study", "TEST", 33, 46], ["IgG", "TEST", 75, 78], ["IgM", "TEST", 83, 86], ["PCR testing", "TEST", 151, 162], ["Serologic Testing", "TEST", 231, 248], ["the disease", "PROBLEM", 277, 288], ["serology", "TEST", 316, 324], ["Symptomatic", "OBSERVATION_MODIFIER", 178, 189], ["disease", "OBSERVATION", 281, 288]]], ["Zhao et al33 evaluated the sensitivity of a total antibody ELISA to the RBD antigen.", [["RBD antigen", "GENE_OR_GENE_PRODUCT", 72, 83], ["RBD antigen", "PROTEIN", 72, 83], ["a total antibody ELISA", "TEST", 42, 64]]], ["In the early (1-7) days post onset of symptoms, the sensitivity was 67% for RT-PCR; this increased to 79% when RT-PCR was combined with ELISA testing.", [["symptoms", "PROBLEM", 38, 46], ["the sensitivity", "TEST", 48, 63], ["RT-PCR", "TEST", 76, 82], ["RT-PCR", "TEST", 111, 117], ["ELISA testing", "TEST", 136, 149]]], ["The sensitivity for RT-PCR decreased to 54% at days 8 to 14 while the ELISA sensitivity increased to 90%.", [["The sensitivity", "TEST", 0, 15], ["RT-PCR", "TEST", 20, 26], ["the ELISA sensitivity", "TEST", 66, 87]]], ["At this time point, the use of both methods resulted in a sensitivity of 97%.", [["a sensitivity", "TEST", 56, 69]]], ["Lastly, on days 15 to 39, RT-PCR sensitivity was reported as 46%, and the ELISA sensitivity was 100%.", [["RT-PCR sensitivity", "TEST", 26, 44], ["the ELISA sensitivity", "TEST", 70, 91]]], ["Similar trends were also observed with an IgM RBD ELISA and IgG NP ELISA.Serology Use in Monitoring Disease Course ::: Practical Implementation of Serologic Testing ::: ResultsNumerous studies indicated that antibody responses may vary according to disease severity, and some reports proposed that monitoring titers may be applied in clinical practice to guide earlier aggressive treatment.", [["RBD", "PROTEIN", 46, 49], ["an IgM RBD ELISA", "TEST", 39, 55], ["Serologic Testing", "TEST", 147, 164], ["ResultsNumerous studies", "TEST", 169, 192], ["antibody responses", "PROBLEM", 208, 226], ["disease severity", "PROBLEM", 249, 265], ["monitoring titers", "TEST", 298, 315], ["earlier aggressive treatment", "TREATMENT", 361, 389]]], ["Traditionally, the hallmarks of a humoral immune response include the early expression of IgM isotype, which then matures into IgG isotype expression.", [["IgM", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgG", "GENE_OR_GENE_PRODUCT", 127, 130], ["IgM isotype", "PROTEIN", 90, 101], ["IgG isotype", "PROTEIN", 127, 138], ["IgM isotype", "PROBLEM", 90, 101], ["IgM isotype", "OBSERVATION", 90, 101], ["IgG isotype expression", "OBSERVATION", 127, 149]]], ["Notably, many reports of SARS-CoV-2 patients indicated that IgM expression was observed concurrently with IgG expression.", [["SARS-CoV-2", "ORGANISM", 25, 35], ["patients", "ORGANISM", 36, 44], ["IgM", "GENE_OR_GENE_PRODUCT", 60, 63], ["IgG", "GENE_OR_GENE_PRODUCT", 106, 109], ["IgM", "PROTEIN", 60, 63], ["IgG", "PROTEIN", 106, 109], ["patients", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["IgM expression", "PROBLEM", 60, 74]]], ["Long et al42 conducted a large multicenter study using an NP and SP targeted CLIA.", [["a large multicenter study", "TEST", 23, 48], ["an NP", "TREATMENT", 55, 60]]], ["The median seroconversion of both isotypes was recorded at day 13.", [["The median seroconversion of both isotypes", "TREATMENT", 0, 42], ["median", "OBSERVATION_MODIFIER", 4, 10], ["seroconversion", "OBSERVATION", 11, 25], ["both isotypes", "OBSERVATION", 29, 42]]], ["In addition, a different NP and SP targeted CLIA studied by Suhandynanata et al45 showed a median seroconversion on days 4 to 5 for IgM and IgG.Serology Use in Monitoring Disease Course ::: Practical Implementation of Serologic Testing ::: ResultsThe goal of several ELISA studies was to define the period of seroconversion, and all demonstrated the higher sensitivity of the assays by the second week post onset of symptoms.20,28,32,33 Zhao et al33 reported that the median seroconversion time of IgM and IgG to RBD antigen was days 12 and 14, respectively.", [["20,28,32,33", "CHEMICAL", 425, 436], ["IgM", "GENE_OR_GENE_PRODUCT", 132, 135], ["IgG", "GENE_OR_GENE_PRODUCT", 140, 143], ["IgM", "GENE_OR_GENE_PRODUCT", 498, 501], ["IgG to RBD antigen", "GENE_OR_GENE_PRODUCT", 506, 524], ["SP", "PROTEIN", 32, 34], ["IgM", "PROTEIN", 132, 135], ["IgG", "PROTEIN", 140, 143], ["IgM", "PROTEIN", 498, 501], ["IgG", "PROTEIN", 506, 509], ["RBD antigen", "PROTEIN", 513, 524], ["a different NP", "TREATMENT", 13, 27], ["a median seroconversion", "PROBLEM", 89, 112], ["IgM", "TEST", 132, 135], ["IgG", "TEST", 140, 143], ["Serologic Testing", "TEST", 218, 235], ["several ELISA studies", "TEST", 259, 280], ["seroconversion", "PROBLEM", 309, 323], ["symptoms", "PROBLEM", 416, 424], ["IgM", "TEST", 498, 501], ["IgG to RBD antigen", "TEST", 506, 524]]], ["Guo et al32 reported the median appearance of IgM and IgA at day 5 and IgG at day 14 post symptom onset.", [["IgM", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgA", "GENE_OR_GENE_PRODUCT", 54, 57], ["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgM", "PROTEIN", 46, 49], ["IgA", "PROTEIN", 54, 57], ["IgG", "PROTEIN", 71, 74], ["IgM", "TEST", 46, 49], ["IgA", "TEST", 54, 57], ["IgG", "TEST", 71, 74], ["IgM", "OBSERVATION", 46, 49]]], ["Their study used serial samples obtained from the same patients and an ELISA for antibody detection to the NP antigen.", [["samples", "ANATOMY", 24, 31], ["patients", "ORGANISM", 55, 63], ["NP antigen", "GENE_OR_GENE_PRODUCT", 107, 117], ["NP antigen", "PROTEIN", 107, 117], ["patients", "SPECIES", 55, 63], ["Their study", "TEST", 0, 11], ["serial samples", "TEST", 17, 31], ["an ELISA", "TEST", 68, 76], ["antibody detection", "TEST", 81, 99], ["the NP antigen", "TEST", 103, 117]]], ["Xiang et al20 also used a NP targeted ELISA and reported the median appearance of antibody at day 4 post onset of symptoms.", [["symptoms", "PROBLEM", 114, 122]]], ["Overall, while these results are similar to that reported in a review of serologic testing for MERS-CoV and SARS-CoV, they may have been affected by choice of target antigens, the various immunoassay kits, and the level of detail of case history used to categorize the time of sample acquisition post onset of symptoms.14Serology Use in Monitoring Disease Course ::: Practical Implementation of Serologic Testing ::: ResultsFew studies have examined the differences in titers by case severity classification, and there was no consensus among the findings.", [["SARS", "DISEASE", 108, 112], ["MERS-CoV", "ORGANISM", 95, 103], ["SARS-CoV", "ORGANISM", 108, 116], ["target antigens", "PROTEIN", 159, 174], ["MERS-CoV", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 108, 116], ["serologic testing", "TEST", 73, 90], ["MERS", "TEST", 95, 99], ["SARS", "PROBLEM", 108, 112], ["the various immunoassay kits", "TEST", 176, 204], ["sample acquisition", "TEST", 277, 295], ["symptoms", "PROBLEM", 310, 318], ["Serologic Testing", "TEST", 395, 412], ["Few studies", "TEST", 424, 435]]], ["Tan et al49 reported that the IgG and IgM detection occurred earlier for severe cases compared to nonsevere cases (P < .05).", [["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgM", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "PROTEIN", 30, 33], ["IgM", "PROTEIN", 38, 41], ["the IgG", "TEST", 26, 33], ["IgM detection", "TEST", 38, 51], ["severe cases", "PROBLEM", 73, 85]]], ["Higher titers were also observed in the former group.", [["Higher titers", "PROBLEM", 0, 13]]], ["Wang et al50 evaluated the titers of IgM and IgG in 116 confirmed cases of which 101 of the cases had mild to moderate disease and 15 patients died.", [["IgM", "GENE_OR_GENE_PRODUCT", 37, 40], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["patients", "ORGANISM", 134, 142], ["IgM", "PROTEIN", 37, 40], ["IgG", "PROTEIN", 45, 48], ["patients", "SPECIES", 134, 142], ["IgM", "TEST", 37, 40], ["IgG", "TEST", 45, 48], ["mild to moderate disease", "PROBLEM", 102, 126], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["disease", "OBSERVATION", 119, 126]]], ["Levels of IgM were significantly higher in deceased patients (P = .019).", [["IgM", "GENE_OR_GENE_PRODUCT", 10, 13], ["patients", "ORGANISM", 52, 60], ["IgM", "PROTEIN", 10, 13], ["patients", "SPECIES", 52, 60], ["Levels of IgM", "TEST", 0, 13], ["P", "TEST", 62, 63], ["IgM", "OBSERVATION", 10, 13]]], ["However, no significant correlation was observed between case outcome and IgG titers.", [["IgG", "GENE_OR_GENE_PRODUCT", 74, 77], ["IgG", "PROTEIN", 74, 77], ["IgG titers", "TEST", 74, 84], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["In contrast, a large study of 338 confirmed COVID-19 patients reported elevated IgM titers but lower IgG levels in critical cases.51 Ma et al44 evaluated IgA titers in a cohort of 216 patients and observed a significant correlation with disease severity (P < .0001) and peak levels of IgA 16 to 20 days after symptom onset.", [["patients", "ORGANISM", 53, 61], ["IgM", "GENE_OR_GENE_PRODUCT", 80, 83], ["IgG", "GENE_OR_GENE_PRODUCT", 101, 104], ["IgA", "GENE_OR_GENE_PRODUCT", 154, 157], ["patients", "ORGANISM", 184, 192], ["IgA", "GENE_OR_GENE_PRODUCT", 285, 288], ["IgM", "PROTEIN", 80, 83], ["IgG", "PROTEIN", 101, 104], ["IgA", "PROTEIN", 154, 157], ["IgA", "PROTEIN", 285, 288], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 184, 192], ["a large study", "TEST", 13, 26], ["COVID", "TEST", 44, 49], ["elevated IgM titers", "PROBLEM", 71, 90], ["lower IgG levels", "TEST", 95, 111], ["IgA titers", "TEST", 154, 164], ["disease severity", "PROBLEM", 237, 253], ["peak levels", "TEST", 270, 281], ["IgA", "TEST", 285, 288], ["symptom onset", "PROBLEM", 309, 322], ["large", "OBSERVATION_MODIFIER", 15, 20], ["elevated", "OBSERVATION_MODIFIER", 71, 79], ["IgM titers", "OBSERVATION", 80, 90]]], ["Sun et al40 reported significantly higher IgG titers to SP antigen in non-ICU patients, whereas IgG titers to NP antigen were elevated in ICU patients.", [["IgG", "ORGANISM_SUBSTANCE", 42, 45], ["SP antigen", "GENE_OR_GENE_PRODUCT", 56, 66], ["patients", "ORGANISM", 78, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 96, 99], ["NP antigen", "GENE_OR_GENE_PRODUCT", 110, 120], ["patients", "ORGANISM", 142, 150], ["IgG", "PROTEIN", 42, 45], ["SP antigen", "PROTEIN", 56, 66], ["IgG", "PROTEIN", 96, 99], ["NP antigen", "PROTEIN", 110, 120], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 142, 150], ["significantly higher IgG titers", "PROBLEM", 21, 52], ["IgG titers", "TEST", 96, 106], ["NP antigen", "TEST", 110, 120]]], ["Lastly, To et al,38 using NP and RBD targeted ELISA observed no correlation between titers and severity.Serology Use in Monitoring Disease Course ::: Practical Implementation of Serologic Testing ::: ResultsPreviously, quantification performed by ELISA and neutralizing antibody assays showed that individuals over 60 years of age had higher antibody titers than young healthy adults with human coronavirus (non\u2013SARS-CoV-2) infection.52 Notably, in a study of patients recovered from COVID-19, samples obtained from elderly and middle-aged individuals had higher titers of SP reactive antibody compared to young adults.53 Thus, while increased age is often associated with severe SARS-CoV-2 disease and poor outcomes, high levels of antibody production do not appear to be detrimental given these preliminary reports.Serology Use for Screening Asymptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsThere were limited reports of testing approaches for the detection of asymptomatic individuals.", [["samples", "ANATOMY", 494, 501], ["human coronavirus", "DISEASE", 389, 406], ["infection", "DISEASE", 424, 433], ["SARS-CoV-2 disease", "DISEASE", 680, 698], ["human", "ORGANISM", 389, 394], ["coronavirus", "ORGANISM", 395, 406], ["non\u2013SARS-CoV-2", "ORGANISM", 408, 422], ["patients", "ORGANISM", 460, 468], ["samples", "CANCER", 494, 501], ["individuals", "ORGANISM", 540, 551], ["SP reactive antibody", "GENE_OR_GENE_PRODUCT", 573, 593], ["Patients", "ORGANISM", 857, 865], ["RBD", "PROTEIN", 33, 36], ["SP reactive antibody", "PROTEIN", 573, 593], ["human", "SPECIES", 389, 394], ["patients", "SPECIES", 460, 468], ["Patients", "SPECIES", 857, 865], ["human coronavirus", "SPECIES", 389, 406], ["NP", "TREATMENT", 26, 28], ["RBD targeted ELISA", "TEST", 33, 51], ["Serologic Testing", "TEST", 178, 195], ["quantification", "TEST", 219, 233], ["ELISA", "TEST", 247, 252], ["neutralizing antibody assays", "TEST", 257, 285], ["higher antibody titers", "PROBLEM", 335, 357], ["human coronavirus", "PROBLEM", 389, 406], ["non\u2013SARS", "TEST", 408, 416], ["infection", "PROBLEM", 424, 433], ["a study", "TEST", 449, 456], ["COVID", "TEST", 484, 489], ["samples", "TEST", 494, 501], ["SP reactive antibody", "PROBLEM", 573, 593], ["severe SARS", "PROBLEM", 673, 684], ["CoV-2 disease", "PROBLEM", 685, 698], ["poor outcomes", "PROBLEM", 703, 716], ["high levels of antibody production", "PROBLEM", 718, 752], ["Serologic Testing", "TEST", 898, 915], ["testing approaches", "TEST", 957, 975], ["asymptomatic individuals", "PROBLEM", 997, 1021], ["infection", "OBSERVATION", 424, 433], ["middle", "ANATOMY_MODIFIER", 528, 534], ["reactive antibody", "OBSERVATION", 576, 593], ["severe", "OBSERVATION_MODIFIER", 673, 679], ["SARS", "OBSERVATION", 680, 684]]], ["Much of the current literature was weakened given the limitations in the experimental design of studies used to validate the serologic methods.", [["studies", "TEST", 96, 103], ["the serologic methods", "TEST", 121, 142]]], ["For example, Paradiso et al54 used an LFIA for IgM and IgG detection to screen 525 health care workers.", [["IgM", "GENE_OR_GENE_PRODUCT", 47, 50], ["IgM", "PROTEIN", 47, 50], ["IgG", "PROTEIN", 55, 58], ["IgM", "TEST", 47, 50], ["IgG detection", "TEST", 55, 68]]], ["Previously, this group reported an overall 30% sensitivity and 89% specificity obtained during the validation of this LFIA.", [["the validation", "TEST", 95, 109], ["this LFIA", "TEST", 113, 122]]], ["It was acknowledged that the reduced sensitivity was related to the selection of validation samples from patients early after the onset of symptoms.21 In the health care worker screening study, only 1.1% of the cases were seropositive; these cases tested negative by RT-PCR.", [["samples", "ANATOMY", 92, 99], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["the reduced sensitivity", "PROBLEM", 25, 48], ["validation samples", "TEST", 81, 99], ["symptoms", "PROBLEM", 139, 147], ["screening study", "TEST", 177, 192], ["the cases", "TEST", 207, 216], ["seropositive", "PROBLEM", 222, 234], ["these cases", "TEST", 236, 247], ["RT", "TEST", 267, 269], ["PCR", "TEST", 270, 273]]], ["All the cases were positive for IgM, and 1 case was positive for both IgM and IgG.", [["IgM", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgM", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgG", "GENE_OR_GENE_PRODUCT", 78, 81], ["IgM", "PROTEIN", 32, 35], ["IgM", "PROTEIN", 70, 73], ["IgG", "PROTEIN", 78, 81], ["All the cases", "TEST", 0, 13], ["IgM", "TEST", 32, 35], ["IgM", "TEST", 70, 73], ["IgG", "TEST", 78, 81]]], ["Another study from the same investigation group examined asymptomatic cases presenting to the emergency department.21 Twenty nine percent of the cases were positive by RT-PCR testing and 21% of the cases were positive by LFIA testing.", [["Another study", "TEST", 0, 13], ["RT", "TEST", 168, 170], ["PCR testing", "TEST", 171, 182], ["the cases", "TEST", 194, 203], ["LFIA testing", "TEST", 221, 233]]], ["As the LFIA was not fully validated, it is problematic to apply these results to develop screening strategies for asymptomatic patients.Serology Use for Screening Asymptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsBendavid et al55 used LFIA in a study of 3,330 individuals from Santa Clara County, CA, and found an unadjusted antibody prevalence of 1.5% (95% confidence interval [CI], 1.11%-1.97%).", [["patients", "ORGANISM", 127, 135], ["Patients", "ORGANISM", 176, 184], ["LFIA", "DNA", 7, 11], ["patients", "SPECIES", 127, 135], ["Patients", "SPECIES", 176, 184], ["screening strategies", "TREATMENT", 89, 109], ["Serologic Testing", "TEST", 217, 234], ["a study", "TEST", 276, 283], ["CA", "TEST", 330, 332], ["an unadjusted antibody prevalence", "TEST", 344, 377], ["CI", "TEST", 412, 414]]], ["The weighted population prevalence was 2.8% (95% CI, 2.24%-3.37%).55 The kit was validated using samples from confirmed negative and positive SARS-CoV-2 patients with a combined IgM/IgG sensitivity of 80% and specificity of 99%.", [["samples", "ANATOMY", 97, 104], ["SARS-CoV", "ORGANISM", 142, 150], ["patients", "ORGANISM", 153, 161], ["IgM", "PROTEIN", 178, 181], ["IgG", "PROTEIN", 182, 185], ["patients", "SPECIES", 153, 161], ["SARS-CoV", "SPECIES", 142, 150], ["The weighted population prevalence", "TEST", 0, 34], ["CI", "TEST", 49, 51], ["samples", "TEST", 97, 104], ["CoV", "TEST", 147, 150], ["a combined IgM", "TEST", 167, 181], ["IgG sensitivity", "TEST", 182, 197], ["specificity", "TEST", 209, 220]]], ["No secondary controls with non\u2013SARS-CoV-2 viral infections were included in the validation study.", [["viral infections", "DISEASE", 42, 58], ["SARS-CoV-2 viral", "ORGANISM", 31, 47], ["SARS-CoV", "SPECIES", 31, 39], ["secondary controls", "PROBLEM", 3, 21], ["SARS", "TEST", 31, 35], ["2 viral infections", "PROBLEM", 40, 58], ["the validation study", "TEST", 76, 96], ["secondary controls", "OBSERVATION", 3, 21], ["viral infections", "OBSERVATION", 42, 58]]], ["As a result, this study likely overestimated the specificity of this LFIA.Serology Use for Screening Asymptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsZhao et al39 used a lab-developed ELISA for the detection of IgG antibody to S1 antigen with reported excellent sensitivity and specificity, as determined by the use of samples from symptomatic hospitalized patients and healthy individuals.", [["samples", "ANATOMY", 353, 360], ["LFIA", "CANCER", 69, 73], ["Patients", "ORGANISM", 114, 122], ["IgG antibody to S1 antigen", "GENE_OR_GENE_PRODUCT", 245, 271], ["patients", "ORGANISM", 391, 399], ["IgG antibody", "PROTEIN", 245, 257], ["S1 antigen", "PROTEIN", 261, 271], ["Patients", "SPECIES", 114, 122], ["patients", "SPECIES", 391, 399], ["this study", "TEST", 13, 23], ["Serologic Testing", "TEST", 155, 172], ["a lab", "TEST", 202, 207], ["ELISA", "TEST", 218, 223], ["the detection", "TEST", 228, 241], ["IgG antibody", "TEST", 245, 257], ["S1 antigen", "TEST", 261, 271]]], ["In a subsequent study, the same ELISA was examined in 276 asymptomatic health care workers.", [["a subsequent study", "TEST", 3, 21]]], ["Samples from a small cohort of close contact individuals were also examined.", [["Samples", "ANATOMY", 0, 7], ["individuals", "ORGANISM", 45, 56], ["Samples", "TEST", 0, 7], ["small", "OBSERVATION_MODIFIER", 15, 20]]], ["All subjects tested negative by RT-PCR, but 1 individual was seropositive.", [["All subjects", "TEST", 0, 12], ["RT-PCR", "TEST", 32, 38], ["seropositive", "PROBLEM", 61, 73]]], ["As with the study by Bendavid et al,55 the specificity of the ELISA assay was not fully assessed; this complicates the interpretation of these results.Serology Use for Screening Asymptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsA report of serologic testing of a family cluster of 6 individuals provided interesting data regarding the complexity of test sensitivity.56 Two family members were hospitalized with SARS-CoV-2 symptoms.", [["SARS-CoV-2 symptoms", "DISEASE", 444, 463], ["Patients", "ORGANISM", 191, 199], ["Patients", "SPECIES", 191, 199], ["the study", "TEST", 8, 17], ["the ELISA assay", "TEST", 58, 73], ["Serologic Testing", "TEST", 232, 249], ["serologic testing", "TEST", 273, 290], ["test sensitivity", "TEST", 382, 398], ["2 symptoms", "PROBLEM", 453, 463]]], ["One individual tested positive by RT-PCR on presentation, and the second patient tested negative twice before obtaining a positive result on day 5.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["RT-PCR", "TEST", 34, 40]]], ["Both individuals were positive for IgM reactivity by ELISA.", [["individuals", "ORGANISM", 5, 16], ["IgM", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgM", "PROTEIN", 35, 38], ["IgM reactivity", "PROBLEM", 35, 49], ["ELISA", "TEST", 53, 58], ["positive for", "UNCERTAINTY", 22, 34], ["IgM reactivity", "OBSERVATION", 35, 49]]], ["The 4 remaining family members remained asymptomatic.", [["asymptomatic", "PROBLEM", 40, 52]]], ["However, 3 of 4 tested positive for IgM reactivity, and 2 of 3 were positive by RT-PCR testing at later dates.", [["IgM", "GENE_OR_GENE_PRODUCT", 36, 39], ["IgM", "PROTEIN", 36, 39], ["IgM reactivity", "TEST", 36, 50], ["RT", "TEST", 80, 82], ["PCR testing", "TEST", 83, 94], ["IgM reactivity", "OBSERVATION", 36, 50]]], ["The fourth individual remained clinically asymptomatic and was negative on all testing.Serology Use for Screening Asymptomatic Patients ::: Practical Implementation of Serologic Testing ::: ResultsImplementation of serology testing to screen the general population and asymptomatic health care workers is currently of significant interest.", [["Patients", "ORGANISM", 127, 135], ["Patients", "SPECIES", 127, 135], ["all testing", "TEST", 75, 86], ["Serologic Testing", "TEST", 168, 185], ["serology testing", "TEST", 215, 231], ["clinically", "OBSERVATION_MODIFIER", 31, 41], ["asymptomatic", "OBSERVATION", 42, 54], ["negative", "OBSERVATION", 63, 71]]], ["With unclear population prevalence and the use of immunoassays that are not fully validated, the limitations of test sensitivity and specificity in the evaluation of asymptomatic individuals may be difficult to overcome.57Utility for Possible Convalescent Serum Donors ::: Practical Implementation of Serologic Testing ::: ResultsMany studies focused on the detection of neutralizing antibodies for the potential use as a predictor of clinical outcome and in the identification of convalescent serum for use in a treatment strategy.", [["serum", "ANATOMY", 494, 499], ["Serum", "ORGANISM_SUBSTANCE", 256, 261], ["convalescent", "ORGANISM", 481, 493], ["serum", "ORGANISM_SUBSTANCE", 494, 499], ["neutralizing antibodies", "PROTEIN", 371, 394], ["immunoassays", "TEST", 50, 62], ["test sensitivity", "TEST", 112, 128], ["the evaluation", "TEST", 148, 162], ["asymptomatic individuals", "PROBLEM", 166, 190], ["Serologic Testing", "TEST", 301, 318], ["Many studies", "TEST", 330, 342], ["the detection", "TEST", 354, 367], ["neutralizing antibodies", "TREATMENT", 371, 394], ["convalescent serum", "TEST", 481, 499], ["a treatment strategy", "TREATMENT", 511, 531]]], ["Several of these studies evaluated the correlation of data from ELISA using RBD, S1, S2, and NP antigens to the presence of neutralizing antibodies.", [["S2", "GENE_OR_GENE_PRODUCT", 85, 87], ["NP antigens", "GENE_OR_GENE_PRODUCT", 93, 104], ["RBD", "PROTEIN", 76, 79], ["S1", "PROTEIN", 81, 83], ["S2", "PROTEIN", 85, 87], ["NP antigens", "PROTEIN", 93, 104], ["neutralizing antibodies", "PROTEIN", 124, 147], ["these studies", "TEST", 11, 24], ["ELISA", "TEST", 64, 69], ["RBD", "TEST", 76, 79], ["neutralizing antibodies", "PROBLEM", 124, 147], ["S2", "ANATOMY", 85, 87], ["neutralizing antibodies", "OBSERVATION", 124, 147]]], ["Wu et al53 studied neutralizing antibodies using a pseudotyped-lentiviral-vector-based assay using plasmids for SARS-CoV and SARS-CoV-2 SP protein.", [["plasmids", "ANATOMY", 99, 107], ["lentiviral", "ORGANISM", 63, 73], ["SARS-CoV", "ORGANISM", 112, 120], ["SARS-CoV-2 SP", "GENE_OR_GENE_PRODUCT", 125, 138], ["Wu et al53 studied neutralizing antibodies", "PROTEIN", 0, 42], ["SARS-CoV and SARS-CoV-2 SP protein", "PROTEIN", 112, 146], ["SARS-CoV", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 125, 133], ["neutralizing antibodies", "TREATMENT", 19, 42], ["a pseudotyped", "TREATMENT", 49, 62], ["lentiviral-vector", "TREATMENT", 63, 80], ["plasmids", "TREATMENT", 99, 107], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["SARS", "TEST", 125, 129], ["CoV", "TEST", 130, 133]]], ["Titers of neutralizing antibodies were reported as ID50 (highest dilution resulting in 50% reduction of luciferase luminescence).", [["luciferase", "GENE_OR_GENE_PRODUCT", 104, 114], ["neutralizing antibodies", "PROTEIN", 10, 33], ["luciferase", "PROTEIN", 104, 114], ["neutralizing antibodies", "TEST", 10, 33], ["50% reduction of luciferase luminescence", "TREATMENT", 87, 127], ["luciferase luminescence", "OBSERVATION", 104, 127]]], ["Parallel ELISA for SARS-CoV and SARS-CoV-2 RBD, S1, and S2 were conducted.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["SARS-CoV-2", "ORGANISM", 32, 42], ["RBD", "PROTEIN", 43, 46], ["S1", "PROTEIN", 48, 50], ["SARS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 32, 40], ["Parallel ELISA", "TEST", 0, 14], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["S1, and S2", "TREATMENT", 48, 58], ["S1", "ANATOMY", 48, 50], ["S2", "ANATOMY", 56, 58]]], ["The study samples were obtained from 175 patients with mild to moderate symptoms who recovered from COVID-19.", [["samples", "ANATOMY", 10, 17], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["The study samples", "TEST", 0, 17], ["mild to moderate symptoms", "PROBLEM", 55, 80], ["COVID", "TEST", 100, 105], ["moderate", "OBSERVATION_MODIFIER", 63, 71]]], ["Levels of neutralizing antibodies were low (ID50, <200) before day 10 and appeared at 10 to 15 days after the onset of symptoms.", [["neutralizing antibodies", "PROTEIN", 10, 33], ["Levels of neutralizing antibodies", "TEST", 0, 33], ["ID50", "TEST", 44, 48], ["symptoms", "PROBLEM", 119, 127]]], ["Titers persisted at similar levels on repeat testing 2 weeks later.", [["Titers", "TEST", 0, 6], ["repeat testing", "TEST", 38, 52]]], ["The levels of neutralizing antibodies in the patients were categorized as follows: low to mid in 17% (ID50, 500-999), mid to high 39% (ID50, 1,000-2,500), and high in 14% (ID50, >2,500).", [["patients", "ORGANISM", 45, 53], ["neutralizing antibodies", "PROTEIN", 14, 37], ["patients", "SPECIES", 45, 53], ["The levels", "TEST", 0, 10], ["neutralizing antibodies", "TEST", 14, 37], ["ID50", "TEST", 102, 106], ["ID50", "TEST", 135, 139], ["ID50", "TEST", 172, 176], ["neutralizing antibodies", "OBSERVATION", 14, 37]]], ["Samples from 30% of patients had very low levels (ID50, <500) and included samples from 10 patients who had reactivity below the level of detection (ID50, <40).", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 75, 82], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 91, 99], ["Samples", "TEST", 0, 7], ["very low levels", "PROBLEM", 33, 48], ["ID50", "TEST", 50, 54], ["ID50", "TEST", 149, 153]]], ["Results obtained from ELISA using RBD, S1, and S2 antigens correlated moderately with neutralizing antibody titers.", [["S1", "GENE_OR_GENE_PRODUCT", 39, 41], ["S2", "GENE_OR_GENE_PRODUCT", 47, 49], ["RBD", "PROTEIN", 34, 37], ["S1", "PROTEIN", 39, 41], ["S2 antigens", "PROTEIN", 47, 58], ["ELISA", "TEST", 22, 27], ["RBD", "TEST", 34, 37], ["S1, and S2 antigens", "TEST", 39, 58], ["neutralizing antibody titers", "PROBLEM", 86, 114], ["S1", "ANATOMY", 39, 41]]], ["Correlation coefficients ranged from 0.42 to 0.51 (P < .0001).", [["Correlation coefficients", "TEST", 0, 24]]], ["Ni et al37 examined RBD and NP ELISA in tandem with the pseudovirus neutralization test in cohorts of 6 patients tested at the time of discharge and 2 weeks later.", [["patients", "ORGANISM", 104, 112], ["RBD", "PROTEIN", 20, 23], ["patients", "SPECIES", 104, 112], ["RBD", "PROBLEM", 20, 23], ["NP ELISA", "TEST", 28, 36], ["the pseudovirus neutralization test", "TEST", 52, 87]]], ["Significant levels of IgM and IgG were present at both time points as determined by ELISA methods.", [["IgM", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgM", "PROTEIN", 22, 25], ["IgG", "PROTEIN", 30, 33], ["Significant levels of IgM and IgG", "PROBLEM", 0, 33], ["IgM", "OBSERVATION", 22, 25]]], ["Notably, while neutralizing antibody was detected at the time of discharge, levels were lower in 5 of 6 patients 2 weeks later.Utility for Possible Convalescent Serum Donors ::: Practical Implementation of Serologic Testing ::: ResultsOkba et al34 compared the results of IgA and IgG ELISA for RBD, S1, and NP to data obtained from a plaque reduction neutralization assay (using Vero E6 cells) and reported a significant correlation (r = 0.88, P < .01) with all ELISA.", [["plaque", "ANATOMY", 334, 340], ["Vero E6 cells", "ANATOMY", 379, 392], ["plaque reduction", "DISEASE", 334, 350], ["patients", "ORGANISM", 104, 112], ["Serum", "ORGANISM_SUBSTANCE", 161, 166], ["IgA", "GENE_OR_GENE_PRODUCT", 272, 275], ["IgG", "GENE_OR_GENE_PRODUCT", 280, 283], ["plaque", "PATHOLOGICAL_FORMATION", 334, 340], ["Vero E6 cells", "CELL", 379, 392], ["neutralizing antibody", "PROTEIN", 15, 36], ["IgA", "PROTEIN", 272, 275], ["IgG", "PROTEIN", 280, 283], ["RBD", "PROTEIN", 294, 297], ["S1", "PROTEIN", 299, 301], ["Vero E6 cells", "CELL_LINE", 379, 392], ["patients", "SPECIES", 104, 112], ["neutralizing antibody", "TEST", 15, 36], ["levels", "TEST", 76, 82], ["Serologic Testing", "TEST", 206, 223], ["IgA", "TEST", 272, 275], ["IgG ELISA", "TEST", 280, 289], ["RBD", "PROBLEM", 294, 297], ["a plaque reduction neutralization assay", "TREATMENT", 332, 371], ["Vero E6 cells", "TREATMENT", 379, 392], ["P", "TEST", 444, 445], ["all ELISA", "TEST", 458, 467], ["S1", "ANATOMY", 299, 301], ["plaque", "OBSERVATION", 334, 340]]], ["The strongest correlation was observed with IgA reactivity (r = 0.93, P < .001).", [["IgA", "GENE_OR_GENE_PRODUCT", 44, 47], ["IgA", "PROTEIN", 44, 47], ["IgA reactivity", "TEST", 44, 58]]], ["It is important to note that various ELISA in this study were validated with a large secondary sample set obtained from patients with other respiratory viral infections (Table 2).Utility for Possible Convalescent Serum Donors ::: Practical Implementation of Serologic Testing ::: ResultsThe identification of novel antigenic epitopes that may be important in the humoral immune response was the focus of a limited number of studies.", [["respiratory viral infections", "DISEASE", 140, 168], ["patients", "ORGANISM", 120, 128], ["Serum", "ORGANISM_SUBSTANCE", 213, 218], ["antigenic epitopes", "PROTEIN", 315, 333], ["patients", "SPECIES", 120, 128], ["this study", "TEST", 46, 56], ["other respiratory viral infections", "PROBLEM", 134, 168], ["Serologic Testing", "TEST", 258, 275], ["novel antigenic epitopes", "PROBLEM", 309, 333], ["respiratory", "ANATOMY", 140, 151], ["viral infections", "OBSERVATION", 152, 168], ["antigenic epitopes", "OBSERVATION", 315, 333], ["may be", "UNCERTAINTY", 339, 345]]], ["Poh et al13 evaluated the reactivity of 25 convalescent serum samples.", [["serum samples", "ANATOMY", 56, 69], ["serum samples", "ORGANISM_SUBSTANCE", 56, 69], ["al13", "DNA", 7, 11], ["the reactivity", "TEST", 22, 36], ["25 convalescent serum samples", "TEST", 40, 69]]], ["Six samples showed significant neutralization activity (ID50, >600) and were selected for further analysis.", [["samples", "ANATOMY", 4, 11], ["Six samples", "TEST", 0, 11], ["significant neutralization activity", "PROBLEM", 19, 54], ["ID50", "TEST", 56, 60], ["further analysis", "TEST", 90, 106], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["neutralization activity", "OBSERVATION", 31, 54]]], ["Additional experiments to characterize antigen targets showed that the S14 and S21 peptides (within the SP) provided the strongest reactivity by ELISA methods, and these results correlated with neutralizing activity.", [["S14", "GENE_OR_GENE_PRODUCT", 71, 74], ["S21 peptides", "GENE_OR_GENE_PRODUCT", 79, 91], ["S14", "PROTEIN", 71, 74], ["SP", "PROTEIN", 104, 106], ["antigen targets", "TEST", 39, 54], ["the S14 and S21 peptides", "PROBLEM", 67, 91], ["ELISA methods", "TEST", 145, 158], ["neutralizing activity", "OBSERVATION", 194, 215]]], ["Jiang at al58 developed a microarray of 28 SARS-CoV-2 proteins to profile IgG/IgM responses of 29 convalescent sera.", [["sera", "ANATOMY", 111, 115], ["CoV-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 74, 77], ["IgM", "GENE_OR_GENE_PRODUCT", 78, 81], ["convalescent", "ORGANISM", 98, 110], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["al58", "PROTEIN", 9, 13], ["28 SARS-CoV-2 proteins", "PROTEIN", 40, 62], ["IgG", "PROTEIN", 74, 77], ["IgM", "PROTEIN", 78, 81], ["a microarray", "TEST", 24, 36], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["profile IgG", "TEST", 66, 77], ["IgM responses", "TEST", 78, 91], ["convalescent sera", "TEST", 98, 115]]], ["All patients had combined IgM/IgG responses to NP and S1 antigens but not to S2 antigen.", [["patients", "ORGANISM", 4, 12], ["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["S2 antigen", "GENE_OR_GENE_PRODUCT", 77, 87], ["IgM", "PROTEIN", 26, 29], ["IgG", "PROTEIN", 30, 33], ["NP and S1 antigens", "PROTEIN", 47, 65], ["S2 antigen", "PROTEIN", 77, 87], ["patients", "SPECIES", 4, 12], ["combined IgM/IgG responses", "PROBLEM", 17, 43]]], ["Furthermore, a significant number of samples were positive for anti-ORF9b and anti-NSP5 antibodies.", [["samples", "ANATOMY", 37, 44], ["samples", "CANCER", 37, 44], ["anti-ORF9b", "GENE_OR_GENE_PRODUCT", 63, 73], ["anti-NSP5 antibodies", "GENE_OR_GENE_PRODUCT", 78, 98], ["anti-ORF9b", "PROTEIN", 63, 73], ["anti-NSP5 antibodies", "PROTEIN", 78, 98], ["samples", "TEST", 37, 44], ["anti-ORF9b", "TEST", 63, 73], ["anti-NSP5 antibodies", "PROBLEM", 78, 98], ["significant", "OBSERVATION_MODIFIER", 15, 26]]], ["These peptides may represent good predictors for immunity and possible therapeutic targets.", [["therapeutic targets", "TREATMENT", 71, 90], ["may represent", "UNCERTAINTY", 15, 28], ["good", "OBSERVATION_MODIFIER", 29, 33]]], ["Overall, understanding the utility of routine serologic methods (ie, ELISA, CLIA) in the prediction of convalescence is complex.", [["routine serologic methods", "TEST", 38, 63]]], ["Further comprehensive studies in this area are warranted.DiscussionNumerous immunoassays for the detection of antibodies to SARS-CoV-2 are rapidly emerging.", [["SARS", "DISEASE", 124, 128], ["SARS-CoV-2", "ORGANISM", 124, 134], ["antibodies", "PROTEIN", 110, 120], ["SARS-CoV", "SPECIES", 124, 132], ["Further comprehensive studies", "TEST", 0, 29], ["Numerous immunoassays", "TEST", 67, 88], ["the detection", "TEST", 93, 106], ["antibodies", "PROBLEM", 110, 120]]], ["These immunoassays have the potential to improve the diagnosis and monitoring of infection in different scenarios.17,59-61 Published and non\u2013peer-reviewed studies varied dramatically in the definition of patient groups, time of sample acquisition, sample size, and inclusion of relevant control sera from patients with non\u2013SARS-CoV-2 respiratory infections.", [["sample", "ANATOMY", 228, 234], ["sample", "ANATOMY", 248, 254], ["sera", "ANATOMY", 295, 299], ["infection", "DISEASE", 81, 90], ["SARS", "DISEASE", 323, 327], ["respiratory infections", "DISEASE", 334, 356], ["patient", "ORGANISM", 204, 211], ["sera", "ORGANISM_SUBSTANCE", 295, 299], ["patients", "ORGANISM", 305, 313], ["SARS-CoV-2", "ORGANISM", 323, 333], ["patient", "SPECIES", 204, 211], ["patients", "SPECIES", 305, 313], ["SARS-CoV", "SPECIES", 323, 331], ["These immunoassays", "TEST", 0, 18], ["infection", "PROBLEM", 81, 90], ["sample acquisition", "TEST", 228, 246], ["sample size", "TEST", 248, 259], ["SARS", "PROBLEM", 323, 327], ["2 respiratory infections", "PROBLEM", 332, 356], ["infection", "OBSERVATION", 81, 90], ["CoV", "OBSERVATION_MODIFIER", 328, 331], ["respiratory", "ANATOMY", 334, 345], ["infections", "OBSERVATION", 346, 356]]], ["These are all critical variables that will affect the sensitivity and specificity of the different immunoassays and should be a fundamental part of the review of any validated assay.15 Determining the final roles of LFIA and ELISA immunoassays in SARS-CoV-2 testing and research is difficult at this time, as this is limited by the pitfalls in the experimental design of many of these foundational studies.", [["LFIA", "SIMPLE_CHEMICAL", 216, 220], ["LFIA", "PROTEIN", 216, 220], ["SARS-CoV", "SPECIES", 247, 255], ["the sensitivity", "TEST", 50, 65], ["the different immunoassays", "TEST", 85, 111], ["any validated assay", "TEST", 162, 181], ["LFIA", "TEST", 216, 220], ["ELISA immunoassays", "TEST", 225, 243], ["SARS", "TEST", 247, 251], ["CoV-2 testing", "TEST", 252, 265], ["these foundational studies", "TEST", 379, 405]]], ["Further well-validated assays determined through studies with rigorous experimental design are needed.DiscussionIn the current literature, the study methods were heterogeneous regarding the specific antigens used and the different isotypes of antibodies measured; few studies compared these variables simultaneously.", [["antibodies", "PROTEIN", 243, 253], ["validated assays", "TEST", 13, 29], ["rigorous experimental design", "TREATMENT", 62, 90], ["the study methods", "TEST", 139, 156], ["the specific antigens", "PROBLEM", 186, 207], ["the different isotypes of antibodies", "PROBLEM", 217, 253], ["few studies", "TEST", 264, 275]]], ["The most common antigens used in the assays included RBD, S1, and NP.", [["RBD", "PROTEIN", 53, 56], ["S1", "PROTEIN", 58, 60], ["the assays", "TEST", 33, 43], ["S1", "ANATOMY", 58, 60]]], ["There was preliminary evidence that the use of particular target antigens may provide value to increase the sensitivity of antibody detection methods.", [["antibody detection methods", "TREATMENT", 123, 149]]], ["However, additional comprehensive studies need to be conducted to reproduce this early reported data.", [["additional comprehensive studies", "TEST", 9, 41]]], ["In addition, antigenic epitopes within the SP appeared to be important in the immune response and thus, this region remains of interest for future detailed studies.DiscussionThere is compelling evidence that using total antibody or combined IgG/IgM detection offered the highest sensitivity of detection.", [["SP", "GENE_OR_GENE_PRODUCT", 43, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 241, 244], ["antigenic epitopes", "PROTEIN", 13, 31], ["SP", "PROTEIN", 43, 45], ["IgG", "PROTEIN", 241, 244], ["IgM", "PROTEIN", 245, 248], ["antigenic epitopes", "PROBLEM", 13, 31], ["future detailed studies", "TEST", 140, 163], ["total antibody", "TEST", 214, 228], ["combined IgG/IgM detection", "TEST", 232, 258], ["antigenic epitopes", "OBSERVATION", 13, 31]]], ["Data from preliminary studies indicated that additional investigations should examine the clinical correlation of different isotypes and titers to disease severity.", [["preliminary studies", "TEST", 10, 29], ["additional investigations", "TEST", 45, 70], ["different isotypes and titers to disease severity", "PROBLEM", 114, 163]]], ["It is also clear that the timing of sample acquisition is a crucial determinant of test accuracy, although this important information was not always clearly presented in the current literature.16 The earliest positive results were reported by day 5 post onset of symptoms, and accuracy peaked by the second week of symptoms.", [["sample", "ANATOMY", 36, 42], ["sample acquisition", "TEST", 36, 54], ["test accuracy", "TEST", 83, 96], ["symptoms", "PROBLEM", 263, 271], ["accuracy", "TEST", 277, 285], ["symptoms", "PROBLEM", 315, 323], ["clear", "OBSERVATION", 11, 16]]], ["Early in the course of the disease, when RT-PCR sensitivity was reported as 50% to 60%, the concomitant use of serologic tests significantly added sensitivity with consistently reported values over 90%.", [["the disease", "PROBLEM", 23, 34], ["RT-PCR sensitivity", "TEST", 41, 59], ["serologic tests", "TEST", 111, 126], ["disease", "OBSERVATION", 27, 34]]], ["Moreover, after 10 to 14 days post onset of symptoms, the sensitivity of RT-PCR dropped significantly while serology testing reached its peak.", [["symptoms", "PROBLEM", 44, 52], ["the sensitivity", "TEST", 54, 69], ["RT-PCR", "TEST", 73, 79], ["serology testing", "TEST", 108, 124]]], ["As fully validated methods become commercially available, serology methods may be utilized as an adjunct tool to RT-PCR testing protocols in patients with suspected infection.DiscussionNearly all of the current literature focused on the results obtained using serologic testing in symptomatic patients.", [["infection", "DISEASE", 165, 174], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 293, 301], ["serology methods", "TEST", 58, 74], ["RT-PCR testing protocols", "TEST", 113, 137], ["suspected infection", "PROBLEM", 155, 174], ["serologic testing", "TEST", 260, 277], ["infection", "OBSERVATION", 165, 174]]], ["It will be essential to define antibody responses in individuals with subclinical and mild disease before immunoassays can be used in screening and seroprevalence studies.", [["antibody responses", "TEST", 31, 49], ["subclinical and mild disease", "PROBLEM", 70, 98], ["immunoassays", "TEST", 106, 118], ["screening", "TEST", 134, 143], ["seroprevalence studies", "TEST", 148, 170], ["mild", "OBSERVATION_MODIFIER", 86, 90], ["disease", "OBSERVATION", 91, 98]]], ["At the time of this writing, while the potential importance of quantitative titers was raised in the literature, testing platforms available to provide this information are largely absent from clinical laboratories.", [["quantitative titers", "TEST", 63, 82], ["testing platforms", "TEST", 113, 130]]], ["Lastly, defining convalescence and the presence of long-lasting immunity to SARS-CoV-2 after infection or future vaccination is important.", [["SARS", "DISEASE", 76, 80], ["infection", "DISEASE", 93, 102], ["SARS-CoV-2", "ORGANISM", 76, 86], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["infection", "PROBLEM", 93, 102], ["future vaccination", "TREATMENT", 106, 124]]], ["Additional studies are needed to determine if ease-of-use assays of antibody detection and quantitation will compare well with traditional neutralizing antibody assays.", [["Additional studies", "TEST", 0, 18], ["assays", "TEST", 58, 64], ["antibody detection", "TEST", 68, 86], ["quantitation", "TEST", 91, 103], ["traditional neutralizing antibody assays", "TEST", 127, 167]]], ["While serologic testing continues to hold promise for various applications, there are still knowledge gaps that must be clarified to give meaningful recommendations for its use in different clinical scenarios.", [["serologic testing", "TEST", 6, 23], ["various applications", "TREATMENT", 54, 74]]]], "a3018164f466492d38016e83371458ce42107ddc": [["IntroductionThe current pandemic of coronavirus disease , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in over 13,000,000 confirmed cases globally and over 135,000 deaths in the United States alone, as of July 16, 2020.", [["coronavirus disease", "DISEASE", 36, 55], ["acute respiratory syndrome coronavirus", "DISEASE", 79, 117], ["deaths", "DISEASE", 208, 214], ["coronavirus", "ORGANISM", 36, 47], ["SARS-CoV-2", "ORGANISM", 121, 131], ["severe acute respiratory syndrome coronavirus", "SPECIES", 72, 117], ["SARS-CoV-2", "SPECIES", 121, 131], ["coronavirus disease", "PROBLEM", 36, 55], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 68, 117], ["SARS-CoV", "TEST", 121, 129], ["coronavirus disease", "OBSERVATION", 36, 55], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory syndrome", "OBSERVATION", 85, 105]]], ["(1) While RT-PCR tests remain the gold standard for diagnosing COVID-19, PCR tests do not provide adequate information on progression of the disease.", [["COVID-19", "DNA", 63, 71], ["RT-PCR tests", "TEST", 10, 22], ["diagnosing COVID", "TEST", 52, 68], ["PCR tests", "TEST", 73, 82], ["the disease", "PROBLEM", 137, 148], ["disease", "OBSERVATION", 141, 148]]], ["Furthermore, PCR tests can give positive 20 results for several weeks after a patient has seroconverted or recovered.(2) Serological tests can identify individuals who have mounted an immune response but cannot necessarily be used for monitoring disease in the early stages of infection.(3-5) SARS-CoV-2 antigen assays can be used for identifying active infection by measuring viral antigens in biofluids and can complement PCR and serological tests.", [["biofluids", "ANATOMY", 395, 404], ["infection", "DISEASE", 277, 286], ["infection", "DISEASE", 354, 363], ["patient", "ORGANISM", 78, 85], ["viral antigens", "PROTEIN", 377, 391], ["patient", "SPECIES", 78, 85], ["PCR tests", "TEST", 13, 22], ["Serological tests", "TEST", 121, 138], ["monitoring disease", "PROBLEM", 235, 253], ["infection", "PROBLEM", 277, 286], ["SARS-CoV-2 antigen assays", "TEST", 293, 318], ["active infection", "PROBLEM", 347, 363], ["measuring viral antigens in biofluids", "PROBLEM", 367, 404], ["complement PCR", "TEST", 413, 427], ["serological tests", "TEST", 432, 449], ["early stages", "OBSERVATION_MODIFIER", 261, 273], ["infection", "OBSERVATION", 277, 286], ["active", "OBSERVATION_MODIFIER", 347, 353], ["infection", "OBSERVATION", 354, 363]]], ["Currently there are two FDA approved SARS-CoV-2 antigen tests that detect 25 nucleocapsid in nasopharyngeal (NP) swabs.(6, 7) However, both tests provide qualitative results and may only detect viral antigen within the first five days of symptom onset.", [["nasopharyngeal (NP) swabs", "ANATOMY", 93, 118], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 37, 55], ["nasopharyngeal", "CANCER", 93, 107], ["viral antigen", "PROTEIN", 194, 207], ["SARS", "TEST", 37, 41], ["CoV-2 antigen tests", "TEST", 42, 61], ["viral antigen", "PROBLEM", 194, 207], ["symptom onset", "PROBLEM", 238, 251], ["nasopharyngeal", "ANATOMY", 93, 107]]], ["Quantitative and ultra-sensitive SARS-CoV-2 antigen assays could enable detection of viral antigens in blood, saliva, or NP swabs.", [["blood", "ANATOMY", 103, 108], ["saliva", "ANATOMY", 110, 116], ["CoV-2", "GENE_OR_GENE_PRODUCT", 38, 43], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["viral antigens", "PROTEIN", 85, 99], ["Quantitative and ultra-sensitive SARS", "TEST", 0, 37], ["CoV-2 antigen assays", "TEST", 38, 58], ["viral antigens in blood, saliva", "PROBLEM", 85, 116], ["NP swabs", "TREATMENT", 121, 129]]], ["In addition, combining quantitative antigen assays with serological assays could enable analysis of COVID-19 progression from early infection to seroconversion.", [["infection", "DISEASE", 132, 141], ["COVID-19", "CELL", 100, 108], ["combining quantitative antigen assays", "TEST", 13, 50], ["serological assays", "TEST", 56, 74], ["COVID", "TEST", 100, 105], ["early infection", "PROBLEM", 126, 141], ["seroconversion", "PROBLEM", 145, 159], ["early", "OBSERVATION_MODIFIER", 126, 131], ["infection", "OBSERVATION", 132, 141]]], ["30 To address the need for a quantitative antigen assay, we developed ultra-sensitive Single Molecule Array (Simoa) SARS-CoV-2 antigen assays for S1, spike (S1-S2 extracellular domain), and nucleocapsid (N).", [["nucleocapsid", "CELLULAR_COMPONENT", 190, 202], ["S1", "PROTEIN", 146, 148], ["S1", "PROTEIN", 157, 159], ["S2 extracellular domain", "PROTEIN", 160, 183], ["nucleocapsid (N)", "PROTEIN", 190, 206], ["a quantitative antigen assay", "TEST", 27, 55], ["ultra-sensitive Single Molecule Array", "TEST", 70, 107], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["antigen assays", "TEST", 127, 141], ["S1", "PROBLEM", 146, 148], ["spike (S1-S2 extracellular domain", "PROBLEM", 150, 183]]], ["The ultra-sensitivity of Simoa enables detection of SARS-CoV-2 antigens in the plasma of COVID-19 positive patients.", [["plasma", "ANATOMY", 79, 85], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 52, 71], ["plasma", "ORGANISM_SUBSTANCE", 79, 85], ["COVID-19", "CELL", 89, 97], ["patients", "ORGANISM", 107, 115], ["Simoa", "PROTEIN", 25, 30], ["SARS-CoV-2 antigens", "PROTEIN", 52, 71], ["patients", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["COVID", "TEST", 89, 94]]], ["Additionally, Simoa provides a dynamic range that allows quantification of antigens over a concentration range of four orders of magnitude.", [["Simoa", "PROTEIN", 14, 19], ["antigens", "PROTEIN", 75, 83]]], ["This 35 precise quantification is advantageous for capturing the wide range of antigen concentrations in COVID-19 patient plasma throughout the course of hospitalization.", [["plasma", "ANATOMY", 122, 128], ["patient", "ORGANISM", 114, 121], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["patient", "SPECIES", 114, 121], ["antigen concentrations", "TREATMENT", 79, 101], ["COVID", "TEST", 105, 110], ["plasma", "TREATMENT", 122, 128]]], ["We combined our Simoa SARS-CoV-2 antigen assays with previously developed Simoa serological assays to detect SARS-CoV-2 antigens and anti-SARS-CoV-2 immunoglobulins in longitudinal plasma samples of COVID-19 patients.", [["plasma samples", "ANATOMY", 181, 195], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 109, 128], ["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 133, 164], ["plasma samples", "ORGANISM_SUBSTANCE", 181, 195], ["patients", "ORGANISM", 208, 216], ["SARS-CoV-2 antigens", "PROTEIN", 109, 128], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 133, 164], ["patients", "SPECIES", 208, 216], ["SARS-CoV", "SPECIES", 109, 117], ["our Simoa SARS", "TEST", 12, 26], ["CoV-2 antigen assays", "TEST", 27, 47], ["Simoa serological assays", "TEST", 74, 98], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["antigens", "TEST", 120, 128], ["anti-SARS", "TEST", 133, 142], ["CoV", "TEST", 143, 146], ["immunoglobulins", "TREATMENT", 149, 164], ["longitudinal plasma samples", "TEST", 168, 195], ["COVID", "TEST", 199, 204]]], ["These measurements show inverse correlation between anti-SARS-CoV-2 40 antibody production and viral antigen clearance from plasma, which provides a unique view of viral infection and immune response from the beginning of hospitalization through recovery or death.", [["plasma", "ANATOMY", 124, 130], ["viral infection", "DISEASE", 164, 179], ["death", "DISEASE", 258, 263], ["anti-SARS-CoV-2 40", "GENE_OR_GENE_PRODUCT", 52, 70], ["plasma", "ORGANISM_SUBSTANCE", 124, 130], ["anti-SARS-CoV-2 40 antibody", "PROTEIN", 52, 79], ["These measurements", "TEST", 0, 18], ["anti-SARS", "TEST", 52, 61], ["CoV", "TEST", 62, 65], ["viral antigen clearance", "TEST", 95, 118], ["viral infection", "PROBLEM", 164, 179], ["immune response", "PROBLEM", 184, 199], ["death", "PROBLEM", 258, 263], ["viral infection", "OBSERVATION", 164, 179]]], ["In addition, we show that the presence of viral antigen in plasma correlates with disease severity in these COVID-19 patients.Results & DiscussionThe SARS-CoV-2 Simoa antigen assays detect S1, spike, and N antigens with limits of detection (LOD) of 5 pg/mL, 70 pg/mL, and 0.02 pg/mL, respectively.", [["plasma", "ANATOMY", 59, 65], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["patients", "ORGANISM", 117, 125], ["N antigens", "GENE_OR_GENE_PRODUCT", 204, 214], ["viral antigen", "PROTEIN", 42, 55], ["S1, spike, and N antigens", "PROTEIN", 189, 214], ["patients", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 150, 158], ["viral antigen", "PROBLEM", 42, 55], ["disease severity", "PROBLEM", 82, 98], ["these COVID", "TEST", 102, 113], ["The SARS", "TEST", 146, 154], ["CoV", "TEST", 155, 158], ["Simoa antigen assays", "TEST", 161, 181], ["spike", "TEST", 193, 198], ["LOD", "TEST", 241, 244], ["viral", "OBSERVATION", 42, 47]]], ["Three types of dye-encoded paramagnetic beads were functionalized with antibodies against each viral antigen and incubated 5 with plasma samples for multiplexed Simoa measurements (Fig. 1a ) as described previously.(8) Commercially available SARS-CoV-2 antibodies were used in combination with an anti-S1 antibody discovered via phage display (Supplemental Materials).", [["plasma samples", "ANATOMY", 130, 144], ["plasma samples", "ORGANISM_SUBSTANCE", 130, 144], ["antibodies", "PROTEIN", 71, 81], ["viral antigen", "PROTEIN", 95, 108], ["SARS-CoV-2 antibodies", "PROTEIN", 242, 263], ["anti-S1 antibody", "PROTEIN", 297, 313], ["dye-encoded paramagnetic beads", "TREATMENT", 15, 45], ["antibodies", "TREATMENT", 71, 81], ["each viral antigen", "TEST", 90, 108], ["plasma samples", "TEST", 130, 144], ["multiplexed Simoa measurements", "TEST", 149, 179], ["SARS", "TEST", 242, 246], ["CoV-2 antibodies", "TREATMENT", 247, 263], ["an anti-S1 antibody", "TEST", 294, 313], ["Supplemental Materials", "TREATMENT", 344, 366]]], ["All SARS-CoV-2 antigen assays were validated in commercial human plasma prior to analysis of clinical plasma samples ( Fig. S1 -S3, Table S3 ).", [["plasma", "ANATOMY", 65, 71], ["plasma samples", "ANATOMY", 102, 116], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 4, 22], ["human", "ORGANISM", 59, 64], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["plasma samples", "ORGANISM_SUBSTANCE", 102, 116], ["Table S3", "GENE_OR_GENE_PRODUCT", 132, 140], ["S1", "PROTEIN", 124, 126], ["human", "SPECIES", 59, 64], ["SARS-CoV", "SPECIES", 4, 12], ["human", "SPECIES", 59, 64], ["All SARS", "TEST", 0, 8], ["CoV-2 antigen assays", "TEST", 9, 29], ["clinical plasma samples", "TEST", 93, 116], ["S3", "ANATOMY", 128, 130], ["Table S3", "ANATOMY", 132, 140]]], ["In addition, we measured anti-SARS-CoV-2 immunoglobulins (total IgA, IgM, and 10 IgG) using our recently established SARS-CoV-2 serological assays (9) to correlate viral antigens with immunoglobulin levels (Fig. 1a) .", [["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 25, 56], ["IgA", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgM", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 81, 84], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 184, 198], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 25, 56], ["IgA", "PROTEIN", 64, 67], ["IgM", "PROTEIN", 69, 72], ["IgG", "PROTEIN", 81, 84], ["viral antigens", "PROTEIN", 164, 178], ["immunoglobulin", "PROTEIN", 184, 198], ["SARS-CoV", "SPECIES", 117, 125], ["anti-SARS", "TEST", 25, 34], ["CoV", "TEST", 35, 38], ["immunoglobulins", "TEST", 41, 56], ["total IgA", "TEST", 58, 67], ["IgM", "TEST", 69, 72], ["IgG", "TEST", 81, 84], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["serological assays", "TEST", 128, 146], ["viral antigens", "TEST", 164, 178], ["immunoglobulin levels", "TEST", 184, 205]]], ["Although total IgG levels correlate with seroconversion in COVID-19 patients, measurements of the IgG subclasses can reveal additional information on patient-specific immune responses.", [["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["patients", "ORGANISM", 68, 76], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["patient", "ORGANISM", 150, 157], ["IgG", "PROTEIN", 15, 18], ["IgG subclasses", "PROTEIN", 98, 112], ["patients", "SPECIES", 68, 76], ["patient", "SPECIES", 150, 157], ["total IgG levels", "TEST", 9, 25], ["seroconversion", "TEST", 41, 55], ["the IgG subclasses", "TEST", 94, 112]]], ["Therefore, we developed SARS-CoV-2 serological Simoa assays for IgG1, IgG2, IgG3, and IgG4 detection (Supplemental Materials Methods).", [["IgG1", "GENE_OR_GENE_PRODUCT", 64, 68], ["IgG2", "GENE_OR_GENE_PRODUCT", 70, 74], ["IgG3", "GENE_OR_GENE_PRODUCT", 76, 80], ["IgG4", "GENE_OR_GENE_PRODUCT", 86, 90], ["IgG1", "PROTEIN", 64, 68], ["IgG2", "PROTEIN", 70, 74], ["IgG3", "PROTEIN", 76, 80], ["IgG4", "PROTEIN", 86, 90], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["serological Simoa assays", "TEST", 35, 59], ["IgG1", "TEST", 64, 68], ["IgG2", "TEST", 70, 74], ["IgG3", "TEST", 76, 80], ["IgG4 detection", "TEST", 86, 100], ["Supplemental Materials Methods", "TREATMENT", 102, 132]]], ["The 15 combined measurements of three SARS-CoV-2 antigens and seven anti-SARS-CoV-2 immunoglobulin isotypes against four SARS-CoV-2 antigens enables quantification of 31 biomarkers from 70 \u00b5L of a plasma sample.Results & DiscussionTo probe for the presence of viral antigens in plasma, we tested samples from COVID-19 positive patients using our SARS-CoV-2 Simoa antigen assays for S1, spike, and N. These patients 20 were determined to be COVID-19 positive by NP RT-PCR and all plasma samples were obtained within the first ten days of the initial NP RT-PCR test.", [["plasma sample", "ANATOMY", 197, 210], ["plasma", "ANATOMY", 278, 284], ["samples", "ANATOMY", 296, 303], ["plasma samples", "ANATOMY", 479, 493], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 83], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 84, 98], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 121, 140], ["plasma", "ORGANISM_SUBSTANCE", 197, 203], ["plasma", "ORGANISM_SUBSTANCE", 278, 284], ["COVID-19", "CELL", 309, 317], ["patients", "ORGANISM", 327, 335], ["patients", "ORGANISM", 406, 414], ["plasma samples", "ORGANISM_SUBSTANCE", 479, 493], ["SARS-CoV-2 antigens", "PROTEIN", 38, 57], ["anti-SARS-CoV-2 immunoglobulin isotypes", "PROTEIN", 68, 107], ["SARS-CoV-2 antigens", "PROTEIN", 121, 140], ["viral antigens", "PROTEIN", 260, 274], ["patients", "SPECIES", 327, 335], ["patients", "SPECIES", 406, 414], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 121, 129], ["SARS-CoV", "SPECIES", 346, 354], ["three SARS", "TEST", 32, 42], ["CoV", "TEST", 43, 46], ["anti-SARS", "TEST", 68, 77], ["CoV", "TEST", 78, 81], ["immunoglobulin isotypes", "TEST", 84, 107], ["four SARS", "TEST", 116, 125], ["CoV", "TEST", 126, 129], ["biomarkers", "TEST", 170, 180], ["a plasma sample", "TEST", 195, 210], ["viral antigens in plasma", "PROBLEM", 260, 284], ["COVID", "TEST", 309, 314], ["our SARS", "TEST", 342, 350], ["CoV", "TEST", 351, 354], ["Simoa antigen assays", "TEST", 357, 377], ["S1", "PROBLEM", 382, 384], ["spike", "PROBLEM", 386, 391], ["COVID", "TEST", 440, 445], ["NP RT-PCR", "TEST", 461, 470], ["all plasma samples", "TEST", 475, 493], ["the initial NP RT", "TREATMENT", 537, 554], ["PCR test", "TEST", 555, 563]]], ["Both S1 and N were detected in 41 of 64 COVID-19 positive patients ( Fig. 1b and 1c ), who we identify as \"viral antigen positive.\"", [["S1", "GENE_OR_GENE_PRODUCT", 5, 7], ["patients", "ORGANISM", 58, 66], ["S1", "PROTEIN", 5, 7], ["patients", "SPECIES", 58, 66], ["Both S1 and N", "TEST", 0, 13], ["COVID", "TEST", 40, 45], ["Fig.", "TEST", 69, 73], ["viral antigen positive", "PROBLEM", 107, 129], ["S1", "ANATOMY", 5, 7]]], ["We observe S1 and N concentrations spanning four orders of magnitude in these plasma samples.", [["plasma samples", "ANATOMY", 78, 92], ["N", "CHEMICAL", 18, 19], ["plasma samples", "ORGANISM_SUBSTANCE", 78, 92], ["these plasma samples", "TEST", 72, 92], ["S1", "ANATOMY", 11, 13]]], ["Despite the presence of S1 and N in some samples, spike was only detectable in 5 of 64 COVID-25 19 positive patients (Fig. S4 ).", [["samples", "ANATOMY", 41, 48], ["S1", "GENE_OR_GENE_PRODUCT", 24, 26], ["samples", "CANCER", 41, 48], ["patients", "ORGANISM", 108, 116], ["S1", "PROTEIN", 24, 26], ["N", "PROTEIN", 31, 32], ["patients", "SPECIES", 108, 116], ["S1 and N in some samples", "PROBLEM", 24, 48], ["spike", "PROBLEM", 50, 55], ["COVID", "TEST", 87, 92], ["S1", "ANATOMY", 24, 26]]], ["Spike may be undetectable in some samples since the LOD is one order of magnitude higher than the LOD of the S1 assay.", [["samples", "ANATOMY", 34, 41], ["Spike", "PROBLEM", 0, 5], ["the LOD", "TEST", 48, 55], ["undetectable", "OBSERVATION_MODIFIER", 13, 25], ["S1", "ANATOMY", 109, 111]]], ["Additionally, in the Simoa assay for spike, the formation of a full immunocomplex depends on spike binding to the S2 subunit capture beads and the S1 subunit detection antibody.", [["S2 subunit", "PROTEIN", 114, 124], ["S1 subunit detection antibody", "PROTEIN", 147, 176], ["the Simoa assay", "TEST", 17, 32], ["spike", "PROBLEM", 37, 42], ["a full immunocomplex", "PROBLEM", 61, 81], ["spike binding", "PROBLEM", 93, 106], ["the S1 subunit detection antibody", "TEST", 143, 176]]], ["Therefore, we hypothesize that free spike antigen in plasma is likely proteolytically cleaved, releasing the S1 subunit, and the remaining spike protein 30 fragment is undetectable by our assay.Results & DiscussionCross-reactivity of the SARS-CoV-2 antigen assays was assessed using samples from three control patient cohorts: (1) samples from individuals who tested negative for COVID-19 by NP RT-PCR, (2) pre-pandemic plasma samples from healthy individuals with no recorded respiratory infection in their medical history at the time of collection, collected before October 1, 2019, and 35 (3) pre-pandemic samples collected from adults with a documented respiratory infection (including bacterial and viral pneumonia) within two months of collection, collected before October 1, 2019.", [["plasma", "ANATOMY", 53, 59], ["samples", "ANATOMY", 283, 290], ["samples", "ANATOMY", 331, 338], ["plasma samples", "ANATOMY", 420, 434], ["respiratory", "ANATOMY", 477, 488], ["samples", "ANATOMY", 609, 616], ["respiratory", "ANATOMY", 657, 668], ["SARS", "DISEASE", 238, 242], ["respiratory infection", "DISEASE", 477, 498], ["respiratory infection", "DISEASE", 657, 678], ["bacterial and viral pneumonia", "DISEASE", 690, 719], ["free spike antigen", "GENE_OR_GENE_PRODUCT", 31, 49], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["S1", "GENE_OR_GENE_PRODUCT", 109, 111], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 238, 256], ["patient", "ORGANISM", 310, 317], ["samples", "CANCER", 331, 338], ["individuals", "ORGANISM", 344, 355], ["plasma samples", "ORGANISM_SUBSTANCE", 420, 434], ["S1 subunit", "PROTEIN", 109, 119], ["spike protein 30 fragment", "PROTEIN", 139, 164], ["patient", "SPECIES", 310, 317], ["free spike antigen in plasma", "PROBLEM", 31, 59], ["the remaining spike protein 30 fragment", "PROBLEM", 125, 164], ["the SARS", "TEST", 234, 242], ["CoV-2 antigen assays", "TEST", 243, 263], ["COVID", "TEST", 380, 385], ["NP RT-PCR", "TEST", 392, 401], ["pre-pandemic plasma samples", "TEST", 407, 434], ["recorded respiratory infection", "PROBLEM", 468, 498], ["pre-pandemic samples", "TEST", 596, 616], ["a documented respiratory infection", "PROBLEM", 644, 678], ["bacterial and viral pneumonia", "PROBLEM", 690, 719], ["likely", "UNCERTAINTY", 63, 69], ["respiratory", "ANATOMY", 477, 488], ["infection", "OBSERVATION", 489, 498], ["respiratory", "ANATOMY", 657, 668], ["infection", "OBSERVATION", 669, 678], ["viral", "OBSERVATION_MODIFIER", 704, 709], ["pneumonia", "OBSERVATION", 710, 719]]], ["Viral antigen concentrations are plotted for each individual patient in Fig. S5 .", [["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 61, 68], ["S5", "GENE_OR_GENE_PRODUCT", 77, 79], ["S5", "PROTEIN", 77, 79], ["patient", "SPECIES", 61, 68], ["Viral antigen concentrations", "TEST", 0, 28]]], ["In the pre-pandemic sick cohort, either S1 or N were detected in 9 of 14 individuals, indicating cross reactivity with other viruses, whereas only one sample from this cohort had both detectable S1 and N levels.", [["cross reactivity", "PROBLEM", 97, 113], ["other viruses", "PROBLEM", 119, 132], ["this cohort", "TEST", 163, 174], ["S1", "ANATOMY", 40, 42], ["cross reactivity", "OBSERVATION_MODIFIER", 97, 113], ["viruses", "OBSERVATION", 125, 132]]], ["Only 40 1 of 20 individuals from the pre-pandemic healthy cohort had detectable levels of both S1 and N. In COVID-19 negative patients, S1 or N was detectable in 6 of 18 individuals.", [["individuals", "ORGANISM", 16, 27], ["patients", "ORGANISM", 126, 134], ["S1", "GENE_OR_GENE_PRODUCT", 136, 138], ["S1", "PROTEIN", 136, 138], ["patients", "SPECIES", 126, 134], ["COVID", "TEST", 108, 113], ["S1", "ANATOMY", 95, 97]]], ["However, analytical specificity was improved when assessing both S1 and N, resulting in only 1 of 18 COVID-19 negative patients with detectable levels of both viral antigens.", [["patients", "ORGANISM", 119, 127], ["S1", "PROTEIN", 65, 67], ["viral antigens", "PROTEIN", 159, 173], ["patients", "SPECIES", 119, 127], ["analytical specificity", "TEST", 9, 31], ["COVID", "TEST", 101, 106], ["detectable levels of both viral antigens", "PROBLEM", 133, 173], ["viral antigens", "OBSERVATION", 159, 173]]], ["We attribute detection of viral antigens in COVID-19 negative patients to either (1) assay cross-reactivity with other 4 received a false negative result.(10) Currently, only two SARS-CoV-2 antigen tests are approved by the FDA and these tests qualitatively detect N antigen in NP swab samples.", [["swab samples", "ANATOMY", 281, 293], ["patients", "ORGANISM", 62, 70], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 179, 197], ["N antigen", "GENE_OR_GENE_PRODUCT", 265, 274], ["viral antigens", "PROTEIN", 26, 40], ["N antigen", "PROTEIN", 265, 274], ["patients", "SPECIES", 62, 70], ["viral antigens", "PROBLEM", 26, 40], ["COVID", "TEST", 44, 49], ["assay cross-reactivity", "TEST", 85, 107], ["CoV-2 antigen tests", "TEST", 184, 203], ["these tests", "TEST", 232, 243], ["NP swab samples", "TEST", 278, 293], ["viral", "OBSERVATION_MODIFIER", 26, 31]]], ["However, the FDA cautions that a positive result does not rule out infection with other viruses, due to cross-reactivity with other coronaviruses.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["other viruses", "PROBLEM", 82, 95], ["other coronaviruses", "PROBLEM", 126, 145], ["infection", "OBSERVATION", 67, 76]]], ["Based on our preliminary results, a multiplexed approach for the detection of S1 and N protein may enhance analytical specificity of these antigen tests.", [["S1", "GENE_OR_GENE_PRODUCT", 78, 80], ["S1", "PROTEIN", 78, 80], ["N protein", "PROTEIN", 85, 94], ["a multiplexed approach", "TEST", 34, 56], ["the detection of S1 and N protein", "TEST", 61, 94], ["these antigen tests", "TEST", 133, 152]]], ["5 The presence of SARS-CoV-2 antigens in plasma can provide unique insight into disease progression in patients.", [["plasma", "ANATOMY", 41, 47], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 18, 37], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["patients", "ORGANISM", 103, 111], ["SARS-CoV-2 antigens", "PROTEIN", 18, 37], ["patients", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["SARS", "OBSERVATION", 18, 22]]], ["However, it remains unclear why only a subset of patients shows detectable levels of antigen in plasma.", [["plasma", "ANATOMY", 96, 102], ["patients", "ORGANISM", 49, 57], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["patients", "SPECIES", 49, 57], ["detectable levels of antigen in plasma", "PROBLEM", 64, 102]]], ["To address this question, we tested the same set of samples using the SARS-CoV-2 serological Simoa assays for IgA, IgM, and IgG to examine correlations between antigen and immunoglobulin levels.", [["samples", "ANATOMY", 52, 59], ["IgA", "GENE_OR_GENE_PRODUCT", 110, 113], ["IgM", "GENE_OR_GENE_PRODUCT", 115, 118], ["IgG", "GENE_OR_GENE_PRODUCT", 124, 127], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 172, 186], ["IgA", "PROTEIN", 110, 113], ["IgM", "PROTEIN", 115, 118], ["IgG", "PROTEIN", 124, 127], ["immunoglobulin", "PROTEIN", 172, 186], ["SARS-CoV", "SPECIES", 70, 78], ["the SARS", "TEST", 66, 74], ["CoV", "TEST", 75, 78], ["serological Simoa assays", "TEST", 81, 105], ["IgA", "TEST", 110, 113], ["IgM", "TEST", 115, 118], ["IgG", "TEST", 124, 127], ["antigen", "TEST", 160, 167], ["immunoglobulin levels", "TEST", 172, 193]]], ["For COVID-19 positive patients, immunoglobulin levels vary 10 by four orders of magnitude (Fig. S6) .", [["COVID-19", "GENE_OR_GENE_PRODUCT", 4, 12], ["patients", "ORGANISM", 22, 30], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 32, 46], ["immunoglobulin", "PROTEIN", 32, 46], ["S6", "PROTEIN", 96, 98], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 4, 9], ["immunoglobulin levels", "TEST", 32, 53]]], ["(9) We observe an inverse correlation when comparing immunoglobulin levels and antigen levels for each COVID-19 positive patient (Fig. 1d) .", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 53, 67], ["patient", "ORGANISM", 121, 128], ["immunoglobulin", "PROTEIN", 53, 67], ["patient", "SPECIES", 121, 128], ["immunoglobulin levels", "TEST", 53, 74], ["antigen levels", "TEST", 79, 93], ["each COVID", "TEST", 98, 108]]], ["Corresponding N levels for each individual patient are plotted in Fig. S7 .", [["patient", "ORGANISM", 43, 50], ["S7", "GENE_OR_GENE_PRODUCT", 71, 73], ["S7", "PROTEIN", 71, 73], ["patient", "SPECIES", 43, 50], ["Corresponding N levels", "TEST", 0, 22]]], ["In several patients with S1 levels below the limit of detection, immunoglobulin levels are high.", [["patients", "ORGANISM", 11, 19], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 65, 79], ["immunoglobulin", "PROTEIN", 65, 79], ["patients", "SPECIES", 11, 19], ["S1 levels", "TEST", 25, 34], ["immunoglobulin levels", "TEST", 65, 86]]], ["Patients with high S1 levels typically have IgG levels below the seroconversion threshold.", [["Patients", "ORGANISM", 0, 8], ["IgG", "GENE_OR_GENE_PRODUCT", 44, 47], ["IgG", "PROTEIN", 44, 47], ["Patients", "SPECIES", 0, 8], ["high S1 levels", "PROBLEM", 14, 28], ["IgG levels", "TEST", 44, 54], ["the seroconversion threshold", "TEST", 61, 89]]], ["However, some patients show 15 detectable levels of both S1 and IgG, whereas other patients show no detectable S1 or IgG.", [["patients", "ORGANISM", 14, 22], ["S1", "GENE_OR_GENE_PRODUCT", 57, 59], ["IgG", "GENE_OR_GENE_PRODUCT", 64, 67], ["patients", "ORGANISM", 83, 91], ["S1", "GENE_OR_GENE_PRODUCT", 111, 113], ["IgG", "GENE_OR_GENE_PRODUCT", 117, 120], ["S1", "PROTEIN", 57, 59], ["IgG", "PROTEIN", 64, 67], ["S1", "PROTEIN", 111, 113], ["IgG", "PROTEIN", 117, 120], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 83, 91], ["IgG", "TEST", 64, 67], ["detectable S1 or IgG", "PROBLEM", 100, 120], ["both", "ANATOMY_MODIFIER", 52, 56], ["S1", "ANATOMY", 57, 59], ["no", "UNCERTAINTY", 97, 99], ["IgG", "OBSERVATION", 117, 120]]], ["These data highlight the diverse viral and immune responses present among COVID-19 patients.Results & Discussion.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["These data", "TEST", 0, 10], ["the diverse viral and immune responses", "PROBLEM", 21, 59], ["diverse", "OBSERVATION_MODIFIER", 25, 32], ["viral", "OBSERVATION", 33, 38]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 326, 342], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure 1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["SARS-CoV-2 Antigen and anti-SARS-CoV-2 Immunoglobulin Detection in Plasma. a.)", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["anti-SARS-CoV-2 Immunoglobulin", "GENE_OR_GENE_PRODUCT", 23, 53], ["anti-SARS", "PROTEIN", 23, 32], ["Immunoglobulin", "PROTEIN", 39, 53], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["Antigen", "TEST", 11, 18], ["anti-SARS", "TEST", 23, 32], ["CoV", "TEST", 33, 36]]], ["Schematic of Simoa detection of SARS-CoV-2 S1, spike, and N antigens and anti-SARS-CoV-2 immunoglobulins IgG, IgA, and IgM.", [["SARS", "DISEASE", 32, 36], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 32, 45], ["N antigens", "GENE_OR_GENE_PRODUCT", 58, 68], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 73, 88], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgA", "GENE_OR_GENE_PRODUCT", 110, 113], ["IgM.", "SIMPLE_CHEMICAL", 119, 123], ["SARS-CoV-2 S1, spike, and N antigens", "PROTEIN", 32, 68], ["anti-SARS", "PROTEIN", 73, 82], ["CoV-2 immunoglobulins IgG", "PROTEIN", 83, 108], ["IgA", "PROTEIN", 110, 113], ["IgM.", "PROTEIN", 119, 123], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["spike", "PROBLEM", 47, 52], ["N antigens", "TEST", 58, 68], ["anti-SARS", "TEST", 73, 82], ["CoV", "TEST", 83, 86], ["immunoglobulins IgG", "TEST", 89, 108], ["IgA", "TEST", 110, 113]]], ["Measurements for all antigens and immunoglobulins can be obtained from a single plasma sample (70 \u00b5L). b-c) Simoa SARS-CoV-2 antigen assay results for plasma samples collected from pre-pandemic healthy patients, pre-pandemic sick patients, COVID-19 negative patients, 5 and COVID-19 positive patients.", [["plasma sample", "ANATOMY", 80, 93], ["plasma samples", "ANATOMY", 151, 165], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 34, 49], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["b-c", "GENE_OR_GENE_PRODUCT", 103, 106], ["CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 119, 132], ["plasma samples", "ORGANISM_SUBSTANCE", 151, 165], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 230, 238], ["patients", "ORGANISM", 258, 266], ["5", "ORGANISM", 268, 269], ["patients", "ORGANISM", 292, 300], ["antigens", "PROTEIN", 21, 29], ["immunoglobulins", "PROTEIN", 34, 49], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 258, 266], ["patients", "SPECIES", 292, 300], ["all antigens", "TEST", 17, 29], ["immunoglobulins", "TEST", 34, 49], ["a single plasma sample", "TEST", 71, 93], ["Simoa SARS", "TEST", 108, 118], ["CoV-2 antigen assay", "TEST", 119, 138], ["plasma samples", "TEST", 151, 165], ["COVID", "TEST", 240, 245], ["COVID", "TEST", 274, 279]]], ["41 of 64 COVID-19 positive patients show detectable b.)", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["COVID", "TEST", 9, 14]]], ["S1 and c.)", [["S1", "PROTEIN", 0, 2]]], ["N levels in plasma.", [["plasma", "ANATOMY", 12, 18], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["N levels in plasma", "TEST", 0, 18]]], ["Top: S1 levels plotted for individual COVID-19 positive patients, data points represent the average concentration values from two replicate measurements.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["S1 levels", "TEST", 5, 14], ["individual COVID", "TEST", 27, 43], ["S1", "ANATOMY", 5, 7]]], ["Dotted lines represent the LOD for S1 assay (5 pg/mL).", [["Dotted lines", "CELL", 0, 12], ["S1 assay", "TREATMENT", 35, 43]]], ["Bottom: IgG against S1 levels plotted for individual COVID-19 positive patients, data points represent average AEB 10 (average enzyme per bead) value from two replicate measurements.", [["IgG", "GENE_OR_GENE_PRODUCT", 8, 11], ["S1", "GENE_OR_GENE_PRODUCT", 20, 22], ["patients", "ORGANISM", 71, 79], ["IgG", "PROTEIN", 8, 11], ["S1", "PROTEIN", 20, 22], ["patients", "SPECIES", 71, 79], ["IgG", "TEST", 8, 11], ["S1 levels", "TEST", 20, 29], ["individual COVID", "TEST", 42, 58], ["AEB", "TEST", 111, 114], ["IgG", "OBSERVATION", 8, 11]]], ["Dotted line represents threshold (AEB >0.1) based on a cut off value that yielded 100% specificity compared to pre-pandemic healthy sample cohort (Fig. S6 ).", [["AEB", "TEST", 34, 37], ["a cut off value", "TEST", 53, 68]]], ["Patient IDs labeled 1-64.(which was not certified by peer review)To understand how antigen and immunoglobulin levels change with time after infection, 15 we performed longitudinal studies in COVID-19 positive patients to monitor viral antigen and immunoglobulin levels during the course of hospitalization.", [["infection", "DISEASE", 140, 149], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 95, 109], ["COVID-19", "CELL", 191, 199], ["patients", "ORGANISM", 209, 217], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 247, 261], ["immunoglobulin", "PROTEIN", 95, 109], ["viral antigen", "PROTEIN", 229, 242], ["immunoglobulin", "PROTEIN", 247, 261], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 209, 217], ["immunoglobulin levels", "TEST", 95, 116], ["infection", "PROBLEM", 140, 149], ["longitudinal studies", "TEST", 167, 187], ["COVID", "TEST", 191, 196], ["viral antigen", "TEST", 229, 242], ["immunoglobulin levels", "TEST", 247, 268]]], ["This can be informative because COVID-19 patients present to the hospital at various stages of disease and show diverse progression patterns.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["disease", "PROBLEM", 95, 102], ["diverse progression patterns", "PROBLEM", 112, 140], ["disease", "OBSERVATION", 95, 102], ["diverse", "OBSERVATION_MODIFIER", 112, 119], ["progression", "OBSERVATION_MODIFIER", 120, 131]]], ["We measured viral antigen levels (S1, spike, and N) and immunoglobulin levels (total IgA, IgM, and IgG and IgG1-4) in serial plasma samples from 39 admitted patients at 20 Brigham and Women's Hospital and Massachusetts General Hospital (patient IDs 1-39).", [["plasma samples", "ANATOMY", 125, 139], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 56, 70], ["IgA", "GENE_OR_GENE_PRODUCT", 85, 88], ["IgM", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgG", "GENE_OR_GENE_PRODUCT", 99, 102], ["IgG1-4", "GENE_OR_GENE_PRODUCT", 107, 113], ["plasma samples", "ORGANISM_SUBSTANCE", 125, 139], ["patients", "ORGANISM", 157, 165], ["patient", "ORGANISM", 237, 244], ["S1", "PROTEIN", 34, 36], ["immunoglobulin", "PROTEIN", 56, 70], ["IgA", "PROTEIN", 85, 88], ["IgM", "PROTEIN", 90, 93], ["IgG", "PROTEIN", 99, 102], ["IgG1", "PROTEIN", 107, 111], ["patients", "SPECIES", 157, 165], ["Women", "SPECIES", 184, 189], ["patient", "SPECIES", 237, 244], ["viral antigen levels", "TEST", 12, 32], ["spike", "TEST", 38, 43], ["immunoglobulin levels", "TEST", 56, 77], ["total IgA", "TEST", 79, 88], ["IgM", "TEST", 90, 93], ["IgG", "TEST", 99, 102], ["IgG1", "TEST", 107, 111], ["serial plasma samples", "TEST", 118, 139]]], ["All patients were diagnosed as COVID-19 positive by NP RT-PCR and serial plasma samples were collected between 0 and 30 days after the first positive NP RT-PCR test during hospitalization.", [["plasma samples", "ANATOMY", 73, 87], ["patients", "ORGANISM", 4, 12], ["plasma samples", "ORGANISM_SUBSTANCE", 73, 87], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 31, 36], ["PCR", "TEST", 58, 61], ["serial plasma samples", "TEST", 66, 87], ["PCR test", "TEST", 156, 164]]], ["SARS-CoV-2 antigen and serological Simoa results for 31 biomarkers from all longitudinal samples are presented in Fig. S8 .", [["samples", "ANATOMY", 89, 96], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 0, 18], ["S8", "GENE_OR_GENE_PRODUCT", 119, 121], ["SARS-CoV-2 antigen", "PROTEIN", 0, 18], ["S8", "PROTEIN", 119, 121], ["SARS-CoV-2 antigen", "TEST", 0, 18], ["serological Simoa", "TEST", 23, 40], ["31 biomarkers", "TEST", 53, 66], ["all longitudinal samples", "TEST", 72, 96]]], ["Longitudinal antigen and immunoglobulin levels for four 25 representative patients are plotted in Fig. 2 ; plots for the remaining 35 patients are shown in the Supplemental Materials.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 25, 39], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 134, 142], ["immunoglobulin", "PROTEIN", 25, 39], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 134, 142], ["Longitudinal antigen", "TEST", 0, 20], ["immunoglobulin levels", "TEST", 25, 46]]], ["For each patient, we plot: (1) the total IgA, IgM, and IgG levels against four viral antigens: N, receptor binding domain (RBD), S1, and spike, for a total of 12 interactions, (2) N antigen levels with IgA, IgM, and IgG against N, (3) S1 antigen levels with IgA, IgM, and IgG against S1, and (4) S1 antigen levels with IgG1-4 against S1.", [["patient", "ORGANISM", 9, 16], ["IgA", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgM", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgG", "GENE_OR_GENE_PRODUCT", 55, 58], ["S1", "GENE_OR_GENE_PRODUCT", 129, 131], ["N antigen", "GENE_OR_GENE_PRODUCT", 180, 189], ["IgA", "GENE_OR_GENE_PRODUCT", 202, 205], ["IgM", "GENE_OR_GENE_PRODUCT", 207, 210], ["IgG against N, (3) S1 antigen", "GENE_OR_GENE_PRODUCT", 216, 245], ["IgA", "GENE_OR_GENE_PRODUCT", 258, 261], ["IgM", "GENE_OR_GENE_PRODUCT", 263, 266], ["IgG", "GENE_OR_GENE_PRODUCT", 272, 275], ["S1 antigen", "GENE_OR_GENE_PRODUCT", 296, 306], ["IgG1-4", "GENE_OR_GENE_PRODUCT", 319, 325], ["S1", "GENE_OR_GENE_PRODUCT", 334, 336], ["IgA", "PROTEIN", 41, 44], ["IgM", "PROTEIN", 46, 49], ["IgG", "PROTEIN", 55, 58], ["viral antigens", "PROTEIN", 79, 93], ["N, receptor binding domain", "PROTEIN", 95, 121], ["RBD", "PROTEIN", 123, 126], ["S1", "PROTEIN", 129, 131], ["IgA", "PROTEIN", 202, 205], ["IgM", "PROTEIN", 207, 210], ["IgG", "PROTEIN", 216, 219], ["IgA", "PROTEIN", 258, 261], ["IgM", "PROTEIN", 263, 266], ["IgG", "PROTEIN", 272, 275], ["S1", "PROTEIN", 284, 286], ["IgG1", "PROTEIN", 319, 323], ["S1", "PROTEIN", 334, 336], ["patient", "SPECIES", 9, 16], ["the total IgA", "TEST", 31, 44], ["IgM", "TEST", 46, 49], ["IgG levels", "TEST", 55, 65], ["four viral antigens", "TEST", 74, 93], ["receptor binding domain", "TEST", 98, 121], ["spike", "PROBLEM", 137, 142], ["N antigen levels", "TEST", 180, 196], ["IgA", "TEST", 202, 205], ["IgM", "TEST", 207, 210], ["IgG", "TEST", 216, 219], ["S1 antigen levels", "TEST", 235, 252], ["IgA", "TEST", 258, 261], ["IgM", "TEST", 263, 266], ["IgG", "TEST", 272, 275], ["S1 antigen levels", "TEST", 296, 313], ["IgG1", "TEST", 319, 323], ["S1", "ANATOMY", 129, 131]]], ["In this patient cohort, 25 of 39 30 patients had detectable levels of both S1 and N antigen in their plasma, whereas only 6 of 39 patients had detectable levels of spike in their plasma during their hospitalization.", [["plasma", "ANATOMY", 101, 107], ["plasma", "ANATOMY", 179, 185], ["patient", "ORGANISM", 8, 15], ["patients", "ORGANISM", 36, 44], ["N antigen", "GENE_OR_GENE_PRODUCT", 82, 91], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["patients", "ORGANISM", 130, 138], ["plasma", "ORGANISM_SUBSTANCE", 179, 185], ["S1", "PROTEIN", 75, 77], ["N antigen", "PROTEIN", 82, 91], ["patient", "SPECIES", 8, 15], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 130, 138], ["detectable levels of both S1 and N antigen", "PROBLEM", 49, 91], ["their plasma", "TEST", 95, 107], ["detectable levels of spike", "PROBLEM", 143, 169], ["S1", "ANATOMY", 75, 77]]], ["(1) the total IgA, IgM, and IgG levels against four viral antigens: nucleocapsid (N), receptor binding domain (RBD), S1, and spike, for a total of 12 interactions, (2) N antigen levels with IgA, IgM, and IgG against N, (3) S1 5 antigen levels with IgA, IgM, and IgG against S1, and (4) S1 antigen levels with IgG1-4 against S1.", [["IgA", "GENE_OR_GENE_PRODUCT", 14, 17], ["IgM", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["nucleocapsid (N), receptor binding domain", "GENE_OR_GENE_PRODUCT", 68, 109], ["S1", "GENE_OR_GENE_PRODUCT", 117, 119], ["N antigen", "GENE_OR_GENE_PRODUCT", 168, 177], ["IgA", "GENE_OR_GENE_PRODUCT", 190, 193], ["IgM", "GENE_OR_GENE_PRODUCT", 195, 198], ["IgG against N, (3) S1 5 antigen", "GENE_OR_GENE_PRODUCT", 204, 235], ["IgA", "GENE_OR_GENE_PRODUCT", 248, 251], ["IgM", "GENE_OR_GENE_PRODUCT", 253, 256], ["IgG", "GENE_OR_GENE_PRODUCT", 262, 265], ["S1 antigen", "GENE_OR_GENE_PRODUCT", 286, 296], ["IgG1-4", "GENE_OR_GENE_PRODUCT", 309, 315], ["S1", "GENE_OR_GENE_PRODUCT", 324, 326], ["IgA", "PROTEIN", 14, 17], ["IgM", "PROTEIN", 19, 22], ["IgG", "PROTEIN", 28, 31], ["viral antigens", "PROTEIN", 52, 66], ["nucleocapsid (N)", "PROTEIN", 68, 84], ["receptor binding domain", "PROTEIN", 86, 109], ["RBD", "PROTEIN", 111, 114], ["S1", "PROTEIN", 117, 119], ["IgA", "PROTEIN", 190, 193], ["IgM", "PROTEIN", 195, 198], ["IgG", "PROTEIN", 204, 207], ["IgA", "PROTEIN", 248, 251], ["IgM", "PROTEIN", 253, 256], ["IgG", "PROTEIN", 262, 265], ["S1", "PROTEIN", 274, 276], ["IgG1", "PROTEIN", 309, 313], ["S1", "PROTEIN", 324, 326], ["the total IgA", "TEST", 4, 17], ["IgM", "TEST", 19, 22], ["IgG levels", "TEST", 28, 38], ["four viral antigens", "TEST", 47, 66], ["receptor binding domain (RBD)", "PROBLEM", 86, 115], ["spike", "PROBLEM", 125, 130], ["N antigen levels", "TEST", 168, 184], ["IgA", "TEST", 190, 193], ["IgM", "TEST", 195, 198], ["IgG", "TEST", 204, 207], ["S1 5 antigen levels", "TEST", 223, 242], ["IgA", "TEST", 248, 251], ["IgM", "TEST", 253, 256], ["IgG", "TEST", 262, 265], ["S1 antigen levels", "TEST", 286, 303], ["IgG1", "TEST", 309, 313], ["S1", "ANATOMY", 117, 119]]], ["10 The ultra-sensitivity of Simoa assays provides quantitative resolution of viral antigen and antibody levels for a detailed view of patient responses over time.", [["patient", "ORGANISM", 134, 141], ["viral antigen", "PROTEIN", 77, 90], ["patient", "SPECIES", 134, 141], ["The ultra-sensitivity of Simoa assays", "TEST", 3, 40], ["viral antigen", "TEST", 77, 90], ["antibody levels", "TEST", 95, 110]]], ["For example, in Fig. 2 , Patient 21 originally had high concentrations of N (1,240 pg/mL) and S1 (75.3 pg/mL) and low concentrations of anti-SARS-CoV-2 immunoglobulins in their plasma on Day 0.", [["plasma", "ANATOMY", 177, 183], ["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 136, 167], ["plasma", "ORGANISM_SUBSTANCE", 177, 183], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 136, 167], ["Patient", "SPECIES", 25, 32], ["anti-SARS", "TEST", 136, 145], ["CoV", "TEST", 146, 149], ["immunoglobulins", "TREATMENT", 152, 167]]], ["As patient 21 mounted an antibody response against the virus, indicated by the increase in immunoglobulin 15 levels over time, we observe a decrease in viral antigen levels in plasma.", [["plasma", "ANATOMY", 176, 182], ["patient", "ORGANISM", 3, 10], ["immunoglobulin 15", "GENE_OR_GENE_PRODUCT", 91, 108], ["plasma", "ORGANISM_SUBSTANCE", 176, 182], ["immunoglobulin 15", "PROTEIN", 91, 108], ["viral antigen", "PROTEIN", 152, 165], ["patient", "SPECIES", 3, 10], ["the virus", "PROBLEM", 51, 60], ["the increase in immunoglobulin 15 levels", "PROBLEM", 75, 115], ["a decrease in viral antigen levels in plasma", "PROBLEM", 138, 182], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["decrease", "OBSERVATION_MODIFIER", 140, 148], ["viral antigen", "OBSERVATION", 152, 165]]], ["The ultra-sensitivity of these SARS-CoV-2 Simoa assays enables us to measure even the earliest stages of seroconversion.", [["these SARS", "TEST", 25, 35], ["CoV", "TEST", 36, 39], ["seroconversion", "PROBLEM", 105, 119], ["seroconversion", "OBSERVATION", 105, 119]]], ["Seroconversion was determined as previously described (See Methods for description) (9) .", [["Seroconversion", "TREATMENT", 0, 14]]], ["This trend is observed for a majority of viral-antigen positive patients (Patient 21, 22, and 26 in Fig. 2 and Patients in Figs.", [["patients", "ORGANISM", 64, 72], ["Patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 64, 72], ["Patient", "SPECIES", 74, 81], ["Patients", "SPECIES", 111, 119]]], ["S10, S12-14, S19-20, S23, S26, S31, S34, S36).", [["S19", "GENE_OR_GENE_PRODUCT", 13, 16], ["S23", "GENE_OR_GENE_PRODUCT", 21, 24], ["S12", "PROTEIN", 5, 8], ["S36", "PROTEIN", 41, 44], ["S12", "OBSERVATION_MODIFIER", 5, 8]]], ["As shown in Fig. 2 , among 20 Patients 21, 22, and 26, once a patient has seroconverted and their plasma immunoglobulin levels reach a steady state, there are typically no detectable levels of viral antigen.", [["plasma", "ANATOMY", 98, 104], ["Patients", "ORGANISM", 30, 38], ["patient", "ORGANISM", 62, 69], ["plasma", "ORGANISM_SUBSTANCE", 98, 104], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 105, 119], ["viral antigen", "GENE_OR_GENE_PRODUCT", 193, 206], ["immunoglobulin", "PROTEIN", 105, 119], ["viral antigen", "PROTEIN", 193, 206], ["Patients", "SPECIES", 30, 38], ["patient", "SPECIES", 62, 69], ["seroconverted", "PROBLEM", 74, 87], ["their plasma immunoglobulin levels", "TEST", 92, 126], ["detectable levels of viral antigen", "PROBLEM", 172, 206], ["viral antigen", "OBSERVATION", 193, 206]]], ["All patients seroconvert an average of 7 \u00b1 1 days (95% CI) after the first NP RT-PCR positive test, in agreement with previous serological studies.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the first NP RT-PCR", "TEST", 65, 84], ["previous serological studies", "TEST", 118, 146]]], ["(11) (12) (13) (14) We defined viral antigen clearance as the first day that both S1 and N were undetectable in patient's plasma.", [["plasma", "ANATOMY", 122, 128], ["(11) (12) (13) (14)", "SIMPLE_CHEMICAL", 0, 19], ["patient", "ORGANISM", 112, 119], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["patient", "SPECIES", 112, 119], ["viral antigen clearance", "TEST", 31, 54], ["patient's plasma", "TEST", 112, 128]]], ["For viral antigen positive patients, full 25 antigen clearance in plasma is observed 5 \u00b1 1 days (95% CI) after seroconversion.(which was not certified by peer review).", [["plasma", "ANATOMY", 66, 72], ["patients", "ORGANISM", 27, 35], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["patients", "SPECIES", 27, 35], ["viral antigen", "TEST", 4, 17], ["seroconversion", "PROBLEM", 111, 125]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Furthermore, we observe a subset of patients with no detectable viral antigen levels in their plasma throughout their hospitalization.", [["plasma", "ANATOMY", 478, 484], ["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 420, 428], ["plasma", "ORGANISM_SUBSTANCE", 478, 484], ["viral antigen", "PROTEIN", 448, 461], ["patients", "SPECIES", 420, 428], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["detectable viral antigen levels", "PROBLEM", 437, 468], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Notably, 13 of 15 patients with undetectable viral antigen levels in plasma were already seroconverted at their first NP RT-PCR test.", [["plasma", "ANATOMY", 69, 75], ["patients", "ORGANISM", 18, 26], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["patients", "SPECIES", 18, 26], ["undetectable viral antigen levels in plasma", "PROBLEM", 32, 75], ["PCR test", "TEST", 124, 132]]], ["For example, Patient 39 in Fig. 2 showed no detectable N or S1 in plasma over ten days during hospitalization.", [["plasma", "ANATOMY", 66, 72], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["Patient", "SPECIES", 13, 20], ["detectable N or S1 in plasma", "PROBLEM", 44, 72], ["no", "UNCERTAINTY", 41, 43], ["detectable", "OBSERVATION_MODIFIER", 44, 54], ["S1", "ANATOMY", 60, 62]]], ["Patient 39 had already seroconverted when the first plasma sample was collected, an observation 5 consistent for a majority of viral antigen negative patients (Fig. S11 , S15-17, S18, S24,S27-28, S30-33, S35, S7-44).We propose three possibilities for the lack of detectable antigen in some patient plasma: (1) patients are presenting to the hospital after seroconversion, and therefore most viral antigens have been cleared from the plasma, (2) patients do not progress to more severe forms of the disease and therefore do not have viral antigen leakage into the blood, or (3) viral antigens are present but are bound to an immunoglobulin and the immunoglobulin blocks a binding epitope of the capture or detection antibody, resulting in an antigen-immunoglobulin complex that is undetectable by our Simoa assays.", [["plasma sample", "ANATOMY", 52, 65], ["plasma", "ANATOMY", 298, 304], ["plasma", "ANATOMY", 433, 439], ["blood", "ANATOMY", 563, 568], ["plasma", "ORGANISM_SUBSTANCE", 52, 58], ["patients", "ORGANISM", 150, 158], ["S15", "GENE_OR_GENE_PRODUCT", 171, 174], ["S18", "GENE_OR_GENE_PRODUCT", 179, 182], ["S24", "GENE_OR_GENE_PRODUCT", 184, 187], ["patient", "ORGANISM", 290, 297], ["plasma", "ORGANISM_SUBSTANCE", 298, 304], ["patients", "ORGANISM", 310, 318], ["plasma", "ORGANISM_SUBSTANCE", 433, 439], ["patients", "ORGANISM", 445, 453], ["blood", "ORGANISM_SUBSTANCE", 563, 568], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 624, 638], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 647, 661], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 749, 763], ["S15", "PROTEIN", 171, 174], ["S30", "PROTEIN", 196, 199], ["S7", "PROTEIN", 209, 211], ["viral antigens", "PROTEIN", 391, 405], ["viral antigens", "PROTEIN", 577, 591], ["immunoglobulin", "PROTEIN", 624, 638], ["immunoglobulin", "PROTEIN", 647, 661], ["binding epitope", "PROTEIN", 671, 686], ["detection antibody", "PROTEIN", 705, 723], ["immunoglobulin complex", "PROTEIN", 749, 771], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 150, 158], ["patient", "SPECIES", 290, 297], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 445, 453], ["the first plasma sample", "TEST", 42, 65], ["an observation", "TEST", 81, 95], ["viral antigen", "TEST", 127, 140], ["S15", "TEST", 171, 174], ["S27", "TEST", 188, 191], ["S30", "TEST", 196, 199], ["detectable antigen", "PROBLEM", 263, 281], ["seroconversion", "TREATMENT", 356, 370], ["most viral antigens", "PROBLEM", 386, 405], ["the disease", "PROBLEM", 494, 505], ["viral antigen leakage into the blood", "PROBLEM", 532, 568], ["viral antigens", "PROBLEM", 577, 591], ["an immunoglobulin", "TEST", 621, 638], ["the immunoglobulin blocks", "TREATMENT", 643, 668], ["detection antibody", "TEST", 705, 723], ["an antigen", "TEST", 738, 748], ["immunoglobulin complex", "PROBLEM", 749, 771], ["disease", "OBSERVATION", 498, 505], ["blood", "ANATOMY", 563, 568]]], ["However, even with no detectable levels of viral antigen, 12 of 16 patients were admitted or transferred to the ICU during hospitalization and intubated, indicating that these patients were severe cases.", [["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 176, 184], ["viral antigen", "PROTEIN", 43, 56], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 176, 184], ["detectable levels of viral antigen", "PROBLEM", 22, 56], ["intubated", "TREATMENT", 143, 152], ["severe cases", "PROBLEM", 190, 202]]], ["Therefore, we propose a third possibility where patients have 15 seroconverted and despite reaching viral clearance, suffer from severe respiratory damage that inhibits recovery.(which was not certified by peer review)To further analyze the 31 biomarkers measured in these longitudinal samples, we performed a cluster map analysis to determine if antigen and immunoglobulin levels in COVID-19 positive patients could differentiate different stages of infection.", [["respiratory", "ANATOMY", 136, 147], ["samples", "ANATOMY", 286, 293], ["respiratory damage", "DISEASE", 136, 154], ["infection", "DISEASE", 451, 460], ["patients", "ORGANISM", 48, 56], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 359, 373], ["patients", "ORGANISM", 402, 410], ["immunoglobulin", "PROTEIN", 359, 373], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 402, 410], ["severe respiratory damage", "PROBLEM", 129, 154], ["the 31 biomarkers", "TEST", 237, 254], ["a cluster map analysis", "TEST", 308, 330], ["antigen", "TEST", 347, 354], ["immunoglobulin levels", "TEST", 359, 380], ["COVID", "TEST", 384, 389], ["infection", "PROBLEM", 451, 460], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["respiratory damage", "OBSERVATION", 136, 154], ["different stages", "OBSERVATION_MODIFIER", 431, 447], ["infection", "OBSERVATION", 451, 460]]], ["We used a Ward variance 20 minimization algorithm (Supplemental Materials Methods) to perform hierarchical clustering.", [["a Ward variance 20 minimization algorithm", "TREATMENT", 8, 49], ["Supplemental Materials Methods", "TREATMENT", 51, 81]]], ["The cluster map shows three dominant branches (Fig. 3) representing three clusters of samples that are grouped based on similarity between the 31 biomarker values.", [["samples", "ANATOMY", 86, 93], ["samples", "CANCER", 86, 93], ["The cluster map", "TEST", 0, 15], ["three", "OBSERVATION_MODIFIER", 22, 27], ["dominant", "OBSERVATION_MODIFIER", 28, 36], ["branches", "OBSERVATION_MODIFIER", 37, 45], ["three", "OBSERVATION_MODIFIER", 68, 73], ["clusters", "OBSERVATION_MODIFIER", 74, 82]]], ["The first branch is observed for early time points where we observe an inverse relationship between high levels of viral antigens and low levels of antibodies.", [["viral antigens", "PROTEIN", 115, 129], ["antibodies", "PROTEIN", 148, 158], ["high levels of viral antigens", "PROBLEM", 100, 129], ["low levels of antibodies", "PROBLEM", 134, 158], ["branch", "OBSERVATION_MODIFIER", 10, 16], ["viral antigens", "OBSERVATION", 115, 129]]], ["The second branch shows a transition in patient samples where 25 antigen levels begin to decrease as total IgM, IgA, and IgG (as well as IgG subclasses IgG1 and IgG3) begin to increase.", [["samples", "ANATOMY", 48, 55], ["patient", "ORGANISM", 40, 47], ["IgM", "GENE_OR_GENE_PRODUCT", 107, 110], ["IgA", "GENE_OR_GENE_PRODUCT", 112, 115], ["IgG", "GENE_OR_GENE_PRODUCT", 121, 124], ["IgG1", "GENE_OR_GENE_PRODUCT", 152, 156], ["IgG3", "GENE_OR_GENE_PRODUCT", 161, 165], ["IgM", "PROTEIN", 107, 110], ["IgA", "PROTEIN", 112, 115], ["IgG", "PROTEIN", 121, 124], ["IgG subclasses", "PROTEIN", 137, 151], ["IgG1", "PROTEIN", 152, 156], ["IgG3", "PROTEIN", 161, 165], ["patient", "SPECIES", 40, 47], ["a transition in patient samples", "PROBLEM", 24, 55], ["25 antigen levels", "TEST", 62, 79], ["total IgM", "TEST", 101, 110], ["IgA", "TEST", 112, 115], ["IgG", "TEST", 121, 124], ["IgG subclasses IgG1", "TEST", 137, 156], ["IgG3", "TEST", 161, 165], ["branch", "ANATOMY_MODIFIER", 11, 17], ["transition", "OBSERVATION_MODIFIER", 26, 36]]], ["In the third branch, we see an even further reduction in antigen levels with small increases in IgG subclasses IgG2 and IgG4 (relative to their average values across samples).", [["samples", "ANATOMY", 166, 173], ["IgG2", "GENE_OR_GENE_PRODUCT", 111, 115], ["IgG4", "GENE_OR_GENE_PRODUCT", 120, 124], ["samples", "CANCER", 166, 173], ["IgG subclasses", "PROTEIN", 96, 110], ["IgG2", "PROTEIN", 111, 115], ["IgG4", "PROTEIN", 120, 124], ["antigen levels", "TEST", 57, 71], ["small increases in IgG subclasses IgG2", "PROBLEM", 77, 115], ["IgG4", "TEST", 120, 124], ["third", "ANATOMY_MODIFIER", 7, 12], ["branch", "ANATOMY_MODIFIER", 13, 19], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["small", "OBSERVATION_MODIFIER", 77, 82], ["increases", "OBSERVATION_MODIFIER", 83, 92], ["IgG subclasses IgG2", "OBSERVATION", 96, 115]]], ["The third branch is observed for later time points where we propose that patients have cleared viral antigens from the plasma and antibodies have reached their steady-state levels.", [["plasma", "ANATOMY", 119, 125], ["patients", "ORGANISM", 73, 81], ["plasma", "ORGANISM_SUBSTANCE", 119, 125], ["viral antigens", "PROTEIN", 95, 109], ["antibodies", "PROTEIN", 130, 140], ["patients", "SPECIES", 73, 81], ["cleared viral antigens", "PROBLEM", 87, 109], ["the plasma and antibodies", "TEST", 115, 140], ["third", "OBSERVATION_MODIFIER", 4, 9], ["branch", "OBSERVATION_MODIFIER", 10, 16]]], ["For all 39 patients 30 in this cohort, we observe that IgG1 and IgG3 show large increases in plasma concentrations over time.", [["plasma", "ANATOMY", 93, 99], ["patients", "ORGANISM", 11, 19], ["IgG1", "GENE_OR_GENE_PRODUCT", 55, 59], ["IgG3", "GENE_OR_GENE_PRODUCT", 64, 68], ["plasma", "ORGANISM_SUBSTANCE", 93, 99], ["IgG1", "PROTEIN", 55, 59], ["IgG3", "PROTEIN", 64, 68], ["patients", "SPECIES", 11, 19], ["IgG1", "TEST", 55, 59], ["IgG3", "TEST", 64, 68], ["large increases in plasma concentrations", "PROBLEM", 74, 114], ["large", "OBSERVATION_MODIFIER", 74, 79], ["increases", "OBSERVATION_MODIFIER", 80, 89], ["plasma concentrations", "OBSERVATION_MODIFIER", 93, 114]]], ["In contrast, IgG2 and IgG4 show little to no changes above background levels over time (note that cluster map data is standardized so all values are relative for each biomarker).", [["IgG2", "GENE_OR_GENE_PRODUCT", 13, 17], ["IgG4", "GENE_OR_GENE_PRODUCT", 22, 26], ["IgG2", "PROTEIN", 13, 17], ["IgG4", "PROTEIN", 22, 26], ["IgG2", "TEST", 13, 17], ["changes above background levels", "PROBLEM", 45, 76], ["map data", "TEST", 106, 114]]], ["Both IgG1 and IgG3 are subclasses of IgG that predominantly respond to viral antigens and mediate neutralization.", [["IgG1", "GENE_OR_GENE_PRODUCT", 5, 9], ["IgG3", "GENE_OR_GENE_PRODUCT", 14, 18], ["IgG", "GENE_OR_GENE_PRODUCT", 37, 40], ["IgG1", "PROTEIN", 5, 9], ["IgG3", "PROTEIN", 14, 18], ["IgG", "PROTEIN", 37, 40], ["viral antigens", "PROTEIN", 71, 85], ["subclasses of IgG", "PROBLEM", 23, 40], ["viral antigens", "OBSERVATION", 71, 85], ["neutralization", "OBSERVATION", 98, 112]]], ["(15) (16) (17) (18) (19) Based on these measurements, the IgG response that is mounted by the 35 immune system is primarily mediated by IgG1 and IgG3 for SARS-CoV-2, in agreement with previous serological studies.", [["(15) (16) (17)", "SIMPLE_CHEMICAL", 0, 14], ["IgG", "GENE_OR_GENE_PRODUCT", 58, 61], ["IgG1", "GENE_OR_GENE_PRODUCT", 136, 140], ["IgG3", "GENE_OR_GENE_PRODUCT", 145, 149], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["IgG", "PROTEIN", 58, 61], ["IgG1", "PROTEIN", 136, 140], ["IgG3", "PROTEIN", 145, 149], ["SARS-CoV", "SPECIES", 154, 162], ["these measurements", "TEST", 34, 52], ["the IgG response", "TEST", 54, 70], ["SARS", "PROBLEM", 154, 158], ["previous serological studies", "TEST", 184, 212]]], ["(4, 5) The neutralization effects of IgG1 and IgG3 on viral antigens should be explored in future studies that include correlative neutralization titer assays.", [["(4, 5)", "CHEMICAL", 0, 6], ["IgG1", "GENE_OR_GENE_PRODUCT", 37, 41], ["IgG3", "GENE_OR_GENE_PRODUCT", 46, 50], ["IgG1", "PROTEIN", 37, 41], ["IgG3", "PROTEIN", 46, 50], ["viral antigens", "PROTEIN", 54, 68], ["IgG1", "TREATMENT", 37, 41], ["IgG3 on viral antigens", "TREATMENT", 46, 68], ["future studies", "TEST", 91, 105], ["correlative neutralization titer assays", "TEST", 119, 158]]], ["In addition to showing the inverse relationship between antigen levels and seroconversion in this patient cohort, we explored how antigen clearance compared with longitudinal RT-PCR tests and clinical outcomes.", [["patient", "ORGANISM", 98, 105], ["antigen", "GENE_OR_GENE_PRODUCT", 130, 137], ["patient", "SPECIES", 98, 105], ["antigen levels", "TEST", 56, 70], ["seroconversion", "TREATMENT", 75, 89], ["antigen clearance", "TEST", 130, 147], ["longitudinal RT-PCR tests", "TEST", 162, 187]]], ["The measured SARS-CoV-2 antigen and immunoglobulin levels in .", [["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 13, 31], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 36, 50], ["SARS-CoV-2 antigen", "PROTEIN", 13, 31], ["immunoglobulin", "PROTEIN", 36, 50], ["The measured SARS", "TEST", 0, 17], ["CoV", "TEST", 18, 21], ["immunoglobulin levels", "TEST", 36, 57]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint plasma, NP RT-PCR tests, and select clinical outcomes for each of these patients are displayed in Fig. 4 and patient features are summarized in Table S4 .", [["plasma", "ANATOMY", 384, 390], ["CC", "CHEMICAL", 0, 2], ["plasma", "ORGANISM_SUBSTANCE", 384, 390], ["patients", "ORGANISM", 456, 464], ["patient", "ORGANISM", 493, 500], ["patients", "SPECIES", 456, 464], ["patient", "SPECIES", 493, 500], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NP RT-PCR tests", "TEST", 392, 407], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For each patient in Fig. 4 , the date that each plasma sample was collected is indicated by an X. Plasma samples with significant detectable levels of antigen (concentrations two times above the LOD) are indicated with a black X and plasma samples with no significant detectable levels of antigen are indicated with a blue X. In this 5 patient cohort, NP RT-PCR tests reported positive results for an average of 15 \u00b1 5 days after viral antigen clearance and 18 \u00b1 4 days after seroconversion.", [["plasma sample", "ANATOMY", 48, 61], ["samples", "ANATOMY", 105, 112], ["plasma samples", "ANATOMY", 233, 247], ["patient", "ORGANISM", 9, 16], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["plasma samples", "ORGANISM_SUBSTANCE", 233, 247], ["patient", "ORGANISM", 336, 343], ["patient", "SPECIES", 9, 16], ["patient", "SPECIES", 336, 343], ["plasma sample", "TEST", 48, 61], ["an X. Plasma samples", "TEST", 92, 112], ["significant detectable levels of antigen", "PROBLEM", 118, 158], ["a black X and plasma samples", "TEST", 219, 247], ["significant detectable levels of antigen", "PROBLEM", 256, 296], ["NP RT-PCR tests", "TEST", 352, 367], ["viral antigen clearance", "TEST", 430, 453], ["seroconversion", "PROBLEM", 476, 490]]], ["Furthermore, several patients never received a negative RT-PCR result before being discharged from the hospital.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["These observations are in agreement with recent virological studies that confirmed persistence of viral RNA and showed how seroconversion was not immediately followed by a decrease in NP viral RNA in 10 hospitalized patients.", [["patients", "ORGANISM", 216, 224], ["viral RNA", "RNA", 98, 107], ["NP viral RNA", "RNA", 184, 196], ["patients", "SPECIES", 216, 224], ["recent virological studies", "TEST", 41, 67], ["viral RNA", "PROBLEM", 98, 107], ["a decrease in NP viral RNA", "PROBLEM", 170, 196], ["viral RNA", "OBSERVATION", 98, 107], ["decrease", "OBSERVATION_MODIFIER", 172, 180], ["viral RNA", "OBSERVATION", 187, 196]]], ["(20) Because RNA shedding can occur for several weeks after infection and recovery, measurements of viral antigens and immunoglobulins may provide more accurate and timely indicators of disease progression and recovery compared to viral RNA.(which was not certified by peer review).", [["infection", "DISEASE", 60, 69], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 119, 134], ["viral antigens", "PROTEIN", 100, 114], ["immunoglobulins", "PROTEIN", 119, 134], ["viral RNA", "RNA", 231, 240], ["RNA shedding", "PROBLEM", 13, 25], ["infection", "PROBLEM", 60, 69], ["viral antigens", "TEST", 100, 114], ["immunoglobulins", "TREATMENT", 119, 134], ["disease progression", "PROBLEM", 186, 205], ["viral RNA", "PROBLEM", 231, 240], ["disease", "OBSERVATION", 186, 193], ["viral RNA", "OBSERVATION", 231, 240]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint dates of each patient are indicated by green squares.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 647, 654], ["patient", "SPECIES", 647, 654], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 354, 357]]], ["Patient IDs are coded black for recovered patients who were discharged from the hospital, whereas patient IDs are coded red for deceased patients.", [["patients", "ORGANISM", 42, 50], ["patient", "ORGANISM", 98, 105], ["patients", "ORGANISM", 137, 145], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 98, 105], ["patients", "SPECIES", 137, 145]]], ["Pink boxes represent the date of seroconversion for each patient.(which was not certified by peer review)Finally, we demonstrate that the presence of viral antigens in plasma correlates with certain 5 indicators of disease severity in COVID-19 patients.", [["plasma", "ANATOMY", 168, 174], ["patient", "ORGANISM", 57, 64], ["plasma", "ORGANISM_SUBSTANCE", 168, 174], ["patients", "ORGANISM", 244, 252], ["viral antigens", "PROTEIN", 150, 164], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 244, 252], ["seroconversion", "TREATMENT", 33, 47], ["viral antigens in plasma correlates", "PROBLEM", 150, 185], ["disease severity", "PROBLEM", 215, 231], ["COVID", "TEST", 235, 240], ["viral", "OBSERVATION", 150, 155], ["disease", "OBSERVATION", 215, 222]]], ["To understand the correlation between SARS-CoV-2 antigen levels and disease severity, clinical features for the 64 COVID-19 positive patients (Fig. 5 , patient IDs 1-64) were compared with viral antigen levels in plasma.", [["plasma", "ANATOMY", 213, 219], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 38, 56], ["patients", "ORGANISM", 133, 141], ["patient", "ORGANISM", 152, 159], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["SARS-CoV-2 antigen", "PROTEIN", 38, 56], ["patients", "SPECIES", 133, 141], ["patient", "SPECIES", 152, 159], ["SARS-CoV-2 antigen levels", "TEST", 38, 63], ["disease severity", "PROBLEM", 68, 84], ["COVID", "TEST", 115, 120], ["patient IDs", "TEST", 152, 163], ["viral antigen levels", "TEST", 189, 209]]], ["It is important to note that all samples were obtained from patients admitted to the hospital, resulting in a cohort of primarily severe cases.", [["samples", "ANATOMY", 33, 40], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["For patients with serial samples, we analyzed the first plasma sample 10 collected after the initial positive NP RT-PCR test.", [["samples", "ANATOMY", 25, 32], ["plasma sample", "ANATOMY", 56, 69], ["patients", "ORGANISM", 4, 12], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["patients", "SPECIES", 4, 12], ["serial samples", "TEST", 18, 32], ["PCR test", "TEST", 116, 124]]], ["Viral-antigen-positive patients show detectable levels of both S1 and N in plasma; however, S1 shows higher correlation with clinical severity (Table S5 -8, Fig. S45 ).", [["plasma", "ANATOMY", 75, 81], ["Viral-antigen", "GENE_OR_GENE_PRODUCT", 0, 13], ["patients", "ORGANISM", 23, 31], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["S1", "PROTEIN", 63, 65], ["S1", "PROTEIN", 92, 94], ["patients", "SPECIES", 23, 31], ["Viral-antigen", "TEST", 0, 13], ["detectable levels of both S1 and N in plasma", "PROBLEM", 37, 81], ["clinical severity", "PROBLEM", 125, 142], ["Table S5", "TEST", 144, 152], ["S1", "ANATOMY", 63, 65]]], ["Therefore, patients were grouped into three categories of S1 concentrations: (1) 23 patients with undetectable S1 levels (below the limit of detection), (2) 23 patients with low levels of S1 (6-50 pg/mL), and (3) 18 patients with high levels of S1 (>50 15 pg/mL).", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 216, 224], ["undetectable S1 levels", "PROBLEM", 98, 120], ["low levels of S1", "PROBLEM", 174, 190], ["high levels of S1", "PROBLEM", 230, 247], ["S1", "ANATOMY", 111, 113], ["S1", "ANATOMY", 188, 190]]], ["The cutoff between groups 2 and 3 (50 pg/mL) was chosen as five standard deviations above the LOD.", [["cutoff", "OBSERVATION", 4, 10]]], ["There is a significant difference in rates of ICU admission upon presentation for patients with varying levels of S1 in plasma (p value: 0.0107).", [["plasma", "ANATOMY", 120, 126], ["patients", "ORGANISM", 82, 90], ["plasma", "ORGANISM_SUBSTANCE", 120, 126], ["S1", "PROTEIN", 114, 116], ["patients", "SPECIES", 82, 90], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33]]], ["Patients with zero, low, and high levels of S1 were admitted to the ICU upon presentation to the hospital at rates of 30%, 52%, and 77%, respectively (Fig. 5a) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["low", "OBSERVATION_MODIFIER", 20, 23], ["S1", "ANATOMY", 44, 46]]], ["However, 13 of 19 patients initially admitted to non-ICU dispositions 20 were later transferred to the ICU during hospitalization, as summarized in Table S4 .", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Among all COVID-19 positive patients, over 60% were intubated during hospitalization with no statistically significant difference in intubation rates among groups (Fig. 5b ).", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["all COVID", "TEST", 6, 15], ["intubated", "TREATMENT", 52, 61]]], ["All patients with high levels of S1 were intubated within one day of hospitalization, whereas patients with zero and low S1 levels were intubated within a range of zero to ten days post-admission (Fig. 5c) .", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 94, 102], ["intubated", "TREATMENT", 41, 50], ["zero and low S1 levels", "PROBLEM", 108, 130], ["S1", "ANATOMY", 33, 35], ["low S1", "ANATOMY", 117, 123]]], ["The difference in mean 25 times to intubation between patients with high levels of S1 and patients with no detectable S1 is significant (p-value: 0.0050).", [["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 90, 98], ["S1", "PROTEIN", 118, 120], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 90, 98], ["intubation", "TREATMENT", 35, 45], ["detectable S1", "PROBLEM", 107, 120], ["p-value", "TEST", 137, 144], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["S1", "ANATOMY", 83, 85]]], ["These results suggest that high S1 levels in plasma upon presentation to the hospital correlate with severe cases of COVID-19 that can result in respiratory failure and require immediate intubation.", [["plasma", "ANATOMY", 45, 51], ["respiratory", "ANATOMY", 145, 156], ["respiratory failure", "DISEASE", 145, 164], ["COVID-19", "CHEMICAL", 117, 125], ["S1", "GENE_OR_GENE_PRODUCT", 32, 34], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["high S1 levels", "PROBLEM", 27, 41], ["COVID", "TEST", 117, 122], ["respiratory failure", "PROBLEM", 145, 164], ["immediate intubation", "TREATMENT", 177, 197], ["respiratory failure", "OBSERVATION", 145, 164], ["intubation", "OBSERVATION", 187, 197]]], ["Among all patients, a broad range of intubation periods, up to 32 days, was observed (Fig. 5d ).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["intubation periods", "TREATMENT", 37, 55]]], ["Once intubated, there is no statistically significant difference in mean 30 intubation periods among patient groups.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["intubated", "TREATMENT", 5, 14], ["no", "UNCERTAINTY", 25, 27], ["statistically", "OBSERVATION_MODIFIER", 28, 41], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["difference", "OBSERVATION_MODIFIER", 54, 64]]], ["No statistically significant difference in death rate was observed for patients with zero, low, and high levels of S1, where 5 of 23, 5 of 23, and 8 of 18 of patients died, respectively (p-value: 0.1921).", [["death", "DISEASE", 43, 48], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 158, 166], ["death rate", "TEST", 43, 53], ["zero, low, and high levels of S1", "PROBLEM", 85, 117], ["p-value", "TEST", 187, 194], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION_MODIFIER", 29, 39], ["low", "OBSERVATION_MODIFIER", 91, 94], ["S1", "ANATOMY", 115, 117]]], ["Although six patients showed detectable levels of spike protein, there was no correlation between spike concentrations and ICU admission, intubation rate, or death rate.", [["death", "DISEASE", 158, 163], ["patients", "ORGANISM", 13, 21], ["spike protein", "PROTEIN", 50, 63], ["patients", "SPECIES", 13, 21], ["detectable levels of spike protein", "PROBLEM", 29, 63], ["spike concentrations", "PROBLEM", 98, 118], ["intubation rate", "TEST", 138, 153], ["death rate", "TEST", 158, 168]]], ["These results show a high level of diversity and complexity in the 35 responses and disease trajectories in each patient.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["disease trajectories", "PROBLEM", 84, 104], ["high", "OBSERVATION_MODIFIER", 21, 25]]], ["There are potentially more features in these data that will lead to further correlations, but a large cohort of patients will need to be tested to elucidate other patterns.(which was not certified by peer review).", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["more features", "OBSERVATION_MODIFIER", 22, 35], ["large", "OBSERVATION_MODIFIER", 96, 101]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Compared to RT-PCR tests, immunoassay-based antigen and serological tests have the advantage of speed and simplicity when integrated into point-of-care platforms.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 326, 342], ["RT-PCR tests", "TEST", 355, 367], ["immunoassay", "TEST", 369, 380], ["based antigen", "TEST", 381, 394], ["serological tests", "TEST", 399, 416], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Plasma is a readily available biofluid from hospitalized patients but is more difficult to obtain in non-clinical settings.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["Saliva is a non-invasive biofluid that is easier to use for wide-scale testing.", [["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["wide-scale testing", "TEST", 60, 78]]], ["Therefore, we explored the presence of SARS-CoV-2 antigens and anti-SARS-CoV-2 immunoglobulins in saliva ( Fig. S47, S48 , S49).", [["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 39, 58], ["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 63, 94], ["saliva", "ORGANISM_SUBSTANCE", 98, 104], ["S49", "CELL", 123, 126], ["SARS-CoV-2 antigens", "PROTEIN", 39, 58], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 63, 94], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["anti-SARS", "TEST", 63, 72], ["CoV", "TEST", 73, 76]]], ["We tested 19 saliva samples from patients presenting to the Emergency Department and show that 8 of 19 patients have detectable levels of S1.", [["saliva samples", "ANATOMY", 13, 27], ["saliva samples", "ORGANISM_SUBSTANCE", 13, 27], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 103, 111], ["S1", "GENE_OR_GENE_PRODUCT", 138, 140], ["S1", "PROTEIN", 138, 140], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 103, 111], ["saliva samples", "TEST", 13, 27], ["detectable levels of S1", "PROBLEM", 117, 140], ["S1", "ANATOMY", 138, 140]]], ["Similar to our observations 15 of antigen and immunoglobulin levels in plasma, saliva S1 and anti-SARS-CoV-2 antibody levels show negative correlation.", [["plasma", "ANATOMY", 71, 77], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 46, 60], ["plasma", "ORGANISM_SUBSTANCE", 71, 77], ["saliva", "ORGANISM_SUBSTANCE", 79, 85], ["anti-SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 93, 117], ["immunoglobulin", "PROTEIN", 46, 60], ["anti-SARS", "PROTEIN", 93, 102], ["our observations", "TEST", 11, 27], ["antigen", "TEST", 34, 41], ["immunoglobulin levels", "TEST", 46, 67], ["plasma", "TEST", 71, 77], ["saliva S1", "TEST", 79, 88], ["anti-SARS", "TEST", 93, 102], ["CoV", "TEST", 103, 106], ["antibody levels", "TEST", 109, 124]]], ["These initial results indicate the presence of SARS-CoV-2 antigens and anti-SARS-CoV-2 immunoglobulins in saliva and highlight the potential for adapting our assays to a diagnostic test for COVID-19.", [["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 47, 66], ["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 71, 102], ["saliva", "ORGANISM_SUBSTANCE", 106, 112], ["SARS-CoV-2 antigens", "PROTEIN", 47, 66], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 71, 102], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["anti-SARS", "TEST", 71, 80], ["CoV", "TEST", 81, 84], ["2 immunoglobulins in saliva", "PROBLEM", 85, 112], ["a diagnostic test", "TEST", 168, 185], ["COVID", "TEST", 190, 195]]], ["Future studies on saliva will include longitudinal sample analysis for mild and severe cases of COVID-19 patients and will explore the potential for 20 developing a saliva-based COVID-19 antigen screening tool.(which was not certified by peer review)Using SARS-CoV-2 Simoa assays, we demonstrate quantitative detection of SARS-CoV-2 antigens and anti-SARS-CoV-2 immunoglobulins in plasma of COVID-19 patients.", [["plasma", "ANATOMY", 381, 387], ["COVID-19 antigen", "CHEMICAL", 178, 194], ["saliva", "ORGANISM_SUBSTANCE", 18, 24], ["patients", "ORGANISM", 105, 113], ["saliva", "ORGANISM_SUBSTANCE", 165, 171], ["COVID-19 antigen", "GENE_OR_GENE_PRODUCT", 178, 194], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 322, 341], ["anti-SARS-CoV-2 immunoglobulins", "GENE_OR_GENE_PRODUCT", 346, 377], ["plasma", "ORGANISM_SUBSTANCE", 381, 387], ["patients", "ORGANISM", 400, 408], ["SARS-CoV-2 antigens", "PROTEIN", 322, 341], ["anti-SARS-CoV-2 immunoglobulins", "PROTEIN", 346, 377], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 400, 408], ["SARS-CoV", "SPECIES", 322, 330], ["Future studies", "TEST", 0, 14], ["saliva", "TREATMENT", 18, 24], ["longitudinal sample analysis", "TEST", 38, 66], ["mild and severe cases of COVID", "PROBLEM", 71, 101], ["a saliva-based COVID", "TEST", 163, 183], ["antigen screening tool", "TEST", 187, 209], ["SARS", "TEST", 256, 260], ["SARS", "TEST", 322, 326], ["CoV", "TEST", 327, 330], ["anti-SARS", "TEST", 346, 355], ["CoV", "TEST", 356, 359], ["COVID", "TEST", 391, 396]]], ["While detection of N in NP swabs has been cited,(6) we present the first report of SARS-CoV-2 spike, S1, and N detection in plasma.", [["plasma", "ANATOMY", 124, 130], ["plasma", "ORGANISM_SUBSTANCE", 124, 130], ["SARS-CoV", "SPECIES", 83, 91], ["N in NP swabs", "PROBLEM", 19, 32], ["SARS", "PROBLEM", 83, 87], ["CoV", "TEST", 88, 91]]], ["The presence of S1 and N in plasma suggest that fragments of virus 25 are entering the bloodstream, potentially due to tissue damage.", [["plasma", "ANATOMY", 28, 34], ["bloodstream", "ANATOMY", 87, 98], ["tissue", "ANATOMY", 119, 125], ["S1", "GENE_OR_GENE_PRODUCT", 16, 18], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["virus 25", "ORGANISM", 61, 69], ["tissue", "TISSUE", 119, 125], ["S1", "PROTEIN", 16, 18], ["S1 and N in plasma", "PROBLEM", 16, 34], ["fragments of virus", "PROBLEM", 48, 66], ["the bloodstream", "PROBLEM", 83, 98], ["tissue damage", "PROBLEM", 119, 132], ["S1", "ANATOMY", 16, 18], ["fragments", "OBSERVATION", 48, 57], ["bloodstream", "ANATOMY", 87, 98], ["potentially due to", "UNCERTAINTY", 100, 118], ["tissue", "ANATOMY", 119, 125], ["damage", "OBSERVATION", 126, 132]]], ["Although spike is undetectable in most COVID-19 patients, possibly due to proteolytic cleavage, six patients show high levels of spike in plasma.", [["plasma", "ANATOMY", 138, 144], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 100, 108], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 100, 108], ["spike", "PROBLEM", 9, 14], ["proteolytic cleavage", "PROBLEM", 74, 94], ["high levels of spike in plasma", "PROBLEM", 114, 144], ["spike", "OBSERVATION_MODIFIER", 9, 14], ["undetectable", "OBSERVATION_MODIFIER", 18, 30], ["possibly due to", "UNCERTAINTY", 58, 73], ["high levels", "OBSERVATION_MODIFIER", 114, 125]]], ["We hypothesize that some spike is not proteolytically cleaved, especially in cases where there are high levels of spike in plasma.", [["plasma", "ANATOMY", 123, 129], ["plasma", "ORGANISM_SUBSTANCE", 123, 129], ["some spike", "PROBLEM", 20, 30], ["high levels of spike in plasma", "PROBLEM", 99, 129], ["high", "OBSERVATION_MODIFIER", 99, 103]]], ["No evidence has been reported yet for full viral particles in blood, though we cannot rule out this possibility.(21) Nonetheless, severe COVID-19 30 cases with acute respiratory distress syndrome can result in damage to endothelial cells and vascular leakage(22-25) and we propose that this damage can lead to discharge of viral antigens into the blood.", [["blood", "ANATOMY", 62, 67], ["respiratory", "ANATOMY", 166, 177], ["endothelial cells", "ANATOMY", 220, 237], ["vascular", "ANATOMY", 242, 250], ["blood", "ANATOMY", 347, 352], ["acute respiratory distress syndrome", "DISEASE", 160, 195], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["endothelial cells", "CELL", 220, 237], ["vascular", "MULTI-TISSUE_STRUCTURE", 242, 250], ["blood", "ORGANISM_SUBSTANCE", 347, 352], ["endothelial cells", "CELL_TYPE", 220, 237], ["viral antigens", "PROTEIN", 323, 337], ["full viral particles in blood", "PROBLEM", 38, 67], ["severe COVID", "PROBLEM", 130, 142], ["acute respiratory distress syndrome", "PROBLEM", 160, 195], ["damage to endothelial cells", "PROBLEM", 210, 237], ["vascular leakage", "PROBLEM", 242, 258], ["this damage", "PROBLEM", 286, 297], ["viral antigens into the blood", "PROBLEM", 323, 352], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory distress", "OBSERVATION", 166, 186], ["endothelial cells", "OBSERVATION", 220, 237], ["vascular", "ANATOMY", 242, 250], ["leakage", "OBSERVATION", 251, 258], ["viral", "OBSERVATION", 323, 328], ["blood", "ANATOMY", 347, 352]]], ["Patients with lung damage can suffer from respiratory failure and require intubation or mechanical ventilation.", [["lung", "ANATOMY", 14, 18], ["respiratory", "ANATOMY", 42, 53], ["lung damage", "DISEASE", 14, 25], ["respiratory failure", "DISEASE", 42, 61], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 14, 18], ["Patients", "SPECIES", 0, 8], ["lung damage", "PROBLEM", 14, 25], ["respiratory failure", "PROBLEM", 42, 61], ["intubation", "TREATMENT", 74, 84], ["mechanical ventilation", "TREATMENT", 88, 110], ["lung", "ANATOMY", 14, 18], ["damage", "OBSERVATION", 19, 25], ["respiratory failure", "OBSERVATION", 42, 61], ["mechanical ventilation", "OBSERVATION", 88, 110]]], ["We also report significant correlation between high S1 levels in plasma and time between hospital admission and intubation.", [["plasma", "ANATOMY", 65, 71], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["S1", "PROTEIN", 52, 54], ["intubation", "TREATMENT", 112, 122], ["significant", "OBSERVATION_MODIFIER", 15, 26]]], ["In situations where ICUs have limited 35 capacity, there is urgent need to prioritize severe COVID-19 patients.", [["COVID", "DISEASE", 93, 98], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["severe COVID", "PROBLEM", 86, 98]]], ["Our initial results suggest that detecting viral antigen levels in plasma could aid in patient stratification and may indicate when patients require immediate medical intervention, such as intubation.", [["plasma", "ANATOMY", 67, 73], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["patient", "ORGANISM", 87, 94], ["patients", "ORGANISM", 132, 140], ["patient", "SPECIES", 87, 94], ["patients", "SPECIES", 132, 140], ["viral antigen levels", "TEST", 43, 63], ["immediate medical intervention", "TREATMENT", 149, 179], ["intubation", "TREATMENT", 189, 199]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint hypothesize that asymptomatic or mild cases will likely not show viral antigen levels in plasma, future studies that include mild cases will be used to probe SARS-CoV-2 antigen and antibody levels over time in comparison to the severe cases presented here. .", [["plasma", "ANATOMY", 432, 438], ["CC", "CHEMICAL", 0, 2], ["plasma", "ORGANISM_SUBSTANCE", 432, 438], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 501, 519], ["SARS-CoV-2 antigen", "PROTEIN", 501, 519], ["SARS-CoV", "SPECIES", 501, 509], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 326, 333], ["asymptomatic", "PROBLEM", 360, 372], ["mild cases", "PROBLEM", 376, 386], ["viral antigen levels", "PROBLEM", 408, 428], ["future studies", "TEST", 440, 454], ["mild cases", "PROBLEM", 468, 478], ["probe SARS", "TEST", 495, 505], ["CoV-2 antigen", "TEST", 506, 519], ["antibody levels", "TEST", 524, 539], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The anti-SARS-CoV-2 Simoa assays in this publication have been licensed by Brigham and Women's Hospital to Quanterix Corporation.(which was not certified by peer review).", [["anti-SARS-CoV-2 Simoa", "DNA", 4, 25], ["Women", "SPECIES", 87, 92], ["The anti-SARS", "TEST", 0, 13], ["CoV", "TEST", 14, 17]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Antigen Assay Spike and Recovery Table S4 .", [["Antigen Assay", "TEST", 0, 13]]], ["Individual patient clinical data Table S5 .", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["Statistics for S1 as predictors of clinical outcomes (3 groups).", [["S1", "PROTEIN", 15, 17]]], ["Table S6 .", [["S6", "PROTEIN", 6, 8]]], ["Statistics for S1 as predictors of clinical outcomes (2 groups).", [["S1", "PROTEIN", 15, 17]]], ["Statistics for Nucleocapsid as predictors of clinical outcomes (2 groups).", [["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 15, 27]]], ["Statistics for death rates.", [["death", "DISEASE", 15, 20], ["death rates", "TEST", 15, 26]]], ["Calibration curves for the two SARS-CoV-2 antigen assays.", [["CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 36, 49], ["Calibration curves", "TEST", 0, 18], ["the two SARS", "TEST", 23, 35], ["CoV-2 antigen assays", "TEST", 36, 56]]], ["Cross-reactivity validation of two-plex Spike (S1/ Spike) assay Figure S3 .", [["S1", "PROTEIN", 47, 49], ["Spike", "PROTEIN", 51, 56], ["Cross-reactivity validation", "TEST", 0, 27], ["two-plex Spike (S1/ Spike", "PROBLEM", 31, 56]]], ["Antigen assay dilution linearity curves 15 Figure S4 .", [["Antigen assay dilution linearity curves", "TEST", 0, 39]]], ["Concentration of SARS-CoV-2 spike in plasma samples from pre-pandemic healthy, pre-pandemic sick patients, COVID-19 negative patients, and COVID-19 positive patients.", [["plasma samples", "ANATOMY", 37, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["plasma samples", "ORGANISM_SUBSTANCE", 37, 51], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 157, 165], ["SARS", "TEST", 17, 21], ["CoV", "TEST", 22, 25], ["plasma samples", "TEST", 37, 51], ["COVID", "TEST", 107, 112], ["COVID", "TEST", 139, 144], ["SARS", "OBSERVATION", 17, 21]]], ["Viral antigen concentrations for each patient Figure S6 .", [["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 38, 45], ["S6", "PROTEIN", 53, 55], ["patient", "SPECIES", 38, 45], ["Viral antigen concentrations", "TEST", 0, 28]]], ["Simoa results for IgG, IgM, and IgG against four viral antigens Figure S7 Figure S13 .", [["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgM", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["IgG", "PROTEIN", 18, 21], ["IgM", "PROTEIN", 23, 26], ["IgG", "PROTEIN", 32, 35], ["viral antigens Figure S7 Figure S13", "PROTEIN", 49, 84], ["IgG", "TEST", 18, 21], ["IgM", "TEST", 23, 26], ["IgG", "TEST", 32, 35], ["four viral antigens", "TEST", 44, 63]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 4.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 5.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 34, 48], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Figure S15 .", [["S15", "GENE_OR_GENE_PRODUCT", 7, 10]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 6.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 7.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 8.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 9.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 10.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 34, 48], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 11.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 34, 48], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 12. .", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure S33 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 27.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 28.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 29.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 30.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 34, 48], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 31.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 32.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 33.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 34.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 35.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 36.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 37.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Viral antigen and anti-SARS-CoV-2 immunoglobulin plots for Patient 38.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 33], ["Viral antigen", "PROTEIN", 0, 13], ["anti-SARS", "PROTEIN", 18, 27], ["Patient", "SPECIES", 59, 66], ["Viral antigen", "TEST", 0, 13], ["anti-SARS", "TEST", 18, 27], ["CoV", "TEST", 28, 31], ["immunoglobulin plots", "TEST", 34, 54]]], ["Clinical data for all COVID-19 positive patients plotted based on nucleocapsid levels in plasma.", [["plasma", "ANATOMY", 89, 95], ["patients", "ORGANISM", 40, 48], ["plasma", "ORGANISM_SUBSTANCE", 89, 95], ["patients", "SPECIES", 40, 48], ["Clinical data", "TEST", 0, 13], ["all COVID", "TEST", 18, 27], ["nucleocapsid levels", "TEST", 66, 85]]], ["S1 concentrations in saliva.", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["saliva", "ORGANISM_SUBSTANCE", 21, 27], ["S1", "PROTEIN", 0, 2], ["S1 concentrations in saliva", "PROBLEM", 0, 27], ["concentrations", "OBSERVATION_MODIFIER", 3, 17], ["saliva", "ANATOMY", 21, 27]]], ["Simoa results for IgG, IgM, and IgG against four viral antigens in saliva.", [["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgM", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["saliva", "ORGANISM_SUBSTANCE", 67, 73], ["IgG", "PROTEIN", 18, 21], ["IgM", "PROTEIN", 23, 26], ["IgG", "PROTEIN", 32, 35], ["viral antigens", "PROTEIN", 49, 63], ["IgG", "TEST", 18, 21], ["IgM", "TEST", 23, 26], ["IgG", "TEST", 32, 35], ["four viral antigens in saliva", "PROBLEM", 44, 73]]], ["Correlated S1 and IgA (against S1) levels in individual patient saliva samples.References (24) 20Supplementary Materials: Antigen and Immunoglobulin Data for All Patient Samples IV.References (24) 20Statistical Analysis V.References (24) 20Saliva Data 30 .", [["saliva samples", "ANATOMY", 64, 78], ["S1", "GENE_OR_GENE_PRODUCT", 11, 13], ["IgA (against S1", "GENE_OR_GENE_PRODUCT", 18, 33], ["patient", "ORGANISM", 56, 63], ["saliva samples", "ORGANISM_SUBSTANCE", 64, 78], ["S1", "PROTEIN", 11, 13], ["IgA", "PROTEIN", 18, 21], ["S1", "PROTEIN", 31, 33], ["patient", "SPECIES", 56, 63], ["Patient", "SPECIES", 162, 169], ["IgA", "TEST", 18, 21], ["individual patient saliva samples", "TEST", 45, 78], ["All Patient Samples IV", "TREATMENT", 158, 180], ["V.References", "TEST", 220, 232]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Anti-S1 antibody discovery and expression 20 The Mehta I/II 2.7x10 10 member non-immunized scFv-phage library was used to perform three rounds of panning against SARS-CoV-2 S1 protein (Sino Biologicals, Wayne, PA).", [["Anti-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 162, 175], ["Anti-S1 antibody", "PROTEIN", 0, 16], ["Mehta I/II 2.7x10 10 member non-immunized scFv-phage library", "DNA", 49, 109], ["SARS-CoV-2 S1 protein", "PROTEIN", 162, 183], ["SARS-CoV", "SPECIES", 162, 170], ["The Mehta I/II", "TREATMENT", 45, 59], ["SARS", "TEST", 162, 166], ["CoV", "TEST", 167, 170]]], ["Nunc MaxiSorp Immuno tubes (Thermo Fisher Scientific, Waltham, MA) were coated with SARS-CoV-2 S1 protein overnight in PBS and the SARS-CoV-2 S1 coating concentration was decreased in each round to increase the affinity of the enriched antibodies.", [["SARS-CoV-2 S1 protein", "PROTEIN", 84, 105], ["enriched antibodies", "PROTEIN", 227, 246], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["PBS", "TEST", 119, 122], ["the SARS", "TEST", 127, 135], ["CoV", "TEST", 136, 139], ["S1 coating concentration", "TREATMENT", 142, 166], ["Immuno tubes", "OBSERVATION", 14, 26], ["enriched antibodies", "OBSERVATION", 227, 246]]], ["Screening of the enriched library 25 was performed by picking single bacterial colonies from the 3 rd round of panning.", [["colonies", "ANATOMY", 79, 87], ["enriched library 25", "DNA", 17, 36], ["single bacterial colonies", "PROBLEM", 62, 87], ["bacterial colonies", "OBSERVATION", 69, 87]]], ["Small scale rescue was performed and the phage supernatant was used to screen via SARS-CoV-2 RBD coated ELISA plates.", [["supernatant", "ANATOMY", 47, 58], ["SARS-CoV-2 RBD coated ELISA plates", "DNA", 82, 116], ["Small scale rescue", "TREATMENT", 0, 18], ["the phage supernatant", "TREATMENT", 37, 58], ["SARS", "TEST", 82, 86], ["CoV-2 RBD coated ELISA plates", "TREATMENT", 87, 116]]], ["The recovered antibody was converted to hIgG1 and expressed transiently by transfection into Expi293F cells via ExpiFectamine (Thermo Fisher Scientific, Waltham, MA).", [["Expi293F cells", "ANATOMY", 93, 107], ["ExpiFectamine", "CHEMICAL", 112, 125], ["ExpiFectamine", "CHEMICAL", 112, 125], ["hIgG1", "GENE_OR_GENE_PRODUCT", 40, 45], ["Expi293F cells", "CELL", 93, 107], ["ExpiFectamine", "SIMPLE_CHEMICAL", 112, 125], ["hIgG1", "PROTEIN", 40, 45], ["Expi293F cells", "CELL_LINE", 93, 107], ["The recovered antibody", "TEST", 0, 22], ["hIgG1", "TREATMENT", 40, 45], ["ExpiFectamine", "TREATMENT", 112, 125], ["antibody", "OBSERVATION", 14, 22]]], ["The cells were cultured for four days before the supernatant was harvested and cells pelleted.", [["cells", "ANATOMY", 4, 9], ["supernatant", "ANATOMY", 49, 60], ["cells", "ANATOMY", 79, 84], ["cells", "CELL", 4, 9], ["cells", "CELL", 79, 84]]], ["The beads were shaken for two hours at 4 \u00b0C for antibody conjugation, washed twice with 200 \u00b5L .", [["beads", "ANATOMY", 4, 9], ["antibody conjugation", "TREATMENT", 48, 68], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["5 Biotinylation of detector antibodies.", [["detector antibodies", "PROTEIN", 19, 38], ["detector antibodies", "TEST", 19, 38]]], ["Each detector antibody was conjugated to EZ-Link NHS-PEG4-Biotin (Thermo Fisher Scientific) by adding 3 \u00b5L NHS-PEG4-Biotin (2 mg freshly dissolved in 383 \u00b5L deionized water) to 100 \u00b5L antibody (1 mg/mL in PBS).", [["EZ", "CHEMICAL", 41, 43], ["NHS-PEG4-Biotin", "CHEMICAL", 49, 64], ["NHS-PEG4-Biotin", "CHEMICAL", 107, 122], ["Biotin", "CHEMICAL", 58, 64], ["Biotin", "CHEMICAL", 116, 122], ["EZ", "SIMPLE_CHEMICAL", 41, 43], ["NHS-PEG4-Biotin", "SIMPLE_CHEMICAL", 49, 64], ["PEG4-Biotin", "SIMPLE_CHEMICAL", 111, 122], ["Each detector antibody", "TEST", 0, 22], ["EZ", "TEST", 41, 43], ["PEG4-Biotin", "TREATMENT", 111, 122]]], ["The mixture was incubated for 30 minutes at room temperature and then purified using a 50 kDa 0.5 mL Amicon filter (MilliporeSigma), with five washes in Biotinylation Reaction Buffer (Quanterix) at 14000xg 10 for five minutes.", [["a 50 kDa 0.5 mL Amicon filter (MilliporeSigma)", "TREATMENT", 85, 131], ["five washes in Biotinylation Reaction Buffer (Quanterix)", "TREATMENT", 138, 194]]], ["The filter was then inverted and centrifuged for two minutes at 1000xg, and washed with 50 \u00b5L Biotinylation Reaction Buffer before centrifuging again for two minutes at 1000xg.", [["The filter", "TREATMENT", 0, 10], ["50 \u00b5L Biotinylation Reaction Buffer", "TREATMENT", 88, 123], ["filter", "OBSERVATION", 4, 10]]], ["The biotinylated antibody concentration was measured with a NanoDrop spectrophotometer.", [["The biotinylated antibody concentration", "TREATMENT", 0, 39], ["a NanoDrop spectrophotometer", "TREATMENT", 58, 86], ["antibody concentration", "OBSERVATION", 17, 39]]], ["15Simoa assays Antigen AssaysSimoa assays were performed on an HD-X Analyzer (Quanterix) in an automated three-step assay format according to the manufacturer's instructions and as previously described.", [["15Simoa assays", "TEST", 0, 14], ["AssaysSimoa assays", "TEST", 23, 41], ["an HD", "TREATMENT", 60, 65]]], ["(24) Plasma samples were diluted 8-fold in Homebrew Detector/Sample Diluent (Quanterix Corp.) with Halt 20 Protease Inhibitor Cocktail (Thermo Fischer Scientific) and EDTA.", [["samples", "ANATOMY", 12, 19], ["EDTA", "CHEMICAL", 167, 171], ["EDTA", "SIMPLE_CHEMICAL", 167, 171], ["Plasma samples", "TEST", 5, 19], ["Detector/Sample Diluent (Quanterix Corp.", "TREATMENT", 52, 92], ["Halt 20 Protease Inhibitor Cocktail", "TREATMENT", 99, 134]]], ["Detector antibodies were diluted in Homebrew Detector/Sample Diluent to 0.3 \u00b5g/mL, and streptavidin-\u03b2-galactosidase (S\u03b2G) concentrate (Quanterix) was diluted to 150 pM in S\u03b2G Diluent (Quanterix).", [["streptavidin-\u03b2-galactosidase", "CHEMICAL", 87, 115], ["S\u03b2G", "CHEMICAL", 117, 120], ["streptavidin-\u03b2-galactosidase", "SIMPLE_CHEMICAL", 87, 115], ["S\u03b2G", "SIMPLE_CHEMICAL", 117, 120], ["Quanterix", "SIMPLE_CHEMICAL", 135, 144], ["\u03b2G Diluent", "SIMPLE_CHEMICAL", 172, 182], ["Detector antibodies", "TEST", 0, 19], ["Detector/Sample Diluent", "TREATMENT", 45, 68], ["streptavidin", "TREATMENT", 87, 99], ["galactosidase (S\u03b2G) concentrate (Quanterix)", "TREATMENT", 102, 145]]], ["Antibodyconjugated capture beads were diluted in Bead Diluent, with a total of 500,000 beads per reaction (125,000 S1 beads, 125,000 S2 beads, and 250,000 647 nm dye-encoded helper beads for the S1/S2 25 multiplex assay, and 125,000 nucleocapsid beads and 375,000 647 nm dye-encoded helper beads for the nucleocapsid assay).", [["S1", "PROTEIN", 195, 197], ["S2", "PROTEIN", 198, 200], ["Antibodyconjugated capture beads", "TREATMENT", 0, 32], ["S2 beads", "TEST", 133, 141], ["the S1/S2", "TEST", 191, 200], ["multiplex assay", "TEST", 204, 219], ["nucleocapsid beads", "TEST", 233, 251], ["nm dye-encoded helper beads", "TREATMENT", 268, 295], ["the nucleocapsid assay", "TEST", 300, 322], ["beads", "OBSERVATION_MODIFIER", 27, 32], ["S1", "ANATOMY", 195, 197], ["S2", "ANATOMY", 198, 200]]], ["All reagents were diluted in plastic bottles that were loaded into the HD-X Analyzer, and all assay steps were performed in an automated manner on the instrument.", [["All reagents", "TREATMENT", 0, 12], ["the HD-X Analyzer", "TREATMENT", 67, 84], ["all assay steps", "TEST", 90, 105]]], ["In each assay, capture beads were incubated with the sample for 15 minutes, detector antibody for 5 minutes, and S\u03b2G for 5 minutes, with washing steps in between.", [["sample", "ANATOMY", 53, 59], ["S\u03b2G", "GENE_OR_GENE_PRODUCT", 113, 116], ["detector antibody", "TEST", 76, 93]]], ["The beads were then resuspended 30 in 25 \u00b5L resorufin-\u03b2-galactopyranoside and loaded into the microwell array for imaging.", [["beads", "ANATOMY", 4, 9], ["resorufin-\u03b2-galactopyranoside", "CHEMICAL", 44, 73], ["resorufin-\u03b2-galactopyranoside", "CHEMICAL", 44, 73], ["resorufin-\u03b2-galactopyranoside", "SIMPLE_CHEMICAL", 44, 73], ["The beads", "TREATMENT", 0, 9], ["galactopyranoside", "TREATMENT", 56, 73], ["imaging", "TEST", 114, 121]]], ["Average enzyme per bead (AEB) and sample concentration values were calculated by the HD-X Analyzer software.", [["sample", "ANATOMY", 34, 40], ["Average enzyme", "TEST", 0, 14], ["AEB", "TEST", 25, 28], ["sample concentration values", "TEST", 34, 61], ["bead", "OBSERVATION_MODIFIER", 19, 23]]], ["All samples were measured in duplicates.35SARs-CoV-2 serological Simoa assays were prepared and preformed as previously described.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["CoV", "TEST", 47, 50], ["serological Simoa assays", "TEST", 53, 77]]], ["(9) Plasma samples were diluted 4000-fold in Homebrew Detector/Sample Diluent (Quanterix Corp.)", [["Plasma samples", "ANATOMY", 4, 18], ["Plasma samples", "ORGANISM_SUBSTANCE", 4, 18], ["Plasma samples", "TEST", 4, 18], ["Detector/Sample Diluent (Quanterix Corp.)", "TREATMENT", 54, 95]]], ["SARs-CoV-2 serological Simoa assays for IgG1, IgG2, IgG3, and IgG4 were developed against 4 viral antigens S1, N, spike, and RBD as previously described.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 5, 10], ["IgG1", "GENE_OR_GENE_PRODUCT", 40, 44], ["IgG2", "GENE_OR_GENE_PRODUCT", 46, 50], ["IgG3", "GENE_OR_GENE_PRODUCT", 52, 56], ["IgG4", "GENE_OR_GENE_PRODUCT", 62, 66], ["IgG1", "PROTEIN", 40, 44], ["IgG2", "PROTEIN", 46, 50], ["IgG3", "PROTEIN", 52, 56], ["IgG4", "PROTEIN", 62, 66], ["viral antigens", "PROTEIN", 92, 106], ["S1", "PROTEIN", 107, 109], ["N", "PROTEIN", 111, 112], ["RBD", "PROTEIN", 125, 128], ["SARs", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["serological Simoa assays", "TEST", 11, 35], ["IgG1", "TEST", 40, 44], ["IgG2", "TEST", 46, 50], ["IgG3", "TEST", 52, 56], ["IgG4", "TEST", 62, 66], ["4 viral antigens S1", "PROBLEM", 90, 109], ["spike", "PROBLEM", 114, 119], ["RBD", "PROBLEM", 125, 128], ["RBD", "OBSERVATION", 125, 128]]], ["The detection antibodies from commercial sources are listed below.", [["detection antibodies", "PROTEIN", 4, 24], ["The detection antibodies", "TEST", 0, 24]]], ["Simoa assays were performed on an HD-X Analyzer 40 (Quanterix) in an automated three-step assay format according to the manufacturer's instructions and as previously described. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Table S1 .", [["Simoa assays", "TEST", 0, 12], ["an HD", "TREATMENT", 31, 36], ["med", "ANATOMY", 215, 218], ["S1", "ANATOMY", 459, 461]]], ["Manufacturer catalog information for commercial IgG subclass antibodies Antibody Target Manufacturer Catalog Number IgG1 Biolegend 409904 IgG2 Biolegend 411102 IgG3 R&D Systems 10122 IgG4 Biolegend 411202Standardizing the biomarkers for visualization and downstream analysisThis standardization was performed so that all the biomarkers can be placed on the same scale.Standardizing the biomarkers for visualization and downstream analysisThroughout the text when we refer to standardized data, the following procedure was performed.", [["411202", "CHEMICAL", 198, 204], ["IgG subclass antibodies Antibody Target Manufacturer Catalog Number IgG1 Biolegend 409904 IgG2 Biolegend 411102 IgG3 R&D Systems 10122 IgG4 Biolegend 411202", "PROTEIN", 48, 204], ["commercial IgG subclass antibodies", "TEST", 37, 71], ["IgG1", "TEST", 116, 120], ["Biolegend", "TEST", 121, 130], ["IgG2", "TEST", 138, 142], ["Standardizing the biomarkers", "TEST", 204, 232], ["visualization", "TEST", 237, 250], ["downstream analysis", "TEST", 255, 274], ["all the biomarkers", "TEST", 317, 335], ["Standardizing the biomarkers", "TEST", 368, 396], ["visualization", "TEST", 401, 414], ["downstream analysis", "TEST", 419, 438], ["the following procedure", "TREATMENT", 494, 517]]], ["15 First, the minimum nonzero value for each biomarker was stored, then the resulting vector was divided by 100 and added to every samples corresponding biomarker value, which is necessary for log transformation.", [["the minimum nonzero value", "TEST", 10, 35], ["each biomarker", "TEST", 40, 54], ["log transformation", "PROBLEM", 193, 211]]], ["The data was log transformed and then a second transformations step was performed such that each biomarker across the samples has an empirical mean of zero and variance of one.", [["a second transformations step", "TEST", 38, 67], ["the samples", "TEST", 114, 125]]], ["This is achieved by computing the mean and variance for each biomarker, subtracting the 20 mean, and then dividing by the variance.Cluster Map AnalysisThe cluster map analysis was performed on the standardized data.", [["each biomarker", "TEST", 56, 70], ["Cluster Map Analysis", "TEST", 131, 151], ["The cluster map analysis", "TEST", 151, 175], ["the standardized data", "TEST", 193, 214]]], ["Samples were removed if they had any missing values (reduced the number of samples from 272 to 252).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["any missing values", "PROBLEM", 33, 51]]], ["Specifically the cluster 25 map is a hierarchical clustering based on the Ward variance minimization algorithm, (https://docs.scipy.org/doc/scipy/reference/generated/scipy.cluster.hierarchy.linkage.html).Cluster Map Analysis.", [["cluster 25 map", "DNA", 17, 31], ["a hierarchical clustering", "PROBLEM", 35, 60], ["Map Analysis", "TEST", 212, 224]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure S1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Calibration curves for the two SARS-CoV-2 antigen assays: (1) single-plex nucleocapsid assay and (2) two-plex Spike (S1/ Spike) assay.", [["S1", "PROTEIN", 117, 119], ["Spike", "PROTEIN", 121, 126], ["Calibration curves", "TEST", 0, 18], ["the two SARS", "TEST", 23, 35], ["CoV-2 antigen assays", "TEST", 36, 56], ["single-plex nucleocapsid assay", "TEST", 62, 92], ["two-plex Spike (S1/ Spike) assay", "PROBLEM", 101, 133]]], ["Error bars represent the standard 10 deviations of duplicate measurements.", [["duplicate measurements", "TEST", 51, 73]]], ["Some errors bars are narrow and encompassed within the data point.II. Antigen Assay Development and Validation.", [["errors", "OBSERVATION_MODIFIER", 5, 11], ["bars", "OBSERVATION_MODIFIER", 12, 16], ["narrow", "OBSERVATION_MODIFIER", 21, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Cross-reactivity validation of two-plex Spike (S1/ Spike) assay.", [["Spike", "GENE_OR_GENE_PRODUCT", 51, 56], ["S1", "PROTEIN", 47, 49], ["Spike", "PROTEIN", 51, 56], ["Cross-reactivity validation", "TEST", 0, 27], ["two-plex Spike (S1/ Spike) assay", "PROBLEM", 31, 63]]], ["Left: S1 assay (S1 capture and S1 detector) captures both S1 and Spike.", [["Spike", "GENE_OR_GENE_PRODUCT", 65, 70], ["S1", "PROTEIN", 58, 60], ["Spike", "PROTEIN", 65, 70], ["S1 assay", "TEST", 6, 14], ["Spike", "PROBLEM", 65, 70], ["S1", "ANATOMY", 6, 8], ["S1", "ANATOMY", 58, 60], ["Spike", "OBSERVATION_MODIFIER", 65, 70]]], ["Right: Spike assay (S2 capture and S1 detector) captures Spike.", [["Spike", "PROTEIN", 57, 62], ["Spike assay", "PROBLEM", 7, 18], ["Spike", "PROBLEM", 57, 62]]], ["There is cross-reactivity in the Spike assay at high concentrations 5 (>400 pg/mL) of S1.", [["cross-reactivity", "PROBLEM", 9, 25], ["the Spike assay", "TEST", 29, 44], ["cross-reactivity", "OBSERVATION", 9, 25], ["Spike", "OBSERVATION_MODIFIER", 33, 38], ["S1", "ANATOMY", 86, 88]]], ["All samples measured in this study had S1 plasma concentrations below 400 pg/mL.", [["samples", "ANATOMY", 4, 11], ["plasma", "ANATOMY", 42, 48], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["All samples", "TEST", 0, 11], ["this study", "TEST", 24, 34], ["S1 plasma concentrations", "TREATMENT", 39, 63]]], ["Error bars represent the standard deviations of duplicate measurements.", [["duplicate measurements", "TEST", 48, 70], ["standard deviations", "OBSERVATION", 25, 44]]], ["Some errors bars are narrow and encompassed within the data point.", [["errors", "OBSERVATION_MODIFIER", 5, 11], ["bars", "OBSERVATION_MODIFIER", 12, 16], ["narrow", "OBSERVATION_MODIFIER", 21, 27]]], ["Samples were then serially diluted to 8X, 16X, and 32X.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Antigen concentrations are plotted as a function of 1/Dilution Factor below in Figure S3 .", [["Antigen concentrations", "TEST", 0, 22], ["a function", "TEST", 38, 48]]], ["20 Data for each sample were fit to a linear regression and R 2 values were calculated.", [["each sample", "TEST", 12, 23], ["a linear regression", "TEST", 36, 55], ["R 2 values", "TEST", 60, 70]]], ["R 2 values for all three plasma samples were >0.98 for S1, >0.95 for Spike, and >0.98 for Nucleocapsid.", [["plasma samples", "ANATOMY", 25, 39], ["R 2", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma samples", "ORGANISM_SUBSTANCE", 25, 39], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 90, 102], ["Spike", "PROTEIN", 69, 74], ["Nucleocapsid", "PROTEIN", 90, 102], ["R 2 values", "TEST", 0, 10], ["all three plasma samples", "TEST", 15, 39], ["S1", "TEST", 55, 57], ["Spike", "TEST", 69, 74], ["Nucleocapsid", "PROBLEM", 90, 102]]], ["Error bars represent the standard deviations of duplicate measurements.", [["duplicate measurements", "TEST", 48, 70], ["standard deviations", "OBSERVATION", 25, 44]]], ["Some errors bars are narrow and encompassed within the data point.Cross-reactivity validation of two-plex Spike (S1/ Spike) assay.", [["Spike", "GENE_OR_GENE_PRODUCT", 117, 122], ["S1", "PROTEIN", 113, 115], ["Spike", "PROTEIN", 117, 122], ["Cross-reactivity validation", "TEST", 66, 93], ["two-plex Spike (S1/ Spike) assay", "PROBLEM", 97, 129], ["errors", "OBSERVATION_MODIFIER", 5, 11], ["bars", "OBSERVATION_MODIFIER", 12, 16], ["narrow", "OBSERVATION_MODIFIER", 21, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For spike and recovery experiments, plasma samples were diluted to 8X and spiked with a final concentration of (1) 2,000 pg/mL, 400 pg/mL, or 80 pg/mL nucleocapsid for the nucleocapsid 5 assay, or (2) 2,000 pg/mL, 400 pg/mL, or 80 pg/mL S1 and Spike for the S1/ Spike assay.", [["plasma samples", "ANATOMY", 36, 50], ["plasma samples", "ORGANISM_SUBSTANCE", 36, 50], ["Spike", "GENE_OR_GENE_PRODUCT", 262, 267], ["S1", "PROTEIN", 258, 260], ["Spike", "PROTEIN", 262, 267], ["spike", "PROBLEM", 4, 9], ["plasma samples", "TEST", 36, 50], ["the nucleocapsid 5 assay", "TEST", 168, 192], ["Spike", "PROBLEM", 244, 249], ["the S1/ Spike assay", "TEST", 254, 273]]], ["Plasma samples at 8X dilution with no spiked recombinant protein (blank sample) were also analyzed.", [["Plasma samples", "ANATOMY", 0, 14], ["Plasma samples", "ORGANISM_SUBSTANCE", 0, 14], ["recombinant protein", "PROTEIN", 45, 64], ["Plasma samples", "TEST", 0, 14], ["8X dilution", "TEST", 18, 29], ["spiked recombinant protein", "PROBLEM", 38, 64], ["blank sample", "TEST", 66, 78]]], ["For each spiked sample, the concentration of antigen in each blank sample (0 pg/mL recombinant protein) was subtracted from the measured concentration before calculating percent recovery.", [["sample", "ANATOMY", 16, 22], ["sample", "ANATOMY", 67, 73], ["recombinant protein", "PROTEIN", 83, 102], ["the concentration of antigen in each blank sample", "TREATMENT", 24, 73]]], ["Percent recoveries for each sample and assay are displayed below in Table S2.", [["Percent recoveries", "TEST", 0, 18], ["each sample and assay", "TEST", 23, 44]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 326, 342], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure S5 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 313, 316]]], ["Viral antigen concentrations for each patient. a.)", [["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["Viral antigen concentrations", "PROBLEM", 0, 28]]], ["S1 (red), spike (black), and nucleocapsid (blue)concentrations plotted per patient from three control cohorts: pre-pandemic healthy, pre-pandemic sick, and patients who tested COVID-19 negative by NP RT-PCR. b.)", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["nucleocapsid (blue)", "GENE_OR_GENE_PRODUCT", 29, 48], ["patient", "ORGANISM", 75, 82], ["patients", "ORGANISM", 156, 164], ["S1", "PROTEIN", 0, 2], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 156, 164], ["spike (black)", "PROBLEM", 10, 23], ["nucleocapsid (blue)concentrations", "PROBLEM", 29, 62], ["COVID", "TEST", 176, 181], ["red", "OBSERVATION", 4, 7], ["spike", "OBSERVATION_MODIFIER", 10, 15]]], ["S1 (red), spike (black), and nucleocapsid (blue)concentrations plotted per patient from patients who 5 tested COVID-19 positive by NP RT-PCR.(which was not certified by peer review).", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["nucleocapsid (blue)", "GENE_OR_GENE_PRODUCT", 29, 48], ["patient", "ORGANISM", 75, 82], ["patients", "ORGANISM", 88, 96], ["S1", "PROTEIN", 0, 2], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 88, 96], ["spike (black)", "PROBLEM", 10, 23], ["nucleocapsid (blue)concentrations", "PROBLEM", 29, 62], ["COVID", "TEST", 110, 115], ["PCR", "TEST", 137, 140], ["red", "OBSERVATION", 4, 7], ["spike", "OBSERVATION_MODIFIER", 10, 15]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure S6 .", [["CC", "CHEMICAL", 0, 2], ["S6", "PROTEIN", 350, 352], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Simoa results for IgG, IgM, and IgG against four viral antigens: for samples collected from pre-pandemic healthy patients, pre-pandemic sick patients, COVID-19 negative patients, and COVID-19 positive patients.", [["samples", "ANATOMY", 69, 76], ["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgM", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 169, 177], ["COVID-19", "ORGANISM", 183, 191], ["patients", "ORGANISM", 201, 209], ["IgG", "PROTEIN", 18, 21], ["IgM", "PROTEIN", 23, 26], ["IgG", "PROTEIN", 32, 35], ["viral antigens", "PROTEIN", 49, 63], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 201, 209], ["IgG", "TEST", 18, 21], ["IgM", "TEST", 23, 26], ["IgG", "TEST", 32, 35], ["four viral antigens", "TEST", 44, 63], ["samples", "TEST", 69, 76], ["COVID", "TEST", 151, 156], ["COVID", "TEST", 183, 188]]], ["Each marker is the average AEB (average enzyme per bead) value from two replicate measurements.", [["AEB", "PROTEIN", 27, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["33 35 23 25 27 29 38 39 36 32 37 31 40 45 49 55 50 53 18 13 7 8 6 64 52 51 9 2 19 28 20 48 11 12 4 34 47 15 26 24 44 17 43 16 63 1 3 60 42 14 21 57 59 22 41 56 54 10 61 62 58Concentration (pg/mL).", [["21 57 59 22 41 56 54 10 61 62 58Concentration", "CHEMICAL", 142, 187]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprintAntigen and Immunoglobulin Data for All Patient SamplesFour plots are shown for each patient: (1) the total IgA, IgM, and IgG against four viral antigens (nucleocapsid, RBD, S1, and spike), (2) nucleocapsid antigen levels with IgA, IgM, and IgG against nucleocapsid, (3) S1 antigen levels with IgA, IgM, and IgG against S1, and (4) S1 antigen levels with IgG1-4 against S1.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprintAntigen", "GENE_OR_GENE_PRODUCT", 534, 557], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 562, 576], ["patient", "ORGANISM", 635, 642], ["IgA", "GENE_OR_GENE_PRODUCT", 658, 661], ["IgM", "GENE_OR_GENE_PRODUCT", 663, 666], ["IgG", "GENE_OR_GENE_PRODUCT", 672, 675], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 705, 717], ["RBD", "GENE_OR_GENE_PRODUCT", 719, 722], ["S1", "GENE_OR_GENE_PRODUCT", 724, 726], ["nucleocapsid antigen", "GENE_OR_GENE_PRODUCT", 744, 764], ["IgA", "GENE_OR_GENE_PRODUCT", 777, 780], ["IgM", "GENE_OR_GENE_PRODUCT", 782, 785], ["IgG against nucleocapsid, (3) S1 antigen", "GENE_OR_GENE_PRODUCT", 791, 831], ["IgA", "GENE_OR_GENE_PRODUCT", 844, 847], ["IgM", "GENE_OR_GENE_PRODUCT", 849, 852], ["IgG", "GENE_OR_GENE_PRODUCT", 858, 861], ["S1 antigen", "GENE_OR_GENE_PRODUCT", 882, 892], ["IgG1-4", "GENE_OR_GENE_PRODUCT", 905, 911], ["S1", "GENE_OR_GENE_PRODUCT", 920, 922], ["IgA", "PROTEIN", 658, 661], ["IgM", "PROTEIN", 663, 666], ["IgG", "PROTEIN", 672, 675], ["viral antigens", "PROTEIN", 689, 703], ["nucleocapsid", "PROTEIN", 705, 717], ["RBD", "PROTEIN", 719, 722], ["S1", "PROTEIN", 724, 726], ["nucleocapsid antigen", "PROTEIN", 744, 764], ["IgA", "PROTEIN", 777, 780], ["IgM", "PROTEIN", 782, 785], ["IgG", "PROTEIN", 791, 794], ["IgA", "PROTEIN", 844, 847], ["IgM", "PROTEIN", 849, 852], ["IgG", "PROTEIN", 858, 861], ["S1", "PROTEIN", 870, 872], ["IgG1", "PROTEIN", 905, 909], ["S1", "PROTEIN", 920, 922], ["Patient", "SPECIES", 590, 597], ["patient", "SPECIES", 635, 642], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintAntigen", "TREATMENT", 534, 557], ["Immunoglobulin Data", "TREATMENT", 562, 581], ["All Patient SamplesFour plots", "TEST", 586, 615], ["the total IgA", "TEST", 648, 661], ["IgM", "TEST", 663, 666], ["IgG", "TEST", 672, 675], ["four viral antigens", "TEST", 684, 703], ["nucleocapsid", "TEST", 705, 717], ["RBD", "TEST", 719, 722], ["S1", "TEST", 724, 726], ["spike", "TEST", 732, 737], ["nucleocapsid antigen levels", "TEST", 744, 771], ["IgA", "TEST", 777, 780], ["IgM", "TEST", 782, 785], ["IgG", "TEST", 791, 794], ["nucleocapsid", "TEST", 803, 815], ["S1 antigen levels", "TEST", 821, 838], ["IgA", "TEST", 844, 847], ["IgM", "TEST", 849, 852], ["IgG", "TEST", 858, 861], ["S1 antigen levels", "TEST", 882, 899], ["IgG1", "TEST", 905, 909], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 313, 316], ["S1", "ANATOMY", 724, 726]]], ["Six patients had detectable levels of Spike in their plasma.", [["plasma", "ANATOMY", 53, 59], ["patients", "ORGANISM", 4, 12], ["Spike", "GENE_OR_GENE_PRODUCT", 38, 43], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["Spike", "PROTEIN", 38, 43], ["patients", "SPECIES", 4, 12], ["Spike in their plasma", "PROBLEM", 38, 59]]], ["5 For those patients, a fifth plot of Spike antigen levels with IgA, IgM, and IgG against Spike is also shown.", [["patients", "ORGANISM", 12, 20], ["Spike antigen", "GENE_OR_GENE_PRODUCT", 38, 51], ["IgA", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgM", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 78, 81], ["Spike antigen", "PROTEIN", 38, 51], ["IgA", "PROTEIN", 64, 67], ["IgM", "PROTEIN", 69, 72], ["IgG", "PROTEIN", 78, 81], ["Spike", "PROTEIN", 90, 95], ["patients", "SPECIES", 12, 20], ["a fifth plot", "TEST", 22, 34], ["Spike antigen levels", "TEST", 38, 58], ["IgA", "TEST", 64, 67], ["IgM", "TEST", 69, 72], ["IgG", "TEST", 78, 81], ["Spike", "PROBLEM", 90, 95]]], ["Plots for Patients 21, 22, 26, and 39 can be found in the main text. .", [["Patients", "ORGANISM", 10, 18], ["Patients", "SPECIES", 10, 18], ["Plots", "TEST", 0, 5], ["main text", "ANATOMY", 58, 67]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 313, 316]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 313, 316]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprintIV.", [["CC", "CHEMICAL", 0, 2], ["CC", "CHEMICAL", 592, 594], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintIV", "TREATMENT", 959, 977], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 313, 316], ["med", "ANATOMY", 697, 700]]], ["Statistical AnalysisStatistical analysis was performed in GraphPad Prism version 8.3.0.", [["Statistical AnalysisStatistical analysis", "TEST", 0, 40]]], ["Statistics for S1 as predictors of clinical outcomes (3 groups).", [["S1", "PROTEIN", 15, 17]]], ["Patients were split into 5 three groups based on S1 levels: (1) undetectable antigen levels (below the limit of detection/LOD), (2) low levels of antigen (6-50 pg/mL), and (3) To confirm that splitting the patients into three groups based on S1 levels in plasma did not 10 affect the results of analysis of clinical outcomes (compared to splitting patients into two groups: undetectable S1 levels and detectable S1 levels), we repeated the statistical analysis using two patient groups.", [["plasma", "ANATOMY", 255, 261], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 206, 214], ["S1", "GENE_OR_GENE_PRODUCT", 242, 244], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["patients", "ORGANISM", 348, 356], ["patient", "ORGANISM", 471, 478], ["S1", "PROTEIN", 242, 244], ["S1", "PROTEIN", 387, 389], ["S1", "PROTEIN", 412, 414], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 348, 356], ["patient", "SPECIES", 471, 478], ["S1 levels", "TEST", 49, 58], ["antigen levels", "TEST", 77, 91], ["detection/LOD", "TEST", 112, 125], ["low levels of antigen", "PROBLEM", 132, 153], ["S1 levels in plasma", "TEST", 242, 261], ["S1 levels", "TEST", 387, 396], ["the statistical analysis", "TEST", 436, 460], ["S1", "ANATOMY", 49, 51]]], ["When split into two groups, the differences in fraction of patients admitted to the ICU and mean days between hospitalization and intubation are still significant.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["intubation", "TREATMENT", 130, 140]]], ["15 Table S6 .", [["S6", "PROTEIN", 9, 11]]], ["Statistics for S1 as predictors of clinical outcomes (2 groups).", [["S1", "PROTEIN", 15, 17]]], ["Patients were split into two groups based on S1 levels: (1) undetectable N levels (below the limit of detection/LOD) and (2) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["S1 levels", "TEST", 45, 54], ["S1", "ANATOMY", 45, 47]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IV.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["IV", "TREATMENT", 202, 204], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Statistical AnalysisThe copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprintDays between hospitalization and intubationMann-Whitney test 0.0138 (significant)Days between hospitalization and intubationLength of intubation Mann-Whitney test 0.2871 (not significant)Days between hospitalization and intubationIn addition to S1, we assessed if nucleocapsid levels in plasma are indicators of disease severity in COVID-19.", [["plasma", "ANATOMY", 448, 454], ["plasma", "ORGANISM_SUBSTANCE", 448, 454], ["medRxiv preprintDays", "TREATMENT", 145, 165], ["intubation", "TREATMENT", 194, 204], ["intubation", "TREATMENT", 295, 305], ["nucleocapsid levels", "TEST", 425, 444], ["disease severity", "PROBLEM", 473, 489], ["COVID", "TEST", 493, 498], ["disease", "OBSERVATION", 473, 480]]], ["The results are plotted below in Figure S43 and the results of the statistical analysis are shown in Table S6 .", [["S6", "PROTEIN", 107, 109], ["the statistical analysis", "TEST", 63, 87]]], ["For nucleocapsid, the difference in fraction of patients admitted to the ICU upon presentation is significantly different between the two groups ( Figure S43A ).", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["nucleocapsid", "PROBLEM", 4, 16]]], ["Statistics for Nucleocapsid as predictors of clinical outcomes (2 groups).", [["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 15, 27]]], ["Patients were split into two groups based on nucleocapsid levels: (1) undetectable antigen levels (below the limit of detection/LOD) and (2) Table S8 .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["nucleocapsid levels", "TEST", 45, 64], ["antigen levels", "TEST", 83, 97], ["LOD", "TEST", 128, 131]]], ["Statistics for death rates.", [["death", "DISEASE", 15, 20], ["death rates", "TEST", 15, 26]]], ["Antigen Test P value S1 (3 groups: 50 pg/mL) Chi-square test 0.1921 (not significant) S1 (2 groups: LOD) Fisher's exact test 0.5636 (not significant) N (2 groups: LOD)Days between hospitalization and intubationFisher's exact test 0.5148 (not significant)Days between hospitalization and intubation.", [["Antigen Test", "TEST", 0, 12], ["value S1", "TEST", 15, 23], ["Chi-square test", "TEST", 45, 60], ["Fisher's exact test", "TEST", 105, 124], ["intubationFisher's exact test", "TEST", 200, 229], ["intubation", "TREATMENT", 287, 297]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Days between hospitalization and intubationThe copyright holder for this preprint this version posted July 26, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["intubation", "TREATMENT", 235, 245], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Days between hospitalization and intubationThe copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint Figure S48 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["intubation", "TREATMENT", 235, 245], ["med", "ANATOMY", 105, 108]]], ["Correlated S1 and IgA (against S1) levels in individual patient saliva samples.", [["saliva samples", "ANATOMY", 64, 78], ["S1", "GENE_OR_GENE_PRODUCT", 11, 13], ["IgA (against S1", "GENE_OR_GENE_PRODUCT", 18, 33], ["patient", "ORGANISM", 56, 63], ["saliva samples", "ORGANISM_SUBSTANCE", 64, 78], ["S1", "PROTEIN", 11, 13], ["IgA", "PROTEIN", 18, 21], ["S1", "PROTEIN", 31, 33], ["patient", "SPECIES", 56, 63], ["IgA", "TEST", 18, 21], ["individual patient saliva samples", "TEST", 45, 78]]], ["S1 levels measured below the LOD (5 pg/mL in saliva) are considered undetectable.", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["saliva", "ORGANISM_SUBSTANCE", 45, 51], ["S1", "PROTEIN", 0, 2], ["S1 levels", "TEST", 0, 9], ["the LOD", "TEST", 25, 32], ["undetectable", "OBSERVATION", 68, 80]]], ["IgA levels with AEB< 0.05 are considered background level readings.", [["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgA", "PROTEIN", 0, 3], ["IgA levels", "TEST", 0, 10], ["AEB", "TEST", 16, 19]]], ["COVID-19 positive patients are plotted on the left side of the graph (S1-S12) and COVID-19 negative patients are plotted on the 5 right side of the graph (S13-S19).S1S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 IgA S1S1.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 100, 108], ["IgA", "GENE_OR_GENE_PRODUCT", 230, 233], ["COVID", "PROTEIN", 82, 87], ["S13", "PROTEIN", 155, 158], ["S1S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 IgA S1S1", "PROTEIN", 164, 238], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 100, 108], ["COVID", "TEST", 0, 5], ["COVID", "TEST", 82, 87], ["left", "ANATOMY_MODIFIER", 46, 50], ["right", "ANATOMY_MODIFIER", 130, 135]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)S1The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20156372 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 105, 108]]]], "05232635a5cc30ce5fe029c9903db924cdbed52e": [["IntroductionPulmonary hypertension (PH) is a chronic and progressive lung disease caused by multiple differing etiologies.", [["IntroductionPulmonary", "ANATOMY", 0, 21], ["lung", "ANATOMY", 69, 73], ["IntroductionPulmonary hypertension", "DISEASE", 0, 34], ["PH", "DISEASE", 36, 38], ["lung disease", "DISEASE", 69, 81], ["lung", "ORGAN", 69, 73], ["IntroductionPulmonary hypertension (PH)", "PROBLEM", 0, 39], ["a chronic", "PROBLEM", 43, 52], ["progressive lung disease", "PROBLEM", 57, 81], ["multiple differing etiologies", "PROBLEM", 92, 121], ["hypertension", "OBSERVATION", 22, 34], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["progressive", "OBSERVATION_MODIFIER", 57, 68], ["lung", "ANATOMY", 69, 73], ["disease", "OBSERVATION", 74, 81], ["multiple", "OBSERVATION_MODIFIER", 92, 100], ["differing", "OBSERVATION_MODIFIER", 101, 110], ["etiologies", "OBSERVATION", 111, 121]]], ["Increasing pulmonary vascular resistance led to overloading of the right ventricle and eventually death.", [["pulmonary vascular", "ANATOMY", 11, 29], ["right ventricle", "ANATOMY", 67, 82], ["overloading of the right ventricle", "DISEASE", 48, 82], ["death", "DISEASE", 98, 103], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 11, 29], ["right ventricle", "MULTI-TISSUE_STRUCTURE", 67, 82], ["Increasing pulmonary vascular resistance", "PROBLEM", 0, 40], ["overloading of the right ventricle", "PROBLEM", 48, 82], ["eventually death", "PROBLEM", 87, 103], ["pulmonary", "ANATOMY_MODIFIER", 11, 20], ["vascular", "ANATOMY", 21, 29], ["resistance", "OBSERVATION", 30, 40], ["overloading", "OBSERVATION", 48, 59], ["right ventricle", "ANATOMY", 67, 82]]], ["1 PH is characterized by a mean pulmonary artery pressure (mPAP) ! 25 mmHg at rest.", [["pulmonary artery", "ANATOMY", 32, 48], ["PH", "DISEASE", 2, 4], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 32, 48], ["a mean pulmonary artery pressure", "TEST", 25, 57], ["pulmonary artery", "ANATOMY", 32, 48], ["pressure", "OBSERVATION_MODIFIER", 49, 57]]], ["In addition to the treatment of relieving symptoms, targeted therapy aiming to improve heart function extended three-year survival of pulmonary arterial hypertension (PAH) from 39% to 75%.", [["heart", "ANATOMY", 87, 92], ["pulmonary arterial", "ANATOMY", 134, 152], ["pulmonary arterial hypertension", "DISEASE", 134, 165], ["PAH", "DISEASE", 167, 170], ["heart", "ORGAN", 87, 92], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 134, 152], ["relieving symptoms", "PROBLEM", 32, 50], ["targeted therapy", "TREATMENT", 52, 68], ["pulmonary arterial hypertension", "PROBLEM", 134, 165], ["heart", "ANATOMY", 87, 92], ["pulmonary arterial", "ANATOMY", 134, 152], ["hypertension", "OBSERVATION", 153, 165]]], ["2, 3 Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in last December.", [["Coronavirus disease", "DISEASE", 5, 24], ["COVID-19", "CHEMICAL", 31, 39], ["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 51, 98], ["SARS-CoV-2", "ORGANISM", 100, 110], ["severe acute respiratory syndrome coronavirus", "SPECIES", 51, 96], ["SARS-CoV-2", "SPECIES", 100, 110], ["3 Coronavirus disease", "PROBLEM", 3, 24], ["COVID", "TEST", 31, 36], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 51, 96], ["Coronavirus disease", "OBSERVATION", 5, 24], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["4 Studies observed severe damage in the lung, which raised the hypothesis that PH patients might be more vulnerable than others.", [["lung", "ANATOMY", 40, 44], ["PH", "DISEASE", 79, 81], ["lung", "ORGAN", 40, 44], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["4 Studies", "TEST", 0, 9], ["severe damage in the lung", "PROBLEM", 19, 44], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["damage", "OBSERVATION", 26, 32], ["lung", "ANATOMY", 40, 44]]], ["5 Subsequently, the whole country was placed in lockdown to prevent the spread of the disease, which potentially could compromise PH patient care.", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["lockdown", "TREATMENT", 48, 56], ["the disease", "PROBLEM", 82, 93], ["PH patient care", "TREATMENT", 130, 145], ["disease", "OBSERVATION", 86, 93]]], ["All these factors made PH patients a potentially vulnerable group.", [["PH", "DISEASE", 23, 25], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Hereby, we designed a questionnaire for PH patients to understand their disease condition, mental condition, medication supplement, and requirements in medical care during COVID-19 outbreak.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["PH patients", "PROBLEM", 40, 51], ["their disease condition", "PROBLEM", 66, 89], ["mental condition", "PROBLEM", 91, 107], ["medication supplement", "TREATMENT", 109, 130]]], ["The survey would provide general information for future medical care and support to PH patients in such conditions.Design and participantsThe study was conducted by experts from Congenital Heart Disease Center at Wuhan Asia Heart Hospital in Wuhan in collaboration with other PH centers and unofficial patients groups.", [["PH", "DISEASE", 84, 86], ["Congenital Heart Disease", "DISEASE", 178, 202], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 87, 95], ["participants", "SPECIES", 126, 138], ["patients", "SPECIES", 302, 310], ["future medical care", "TREATMENT", 49, 68], ["The study", "TEST", 138, 147], ["Heart", "ANATOMY", 189, 194], ["Disease", "OBSERVATION", 195, 202]]], ["Patients diagnosed with PH and their families were considered for the survey.", [["PH", "DISEASE", 24, 26], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["PH", "TEST", 24, 26]]], ["PH was defined as mPAP ! 25 mmHg at rest.", [["PH", "DISEASE", 0, 2], ["mPAP", "PROTEIN", 18, 22], ["PH", "TEST", 0, 2], ["mPAP", "TEST", 18, 22]]], ["All diagnosis was made according to right heart catheter examination.Design and participantsA small-scale national online survey was performed.", [["right heart", "ANATOMY", 36, 47], ["heart", "ORGAN", 42, 47], ["participants", "SPECIES", 80, 92], ["right heart catheter examination", "TEST", 36, 68], ["right", "ANATOMY_MODIFIER", 36, 41], ["heart", "ANATOMY", 42, 47], ["catheter", "OBSERVATION", 48, 56]]], ["PH patients and one of their family members were invited to participate in the survey via Quick Response (QR) code.", [["PH", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["The study protocol and questionnaire were reviewed and approved by the Ethics Committee of Wuhan Asia Heart Hospital (2020-S-002).", [["The study protocol", "TEST", 0, 18]]], ["Participants were given informed consent during the survey.Design and participantsThe questionnaire was designed by experts on PH in Wuhan Asia Heart Hospital, Wuhan, China.", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 70, 82]]], ["To understand the status of PH patients during COVID-19 outbreak in China, the questions were designed to cover the following issues: (1) basic clinical information of the patients, including age, gender, medical history of PH, and current heart function; (2) physical and mental conditions associated with COVID-19; and (3) details of the medications they were using and requirements for medical care if any.", [["heart", "ANATOMY", 240, 245], ["PH", "DISEASE", 28, 30], ["PH", "DISEASE", 224, 226], ["COVID-19", "CHEMICAL", 307, 315], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 172, 180], ["heart", "ORGAN", 240, 245], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 172, 180], ["PH", "PROBLEM", 224, 226], ["current heart function", "PROBLEM", 232, 254], ["physical and mental conditions", "PROBLEM", 260, 290], ["COVID", "TEST", 307, 312], ["the medications", "TREATMENT", 336, 351], ["medical care", "TREATMENT", 389, 401], ["heart", "ANATOMY", 240, 245]]], ["The questionnaire is still open for recruitment (questionnaire in Supplement).", [["recruitment (questionnaire in Supplement", "TREATMENT", 36, 76]]], ["Here, we present the preliminary data from the first respondents.Statistical analysisBaseline characteristics are presented as number for categorical data, and mean AE standard deviation or median with interquartile range as appropriate for continuous data.", [["categorical data", "TEST", 138, 154], ["continuous data", "TEST", 241, 256]]], ["Comparison was made between variables using Student's t-test or Wilcoxon signed-rank test for continuous variables regarding their distributions and with the v 2 test for categorical variables.", [["Student's t-test", "TEST", 44, 60], ["rank test", "TEST", 80, 89], ["the v 2 test", "TEST", 154, 166], ["categorical variables", "TEST", 171, 192]]], ["A p-value of < 0.05 was considered as statistically significant.", [["A p-value", "TEST", 0, 9]]], ["All statistical analyses were performed with SPSS 23.0 (IBM Corp, Armonk, NY).ParticipantsOver 300 individuals were invited to participate in this survey.", [["All statistical analyses", "TEST", 0, 24], ["SPSS", "TEST", 45, 49]]], ["A total of 120 PH patients and 23 family members from 16 provinces responded from 1 March 2020 to 11 March 2020.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["All questionnaires were included in final analysis.", [["All questionnaires", "TEST", 0, 18], ["final analysis", "TEST", 36, 50]]], ["A total of 64.8% (n \u00bc 87) participants were from Hubei, among which 29.9% (n \u00bc 26) were from Wuhan; 13.3% (n \u00bc 19) were from Henan, 7.0% (n \u00bc 10) from Anhui, and 18.9% (n \u00bc 27) came from other 13 provinces (as shown in Fig. 1 ).", [["participants", "ORGANISM", 26, 38], ["participants", "SPECIES", 26, 38], ["A total", "TEST", 0, 7], ["Henan", "TEST", 125, 130], ["Anhui", "TEST", 151, 156], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Both patients and their family members completed the survey in 13 families; however, we failed to identify them due to the design.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Table 1 shows general information of the participants.", [["participants", "SPECIES", 41, 53]]], ["Overall participants were aged 32.3 AE 11.5 years.", [["participants", "ORGANISM", 8, 20], ["participants", "SPECIES", 8, 20]]], ["A total of 61 patients suffered PH more than seven years.", [["PH", "DISEASE", 32, 34], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Three family participants did not know PH history of their relatives.", [["participants", "SPECIES", 13, 25]]], ["Possibly due to the different etiology, 6 CHD-PAH contributed most in PH groups (79, 65.8% in patients; 13, 56.5% in family participants; p < 0.001).New onset symptomsA total of 98.6% (n \u00bc 141) participants were in home quarantine during COVID-19 outbreak.", [["CHD", "DISEASE", 42, 45], ["PAH", "DISEASE", 46, 49], ["PH", "DISEASE", 70, 72], ["PAH", "CHEMICAL", 46, 49], ["patients", "ORGANISM", 94, 102], ["participants", "ORGANISM", 194, 206], ["patients", "SPECIES", 94, 102], ["participants", "SPECIES", 124, 136], ["participants", "SPECIES", 194, 206], ["PAH", "PROBLEM", 46, 49], ["PH groups", "TEST", 70, 79], ["New onset symptomsA", "PROBLEM", 149, 168], ["onset", "OBSERVATION_MODIFIER", 153, 158], ["symptomsA", "OBSERVATION_MODIFIER", 159, 168], ["total", "OBSERVATION_MODIFIER", 169, 174]]], ["Table 1 shows the majority of participants (121, 84.6%) felt not much change on disease progress.", [["participants", "ORGANISM", 30, 42], ["participants", "SPECIES", 30, 42]]], ["Surprisingly, most patients were with less severe symptoms as 46.9% (n \u00bc 67) participants proclaimed New York Heart Association heart functional class I and 44 (30.8%) were class II.", [["heart", "ANATOMY", 128, 133], ["heart functional class I", "DISEASE", 128, 152], ["patients", "ORGANISM", 19, 27], ["heart", "ORGAN", 128, 133], ["patients", "SPECIES", 19, 27], ["participants", "SPECIES", 77, 89], ["less severe symptoms", "PROBLEM", 38, 58], ["heart", "ANATOMY", 128, 133]]], ["A total of 83.3% (n \u00bc 100) patients and 91.3% (n \u00bc 21) family participants reported the disease progression was the same as before.", [["patients", "ORGANISM", 27, 35], ["participants", "ORGANISM", 62, 74], ["patients", "SPECIES", 27, 35], ["participants", "SPECIES", 62, 74], ["A total", "TEST", 0, 7], ["the disease progression", "PROBLEM", 84, 107], ["disease", "OBSERVATION", 88, 95]]], ["Fatigue and less active was more reported in patients (20% vs 0, p \u00bc 0.026); however, cough was common in both patients and family participants (5.8% vs 13.0%, p \u00bc 0.203) (as shown in Fig. 2 ).", [["Fatigue", "DISEASE", 0, 7], ["cough", "DISEASE", 86, 91], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 111, 119], ["participants", "SPECIES", 131, 143], ["Fatigue", "PROBLEM", 0, 7], ["cough", "PROBLEM", 86, 91], ["less", "OBSERVATION_MODIFIER", 12, 16], ["active", "OBSERVATION_MODIFIER", 17, 23]]], ["Symptoms in ''Others'' included not sleeping well, chest pain, aching pain in limbs, and catching a cold but recovered.", [["chest", "ANATOMY", 51, 56], ["limbs", "ANATOMY", 78, 83], ["chest pain", "DISEASE", 51, 61], ["pain", "DISEASE", 70, 74], ["chest", "ORGANISM_SUBDIVISION", 51, 56], ["limbs", "ORGANISM_SUBDIVISION", 78, 83], ["Symptoms", "PROBLEM", 0, 8], ["chest pain", "PROBLEM", 51, 61], ["aching pain in limbs", "PROBLEM", 63, 83], ["catching a cold", "PROBLEM", 89, 104], ["chest", "ANATOMY", 51, 56], ["limbs", "ANATOMY", 78, 83]]], ["There were three (2.5%) patients hospitalized during COVID-19 outbreak, two of them were because of heart failure and one was due to pneumonia.", [["heart", "ANATOMY", 100, 105], ["heart failure", "DISEASE", 100, 113], ["pneumonia", "DISEASE", 133, 142], ["patients", "ORGANISM", 24, 32], ["heart", "ORGAN", 100, 105], ["patients", "SPECIES", 24, 32], ["COVID", "TEST", 53, 58], ["heart failure", "PROBLEM", 100, 113], ["pneumonia", "PROBLEM", 133, 142], ["heart", "ANATOMY", 100, 105], ["failure", "OBSERVATION", 106, 113], ["pneumonia", "OBSERVATION", 133, 142]]], ["None of the family participants reported death of patients.", [["death", "DISEASE", 41, 46], ["patients", "ORGANISM", 50, 58], ["participants", "SPECIES", 19, 31], ["patients", "SPECIES", 50, 58]]], ["Actually, three patients passed away by 11 March 2020.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["One of the patients died due to an unexpected fall and unable to go to hospital during outbreak.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["an unexpected fall", "PROBLEM", 32, 50], ["fall", "OBSERVATION", 46, 50]]], ["Two died from worsening of PAH.", [["PAH", "DISEASE", 27, 30], ["PAH", "CHEMICAL", 27, 30], ["PAH", "PROBLEM", 27, 30], ["worsening", "OBSERVATION_MODIFIER", 14, 23], ["PAH", "OBSERVATION", 27, 30]]], ["All deaths were reported by family privately, and not included in the survey.New onset symptomsFever is an important symptom indicating COVID-19.", [["deaths", "DISEASE", 4, 10], ["symptomsFever", "DISEASE", 87, 100], ["New onset symptomsFever", "PROBLEM", 77, 100], ["an important symptom", "PROBLEM", 104, 124], ["COVID", "TEST", 136, 141]]], ["In our survey, 5.0% (n \u00bc 6) patients had fever with highest temperature of 39.8 C. One patient was confirmed SARS-CoV-2 infection, and two patients reported COVID-19 related symptoms (cough) in their families.", [["fever", "DISEASE", 41, 46], ["SARS-CoV-2 infection", "DISEASE", 109, 129], ["cough", "DISEASE", 184, 189], ["patients", "ORGANISM", 28, 36], ["patient", "ORGANISM", 87, 94], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 28, 36], ["patient", "SPECIES", 87, 94], ["patients", "SPECIES", 139, 147], ["SARS-CoV-2", "SPECIES", 109, 119], ["fever", "PROBLEM", 41, 46], ["highest temperature", "TEST", 52, 71], ["SARS", "PROBLEM", 109, 113], ["CoV-2 infection", "PROBLEM", 114, 129], ["COVID", "TEST", 157, 162], ["related symptoms", "PROBLEM", 166, 182], ["cough", "PROBLEM", 184, 189], ["infection", "OBSERVATION", 120, 129]]], ["All family participants denied COVID-19 related symptoms in either themselves or patients.MedicationsBosentan, Ambrisentan, Tadalafil, and Sildenafil were most commonly used medications for target therapy (as shown in Fig. 3 ).", [["Bosentan", "CHEMICAL", 101, 109], ["Ambrisentan", "CHEMICAL", 111, 122], ["Tadalafil", "CHEMICAL", 124, 133], ["Sildenafil", "CHEMICAL", 139, 149], ["Bosentan", "CHEMICAL", 101, 109], ["Ambrisentan", "CHEMICAL", 111, 122], ["Tadalafil", "CHEMICAL", 124, 133], ["Sildenafil", "CHEMICAL", 139, 149], ["patients", "ORGANISM", 81, 89], ["Bosentan", "SIMPLE_CHEMICAL", 101, 109], ["Ambrisentan", "SIMPLE_CHEMICAL", 111, 122], ["Tadalafil", "SIMPLE_CHEMICAL", 124, 133], ["Sildenafil", "SIMPLE_CHEMICAL", 139, 149], ["participants", "SPECIES", 11, 23], ["patients", "SPECIES", 81, 89], ["COVID-19 related symptoms", "PROBLEM", 31, 56], ["Medications", "TREATMENT", 90, 101], ["Bosentan", "TREATMENT", 101, 109], ["Ambrisentan", "TREATMENT", 111, 122], ["Tadalafil", "TREATMENT", 124, 133], ["Sildenafil", "TREATMENT", 139, 149], ["medications", "TREATMENT", 174, 185], ["target therapy", "TREATMENT", 190, 204]]], ["Specifically, Ambrisentan was preferred in 57.5% (n \u00bc 69) patients and 60.9% (n \u00bc 14) family participants.", [["Ambrisentan", "CHEMICAL", 14, 25], ["Ambrisentan", "CHEMICAL", 14, 25], ["Ambrisentan", "SIMPLE_CHEMICAL", 14, 25], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["participants", "SPECIES", 93, 105], ["Ambrisentan", "TREATMENT", 14, 25]]], ["A total of 21.6% (n \u00bc 26) patients and 26.1% (n \u00bc 6) family participants chose Chinese generic Ambrisentan because of the lower price in Chinese generic medication.", [["Ambrisentan", "CHEMICAL", 95, 106], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["participants", "SPECIES", 60, 72], ["A total", "TEST", 0, 7], ["Chinese generic Ambrisentan", "TREATMENT", 79, 106], ["the lower price", "TREATMENT", 118, 133], ["Chinese generic medication", "TREATMENT", 137, 163], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["There were 17 patients enrolling in clinical trial and using Macitentan for free.", [["Macitentan", "CHEMICAL", 61, 71], ["patients", "ORGANISM", 14, 22], ["Macitentan", "SIMPLE_CHEMICAL", 61, 71], ["patients", "SPECIES", 14, 22], ["Macitentan", "TREATMENT", 61, 71]]], ["Patients were more sensitive to the shortage of medications than family participants (62, 51.7% vs 4, 17.4%, p \u00bc 0.003).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["participants", "SPECIES", 72, 84], ["medications", "TREATMENT", 48, 59]]], ["There were 26.6% participants (29 in patients; 9 in family participants) who thought they had enough medications by the time of survey, when it was at least 40 days after national lockdown (as shown in Fig. 4a) .", [["patients", "ORGANISM", 37, 45], ["participants", "SPECIES", 17, 29], ["patients", "SPECIES", 37, 45], ["participants", "SPECIES", 59, 71], ["medications", "TREATMENT", 101, 112]]], ["A total of 40.0% (n \u00bc 48) patients were able to buy more medications with great effort; however, 24.2% (n \u00bc 29) discontinued one or more medications.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["A total", "TEST", 0, 7], ["medications", "TREATMENT", 57, 68], ["medications", "TREATMENT", 137, 148], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["There were 10 (7.0%) patients changing their medications without consulting their doctors (as shown in Fig. 4a) , two of which previously took Macitentan.", [["Macitentan", "CHEMICAL", 143, 153], ["Macitentan", "CHEMICAL", 143, 153], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["their medications", "TREATMENT", 39, 56], ["Macitentan", "TREATMENT", 143, 153]]], ["A total of 100 participants (69.9%) thought they had medications shortage during COVID-19 outbreak (as shown in Fig. 4b ).MedicationsPsychological conditions Over 20.0% patients (n \u00bc 29) and family participants (n \u00bc 6) had panic, but most of them (89, 62.2%) thought protection was important (as shown in Fig. 5a ).", [["panic", "DISEASE", 223, 228], ["patients", "ORGANISM", 169, 177], ["participants", "SPECIES", 15, 27], ["patients", "SPECIES", 169, 177], ["participants", "SPECIES", 198, 210], ["medications", "TREATMENT", 53, 64], ["COVID", "TEST", 81, 86], ["Medications", "TREATMENT", 122, 133], ["Psychological conditions", "PROBLEM", 133, 157], ["panic", "PROBLEM", 223, 228]]], ["Though 48.3% (n \u00bc 58) patients and 39.1% (n \u00bc 9) family participants felt bad due to the disease, more than 70% (85 in patients; 18 in family participants) participants still kept optimistic at the same time (as shown in Fig. 5b ).Further requirement in medical careBoth PH patients and their families requested further medical care despite of a lack of clear clinical worsening according to our survey.", [["patients", "ORGANISM", 22, 30], ["participants", "ORGANISM", 56, 68], ["patients", "ORGANISM", 119, 127], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 22, 30], ["participants", "SPECIES", 56, 68], ["patients", "SPECIES", 119, 127], ["participants", "SPECIES", 142, 154], ["participants", "SPECIES", 156, 168], ["patients", "SPECIES", 274, 282], ["the disease", "PROBLEM", 85, 96], ["further medical care", "TREATMENT", 312, 332], ["clear clinical worsening", "PROBLEM", 354, 378], ["disease", "OBSERVATION", 89, 96]]], ["A total of 11.7% (n \u00bc 14) patients and 26.1% (n \u00bc 6) family participants would like to contact their doctors during COVID-19 outbreak; 61.7% (n \u00bc 74) patients would go to the hospital for follow-up immediately after public transportation was available, eight of whom preferred hospitalization; and 60.9% (n \u00bc 14) family participants would ask their relatives with PH go to the hospital as soon as possible, which was similar to patients.", [["patients", "ORGANISM", 26, 34], ["participants", "ORGANISM", 60, 72], ["patients", "ORGANISM", 150, 158], ["participants", "ORGANISM", 320, 332], ["patients", "ORGANISM", 428, 436], ["patients", "SPECIES", 26, 34], ["participants", "SPECIES", 60, 72], ["patients", "SPECIES", 150, 158], ["participants", "SPECIES", 320, 332], ["patients", "SPECIES", 428, 436], ["A total", "TEST", 0, 7], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Additionally, 73.9% (n \u00bc 17) family participants would also encourage patients to be more positive.DiscussionThe outbreak of COVID-19 changed most people's life in last winter.", [["COVID-19", "CHEMICAL", 125, 133], ["COVID-19", "CHEMICAL", 125, 133], ["participants", "ORGANISM", 36, 48], ["patients", "ORGANISM", 70, 78], ["people", "ORGANISM", 147, 153], ["participants", "SPECIES", 36, 48], ["patients", "SPECIES", 70, 78], ["people", "SPECIES", 147, 153]]], ["Specifically, patients with chronic diseases might suffer from the high risk of COVID-19 and uncontrolled existing diseases at the same time.", [["chronic diseases", "DISEASE", 28, 44], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["chronic diseases", "PROBLEM", 28, 44], ["COVID", "TEST", 80, 85], ["uncontrolled existing diseases", "PROBLEM", 93, 123], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["diseases", "OBSERVATION", 36, 44], ["diseases", "OBSERVATION", 115, 123]]], ["PH patients require sustained medical care similar to other chronic diseases.", [["PH", "DISEASE", 0, 2], ["chronic diseases", "DISEASE", 60, 76], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["sustained medical care", "TREATMENT", 20, 42], ["other chronic diseases", "PROBLEM", 54, 76], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["diseases", "OBSERVATION", 68, 76]]], ["Any interruption in medications may result in clinical worsening and death.", [["death", "DISEASE", 69, 74], ["medications", "TREATMENT", 20, 31], ["clinical worsening", "PROBLEM", 46, 64], ["death", "PROBLEM", 69, 74]]], ["However, their living condition during COVID-19 was unknown.", [["COVID-19", "CHEMICAL", 39, 47], ["COVID", "TEST", 39, 44]]], ["Our small-scale national survey brought an insight to this group.", [["small", "OBSERVATION_MODIFIER", 4, 9]]], ["The results of the questionnaire indicated that the incidence of COVID-19 was not higher in PH patients according to our survey.", [["PH", "DISEASE", 92, 94], ["COVID-19", "CHEMICAL", 65, 73], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["COVID", "TEST", 65, 70]]], ["Regardless of incidental cough and fever in our patients, only one patient was confirmed SARS-CoV-2 infection.", [["cough", "DISEASE", 25, 30], ["fever", "DISEASE", 35, 40], ["SARS-CoV-2 infection", "DISEASE", 89, 109], ["patients", "ORGANISM", 48, 56], ["patient", "ORGANISM", 67, 74], ["SARS-CoV-2", "ORGANISM", 89, 99], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 67, 74], ["incidental cough", "PROBLEM", 14, 30], ["fever", "PROBLEM", 35, 40], ["SARS", "PROBLEM", 89, 93], ["CoV-2 infection", "PROBLEM", 94, 109], ["incidental", "OBSERVATION_MODIFIER", 14, 24], ["cough", "OBSERVATION", 25, 30], ["fever", "OBSERVATION", 35, 40], ["infection", "OBSERVATION", 100, 109]]], ["Medication insufficiency was the most common problem in our patients as nearly 70% participants implied their medications shortage during COVID-19 outbreak.", [["Medication insufficiency", "DISEASE", 0, 24], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["participants", "SPECIES", 83, 95], ["Medication insufficiency", "PROBLEM", 0, 24], ["COVID", "TEST", 138, 143], ["insufficiency", "OBSERVATION", 11, 24], ["most common", "OBSERVATION_MODIFIER", 33, 44]]], ["A total of 24.2% patients discontinued medications, and 7.0% patients changed their medications without consulting their doctor.", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 61, 69], ["medications", "TREATMENT", 39, 50], ["their medications", "TREATMENT", 78, 95]]], ["A total of 98.6% participants stayed at home during outbreak, and most of them were not depressed by either PH or COVID-19 according to our survey.", [["depressed", "DISEASE", 88, 97], ["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["However, further requirements in medical care might significantly increase due to the high desire of follow-up, even hospitalization, from both patients and their families when COVID-19 outbreak is over.DiscussionIn early studies, COVID-19 patients often stayed in Wuhan for a while or had a history of exposure to confirmed cases.", [["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 240, 248], ["COVID", "TEST", 177, 182]]], ["7 There were 18.2% (n \u00bc 26) participants from Wuhan in our study, which might be the result of hospital location, and one of the patients groups were from Hubei.", [["participants", "ORGANISM", 28, 40], ["patients", "ORGANISM", 129, 137], ["participants", "SPECIES", 28, 40], ["patients", "SPECIES", 129, 137], ["our study", "TEST", 55, 64]]], ["None of them reported COVID-19, neither in patients nor in family participants.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["participants", "SPECIES", 66, 78]]], ["Person-to-person transmission is confirmed in COVID-19, 8 and lockdown in Wuhan began in 24 January 2020 to prevent further spread of this infectious disease.", [["infectious disease", "DISEASE", 139, 157], ["person", "SPECIES", 10, 16], ["this infectious disease", "PROBLEM", 134, 157], ["infectious", "OBSERVATION", 139, 149]]], ["A total of 98.6% of our patients and their families were in home quarantine during COVID-19 outbreak, which might be a key factor that prevented our patients being infected.", [["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 149, 157], ["infected", "OBSERVATION", 164, 172]]], ["Previous studies showed 32-51% patients with COVID-19 had existing diseases, such as diabetes, hypertension, and other cardiovascular diseases.", [["cardiovascular", "ANATOMY", 119, 133], ["diabetes", "DISEASE", 85, 93], ["hypertension", "DISEASE", 95, 107], ["cardiovascular diseases", "DISEASE", 119, 142], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Previous studies", "TEST", 0, 16], ["COVID", "TEST", 45, 50], ["existing diseases", "PROBLEM", 58, 75], ["diabetes", "PROBLEM", 85, 93], ["hypertension", "PROBLEM", 95, 107], ["other cardiovascular diseases", "PROBLEM", 113, 142], ["diseases", "OBSERVATION", 67, 75], ["diabetes", "OBSERVATION", 85, 93], ["hypertension", "OBSERVATION", 95, 107], ["cardiovascular", "ANATOMY", 119, 133], ["diseases", "OBSERVATION", 134, 142]]], ["Males were more vulnerable.", [["vulnerable", "OBSERVATION_MODIFIER", 16, 26]]], ["Mean age of the patients were 49-55 years from different study cohort.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["[9] [10] [11] Our participants were 33 years old at mean age, which was much younger than previous COVID-19 patients.", [["participants", "ORGANISM", 18, 30], ["patients", "ORGANISM", 108, 116], ["participants", "SPECIES", 18, 30], ["patients", "SPECIES", 108, 116]]], ["Our study cohort consisted of 80% females, which was quite different from the proportion of COVID-19.", [["Our study cohort", "TEST", 0, 16], ["COVID", "TEST", 92, 97]]], ["In addition, most of our patients were CHD-PAH and maintained a fairly well heart function.", [["heart", "ANATOMY", 76, 81], ["CHD", "DISEASE", 39, 42], ["PAH", "DISEASE", 43, 46], ["PAH", "CHEMICAL", 43, 46], ["patients", "ORGANISM", 25, 33], ["heart", "ORGAN", 76, 81], ["patients", "SPECIES", 25, 33], ["CHD", "PROBLEM", 39, 42], ["PAH", "PROBLEM", 43, 46], ["PAH", "OBSERVATION", 43, 46], ["heart", "ANATOMY", 76, 81], ["function", "OBSERVATION", 82, 90]]], ["Therefore, the younger age, more females, different etiology, and better cardiac function in our PH patients might result in a lower incidence of COVID-19.DiscussionSimilar to any other chronic diseases, PH patients have to take life-time medications, and most of them had higher medication adherence.", [["cardiac", "ANATOMY", 73, 80], ["PH", "DISEASE", 97, 99], ["chronic diseases", "DISEASE", 186, 202], ["PH", "DISEASE", 204, 206], ["COVID-19", "CHEMICAL", 146, 154], ["cardiac", "ORGAN", 73, 80], ["patients", "ORGANISM", 100, 108], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 207, 215], ["COVID", "TEST", 146, 151], ["any other chronic diseases", "PROBLEM", 176, 202], ["medications", "TREATMENT", 239, 250], ["chronic", "OBSERVATION_MODIFIER", 186, 193], ["diseases", "OBSERVATION", 194, 202]]], ["12 Bosentan was first used in PAH in 2002, 13 and it significantly improved six-minute walk distance and heart function.", [["heart", "ANATOMY", 105, 110], ["Bosentan", "CHEMICAL", 3, 11], ["PAH", "CHEMICAL", 30, 33], ["PAH", "CHEMICAL", 30, 33], ["heart", "ORGAN", 105, 110], ["Bosentan", "TREATMENT", 3, 11], ["Bosentan", "OBSERVATION", 3, 11], ["heart", "ANATOMY", 105, 110]]], ["Since then, targeted treatment has extended more than half of patients' life to three or even five years.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["targeted treatment", "TREATMENT", 12, 30]]], ["14 Combination therapy recommended in recent years has further reduced adverse events and slowed down the PH progression.", [["PH", "DISEASE", 106, 108], ["Combination therapy", "TREATMENT", 3, 22], ["further reduced adverse events", "PROBLEM", 55, 85], ["the PH progression", "PROBLEM", 102, 120]]], ["3, [15] [16] [17] In our study, patients took Ambrisentan more than Bosentan partly due to the lower price in Chinese generic medication.", [["Ambrisentan", "CHEMICAL", 46, 57], ["Ambrisentan", "CHEMICAL", 46, 57], ["[15] [16] [17", "SIMPLE_CHEMICAL", 3, 16], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["our study", "TEST", 21, 30], ["Ambrisentan", "TREATMENT", 46, 57], ["Bosentan", "TREATMENT", 68, 76], ["Chinese generic medication", "TREATMENT", 110, 136]]], ["A total of 17 patients were taking Macitentan for free.", [["Macitentan", "CHEMICAL", 35, 45], ["Macitentan", "CHEMICAL", 35, 45], ["patients", "ORGANISM", 14, 22], ["Macitentan", "SIMPLE_CHEMICAL", 35, 45], ["patients", "SPECIES", 14, 22], ["Macitentan", "TREATMENT", 35, 45]]], ["Treprostinil was used in very few patients because of the high price and inconvenience of CHD-PAH: pulmonary arterial hypertension associated with congenital heart disease; CTEPH: chronic thrombotic embolism pulmonary hypertension; CTD-PAH: pulmonary arterial hypertension associated with connective tissue disease; iPAH: idiopathic pulmonary arterial hypertension; NA: not applicable; NYHA: New York Heart Association; PH: pulmonary hypertension.Discussionintravenous application.", [["pulmonary arterial", "ANATOMY", 99, 117], ["heart", "ANATOMY", 158, 163], ["pulmonary", "ANATOMY", 208, 217], ["pulmonary", "ANATOMY", 241, 250], ["arterial", "ANATOMY", 251, 259], ["connective tissue", "ANATOMY", 289, 306], ["pulmonary", "ANATOMY", 333, 342], ["arterial", "ANATOMY", 343, 351], ["pulmonary", "ANATOMY", 424, 433], ["Treprostinil", "CHEMICAL", 0, 12], ["CHD", "DISEASE", 90, 93], ["PAH", "CHEMICAL", 94, 97], ["pulmonary arterial hypertension", "DISEASE", 99, 130], ["congenital heart disease", "DISEASE", 147, 171], ["CTEPH", "DISEASE", 173, 178], ["thrombotic embolism pulmonary hypertension", "DISEASE", 188, 230], ["PAH", "DISEASE", 236, 239], ["pulmonary arterial hypertension", "DISEASE", 241, 272], ["connective tissue disease", "DISEASE", 289, 314], ["iPAH", "DISEASE", 316, 320], ["idiopathic pulmonary arterial hypertension", "DISEASE", 322, 364], ["PH", "DISEASE", 420, 422], ["pulmonary hypertension", "DISEASE", 424, 446], ["Treprostinil", "CHEMICAL", 0, 12], ["PAH", "CHEMICAL", 94, 97], ["PAH", "CHEMICAL", 236, 239], ["Treprostinil", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 34, 42], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 99, 117], ["heart", "ORGAN", 158, 163], ["pulmonary", "ORGAN", 208, 217], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 241, 259], ["connective tissue", "TISSUE", 289, 306], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 333, 351], ["pulmonary", "ORGAN", 424, 433], ["patients", "SPECIES", 34, 42], ["Treprostinil", "TREATMENT", 0, 12], ["CHD", "PROBLEM", 90, 93], ["pulmonary arterial hypertension", "PROBLEM", 99, 130], ["congenital heart disease", "PROBLEM", 147, 171], ["CTEPH", "PROBLEM", 173, 178], ["chronic thrombotic embolism", "PROBLEM", 180, 207], ["pulmonary hypertension", "PROBLEM", 208, 230], ["CTD", "PROBLEM", 232, 235], ["pulmonary arterial hypertension", "PROBLEM", 241, 272], ["connective tissue disease", "PROBLEM", 289, 314], ["idiopathic pulmonary arterial hypertension", "PROBLEM", 322, 364], ["pulmonary hypertension", "PROBLEM", 424, 446], ["Discussionintravenous application", "TREATMENT", 447, 480], ["PAH", "OBSERVATION", 94, 97], ["pulmonary arterial", "ANATOMY", 99, 117], ["hypertension", "OBSERVATION", 118, 130], ["heart", "ANATOMY", 158, 163], ["disease", "OBSERVATION", 164, 171], ["CTEPH", "OBSERVATION", 173, 178], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["thrombotic", "OBSERVATION_MODIFIER", 188, 198], ["embolism", "OBSERVATION", 199, 207], ["pulmonary", "ANATOMY", 208, 217], ["hypertension", "OBSERVATION", 218, 230], ["PAH", "OBSERVATION", 236, 239], ["pulmonary arterial", "ANATOMY", 241, 259], ["hypertension", "OBSERVATION", 260, 272], ["connective tissue disease", "OBSERVATION", 289, 314], ["idiopathic", "OBSERVATION", 322, 332], ["pulmonary arterial", "ANATOMY", 333, 351], ["hypertension", "OBSERVATION", 352, 364], ["Heart", "ANATOMY", 401, 406], ["pulmonary", "ANATOMY", 424, 433], ["hypertension", "OBSERVATION", 434, 446]]], ["18 Luckily, 40.0% of patients were able to continue their medications with great effort during the national lockdown.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["their medications", "TREATMENT", 52, 69]]], ["Different from other cardiovascular diseases, PH target medications are expensive and unavailable in small cities, which might result in the shortage of medications in our PH patients.", [["cardiovascular", "ANATOMY", 21, 35], ["cardiovascular diseases", "DISEASE", 21, 44], ["PH", "DISEASE", 172, 174], ["cardiovascular", "ANATOMICAL_SYSTEM", 21, 35], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["other cardiovascular diseases", "PROBLEM", 15, 44], ["PH target medications", "TREATMENT", 46, 67], ["medications", "TREATMENT", 153, 164], ["cardiovascular", "ANATOMY", 21, 35], ["diseases", "OBSERVATION", 36, 44], ["small", "OBSERVATION_MODIFIER", 101, 106]]], ["The lockdown in cities additionally prevented patients from getting supplement.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["The lockdown in cities", "TREATMENT", 0, 22]]], ["Nearly 30% of patients either discontinued their medications or changed without consultation.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["their medications", "TREATMENT", 43, 60]]], ["We have tried to help some of our patients to buy medications; however, shutdown of most public transportations made the process very difficult.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["medications", "TREATMENT", 50, 61]]], ["We could hardly predict the prognosis of those who changed their treatment for less than 40 days.", [["their treatment", "TREATMENT", 59, 74]]], ["An interruption of treatment around three days might be tolerated, 19 but clinical worsening might happen due to the discontinuation of medications.", [["treatment", "TREATMENT", 19, 28], ["medications", "TREATMENT", 136, 147]]], ["20 Patients preferred clinic visiting to consult doctors for any modification.", [["Patients", "ORGANISM", 3, 11], ["Patients", "SPECIES", 3, 11]]], ["Our patients showed higher desire to contact their doctors even though we had provided online consultation before the survey.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Mental condition of PH patients has aroused attentions in recent years.", [["PH", "DISEASE", 20, 22], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["Mental condition of PH", "PROBLEM", 0, 22]]], ["Their concerns about the invasive examination, disease progression, and social interactions may directly impact their tolerance to treatment.", [["the invasive examination", "TEST", 21, 45], ["disease progression", "PROBLEM", 47, 66], ["treatment", "TREATMENT", 131, 140]]], ["21 The outbreak of COVID-19 brought an unexpected crisis first in Wuhan, then spread to other cities.", [["COVID-19", "CHEMICAL", 19, 27], ["COVID", "TEST", 19, 24]]], ["Surprisingly, our PH patients and their families were mostly not panicking during the outbreak.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["They were overall positive and optimistic even though there were shortages on their medications.", [["their medications", "TREATMENT", 78, 95], ["positive", "OBSERVATION", 18, 26]]], ["The reasons for such response might be as follows: first, most PH patients stayed at home which was familiar and comfort for them.", [["PH", "DISEASE", 63, 65], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["Second, there were not many clinical worsening in our patients.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["worsening", "OBSERVATION_MODIFIER", 37, 46]]], ["Their disease condition was mostly constant during the outbreak, which maintained their optimism.", [["Their disease condition", "PROBLEM", 0, 23], ["disease", "OBSERVATION", 6, 13], ["mostly", "OBSERVATION_MODIFIER", 28, 34], ["constant", "OBSERVATION_MODIFIER", 35, 43]]], ["Third, we, the doctors, were active in patients groups, including being available for consultation online, and offering assistance for medication supplement.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["medication supplement", "TREATMENT", 135, 156]]], ["All these might be helpful to reduce their anxiety.DiscussionOur results provided preliminary view in living condition of PH patients during COVID-19 in China; however, several limitations in our study need to be addressed: first of all, there were only 120 PH patients participating in the survey.", [["anxiety", "DISEASE", 43, 50], ["PH", "DISEASE", 122, 124], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 261, 269], ["their anxiety", "PROBLEM", 37, 50], ["COVID", "TEST", 141, 146], ["our study", "TEST", 192, 201]]], ["The small-scale survey might give us some general information, which also might bring bias in some aspects.", [["small", "OBSERVATION_MODIFIER", 4, 9]]], ["The results might highlight CHD-PAH, due to that CHD-PAH contributed most in the study population.", [["CHD-PAH", "DISEASE", 28, 35], ["CHD", "DISEASE", 49, 52], ["PAH", "CHEMICAL", 53, 56], ["PAH", "CHEMICAL", 32, 35], ["PAH", "CHEMICAL", 53, 56], ["CHD", "PROBLEM", 28, 31], ["PAH", "PROBLEM", 32, 35], ["CHD", "PROBLEM", 49, 52], ["PAH", "PROBLEM", 53, 56], ["PAH", "OBSERVATION", 32, 35], ["PAH", "OBSERVATION", 53, 56]]], ["Further study should try to include more patients to get more details.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Further study", "TEST", 0, 13]]], ["The questionnaire was designed to generate the information from both patients and their family members; however, we failed to match patients with their family members from the beginning.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 132, 140]]], ["Studies could avoid such mistakes and focus on patients more.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Studies", "TEST", 0, 7], ["such mistakes", "PROBLEM", 20, 33]]], ["Most PH patients might be still stable in such a short time.", [["PH", "DISEASE", 5, 7], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["stable", "OBSERVATION", 32, 38]]], ["Studies conducted later or longer might observe more clinical worsening and anxiety in patients and their families.", [["anxiety", "DISEASE", 76, 83], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Studies", "TEST", 0, 7], ["anxiety", "PROBLEM", 76, 83]]], ["Although no death was reported in our survey, three patients passed away based on our knowledge.", [["death", "DISEASE", 12, 17], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["death", "PROBLEM", 12, 17], ["no", "UNCERTAINTY", 9, 11]]], ["Neither patients nor their families would participate in the survey if they were in critical condition.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["Third, there were many uncertainties in online survey.", [["many", "OBSERVATION_MODIFIER", 18, 22], ["uncertainties", "OBSERVATION", 23, 36]]], ["We involved a question to estimate whether participants were seriously taking the survey.", [["participants", "SPECIES", 43, 55]]], ["The result showed 86.7% patients and 91.0% family participants went through the survey carefully, which indicated there might be misunderstanding and incorrect answers.DiscussionOur small-scale national survey first investigated the living condition of PH patients during COVID-19.", [["PH", "DISEASE", 253, 255], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 24, 32], ["participants", "SPECIES", 50, 62], ["patients", "SPECIES", 256, 264], ["The result", "TEST", 0, 10], ["COVID", "TEST", 272, 277]]], ["As the disease is spreading all over the world, doctors should be aware that PH patients could be invulnerable to COVID-19 if they are in good protection.", [["PH", "DISEASE", 77, 79], ["COVID-19", "CHEMICAL", 114, 122], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["COVID", "TEST", 114, 119], ["disease", "OBSERVATION", 7, 14], ["spreading", "OBSERVATION_MODIFIER", 18, 27]]], ["Sustaining medical care, including medication supplement, is important for PH patients at this time.", [["PH", "DISEASE", 75, 77], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Sustaining medical care", "TREATMENT", 0, 23], ["medication supplement", "TREATMENT", 35, 56], ["PH patients", "TREATMENT", 75, 86]]], ["COVID-19 might impact PH patients psychologically other than physically.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 0, 5]]], ["Higher hospitalization even death might been seen when the outbreak is over.", [["death", "DISEASE", 28, 33], ["death", "PROBLEM", 28, 33]]]], "f3a63003f0b0c19970acfacb0043459e0ea4dd96": [["settings where potentially infected individuals (e.g., sick patients in hospitals) might otherwise pose a risk.", [["individuals", "ORGANISM", 36, 47], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["infected", "OBSERVATION", 27, 35]]], ["Unfortunately, these hypothetical scenarios are not reality.", [["hypothetical scenarios", "OBSERVATION", 21, 43]]], ["However, with this ideal situation as a guide, what we do have available as tests today should be carefully considered in terms of how they can be leveraged to move the current crisis closer to the ideal situation, especially in the absence of therapeutics or vaccines.", [["vaccines", "TREATMENT", 260, 268]]]], "PMC7102844": [["IntroductionMiddle East Respiratory Syndrome Coronavirus (MERS) is transmitted via interactions among individuals.", [["IntroductionMiddle East Respiratory Syndrome Coronavirus", "DISEASE", 0, 56], ["IntroductionMiddle East Respiratory Syndrome Coronavirus", "PROBLEM", 0, 56], ["Respiratory Syndrome", "OBSERVATION", 24, 44]]], ["The danger of infection is highest for groups of individuals living in close proximity.", [["infection", "DISEASE", 14, 23], ["infection", "PROBLEM", 14, 23], ["infection", "OBSERVATION", 14, 23]]], ["From the intermittent transmission that occurred in animal-to-human, many human-to-human cases of MERS have also been documented within family and healthcare facilities [1], [2], [3].", [["MERS", "DISEASE", 98, 102], ["human", "ORGANISM", 62, 67], ["human", "ORGANISM", 74, 79], ["human", "ORGANISM", 83, 88], ["MERS", "CANCER", 98, 102], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 83, 88]]], ["Transmission of MERS pathogen can form networks of infected individuals that were connected either directly or indirectly.", [["MERS", "GENE_OR_GENE_PRODUCT", 16, 20], ["MERS pathogen", "PROBLEM", 16, 29], ["infected individuals", "PROBLEM", 51, 71], ["infected", "OBSERVATION", 51, 59]]], ["One should expect in such environments the formation of large clusters of infections as observed during the outbreak in the Kingdom of Saudi Arabia (KSA) [4] and South Korea (SK) [5].", [["infections", "DISEASE", 74, 84], ["large clusters of infections", "PROBLEM", 56, 84], ["large", "OBSERVATION_MODIFIER", 56, 61], ["clusters", "OBSERVATION_MODIFIER", 62, 70], ["infections", "OBSERVATION", 74, 84]]], ["Cluster size of human-to-human transmissions of MERS has been shown to vary and a high variability and heterogeneity in the transmission potential have been underscored [6], [7].IntroductionThe first case of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was reported in 2012.", [["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 212, 256], ["human", "ORGANISM", 16, 21], ["human", "ORGANISM", 25, 30], ["Middle East Respiratory", "ORGANISM", 212, 235], ["MERS-CoV", "ORGANISM", 258, 266], ["MERS", "PROTEIN", 48, 52], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 25, 30], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 212, 266], ["a high variability", "PROBLEM", 80, 98], ["the Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 208, 256], ["size", "OBSERVATION_MODIFIER", 8, 12], ["high variability", "OBSERVATION_MODIFIER", 82, 98], ["Middle", "ANATOMY_MODIFIER", 212, 218], ["Respiratory Syndrome", "OBSERVATION", 224, 244]]], ["By February 2018, a total of 2182 laboratory-confirmed MERS-CoV infections had been reported to the World Health Organization (WHO) [8].", [["MERS-CoV infections", "DISEASE", 55, 74], ["MERS-CoV", "ORGANISM", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["MERS", "PROBLEM", 55, 59], ["CoV infections", "PROBLEM", 60, 74], ["infections", "OBSERVATION", 64, 74]]], ["The disease has now spread to over 27 countries with most index patients either residing or recently traveling to areas neighboring the Arabian Peninsula [9], [10].", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["spread", "OBSERVATION_MODIFIER", 20, 26]]], ["Similarly, the vast majority of the total cases (82%) occurred in KSA [8].", [["vast", "OBSERVATION_MODIFIER", 15, 19], ["majority", "OBSERVATION_MODIFIER", 20, 28]]], ["The global mortality rate was highest (58%) at the beginning of the epidemics (September 2012\u2013February 2013) and it dropped continuously to an absolute low of 23% during September 2015\u2013February 2016.", [["The global mortality rate", "TEST", 0, 25], ["global", "OBSERVATION_MODIFIER", 4, 10], ["mortality", "OBSERVATION_MODIFIER", 11, 20], ["absolute", "OBSERVATION_MODIFIER", 143, 151], ["low", "OBSERVATION_MODIFIER", 152, 155]]], ["As of February 2018, these infections has led to 779 documented deaths (a mortality rate of 36%) [8].", [["infections", "DISEASE", 27, 37], ["deaths", "DISEASE", 64, 70], ["these infections", "PROBLEM", 21, 37], ["a mortality rate", "TEST", 72, 88], ["infections", "OBSERVATION", 27, 37]]], ["People within the age-group 50\u201359 years are at the highest risk of being infected as primary cases and have the highest mortality rate [8].", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["infected", "OBSERVATION", 73, 81]]], ["Forty-five day survival rate was lowest in patients older than 65 years (44.86%) [11].", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["survival rate", "TEST", 15, 28]]], ["Also, healthcare workers (HCW) are regularly exposed to MERS due to their regular contacts with MERS patients and are at greater risk of being infected; however, they are less likely to die of the disease [10], [12], [13], [14].IntroductionStrong links between healthcare facilities and the spread of the MERS disease have been found in KSA, where the majority of patients were in contact with other patients at healthcare facilities [15], [16], [17], [18].", [["MERS disease", "DISEASE", 305, 317], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 364, 372], ["patients", "ORGANISM", 400, 408], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 364, 372], ["patients", "SPECIES", 400, 408], ["the disease", "PROBLEM", 193, 204], ["the MERS disease", "PROBLEM", 301, 317], ["infected", "OBSERVATION", 143, 151]]], ["Unfortunately, this phenomenon is widespread and well-known as nosocomial infections (hospital-acquired infections) which occur frequently with surgical-site infections (SSIs), pneumonia and gastrointestinal infections among the top hospital-acquired infections (HAIs) [19], [20].IntroductionThere has been a number of documented outbreaks of MERS infection within clusters of healthcare facilities among hospitalized patients and healthcare worker [15], [17], [18].", [["gastrointestinal", "ANATOMY", 191, 207], ["nosocomial infections", "DISEASE", 63, 84], ["hospital-acquired infections", "DISEASE", 86, 114], ["surgical-site infections", "DISEASE", 144, 168], ["SSIs", "DISEASE", 170, 174], ["pneumonia", "DISEASE", 177, 186], ["gastrointestinal infections", "DISEASE", 191, 218], ["infections", "DISEASE", 251, 261], ["HAIs", "DISEASE", 263, 267], ["infection", "DISEASE", 348, 357], ["gastrointestinal", "ORGAN", 191, 207], ["patients", "ORGANISM", 418, 426], ["patients", "SPECIES", 418, 426], ["this phenomenon", "PROBLEM", 15, 30], ["nosocomial infections", "PROBLEM", 63, 84], ["acquired infections", "PROBLEM", 95, 114], ["surgical-site infections", "PROBLEM", 144, 168], ["SSIs", "PROBLEM", 170, 174], ["pneumonia", "PROBLEM", 177, 186], ["gastrointestinal infections", "PROBLEM", 191, 218], ["acquired infections", "PROBLEM", 242, 261], ["MERS infection", "PROBLEM", 343, 357], ["widespread", "OBSERVATION_MODIFIER", 34, 44], ["nosocomial", "OBSERVATION_MODIFIER", 63, 73], ["infections", "OBSERVATION", 74, 84], ["infections", "OBSERVATION", 158, 168], ["pneumonia", "OBSERVATION", 177, 186], ["gastrointestinal", "ANATOMY", 191, 207], ["infections", "OBSERVATION", 208, 218]]], ["In 2015, cases of MERS were reported in SK when the index patient returned from his trip to the Arabian Peninsula where he had contracted MERS [18].", [["MERS", "DISEASE", 18, 22], ["SK", "CHEMICAL", 40, 42], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["MERS", "PROBLEM", 18, 22], ["contracted MERS", "PROBLEM", 127, 142]]], ["The disease spread out across various cities in SK within two months, expanding from one to 17 hospitals and infecting a total of 186 people.", [["SK", "CHEMICAL", 48, 50], ["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["The disease spread", "PROBLEM", 0, 18], ["disease", "OBSERVATION", 4, 11]]], ["The escalation of the Riyadh outbreak was linked to extended healthcare-related human-to-human transmissions [4], [17], [21], [22.", [["human", "ORGANISM", 80, 85], ["human", "ORGANISM", 89, 94], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 89, 94], ["escalation", "OBSERVATION_MODIFIER", 4, 14]]], ["These outbreaks were attributed to few index cases and the level of their spreading depended on interactions between individuals.", [["few index cases", "PROBLEM", 35, 50], ["few", "OBSERVATION_MODIFIER", 35, 38]]], ["For example, 82 out of the 186 infected patients in SK were traced back to one index patient alone due to the overcrowded emergency room with patients, visitors and healthcare worker [23].IntroductionThis study focused on cases of hospital-acquired MERS (HA-MERS) in Saudi Arabia.", [["SK", "CHEMICAL", 52, 54], ["MERS", "DISEASE", 249, 253], ["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 85, 92], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 142, 150], ["This study", "TEST", 200, 210]]], ["The objectives of this study were to explore the structure of transmission networks formed by these outbreaks in order to describe its routes and the relationship between patients\u2019 characteristics and the disease network metrics.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["this study", "TEST", 18, 28], ["the disease network metrics", "PROBLEM", 201, 228]]], ["Specifically, we will investigate the effects of place of exposure in the transmission mechanisms of MERS, whether outbreaks in the hospital vs. outbreaks elsewhere in the community have significant differences in the length of hospital stay (LOS).", [["significant", "OBSERVATION_MODIFIER", 187, 198]]], ["Similarly, we estimate the risk of death associated with MERS diseases between HA-MERS and non HA-MERS.Data source ::: Materials and methodsThe data for this study was based on laboratory confirmed and probable cases of MERS-CoV infection in the KSA between 2012 and 2016 from various sources such as WHO bulletins, media reports and Kingdom of Saudi Arabia Ministry of Health (MoH), and obtained from the case-by-case list compiled and maintained by Dr. Andrew Rambaut [24].", [["death", "DISEASE", 35, 40], ["MERS diseases", "DISEASE", 57, 70], ["MERS-CoV infection", "DISEASE", 220, 238], ["MERS-CoV", "ORGANISM", 220, 228], ["MERS-CoV", "SPECIES", 220, 228], ["death", "PROBLEM", 35, 40], ["MERS diseases", "PROBLEM", 57, 70], ["HA", "PROBLEM", 79, 81], ["this study", "TEST", 153, 163], ["MERS", "PROBLEM", 220, 224], ["CoV infection", "PROBLEM", 225, 238], ["CoV", "OBSERVATION_MODIFIER", 225, 228], ["infection", "OBSERVATION", 229, 238]]], ["The data sets were also assessed for accuracy with those reported by Flu Trackers, KSA MoH and WHO.", [["accuracy", "TEST", 37, 45]]], ["The data contains information on patient demographics, clinical outcome, whether the patient was a healthcare worker (HCW), comorbidity status of the patient, and place of exposure to known risk factors.", [["patient", "ORGANISM", 33, 40], ["patient", "ORGANISM", 85, 92], ["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 33, 40], ["patient", "SPECIES", 85, 92], ["patient", "SPECIES", 150, 157], ["known risk factors", "PROBLEM", 184, 202]]], ["We used the following approaches to estimate length of hospital stay (LOS): (1) we restricted our analysis to those patients who are still alive and those that died within 60 days for short-time risk of death analysis (2) LOS was calculated as the difference between the date of onset of disease (or date reported whenever date of onset was not available) and date of death/discharged.Study population and definitions ::: Materials and methodsThe study population consisted of patients with confirmed MERS infection.", [["death", "DISEASE", 203, 208], ["death", "DISEASE", 368, 373], ["MERS infection", "DISEASE", 501, 515], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 477, 485], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 477, 485], ["death analysis", "TEST", 203, 217], ["LOS", "TEST", 222, 225], ["disease", "PROBLEM", 288, 295], ["The study population", "TEST", 443, 463], ["MERS infection", "PROBLEM", 501, 515], ["disease", "OBSERVATION", 288, 295], ["infection", "OBSERVATION", 506, 515]]], ["The cases were confirmed via real-time RNA-positive using Reverse transcription polymerase chain reaction (RT-PCR) showing positive PCR on at least two specific genomic targets upstream E protein (upE) and ORF1a or a single positive target (upE) with sequencing of a second target (RdRpSeq assay) or N gene (NSeq assay) [25].", [["E protein", "GENE_OR_GENE_PRODUCT", 186, 195], ["upE", "GENE_OR_GENE_PRODUCT", 197, 200], ["ORF1a", "GENE_OR_GENE_PRODUCT", 206, 211], ["E protein", "DNA", 186, 195], ["upE", "DNA", 197, 200], ["ORF1a", "DNA", 206, 211], ["positive target", "DNA", 224, 239], ["upE", "DNA", 241, 244], ["RdRpSeq", "DNA", 282, 289], ["N gene", "DNA", 300, 306], ["Reverse transcription polymerase chain reaction", "PROBLEM", 58, 105], ["RT-PCR", "TEST", 107, 113], ["positive PCR", "PROBLEM", 123, 135], ["ORF1a", "TEST", 206, 211], ["a second target (RdRpSeq assay)", "TREATMENT", 265, 296]]], ["Overall, 787 patients with known contact history to identify the place of exposure which was classified as HA-MERS or non HA-MERS were included in this study.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["HA", "PROBLEM", 107, 109], ["MERS", "PROBLEM", 110, 114], ["non HA", "PROBLEM", 118, 124], ["MERS", "PROBLEM", 125, 129], ["this study", "TEST", 147, 157]]], ["A MERS infection is described as hospital acquired (HA-MERS) if the patient has contact with confirmed patients (alive or deceased) or healthcare workers, or healthcare facilities which had MERS-CoV outbreak while non HA-MERS were those acquired elsewhere such as community, household/family [26].Statistical analysis ::: Materials and methodsThe data was analysed in three stages.", [["MERS infection", "DISEASE", 2, 16], ["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 103, 111], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 190, 198], ["A MERS infection", "PROBLEM", 0, 16], ["The data", "TEST", 343, 351], ["infection", "OBSERVATION", 7, 16]]], ["First, descriptive statistics were presented as medians and interquartile range for continuous variables, and frequencies and percentages for categorical variables.", [["continuous variables", "TEST", 84, 104], ["categorical variables", "TEST", 142, 163]]], ["Odds ratios (OR) together with their 95% confidence interval were also used for categorical variables.", [["categorical variables", "TEST", 80, 101]]], ["The chi-square test was used to compare patient\u2019s attributes (categorical variables) for those infections acquired in the hospital and those acquired elsewhere in the community while the Mann-Whitney U-test was used to compare continuous attributes (continuous variables).Statistical analysis ::: Materials and methodsIn the second stage, the unit of analysis for the networked data were the nodes representing individuals infected with MERS.", [["infections", "DISEASE", 95, 105], ["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["The chi-square test", "TEST", 0, 19], ["those infections", "PROBLEM", 89, 105], ["analysis", "TEST", 351, 359], ["the networked data", "TEST", 364, 382], ["nodes", "OBSERVATION", 392, 397]]], ["In network analysis, the nodes (individual patients) have distinguishable attributes such as age, gender, etc., while interactions or relationships between nodes are called edges or links [27].", [["nodes", "ANATOMY", 25, 30], ["nodes", "ANATOMY", 156, 161], ["nodes", "MULTI-TISSUE_STRUCTURE", 25, 30], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["nodes", "OBSERVATION", 25, 30], ["nodes", "OBSERVATION", 156, 161]]], ["A network can be defined as a collection of nodes connected by edges where nodes and/or edges have attributes [28].", [["nodes", "ANATOMY", 44, 49], ["nodes", "ANATOMY", 75, 80], ["a collection of nodes", "PROBLEM", 28, 49], ["nodes", "OBSERVATION", 44, 49], ["edges", "OBSERVATION_MODIFIER", 63, 68], ["nodes", "OBSERVATION", 75, 80]]], ["Each patient (node) was assigned a unique identification number and his/her contact history was tracked within 14 days of the onset of the disease.", [["node", "ANATOMY", 14, 18], ["patient", "ORGANISM", 5, 12], ["node", "MULTI-TISSUE_STRUCTURE", 14, 18], ["patient", "SPECIES", 5, 12], ["the disease", "PROBLEM", 135, 146], ["node", "OBSERVATION", 14, 18], ["disease", "OBSERVATION", 139, 146]]], ["MERS patients who were in contact with other laboratory-confirmed MERS patients were identified and a list of each patient-contact pair (dyad) was prepared.", [["MERS", "DISEASE", 66, 70], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 71, 79], ["patient", "ORGANISM", 115, 122], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 115, 122]]], ["A dyad is a linked pair of patients (nodes) in the network that is the fundamental unit for deriving network metrics.", [["patients", "ORGANISM", 27, 35], ["nodes", "MULTI-TISSUE_STRUCTURE", 37, 42], ["network", "MULTI-TISSUE_STRUCTURE", 101, 108], ["patients", "SPECIES", 27, 35], ["nodes", "OBSERVATION", 37, 42]]], ["The outbreak network visualization and network analysis were conducted in UCINET 6.0 Version 1.00 [29].", [["network analysis", "TEST", 39, 55]]], ["The following centrality metrics were used to measure the structural importance of patients (nodes) in a network.", [["patients", "ORGANISM", 83, 91], ["nodes", "MULTI-TISSUE_STRUCTURE", 93, 98], ["patients", "SPECIES", 83, 91], ["nodes", "OBSERVATION", 93, 98]]], ["\u201cDegree centrality\u201d was used to reveal the most active nodes in the network and how well a node is connected with its neighbours \u2014 a node degree is the number of edge incidents on a node; the \u201cbetweenness centrality\u201d was used to measure how many pairs of nodes a node can be connected to through a shortest path while \u201ceigenvector centrality\u201d was used to measure the importance of a node depending on the importance of its neighbours [27], [29].Statistical analysis ::: Materials and methodsIn the final analysis, a covariate-adjusted multivariable logistic regression model was used to assess the effects of individual level risk factors and network level metrics (patients nested within networks) on risk of deaths from MERS between HA-MERS and non-HA-MERS patients.", [["node", "ANATOMY", 91, 95], ["node", "ANATOMY", 133, 137], ["node", "ANATOMY", 182, 186], ["node", "ANATOMY", 263, 267], ["node", "ANATOMY", 383, 387], ["deaths", "DISEASE", 710, 716], ["nodes", "MULTI-TISSUE_STRUCTURE", 55, 60], ["node", "MULTI-TISSUE_STRUCTURE", 263, 267], ["patients", "ORGANISM", 666, 674], ["patients", "ORGANISM", 759, 767], ["patients", "SPECIES", 666, 674], ["patients", "SPECIES", 759, 767], ["the most active nodes in the network", "PROBLEM", 39, 75], ["a node", "TREATMENT", 180, 186], ["nodes a node", "PROBLEM", 255, 267], ["a node", "PROBLEM", 381, 387], ["a covariate-adjusted multivariable logistic regression model", "TREATMENT", 514, 574], ["individual level risk factors", "PROBLEM", 609, 638], ["HA", "PROBLEM", 735, 737], ["MERS", "PROBLEM", 738, 742], ["most", "OBSERVATION_MODIFIER", 43, 47], ["active", "OBSERVATION_MODIFIER", 48, 54], ["nodes", "OBSERVATION", 55, 60], ["node", "OBSERVATION", 91, 95], ["node", "OBSERVATION", 133, 137], ["edge", "OBSERVATION_MODIFIER", 162, 166], ["node", "OBSERVATION", 182, 186], ["nodes", "OBSERVATION", 255, 260], ["node", "OBSERVATION", 263, 267], ["node", "OBSERVATION", 383, 387]]], ["Similarly, we used a generalized linear model to identify disease-risk factors associated with the increase in the length of stay (LOS) between HA-MERS and non-HA-MERS patients.Statistical analysis ::: Materials and methodsWe used stepwise selection to select the variables for inclusion in the regression models.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["a generalized linear model", "TREATMENT", 19, 45], ["disease", "PROBLEM", 58, 65], ["risk factors", "PROBLEM", 66, 78], ["HA", "PROBLEM", 144, 146], ["stepwise selection", "TREATMENT", 231, 249], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["All statistical analyses were conducted in SAS 9.3 Software Version 6 of the SAS System for Windows [30] and inference was at 5% level of significance.Transmission network ::: ResultsThe network structure of HA-MERS infection is presented in Fig. 2together with the degree centrality metrics.", [["infection", "DISEASE", 216, 225], ["HA-MERS", "GENE_OR_GENE_PRODUCT", 208, 215], ["All statistical analyses", "TEST", 0, 24], ["SAS", "TEST", 43, 46], ["Software Version", "TEST", 51, 67], ["HA", "PROBLEM", 208, 210], ["MERS infection", "PROBLEM", 211, 225], ["infection", "OBSERVATION", 216, 225]]], ["Because these network centrality metrics were highly correlated, we shall limit our focus to degree centrality.", [["network", "MULTI-TISSUE_STRUCTURE", 14, 21]]], ["The network density of HA-MERS was 0.019 (1.9%) with an average degree of 1.8 contacts.", [["network", "MULTI-TISSUE_STRUCTURE", 4, 11], ["HA-MERS", "GENE_OR_GENE_PRODUCT", 23, 30], ["HA", "PROBLEM", 23, 25], ["MERS", "PROBLEM", 26, 30], ["density", "OBSERVATION_MODIFIER", 12, 19]]], ["Greater degree centrality was associated with increased risk of death from MERS.", [["death", "DISEASE", 64, 69], ["MERS", "DISEASE", 75, 79], ["Greater degree centrality", "PROBLEM", 0, 25], ["death", "PROBLEM", 64, 69], ["MERS", "PROBLEM", 75, 79], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["death", "OBSERVATION", 64, 69]]], ["Our results suggest that healthcare workers have on average significantly lower degree centrality scores than non-healthcare workers.", [["lower degree", "OBSERVATION_MODIFIER", 74, 86]]], ["Although HA-MERS were more connected, we have found no significant difference in degree centrality between HA-MERS and non HA-MERS cases.", [["HA-MERS", "GENE_OR_GENE_PRODUCT", 9, 16], ["MERS", "PROTEIN", 12, 16], ["HA", "PROBLEM", 9, 11], ["MERS", "PROBLEM", 12, 16], ["significant difference in degree centrality", "PROBLEM", 55, 98], ["HA", "PROBLEM", 107, 109], ["MERS", "PROBLEM", 110, 114], ["no", "UNCERTAINTY", 52, 54], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["difference", "OBSERVATION", 67, 77]]], ["Patient\u2019s transmission degree centrality was significantly negatively correlated with age.", [["Patient", "SPECIES", 0, 7]]], ["As depicted in Fig. 2, the larger node size represents the prioritized patients (1664, 124, 1025, 133, 897, 898) based on the degree centrality metrics because they have the most ties to other patients within the network.Length of stay and risk of death ::: ResultsOn the basis of unadjusted analysis, HA-MERS, hospitalized patients, older patients and patients with comorbidities were positively associated with length of hospital stay while being HWC has a negative association.", [["node", "ANATOMY", 34, 38], ["death", "DISEASE", 248, 253], ["HWC", "CHEMICAL", 449, 452], ["node", "MULTI-TISSUE_STRUCTURE", 34, 38], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 324, 332], ["patients", "ORGANISM", 340, 348], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 324, 332], ["patients", "SPECIES", 340, 348], ["patients", "SPECIES", 353, 361], ["unadjusted analysis", "TEST", 281, 300], ["HA", "PROBLEM", 302, 304], ["comorbidities", "PROBLEM", 367, 380], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["node", "OBSERVATION", 34, 38], ["size", "OBSERVATION_MODIFIER", 39, 43]]], ["Results from further investigation of the associated risk factors for increased LOS among MERS patients after controlling for other risk factors revealed that only patients with comorbidities significantly increased the length of hospital stay (Table 3).Length of stay and risk of death ::: Results", [["MERS", "DISEASE", 90, 94], ["death", "DISEASE", 281, 286], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 164, 172], ["further investigation", "TEST", 13, 34], ["increased LOS", "PROBLEM", 70, 83], ["other risk factors", "PROBLEM", 126, 144], ["comorbidities", "PROBLEM", 178, 191]]]], "PMC7094909": [["IntroductionThe Sinus and Allergy Health Partnership, in consultation with representatives of the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and individuals from the fields of infectious disease, pediatric infectious disease, microbiology, clinical pharmacy, and clinical pharmacology, have developed these guidelines as an educational tool for the healthcare provider involved in treating patients with acute bacterial rhinosinustis (ABRS).IntroductionThere are several problems we attempted to address during the process of writing this document: (1) the diagnosis of bacterial \u201csinusitis\u201d is made too frequently; patients with viral illnesses of only a few days' duration are inappropriately labeled as having bacterial disease and, therefore, (2) patients are prescribed an antibiotic that is not only ineffective against a viral pathogen but also has the risk of leading to (3) the development and/or increase of resistance of various bacteria, including S pneumoniae.", [["infectious disease", "DISEASE", 223, 241], ["infectious disease", "DISEASE", 253, 271], ["acute bacterial rhinosinustis", "DISEASE", 451, 480], ["ABRS", "DISEASE", 482, 486], ["sinusitis", "DISEASE", 628, 637], ["viral illnesses", "DISEASE", 677, 692], ["bacterial disease", "DISEASE", 760, 777], ["patients", "ORGANISM", 437, 445], ["ABRS", "CANCER", 482, 486], ["patients", "ORGANISM", 663, 671], ["patients", "ORGANISM", 798, 806], ["S pneumoniae", "ORGANISM", 1007, 1019], ["patients", "SPECIES", 437, 445], ["patients", "SPECIES", 663, 671], ["patients", "SPECIES", 798, 806], ["S pneumoniae", "SPECIES", 1007, 1019], ["S pneumoniae", "SPECIES", 1007, 1019], ["Disease Control", "TREATMENT", 110, 125], ["acute bacterial rhinosinustis", "PROBLEM", 451, 480], ["several problems", "PROBLEM", 510, 526], ["bacterial \u201csinusitis", "PROBLEM", 617, 637], ["viral illnesses", "PROBLEM", 677, 692], ["bacterial disease", "PROBLEM", 760, 777], ["an antibiotic", "TREATMENT", 822, 835], ["a viral pathogen", "PROBLEM", 873, 889], ["various bacteria", "PROBLEM", 979, 995], ["S pneumoniae", "PROBLEM", 1007, 1019], ["Sinus", "ANATOMY", 16, 21], ["infectious", "OBSERVATION", 223, 233], ["sinusitis", "OBSERVATION", 628, 637], ["bacterial disease", "OBSERVATION", 760, 777], ["pneumoniae", "OBSERVATION", 1009, 1019]]], ["Another problem frequently encountered is that in bacterial infections, antibiotics are frequently used without regard to an understanding of their efficacy against the typical bacterial causes of ABRS.", [["bacterial infections", "DISEASE", 50, 70], ["ABRS", "DISEASE", 197, 201], ["ABRS", "CANCER", 197, 201], ["bacterial infections", "PROBLEM", 50, 70], ["antibiotics", "TREATMENT", 72, 83], ["ABRS", "PROBLEM", 197, 201], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["infections", "OBSERVATION", 60, 70]]], ["Little logic exists when a patient with ABRS is first prescribed TMP/SMX, then is switched to cefaclor when symptoms do not improve, and subsequently is prescribed azithromycin when again there is still no improvement.", [["ABRS", "DISEASE", 40, 44], ["TMP", "CHEMICAL", 65, 68], ["SMX", "CHEMICAL", 69, 72], ["cefaclor", "CHEMICAL", 94, 102], ["azithromycin", "CHEMICAL", 164, 176], ["TMP", "CHEMICAL", 65, 68], ["SMX", "CHEMICAL", 69, 72], ["cefaclor", "CHEMICAL", 94, 102], ["azithromycin", "CHEMICAL", 164, 176], ["patient", "ORGANISM", 27, 34], ["TMP", "SIMPLE_CHEMICAL", 65, 68], ["SMX", "SIMPLE_CHEMICAL", 69, 72], ["cefaclor", "SIMPLE_CHEMICAL", 94, 102], ["azithromycin", "SIMPLE_CHEMICAL", 164, 176], ["patient", "SPECIES", 27, 34], ["ABRS", "PROBLEM", 40, 44], ["TMP/SMX", "TREATMENT", 65, 72], ["cefaclor", "TREATMENT", 94, 102], ["symptoms", "PROBLEM", 108, 116], ["azithromycin", "TREATMENT", 164, 176], ["no", "UNCERTAINTY", 203, 205], ["improvement", "OBSERVATION", 206, 217]]], ["No agent in this example provides adequate empirical treatment for S pneumoniae or H influenzae, both major bacterial pathogens in ABRS.IntroductionIn this paper the reader is taken on a step-by-step approach to ABRS.", [["S pneumoniae", "ORGANISM", 67, 79], ["H influenzae", "ORGANISM", 83, 95], ["ABRS", "CANCER", 131, 135], ["S pneumoniae", "SPECIES", 67, 79], ["H influenzae", "SPECIES", 83, 95], ["S pneumoniae", "SPECIES", 67, 79], ["H influenzae", "SPECIES", 83, 95], ["agent", "TREATMENT", 3, 8], ["S pneumoniae", "PROBLEM", 67, 79], ["H influenzae", "PROBLEM", 83, 95], ["major bacterial pathogens in ABRS", "PROBLEM", 102, 135]]], ["The terminology, incidence, and definition of ABRS are presented.", [["ABRS", "DISEASE", 46, 50], ["ABRS", "PROBLEM", 46, 50]]], ["Rather than just create a list of antibiotics, numerous factors (eg, microbiology of ABRS, pharmacodynamic/pharmacokinetic principles, features of common oral antibiotics, the resistance mechanisms of bacterial pathogens, and the results of surveillance studies focused on prevalence of resistant pathogens) assisting in the selection of antimicrobial agents are discussed.", [["oral", "ANATOMY", 154, 158], ["oral", "ORGANISM_SUBDIVISION", 154, 158], ["antibiotics", "TREATMENT", 34, 45], ["ABRS", "TEST", 85, 89], ["pharmacodynamic/pharmacokinetic principles", "TREATMENT", 91, 133], ["common oral antibiotics", "TREATMENT", 147, 170], ["bacterial pathogens", "PROBLEM", 201, 220], ["surveillance studies", "TEST", 241, 261], ["resistant pathogens", "PROBLEM", 287, 306], ["antimicrobial agents", "TREATMENT", 338, 358], ["antimicrobial agents", "OBSERVATION", 338, 358]]], ["All this information, in conjunction with a mathematical model for analyzing treatment outcomes, leads to the development of rational treatment guidelines that will assist clinicians in providing optimal treatment for their patients.IntroductionOur hope is that these guidelines will be a part of national and international efforts coordinated by the CDC and aimed at educating health care providers and patients about the abuses and overuses of antibiotics.", [["patients", "ORGANISM", 224, 232], ["patients", "ORGANISM", 404, 412], ["patients", "SPECIES", 224, 232], ["patients", "SPECIES", 404, 412], ["analyzing treatment outcomes", "TREATMENT", 67, 95], ["rational treatment guidelines", "TREATMENT", 125, 154], ["antibiotics", "TREATMENT", 446, 457]]], ["The misuse of antibiotics should not be a replacement for spending time talking with and examining the patient and teaching that patient and/or the patient's family the differences between viral and bacterial infections.IntroductionWe cannot rely on the pharmaceutical industry to develop new drugs as organisms become resistant; rather, we must decrease unnecessary antimicrobial use as a means to reduce the spread of resistance.IntroductionWe believe further research is necessary to (1) develop better methods to diagnose ABRS, (2) further explore the clinical application of the antibiotic recommendations presented in this document, and (3) monitor the levels of bacterial resistance\u2014especially those of S pneumoniae and H influenzae.Viral respiratory tract infections versus ABRSIn the United States, the average child has 3 to 8 and the average adult has 2 to 3 acute viral respiratory illnesses per year.1, 2 Because up to 90% of these patients will have CT scan evidence of paranasal sinus involvement, they are considered to have a self-limiting viral rhinosinusitis (VRS).1, 3 Bacterial infections, also referred to as ABRS, complicate roughly 0.5% to 2% of VRS.1, 4 It is estimated that more than 1 billion cases of VRS occur annually in the United States.", [["respiratory", "ANATOMY", 882, 893], ["paranasal sinus", "ANATOMY", 984, 999], ["viral and bacterial infections", "DISEASE", 189, 219], ["ABRS", "DISEASE", 526, 530], ["Viral respiratory tract infections", "DISEASE", 740, 774], ["viral respiratory illnesses", "DISEASE", 876, 903], ["paranasal sinus involvement", "DISEASE", 984, 1011], ["viral rhinosinusitis", "DISEASE", 1057, 1077], ["VRS", "DISEASE", 1079, 1082], ["Bacterial infections", "DISEASE", 1089, 1109], ["ABRS", "DISEASE", 1131, 1135], ["VRS", "DISEASE", 1170, 1173], ["VRS", "DISEASE", 1229, 1232], ["patient", "ORGANISM", 103, 110], ["patient", "ORGANISM", 129, 136], ["patient", "ORGANISM", 148, 155], ["S pneumoniae", "ORGANISM", 710, 722], ["H influenzae", "ORGANISM", 727, 739], ["Viral respiratory tract", "ORGANISM", 740, 763], ["patients", "ORGANISM", 945, 953], ["paranasal sinus", "MULTI-TISSUE_STRUCTURE", 984, 999], ["VRS", "PATHOLOGICAL_FORMATION", 1170, 1173], ["patient", "SPECIES", 103, 110], ["patient", "SPECIES", 129, 136], ["patient", "SPECIES", 148, 155], ["S pneumoniae", "SPECIES", 710, 722], ["H influenzae", "SPECIES", 727, 739], ["patients", "SPECIES", 945, 953], ["S pneumoniae", "SPECIES", 710, 722], ["H influenzae", "SPECIES", 727, 739], ["antibiotics", "TREATMENT", 14, 25], ["a replacement", "TREATMENT", 40, 53], ["viral and bacterial infections", "PROBLEM", 189, 219], ["new drugs", "TREATMENT", 289, 298], ["organisms", "PROBLEM", 302, 311], ["unnecessary antimicrobial use", "TREATMENT", 355, 384], ["the antibiotic recommendations", "TREATMENT", 580, 610], ["bacterial resistance\u2014especially", "PROBLEM", 669, 700], ["S pneumoniae", "PROBLEM", 710, 722], ["H influenzae", "PROBLEM", 727, 739], ["Viral respiratory tract infections", "PROBLEM", 740, 774], ["3 acute viral respiratory illnesses", "PROBLEM", 868, 903], ["CT scan", "TEST", 964, 971], ["paranasal sinus involvement", "PROBLEM", 984, 1011], ["a self-limiting viral rhinosinusitis", "PROBLEM", 1041, 1077], ["3 Bacterial infections", "PROBLEM", 1087, 1109], ["ABRS", "TEST", 1131, 1135], ["VRS", "PROBLEM", 1170, 1173], ["bacterial infections", "OBSERVATION", 199, 219], ["bacterial resistance\u2014especially", "OBSERVATION", 669, 700], ["respiratory tract", "ANATOMY", 746, 763], ["infections", "OBSERVATION", 764, 774], ["acute", "OBSERVATION_MODIFIER", 870, 875], ["viral respiratory illnesses", "OBSERVATION", 876, 903], ["paranasal sinus", "ANATOMY", 984, 999], ["viral", "OBSERVATION_MODIFIER", 1057, 1062], ["rhinosinusitis", "OBSERVATION", 1063, 1077], ["Bacterial", "OBSERVATION_MODIFIER", 1089, 1098], ["infections", "OBSERVATION", 1099, 1109]]], ["Assuming a 2% bacterial complication rate, 20 million cases of VRS are complicated by ABRS annually.", [["VRS", "DISEASE", 63, 66], ["ABRS", "DISEASE", 86, 90], ["a 2% bacterial complication rate", "PROBLEM", 9, 41], ["VRS", "PROBLEM", 63, 66], ["ABRS", "PROBLEM", 86, 90]]], ["In addition to its public health implications, rhinosinusitis has a considerable economic impact.", [["rhinosinusitis", "DISEASE", 47, 61], ["rhinosinusitis", "PROBLEM", 47, 61], ["rhinosinusitis", "OBSERVATION", 47, 61], ["considerable", "OBSERVATION_MODIFIER", 68, 80], ["economic", "OBSERVATION_MODIFIER", 81, 89], ["impact", "OBSERVATION", 90, 96]]], ["In 1996, the primary diagnosis of rhinosinusitis led to expenditures of approximately $3.39 billion in the United States.5", [["rhinosinusitis", "DISEASE", 34, 48], ["rhinosinusitis", "PROBLEM", 34, 48], ["rhinosinusitis", "OBSERVATION", 34, 48]]]], "7b1eaf6b846a32ddf1cdb469413dd2f820d71c4f": [["In Meghalaya, bay leaf unit production ranges from 30 to 70 kg per tree per year, but in Nepal, the average range is 13 kg of the dry leaves.", [["leaves", "ANATOMY", 134, 140]]], ["About 900 tons of bay leaf are produced in Udaipur district, and 2100 tons are exported by Nepal to India (Choudhary et al., 2014) .", [["leaf", "ANATOMY", 22, 26], ["leaf", "ORGAN", 22, 26]]], ["Aegean and Eastern Mediterranean regions are the biggest collection areas of bay leaf for export (Nurba\u015f and Bal, 2005) .", [["leaf", "ANATOMY", 81, 85], ["leaf", "ORGAN", 81, 85], ["biggest", "OBSERVATION_MODIFIER", 49, 56], ["bay leaf", "OBSERVATION", 77, 85]]], ["Turkey exported 4869 tons of bay leaf to the United States in 2002 (Deniz, 2012) .History/OriginThe origin of bay leaf is most probably South Asia, from where it spread to Asia Minor and all over the world.Demography/LocationBay leaf is grown in different ecologic and climatic conditions.", [["leaf", "ANATOMY", 33, 37], ["leaf", "ANATOMY", 114, 118], ["leaf", "ANATOMY", 229, 233], ["leaf", "ORGAN", 33, 37], ["leaf", "ORGAN", 114, 118], ["origin", "ANATOMY_MODIFIER", 100, 106], ["bay leaf", "OBSERVATION", 110, 118], ["most probably", "UNCERTAINTY", 122, 135], ["grown", "OBSERVATION_MODIFIER", 237, 242], ["climatic conditions", "OBSERVATION", 269, 288]]], ["Wet, sandy soil that has a large quantity of water or some moist atmospheric conditions close to the ocean shore are optimum and the best conditions for rapid luxuriant growth (Patrakar et al., 2012) .", [["some moist atmospheric conditions", "PROBLEM", 54, 87], ["rapid luxuriant growth", "PROBLEM", 153, 175], ["large", "OBSERVATION_MODIFIER", 27, 32], ["quantity", "OBSERVATION_MODIFIER", 33, 41], ["moist", "OBSERVATION_MODIFIER", 59, 64], ["atmospheric conditions", "OBSERVATION", 65, 87]]], ["In warmer weather, leaves may burn; therefore partial sun shade, well-drained sandy soil that has some moisture, and a pH range of 4.5e8.2 are preferred.", [["leaves", "ANATOMY", 19, 25], ["leaves", "ORGANISM_SUBDIVISION", 19, 25], ["partial sun shade", "TREATMENT", 46, 63], ["a pH range", "TEST", 117, 127], ["moisture", "OBSERVATION_MODIFIER", 103, 111]]], ["Bay bears black fruit and yellowish-white fluffy flowers in warmer areas.", [["black fruit", "PROBLEM", 10, 21], ["yellowish-white fluffy flowers", "PROBLEM", 26, 56], ["black fruit", "OBSERVATION", 10, 21], ["yellowish", "OBSERVATION_MODIFIER", 26, 35], ["white", "OBSERVATION_MODIFIER", 36, 41], ["fluffy", "OBSERVATION_MODIFIER", 42, 48], ["flowers", "OBSERVATION_MODIFIER", 49, 56], ["warmer", "OBSERVATION_MODIFIER", 60, 66], ["areas", "OBSERVATION_MODIFIER", 67, 72]]], ["Temperatures below 28 F and extensive freezing will kill the bay (Kemp et al., 1983) .", [["Temperatures", "TEST", 0, 12]]], ["Bay is widely growing in the following countries: India, Pakistan, other Southeast Asian countries, some Pacific islands, Australia, around the coast of the Mediterranean and Southern Europe, Greece, Portugal, France, Turkey, Spain, Algeria, Morocco, Belgium, Central America, Mexico, Southern United States, and the Canary Islands (Parthasarathy et al., 2008) .Botany, Morphology, EcologyBay leaf is native to South Europe (Patrakar et al., 2012) .", [["some Pacific islands", "PROBLEM", 100, 120], ["widely", "OBSERVATION_MODIFIER", 7, 13], ["growing", "OBSERVATION_MODIFIER", 14, 21], ["Pacific islands", "OBSERVATION", 105, 120], ["Mediterranean", "ANATOMY", 157, 170], ["Central", "ANATOMY_MODIFIER", 260, 267], ["Morphology", "OBSERVATION_MODIFIER", 370, 380]]], ["It is a multibranched, deciduous shrub having height up to 6e8 m and diameter up to 15e40 cm with smooth, thin, and brown bark containing a shady crown (Patrakar et al., 2012) .", [["bark", "TISSUE", 122, 126], ["height", "TEST", 46, 52], ["diameter", "TEST", 69, 77], ["deciduous", "OBSERVATION_MODIFIER", 23, 32], ["shrub", "OBSERVATION_MODIFIER", 33, 38], ["height", "OBSERVATION_MODIFIER", 46, 52], ["diameter", "OBSERVATION_MODIFIER", 69, 77], ["15e40 cm", "OBSERVATION_MODIFIER", 84, 92], ["smooth", "OBSERVATION_MODIFIER", 98, 104], ["thin", "OBSERVATION_MODIFIER", 106, 110], ["brown bark", "OBSERVATION_MODIFIER", 116, 126]]], ["Leaves are alternate, lanceolate, and bipinnate compounds with smooth or sharp margins 29e30 cm long containing 24 leaflets that are lanceolate, 4.8e4.9 cm long, and 1.7e1.8 cm wide with 0.5 cm long petiole.", [["Leaves", "ANATOMY", 0, 6], ["petiole", "ANATOMY", 199, 206], ["Leaves", "ORGAN", 0, 6], ["lanceolate", "TREATMENT", 22, 32], ["lanceolate", "TEST", 133, 143], ["smooth", "OBSERVATION_MODIFIER", 63, 69], ["sharp", "OBSERVATION_MODIFIER", 73, 78], ["margins", "OBSERVATION_MODIFIER", 79, 86], ["leaflets", "ANATOMY_MODIFIER", 115, 123], ["4.8e4.9 cm", "OBSERVATION_MODIFIER", 145, 155], ["1.8 cm", "OBSERVATION_MODIFIER", 170, 176], ["wide", "OBSERVATION_MODIFIER", 177, 181], ["0.5 cm", "OBSERVATION_MODIFIER", 187, 193]]], ["Flowers are ebracteate, four-lobed, white, scented, and small, having eight to 12 male stamens and two to four female staminoids, and the fruit is 10e15 mm, in small clusters, ovoid, thin pericarp enclosing spinach-green seeds and black when ripe.", [["stamens", "ANATOMY", 87, 94], ["staminoids", "ANATOMY", 118, 128], ["pericarp", "ANATOMY", 188, 196], ["seeds", "ANATOMY", 221, 226], ["staminoids", "CANCER", 118, 128], ["pericarp", "TISSUE", 188, 196], ["ebracteate", "OBSERVATION_MODIFIER", 12, 22], ["four", "OBSERVATION_MODIFIER", 24, 28], ["white", "OBSERVATION_MODIFIER", 36, 41], ["scented", "OBSERVATION_MODIFIER", 43, 50], ["small", "OBSERVATION_MODIFIER", 56, 61], ["staminoids", "ANATOMY", 118, 128], ["fruit", "OBSERVATION", 138, 143], ["10e15 mm", "OBSERVATION_MODIFIER", 147, 155], ["small", "OBSERVATION_MODIFIER", 160, 165], ["clusters", "OBSERVATION_MODIFIER", 166, 174], ["ovoid", "OBSERVATION_MODIFIER", 176, 181], ["thin pericarp", "OBSERVATION", 183, 196], ["green seeds", "OBSERVATION", 215, 226], ["black", "OBSERVATION_MODIFIER", 231, 236]]], ["Calyx is pubescent having five clefts and five petals along with glabrous glands, free and white.CHEMISTRYBay leaf has a sharp and bitter taste.", [["petals", "ANATOMY", 47, 53], ["glabrous glands", "ANATOMY", 65, 80], ["leaf", "ANATOMY", 110, 114], ["clefts", "DISEASE", 31, 37], ["petals", "ORGAN", 47, 53], ["glabrous glands", "ORGAN", 65, 80], ["leaf", "ORGAN", 110, 114], ["five clefts", "PROBLEM", 26, 37], ["glabrous glands", "PROBLEM", 65, 80], ["a sharp and bitter taste", "PROBLEM", 119, 143], ["pubescent", "OBSERVATION_MODIFIER", 9, 18], ["glabrous glands", "ANATOMY", 65, 80], ["free", "OBSERVATION_MODIFIER", 82, 86], ["sharp", "OBSERVATION_MODIFIER", 121, 126]]], ["The difference in fragrance and aroma is due to the presence of essential oils in leaves and other parts of the plant.", [["oils", "ANATOMY", 74, 78], ["leaves", "ANATOMY", 82, 88], ["leaves", "ORGANISM_SUBDIVISION", 82, 88], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["fragrance", "OBSERVATION", 18, 27], ["essential", "OBSERVATION_MODIFIER", 64, 73], ["oils", "OBSERVATION", 74, 78], ["plant", "OBSERVATION", 112, 117]]], ["It has flavonoids, tannins, eugenol, citric acid, carbohydrate, steroids, alkaloids, triterpenoids, and essential oils.", [["oils", "ANATOMY", 114, 118], ["flavonoids, tannins, eugenol, citric acid, carbohydrate, steroids, alkaloids, triterpenoids", "CHEMICAL", 7, 98], ["flavonoids", "CHEMICAL", 7, 17], ["tannins", "CHEMICAL", 19, 26], ["eugenol", "CHEMICAL", 28, 35], ["citric acid", "CHEMICAL", 37, 48], ["carbohydrate", "CHEMICAL", 50, 62], ["steroids", "CHEMICAL", 64, 72], ["triterpenoids", "CHEMICAL", 85, 98], ["flavonoids", "SIMPLE_CHEMICAL", 7, 17], ["tannins", "SIMPLE_CHEMICAL", 19, 26], ["eugenol", "SIMPLE_CHEMICAL", 28, 35], ["citric acid", "SIMPLE_CHEMICAL", 37, 48], ["carbohydrate", "SIMPLE_CHEMICAL", 50, 62], ["steroids", "SIMPLE_CHEMICAL", 64, 72], ["alkaloids", "SIMPLE_CHEMICAL", 74, 83], ["triterpenoids", "SIMPLE_CHEMICAL", 85, 98], ["flavonoids", "TREATMENT", 7, 17], ["tannins", "TREATMENT", 19, 26], ["eugenol", "TREATMENT", 28, 35], ["citric acid", "TREATMENT", 37, 48], ["carbohydrate", "TREATMENT", 50, 62], ["steroids", "TREATMENT", 64, 72], ["alkaloids", "TREATMENT", 74, 83], ["triterpenoids", "TREATMENT", 85, 98], ["essential oils", "TREATMENT", 104, 118], ["flavonoids", "OBSERVATION_MODIFIER", 7, 17]]], ["Antioxidant properties were discovered in the extract of bay leaf to have phenolic compounds.", [["extract", "ANATOMY", 46, 53], ["leaf", "ANATOMY", 61, 65], ["leaf", "ORGAN", 61, 65], ["Antioxidant properties", "TREATMENT", 0, 22], ["phenolic compounds", "PROBLEM", 74, 92], ["phenolic compounds", "OBSERVATION", 74, 92]]], ["Each of these chemical constituents varies depending on the type of species.", [["chemical", "OBSERVATION_MODIFIER", 14, 22], ["constituents", "OBSERVATION", 23, 35]]], ["Tanine is a liquid glycoside derived from polypeptide and ester polymer that can be hydrolyzed by the secretion of bile (3, 4, 5etrinidrokside benzoic acid) and glucose (Sumono, 2008) .", [["Tanine", "CHEMICAL", 0, 6], ["ester polymer", "CHEMICAL", 58, 71], ["3, 4, 5etrinidrokside benzoic acid", "CHEMICAL", 121, 155], ["glucose", "CHEMICAL", 161, 168], ["ester", "CHEMICAL", 58, 63], ["bile (3, 4, 5etrinidrokside benzoic acid", "CHEMICAL", 115, 155], ["glucose", "CHEMICAL", 161, 168], ["Tanine", "SIMPLE_CHEMICAL", 0, 6], ["ester polymer", "SIMPLE_CHEMICAL", 58, 71], ["bile", "SIMPLE_CHEMICAL", 115, 119], ["3, 4, 5etrinidrokside benzoic acid", "SIMPLE_CHEMICAL", 121, 155], ["glucose", "SIMPLE_CHEMICAL", 161, 168], ["a liquid glycoside", "TREATMENT", 10, 28], ["polypeptide and ester polymer", "TREATMENT", 42, 71], ["5etrinidrokside benzoic acid", "TEST", 127, 155], ["glucose", "TEST", 161, 168], ["bile", "ANATOMY", 115, 119]]], ["Tanine or tanat acid isolated from some part of plants can be found in the market.", [["Tanine", "CHEMICAL", 0, 6], ["tanat acid", "CHEMICAL", 10, 20], ["Tanine", "CHEMICAL", 0, 6], ["tanat acid", "CHEMICAL", 10, 20], ["Tanine", "SIMPLE_CHEMICAL", 0, 6], ["tanat acid", "SIMPLE_CHEMICAL", 10, 20], ["tanat acid isolated", "PROBLEM", 10, 29], ["plants", "OBSERVATION", 48, 54]]], ["It is a cream-colored powder, aromatic, with astringent taste (Sumono, 2008) .", [["a cream-colored powder", "TREATMENT", 6, 28]]], ["Tanine is used as an astringent for the gastrointestinal tract or skin and can cause precipitation of the cell membrane protein.", [["gastrointestinal tract", "ANATOMY", 40, 62], ["skin", "ANATOMY", 66, 70], ["cell membrane", "ANATOMY", 106, 119], ["Tanine", "CHEMICAL", 0, 6], ["Tanine", "SIMPLE_CHEMICAL", 0, 6], ["gastrointestinal tract", "ORGAN", 40, 62], ["skin", "ORGAN", 66, 70], ["cell membrane", "CELLULAR_COMPONENT", 106, 119], ["cell membrane protein", "PROTEIN", 106, 127], ["Tanine", "TREATMENT", 0, 6], ["an astringent", "TREATMENT", 18, 31], ["the cell membrane protein", "PROBLEM", 102, 127], ["gastrointestinal tract", "ANATOMY", 40, 62], ["skin", "ANATOMY", 66, 70], ["cell membrane protein", "OBSERVATION", 106, 127]]], ["It also has a little penetration activity, so it can influence the permeability of the cell membrane.CHEMISTRYBay leaf has traces of fats; (that is, a low amount is present) so it has low caloric value.", [["cell membrane", "ANATOMY", 87, 100], ["leaf", "ANATOMY", 114, 118], ["fats", "ANATOMY", 133, 137], ["cell membrane", "CELLULAR_COMPONENT", 87, 100], ["leaf", "ORGAN", 114, 118], ["fats", "ORGANISM_SUBDIVISION", 133, 137], ["a little penetration activity", "PROBLEM", 12, 41], ["little", "OBSERVATION_MODIFIER", 14, 20], ["penetration activity", "OBSERVATION", 21, 41], ["cell membrane", "OBSERVATION", 87, 100], ["fats", "OBSERVATION", 133, 137], ["low amount", "OBSERVATION_MODIFIER", 151, 161], ["low", "OBSERVATION_MODIFIER", 184, 187], ["caloric value", "OBSERVATION", 188, 201]]], ["It is also known as a good and main source of vitamin A and many minerals.", [["vitamin A", "CHEMICAL", 46, 55], ["vitamin A", "CHEMICAL", 46, 55], ["vitamin A", "SIMPLE_CHEMICAL", 46, 55], ["vitamin A", "TREATMENT", 46, 55]]], ["One ounce of bay leaf gives 54 calories, 1e1.2 g protein, 12e13 g carbohydrates, a trace of fat, 1e1.5 mg of iron (Fe), 51e53 mg of calcium (Ca), 2000e3000 IU of vitamin A, 14e15 mg of vitamin C, and a small amount of potassium.", [["leaf", "ANATOMY", 17, 21], ["iron", "CHEMICAL", 109, 113], ["Fe", "CHEMICAL", 115, 117], ["calcium", "CHEMICAL", 132, 139], ["Ca", "CHEMICAL", 141, 143], ["vitamin A", "CHEMICAL", 162, 171], ["vitamin C", "CHEMICAL", 185, 194], ["potassium", "CHEMICAL", 218, 227], ["carbohydrates", "CHEMICAL", 66, 79], ["iron", "CHEMICAL", 109, 113], ["Fe", "CHEMICAL", 115, 117], ["calcium", "CHEMICAL", 132, 139], ["Ca", "CHEMICAL", 141, 143], ["vitamin A", "CHEMICAL", 162, 171], ["vitamin C", "CHEMICAL", 185, 194], ["potassium", "CHEMICAL", 218, 227], ["leaf", "ORGAN", 17, 21], ["fat", "TISSUE", 92, 95], ["iron", "SIMPLE_CHEMICAL", 109, 113], ["Fe", "SIMPLE_CHEMICAL", 115, 117], ["calcium", "SIMPLE_CHEMICAL", 132, 139], ["Ca", "SIMPLE_CHEMICAL", 141, 143], ["vitamin A", "SIMPLE_CHEMICAL", 162, 171], ["vitamin C", "SIMPLE_CHEMICAL", 185, 194], ["potassium", "SIMPLE_CHEMICAL", 218, 227], ["iron (Fe)", "TREATMENT", 109, 118], ["calcium (Ca", "TREATMENT", 132, 143], ["vitamin A", "TREATMENT", 162, 171], ["vitamin C", "TREATMENT", 185, 194], ["a small amount of potassium", "TREATMENT", 200, 227]]], ["Bay seeds are rich in dietary fibers.", [["dietary fibers", "ANATOMY", 22, 36], ["fibers", "CELLULAR_COMPONENT", 30, 36], ["dietary fibers", "OBSERVATION", 22, 36]]], ["In bay leaf, compounds like eugenol (11%e12%), methyl eugenol (9%e12%), and elemicin (1%e12%) are significant for the spicy aroma of bay leaves, and for determining effective quality of bay leaf, these are used as significant influencers (Biondi et al., 1993) .", [["leaf", "ANATOMY", 7, 11], ["leaves", "ANATOMY", 137, 143], ["leaf", "ANATOMY", 190, 194], ["eugenol", "CHEMICAL", 28, 35], ["methyl eugenol", "CHEMICAL", 47, 61], ["elemicin", "CHEMICAL", 76, 84], ["eugenol", "CHEMICAL", 28, 35], ["methyl eugenol", "CHEMICAL", 47, 61], ["elemicin", "CHEMICAL", 76, 84], ["leaf", "ORGAN", 7, 11], ["eugenol", "SIMPLE_CHEMICAL", 28, 35], ["methyl eugenol", "SIMPLE_CHEMICAL", 47, 61], ["elemicin", "SIMPLE_CHEMICAL", 76, 84], ["leaf", "ORGAN", 190, 194], ["eugenol", "TEST", 28, 35], ["methyl eugenol", "TREATMENT", 47, 61], ["elemicin", "TREATMENT", 76, 84], ["leaf", "OBSERVATION_MODIFIER", 7, 11]]], ["The essential oils in leaves vary from 0.8% to 3% and dry bay fruits from 0.6% to 10%.", [["oils", "ANATOMY", 14, 18], ["leaves", "ANATOMY", 22, 28], ["fruits", "ANATOMY", 62, 68], ["leaves", "ORGAN", 22, 28], ["fruits", "ORGANISM_SUBDIVISION", 62, 68], ["dry bay fruits", "TREATMENT", 54, 68], ["essential", "OBSERVATION_MODIFIER", 4, 13], ["oils", "OBSERVATION_MODIFIER", 14, 18], ["leaves", "OBSERVATION_MODIFIER", 22, 28], ["vary", "OBSERVATION_MODIFIER", 29, 33]]], ["Structures of some active compounds found in bay leaf are given in Fig. 5POSTHARVESTING TECHNOLOGYBay leaf can be harvested at any time of the year from a fully mature plant.", [["leaf", "ANATOMY", 49, 53], ["leaf", "ANATOMY", 102, 106], ["leaf", "ORGAN", 49, 53], ["leaf", "ORGAN", 102, 106], ["some active compounds", "PROBLEM", 14, 35], ["some", "OBSERVATION_MODIFIER", 14, 18], ["active", "OBSERVATION_MODIFIER", 19, 25], ["compounds", "OBSERVATION", 26, 35], ["harvested", "OBSERVATION", 114, 123]]], ["Fresh bay leaves have a bitter and pungent taste; therefore before use, leaves should be dried.", [["leaves", "ANATOMY", 10, 16], ["a bitter and pungent taste", "TREATMENT", 22, 48]]], ["After picking the leaf, it should be left for 48e72 hours for drying.", [["leaf", "ANATOMY", 18, 22], ["leaf", "ORGAN", 18, 22], ["leaf", "ANATOMY", 18, 22]]], ["Better and deeper flavor is observed in freshly dried leaves.", [["leaves", "ANATOMY", 54, 60]]], ["Harvesting should be avoided, when plant is wet.PROCESSINGBay is consumed in a variety of ways and for various purposes.", [["Harvesting", "TREATMENT", 0, 10]]], ["In addition to its fresh leaves, other common processed forms of bay include whole dry leaves, frozen, powdered leaves, and extracted essential oils.BAY LEAFLeaves can be stored frozen for the sake of use for extended time beyond its fresh shelf life.", [["leaves", "ANATOMY", 25, 31], ["leaves", "ANATOMY", 87, 93], ["leaves", "ANATOMY", 112, 118], ["oils", "ANATOMY", 144, 148], ["BAY", "CHEMICAL", 149, 152], ["BAY", "SIMPLE_CHEMICAL", 149, 152]]], ["For drying of bay leaf, different drying methods are available.", [["leaf", "ANATOMY", 18, 22], ["leaf", "ORGAN", 18, 22], ["different drying methods", "TREATMENT", 24, 48]]], ["Traditionally, it is dried in open air for 10e12 days.", [["dried", "OBSERVATION_MODIFIER", 21, 26], ["air", "OBSERVATION", 35, 38]]], ["Sun drying has some disadvantages, like natural color loss and essential oil loss that result in low market value of bay leaf.", [["oil", "ANATOMY", 73, 76], ["leaf", "ANATOMY", 121, 125], ["oil", "ORGANISM_SUBSTANCE", 73, 76], ["leaf", "ORGANISM_SUBDIVISION", 121, 125], ["some disadvantages", "PROBLEM", 15, 33], ["natural color loss", "PROBLEM", 40, 58], ["essential oil loss", "PROBLEM", 63, 81], ["some", "OBSERVATION_MODIFIER", 15, 19], ["disadvantages", "OBSERVATION", 20, 33], ["natural color loss", "OBSERVATION", 40, 58], ["essential", "OBSERVATION_MODIFIER", 63, 72], ["oil loss", "OBSERVATION", 73, 81], ["low market", "OBSERVATION_MODIFIER", 97, 107]]], ["Hot air drying at 60 C is the best method for producing bay leaves.", [["Hot air drying", "PROBLEM", 0, 14]]], ["Steam distillation is the best method for the recovery of essential oils from the bay leaf plant.", [["oils", "ANATOMY", 68, 72], ["leaf", "ORGANISM_SUBDIVISION", 86, 90], ["Steam distillation", "TREATMENT", 0, 18], ["leaf plant", "OBSERVATION", 86, 96]]], ["Essential oil extracted from bay leaf is in two forms, fixed oil and volatile oil, that are collected from bay fruits (Bozan and Karakaplan, 2007) .VALUE ADDITIONBay leaf can be combined with a variety of other herbs including cloves, thyme, tomato, mustard, parsley, paprika, sage, and pepper for use in soups, stews, as well as with fish, vegetables, and meat.", [["oil", "ANATOMY", 10, 13], ["leaf", "ANATOMY", 33, 37], ["oil", "ANATOMY", 61, 64], ["volatile oil", "ANATOMY", 69, 81], ["fruits", "ANATOMY", 111, 117], ["leaf", "ANATOMY", 166, 170], ["parsley", "ANATOMY", 259, 266], ["vegetables", "ANATOMY", 341, 351], ["meat", "ANATOMY", 357, 361], ["cloves, thyme, tomato, mustard, parsley, paprika, sage, and pepper", "CHEMICAL", 227, 293], ["oil", "ORGANISM_SUBSTANCE", 10, 13], ["leaf", "ORGAN", 33, 37], ["oil", "ORGANISM_SUBSTANCE", 61, 64], ["oil", "ORGANISM_SUBSTANCE", 78, 81], ["fruits", "ORGANISM_SUBDIVISION", 111, 117], ["leaf", "ORGAN", 166, 170], ["thyme", "ORGANISM_SUBDIVISION", 235, 240], ["tomato", "ORGANISM_SUBDIVISION", 242, 248], ["mustard", "SIMPLE_CHEMICAL", 250, 257], ["parsley", "TISSUE", 259, 266], ["pepper", "ORGANISM_SUBDIVISION", 287, 293], ["fish", "ORGANISM_SUBDIVISION", 335, 339], ["vegetables", "ORGANISM_SUBDIVISION", 341, 351], ["meat", "ORGANISM_SUBDIVISION", 357, 361], ["thyme", "SPECIES", 235, 240], ["tomato", "SPECIES", 242, 248], ["parsley", "SPECIES", 259, 266], ["thyme", "SPECIES", 235, 240], ["tomato", "SPECIES", 242, 248], ["parsley", "SPECIES", 259, 266], ["pepper", "SPECIES", 287, 293], ["oil", "OBSERVATION_MODIFIER", 10, 13], ["bay leaf", "OBSERVATION", 29, 37], ["volatile oil", "OBSERVATION", 69, 81]]], ["Bay leaf with cloves and thyme is used to form tomato sherbet.", [["leaf", "ANATOMY", 4, 8], ["thyme", "ORGANISM_SUBDIVISION", 25, 30], ["tomato", "ORGANISM", 47, 53], ["tomato", "SPECIES", 47, 53], ["tomato", "SPECIES", 47, 53], ["cloves and thyme", "TREATMENT", 14, 30]]], ["Bay leaf with beef stock and large egg yolks forms Provencal bay tomato soup.", [["leaf", "ANATOMY", 4, 8], ["egg yolks", "ANATOMY", 35, 44], ["leaf", "ORGAN", 4, 8], ["egg yolks", "ORGANISM_SUBSTANCE", 35, 44], ["beef", "SPECIES", 14, 18], ["tomato", "SPECIES", 65, 71], ["beef", "SPECIES", 14, 18], ["Provencal bay tomato", "SPECIES", 51, 71], ["beef stock", "TREATMENT", 14, 24], ["large egg yolks", "TREATMENT", 29, 44], ["beef stock", "OBSERVATION", 14, 24], ["large", "OBSERVATION_MODIFIER", 29, 34], ["egg yolks", "OBSERVATION", 35, 44], ["tomato soup", "OBSERVATION", 65, 76]]], ["Bay leaves with whole celery seeds, whole cloves, peppercorns, dried parsley, and thyme can be used in bouquet garni.", [["leaves", "ANATOMY", 4, 10], ["seeds", "ANATOMY", 29, 34], ["cloves", "ANATOMY", 42, 48], ["peppercorns", "ANATOMY", 50, 61], ["parsley", "ANATOMY", 69, 76], ["thyme", "ORGANISM_SUBDIVISION", 82, 87], ["bouquet garni", "CELL", 103, 116], ["celery", "SPECIES", 22, 28], ["parsley", "SPECIES", 69, 76], ["bouquet garni", "SPECIES", 103, 116], ["whole celery seeds", "TREATMENT", 16, 34], ["whole cloves", "TREATMENT", 36, 48], ["peppercorns", "TREATMENT", 50, 61], ["thyme", "TREATMENT", 82, 87]]], ["Bay leaf pound cake can be made by using milk, sugar, butter, eggs, cake flour, and baking powder with bayVALUE ADDITIONFIGURE 5.2 Structures of some active compounds found in bay leaf.VALUE ADDITIONleaves.", [["leaf", "ANATOMY", 4, 8], ["milk", "ANATOMY", 41, 45], ["eggs", "ANATOMY", 62, 66], ["leaf", "ANATOMY", 180, 184], ["milk, sugar, butter, eggs, cake flour", "CHEMICAL", 41, 78], ["sugar", "CHEMICAL", 47, 52], ["milk", "ORGANISM_SUBSTANCE", 41, 45], ["sugar", "SIMPLE_CHEMICAL", 47, 52], ["butter", "ORGANISM_SUBDIVISION", 54, 60], ["eggs", "ORGANISM_SUBDIVISION", 62, 66], ["leaf", "ORGAN", 180, 184], ["some active compounds", "PROBLEM", 145, 166], ["active", "OBSERVATION_MODIFIER", 150, 156], ["compounds", "OBSERVATION", 157, 166]]], ["The leaves of bay have a camphor-like volatile oil that can be used as a coolant, insecticide, germicide, and irritant.", [["leaves", "ANATOMY", 4, 10], ["volatile oil", "ANATOMY", 38, 50], ["camphor", "CHEMICAL", 25, 32], ["germicide", "CHEMICAL", 95, 104], ["camphor", "CHEMICAL", 25, 32], ["camphor", "SIMPLE_CHEMICAL", 25, 32], ["oil", "ORGANISM_SUBSTANCE", 47, 50], ["germicide", "SIMPLE_CHEMICAL", 95, 104], ["a camphor-like volatile oil", "TREATMENT", 23, 50], ["a coolant", "TREATMENT", 71, 80], ["germicide", "TREATMENT", 95, 104], ["irritant", "OBSERVATION", 110, 118]]], ["Roasting of bay seeds gives them a spicy, coffee-like flavor, and by removing pungency, they become crispy and brown.", [["brown", "OBSERVATION", 111, 116]]], ["Small leaves of bay are used in salads, rice, and vegetarian dishes.", [["leaves", "ANATOMY", 6, 12], ["salads", "ORGANISM_SUBDIVISION", 32, 38], ["rice", "SPECIES", 40, 44], ["rice", "SPECIES", 40, 44], ["leaves", "OBSERVATION_MODIFIER", 6, 12], ["vegetarian dishes", "OBSERVATION", 50, 67]]], ["Its woody branches can be used in steamed meat, drinks, and soups, while leaf bark is used as a condiment in many spices.", [["meat", "ANATOMY", 42, 46], ["leaf bark", "ANATOMY", 73, 82], ["meat", "ORGANISM_SUBDIVISION", 42, 46], ["leaf bark", "ORGANISM_SUBSTANCE", 73, 82], ["woody", "OBSERVATION_MODIFIER", 4, 9], ["branches", "OBSERVATION_MODIFIER", 10, 18], ["leaf bark", "ANATOMY", 73, 82]]], ["Bay leaf has universal industrial importance as dried leaves and essential oils give courtesy flavor to foods as in meat products, canned soups, stews, baked goods, sausages, fish, cosmetics, and drugs.", [["leaf", "ANATOMY", 4, 8], ["leaves", "ANATOMY", 54, 60], ["oils", "ANATOMY", 75, 79], ["meat", "ANATOMY", 116, 120], ["stews", "ANATOMY", 145, 150], ["sausages", "ANATOMY", 165, 173], ["leaf", "ORGAN", 4, 8], ["leaves", "ORGANISM_SUBDIVISION", 54, 60], ["meat", "ORGANISM_SUBDIVISION", 116, 120], ["fish", "ORGANISM_SUBDIVISION", 175, 179], ["drugs", "TREATMENT", 196, 201]]], ["Spices and essential oils of bay leaf may extend storage life of foods, as they have antimicrobial and antioxidant activities (El et al., 2014) .", [["oils", "ANATOMY", 21, 25], ["leaf", "ANATOMY", 33, 37], ["leaf", "ORGAN", 33, 37], ["antimicrobial and antioxidant activities", "TREATMENT", 85, 125], ["oils", "OBSERVATION_MODIFIER", 21, 25]]], ["Chilling of bay leaf retains the taste of this shrub more effectively than drying.USESMany herbs and spices contribute significantly to health despite low amounts of consumption, as they are full of antioxidants and certain mineral compounds.", [["leaf", "ANATOMY", 16, 20], ["leaf", "ORGAN", 16, 20], ["spices", "ORGANISM_SUBDIVISION", 101, 107], ["bay leaf", "OBSERVATION", 12, 20]]], ["Nevertheless, bay is full of antioxidants and is a good source of minerals and dietary fibers.", [["dietary fibers", "ANATOMY", 79, 93], ["minerals", "SIMPLE_CHEMICAL", 66, 74]]], ["It complements food flavor, and bay tea is used to treat stomachaches, clear up mucus in the lungs, colds, and sore throat.", [["stomachaches", "ANATOMY", 57, 69], ["mucus", "ANATOMY", 80, 85], ["lungs", "ANATOMY", 93, 98], ["stomachaches", "DISEASE", 57, 69], ["colds", "DISEASE", 100, 105], ["sore throat", "DISEASE", 111, 122], ["tea", "ORGANISM_SUBDIVISION", 36, 39], ["mucus", "ORGANISM_SUBSTANCE", 80, 85], ["lungs", "ORGAN", 93, 98], ["throat", "ORGANISM_SUBDIVISION", 116, 122], ["stomachaches", "PROBLEM", 57, 69], ["clear up mucus in the lungs", "PROBLEM", 71, 98], ["colds", "PROBLEM", 100, 105], ["sore throat", "PROBLEM", 111, 122], ["mucus", "OBSERVATION", 80, 85], ["lungs", "ANATOMY", 93, 98], ["colds", "OBSERVATION", 100, 105], ["sore throat", "ANATOMY", 111, 122]]], ["Poultice of bay leaves is used for the treatment of rheumatism and neuralgia (Goodrich et al., 1980) .", [["rheumatism", "DISEASE", 52, 62], ["neuralgia", "DISEASE", 67, 76], ["rheumatism", "PROBLEM", 52, 62], ["neuralgia", "PROBLEM", 67, 76], ["rheumatism", "OBSERVATION", 52, 62], ["neuralgia", "OBSERVATION", 67, 76]]], ["To treat headache, leaf of bay is kept in a nostril or under the headbands to relieve this pain.", [["leaf", "ANATOMY", 19, 23], ["nostril", "ANATOMY", 44, 51], ["headache", "DISEASE", 9, 17], ["pain", "DISEASE", 91, 95], ["nostril", "ORGANISM_SUBDIVISION", 44, 51], ["headache", "PROBLEM", 9, 17], ["this pain", "PROBLEM", 86, 95]]], ["Traditionally, it has been used for the treatment of gastrointestinal problems such as impaired digestion, flatulence, eructation, and epigastric bloating and used as diuretic and has many analgesic effects (Elmasta\u015f et al., 2006) .", [["gastrointestinal", "ANATOMY", 53, 69], ["epigastric", "ANATOMY", 135, 145], ["gastrointestinal problems", "DISEASE", 53, 78], ["impaired digestion", "DISEASE", 87, 105], ["flatulence", "DISEASE", 107, 117], ["eructation", "DISEASE", 119, 129], ["epigastric bloating", "DISEASE", 135, 154], ["gastrointestinal", "ORGAN", 53, 69], ["epigastric", "ORGANISM_SUBDIVISION", 135, 145], ["gastrointestinal problems", "PROBLEM", 53, 78], ["impaired digestion", "PROBLEM", 87, 105], ["flatulence", "PROBLEM", 107, 117], ["eructation", "PROBLEM", 119, 129], ["epigastric bloating", "PROBLEM", 135, 154], ["diuretic", "TREATMENT", 167, 175], ["many analgesic effects", "TREATMENT", 184, 206], ["gastrointestinal", "ANATOMY", 53, 69], ["impaired", "OBSERVATION_MODIFIER", 87, 95], ["digestion", "OBSERVATION", 96, 105], ["epigastric", "ANATOMY", 135, 145], ["bloating", "OBSERVATION", 146, 154]]], ["Bay is great to add flavor and taste to food and many dishes with added health benefits.USESBay has many uses ranging from culinary to religious.", [["USESBay", "CHEMICAL", 88, 95]]], ["There are number of curious beliefs associated with the historical use of bay leaf.", [["leaf", "ANATOMY", 78, 82], ["leaf", "ORGANISM_SUBDIVISION", 78, 82]]], ["The roof was made of bay leaves, and priestesses would have to eat bay before giving their oracles.", [["leaves", "ANATOMY", 25, 31]]], ["Thus bay leaves are said to aid with psychic powers, particularly prophetic dreams, clairvoyance, protection, healing, purification, strength, wishes, magic, exorcism, divination, visions, inspiration, wisdom, meditation, defense, and accessing the creative world.", [["psychic powers", "TREATMENT", 37, 51], ["clairvoyance", "TREATMENT", 84, 96], ["protection", "TREATMENT", 98, 108], ["healing", "PROBLEM", 110, 117]]], ["Israelite society consider the bay leaf as a symbol of victory over misfortune; they were very impressed by this tree.", [["leaf", "ANATOMY", 35, 39], ["leaf", "ORGAN", 35, 39]]], ["The Romans and Greeks used this as a head band mainly for their respected citizens, poets, heroes, and priests, and they consider sleeping with bay leaves to make a man a poet.", [["head", "ANATOMY", 37, 41], ["head", "ORGANISM_SUBDIVISION", 37, 41], ["man", "SPECIES", 165, 168], ["a head band", "TREATMENT", 35, 46]]], ["Romans also believed that this tree protects from lightning, so Emperor Tiberius always kept a bay leaf hat because he had a fear of thunderstorms; and from witches and wizards.", [["fear of thunderstorms", "DISEASE", 125, 146]]], ["The French sometimes call bay the \"berries of bay,\" and they crowned intelligent people with its berries and leaves, which are burned to increase the psychic powers and protect from evil and negativity.", [["berries", "ANATOMY", 97, 104], ["people", "ORGANISM", 81, 87], ["berries", "ORGANISM_SUBDIVISION", 97, 104], ["leaves", "ORGANISM_SUBDIVISION", 109, 115], ["people", "SPECIES", 81, 87]]], ["Chinese have a belief that to remove evil messes and crossed conditions, bay leaf with washed water can be used.", [["leaf", "ANATOMY", 77, 81], ["leaf", "ORGAN", 77, 81], ["crossed conditions", "PROBLEM", 53, 71]]], ["Many people kept them in mojo bags to prevent unwanted interference from people.USESGoing beyond the ritualistic uses, bay has been used in cooking, and it is versatile as used in wide range of dishes, sauces, and condiments.", [["people", "ORGANISM", 5, 11], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 5, 11], ["people", "SPECIES", 73, 79], ["mojo bags", "TREATMENT", 25, 34]]], ["It is an essential ingredient of many herbs and used in soups, stews, and stuffings, as well as fish, meats, vegetables, sauce, pickles, and sausages.", [["stews", "ANATOMY", 63, 68], ["meats", "ANATOMY", 102, 107], ["vegetables", "ANATOMY", 109, 119], ["pickles", "ANATOMY", 128, 135], ["sausages", "ANATOMY", 141, 149], ["fish", "ORGANISM", 96, 100], ["meats", "ORGANISM_SUBDIVISION", 102, 107], ["vegetables", "ORGANISM_SUBDIVISION", 109, 119], ["sauce", "ORGANISM_SUBDIVISION", 121, 126], ["sauce", "SPECIES", 121, 126], ["essential", "OBSERVATION_MODIFIER", 9, 18], ["ingredient", "OBSERVATION_MODIFIER", 19, 29], ["many", "OBSERVATION_MODIFIER", 33, 37], ["herbs", "OBSERVATION", 38, 43]]], ["It is easily blended with many other herbs such as garlic, mustard, pepper, parsley, rosemary, thyme, and oregano.", [["parsley", "ANATOMY", 76, 83], ["garlic, mustard, pepper, parsley, rosemary, thyme, and oregano", "CHEMICAL", 51, 113], ["garlic", "SIMPLE_CHEMICAL", 51, 57], ["mustard", "SIMPLE_CHEMICAL", 59, 66], ["pepper", "ORGANISM_SUBDIVISION", 68, 74], ["parsley", "TISSUE", 76, 83], ["rosemary", "TISSUE", 85, 93], ["thyme", "TISSUE", 95, 100], ["oregano", "ORGANISM_SUBDIVISION", 106, 113], ["garlic", "SPECIES", 51, 57], ["parsley", "SPECIES", 76, 83], ["rosemary", "SPECIES", 85, 93], ["oregano", "SPECIES", 106, 113], ["thyme", "ANATOMY", 95, 100]]], ["Bay can also be an important ingredient in teas, oils, cheeses, and liquors, and its essential oil is used in the cosmetic industry for soaps, perfumes, prepared foods, beverages, and dental products.", [["oils", "ANATOMY", 49, 53], ["oil", "ANATOMY", 95, 98], ["teas", "ORGANISM_SUBDIVISION", 43, 47], ["oils", "TISSUE", 49, 53], ["oil", "ORGANISM_SUBSTANCE", 95, 98], ["teas", "SPECIES", 43, 47], ["dental products", "TREATMENT", 184, 199]]], ["Leaves are used for the treatment of skin rashes, earaches, and rheumatism.", [["Leaves", "ANATOMY", 0, 6], ["skin", "ANATOMY", 37, 41], ["skin rashes", "DISEASE", 37, 48], ["earaches", "DISEASE", 50, 58], ["rheumatism", "DISEASE", 64, 74], ["Leaves", "ORGAN", 0, 6], ["skin", "ORGAN", 37, 41], ["skin rashes", "PROBLEM", 37, 48], ["earaches", "PROBLEM", 50, 58], ["rheumatism", "PROBLEM", 64, 74], ["skin", "ANATOMY", 37, 41], ["rashes", "OBSERVATION", 42, 48], ["rheumatism", "OBSERVATION", 64, 74]]], ["The leaves have aromatic fragrance, so they are kept in cloths and used to cover up bad mouth odor.", [["leaves", "ANATOMY", 4, 10], ["leaves", "ORGANISM_SUBDIVISION", 4, 10], ["mouth", "ORGANISM_SUBDIVISION", 88, 93], ["aromatic fragrance", "PROBLEM", 16, 34], ["bad mouth odor", "PROBLEM", 84, 98], ["aromatic fragrance", "OBSERVATION", 16, 34]]], ["The leaves of this plant, having a pepper odor and clove-like taste, are used in cooking.", [["leaves", "ANATOMY", 4, 10], ["clove", "SPECIES", 51, 56], ["pepper", "SPECIES", 35, 41], ["a pepper odor", "PROBLEM", 33, 46]]], ["In addition to cooking, leaves and bark are used in treatment of rheumatism, nausea, vomiting, fever, anemia, body odor, diarrhea, and colic due to having astringent, aromatic, stimulant, and carminative qualities.", [["leaves", "ANATOMY", 24, 30], ["bark", "ANATOMY", 35, 39], ["body", "ANATOMY", 110, 114], ["rheumatism", "DISEASE", 65, 75], ["nausea", "DISEASE", 77, 83], ["vomiting", "DISEASE", 85, 93], ["fever", "DISEASE", 95, 100], ["anemia", "DISEASE", 102, 108], ["diarrhea", "DISEASE", 121, 129], ["colic", "DISEASE", 135, 140], ["bark", "TISSUE", 35, 39], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["rheumatism", "PROBLEM", 65, 75], ["nausea", "PROBLEM", 77, 83], ["vomiting", "PROBLEM", 85, 93], ["fever", "PROBLEM", 95, 100], ["anemia", "PROBLEM", 102, 108], ["body odor", "PROBLEM", 110, 119], ["diarrhea", "PROBLEM", 121, 129], ["colic", "PROBLEM", 135, 140], ["rheumatism", "OBSERVATION", 65, 75], ["anemia", "OBSERVATION", 102, 108], ["diarrhea", "OBSERVATION", 121, 129], ["colic", "ANATOMY", 135, 140]]], ["Seeds mixed with honey or sugars are used in cough and dysentery in children.USESBay leaves having antidiarrheal, antiinflammatory, and antidiabetic activity are used for the improvement of the immune system.", [["immune system", "ANATOMY", 194, 207], ["cough and dysentery", "DISEASE", 45, 64], ["sugars", "CHEMICAL", 26, 32], ["honey", "ORGANISM_SUBSTANCE", 17, 22], ["sugars", "SIMPLE_CHEMICAL", 26, 32], ["cough", "ORGANISM_SUBDIVISION", 45, 50], ["children", "ORGANISM", 68, 76], ["immune system", "ANATOMICAL_SYSTEM", 194, 207], ["children", "SPECIES", 68, 76], ["cough", "PROBLEM", 45, 50], ["dysentery", "PROBLEM", 55, 64], ["antidiarrheal", "TREATMENT", 99, 112], ["antiinflammatory", "TREATMENT", 114, 130], ["antidiabetic activity", "TREATMENT", 136, 157], ["dysentery", "OBSERVATION_MODIFIER", 55, 64], ["antidiarrheal", "OBSERVATION_MODIFIER", 99, 112], ["antiinflammatory", "OBSERVATION_MODIFIER", 114, 130]]], ["Antioxidants such as vitamin C, vitamin E, and carotenoids are used in many dietary sources and are used to lower blood cholesterol and uric acid level.", [["blood", "ANATOMY", 114, 119], ["vitamin C", "CHEMICAL", 21, 30], ["vitamin E", "CHEMICAL", 32, 41], ["carotenoids", "CHEMICAL", 47, 58], ["cholesterol", "CHEMICAL", 120, 131], ["uric acid", "CHEMICAL", 136, 145], ["vitamin C", "CHEMICAL", 21, 30], ["vitamin E", "CHEMICAL", 32, 41], ["cholesterol", "CHEMICAL", 120, 131], ["uric acid", "CHEMICAL", 136, 145], ["vitamin C", "SIMPLE_CHEMICAL", 21, 30], ["vitamin E", "SIMPLE_CHEMICAL", 32, 41], ["carotenoids", "SIMPLE_CHEMICAL", 47, 58], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["cholesterol", "SIMPLE_CHEMICAL", 120, 131], ["uric acid", "SIMPLE_CHEMICAL", 136, 145], ["Antioxidants", "TREATMENT", 0, 12], ["vitamin C", "TREATMENT", 21, 30], ["vitamin E", "TREATMENT", 32, 41], ["carotenoids", "TREATMENT", 47, 58], ["blood cholesterol", "TEST", 114, 131], ["uric acid level", "TEST", 136, 151]]], ["Bay leaves have many sesquiterpene lactones that are responsible for inhibition of NO production, i.e., antiinflammatory, inhibition of alcohol absorption, and may improve liver glutathione S-transferase activity (Fang et al., 2005) .", [["liver", "ANATOMY", 172, 177], ["sesquiterpene lactones", "CHEMICAL", 21, 43], ["NO", "CHEMICAL", 83, 85], ["alcohol", "CHEMICAL", 136, 143], ["glutathione", "CHEMICAL", 178, 189], ["sesquiterpene lactones", "CHEMICAL", 21, 43], ["NO", "CHEMICAL", 83, 85], ["alcohol", "CHEMICAL", 136, 143], ["glutathione", "CHEMICAL", 178, 189], ["S", "CHEMICAL", 190, 191], ["sesquiterpene lactones", "SIMPLE_CHEMICAL", 21, 43], ["NO", "SIMPLE_CHEMICAL", 83, 85], ["alcohol", "SIMPLE_CHEMICAL", 136, 143], ["liver", "ORGAN", 172, 177], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 178, 203], ["liver glutathione S-transferase", "PROTEIN", 172, 203], ["many sesquiterpene lactones", "TREATMENT", 16, 43], ["sesquiterpene lactones", "OBSERVATION", 21, 43], ["liver", "ANATOMY", 172, 177]]], ["Using bioassay-directed isolation study, different cytotoxic and apoptosis-induced compounds are identified in bay leaf.", [["leaf", "ANATOMY", 115, 119], ["leaf", "ORGAN", 115, 119], ["bioassay", "TEST", 6, 14], ["directed isolation study", "TEST", 15, 39], ["different cytotoxic and apoptosis", "PROBLEM", 41, 74], ["cytotoxic", "OBSERVATION_MODIFIER", 51, 60]]], ["Many components of essential oil of bay leaf such as eugenol, methyl eugenol, and pinene have anticonvulsant activity, while eugenol, methyl eugenol, and cineole produce sedation and motor impairment (Sayyah et al., 2002) .", [["oil", "ANATOMY", 29, 32], ["leaf", "ANATOMY", 40, 44], ["eugenol", "CHEMICAL", 53, 60], ["methyl eugenol", "CHEMICAL", 62, 76], ["pinene", "CHEMICAL", 82, 88], ["eugenol", "CHEMICAL", 125, 132], ["methyl eugenol", "CHEMICAL", 134, 148], ["cineole", "CHEMICAL", 154, 161], ["motor impairment", "DISEASE", 183, 199], ["eugenol", "CHEMICAL", 53, 60], ["methyl eugenol", "CHEMICAL", 62, 76], ["pinene", "CHEMICAL", 82, 88], ["eugenol", "CHEMICAL", 125, 132], ["methyl eugenol", "CHEMICAL", 134, 148], ["cineole", "CHEMICAL", 154, 161], ["oil", "ORGANISM_SUBSTANCE", 29, 32], ["leaf", "ORGAN", 40, 44], ["eugenol", "SIMPLE_CHEMICAL", 53, 60], ["methyl eugenol", "SIMPLE_CHEMICAL", 62, 76], ["pinene", "SIMPLE_CHEMICAL", 82, 88], ["eugenol", "SIMPLE_CHEMICAL", 125, 132], ["methyl eugenol", "SIMPLE_CHEMICAL", 134, 148], ["cineole", "SIMPLE_CHEMICAL", 154, 161], ["eugenol, methyl eugenol", "TREATMENT", 53, 76], ["pinene", "TREATMENT", 82, 88], ["anticonvulsant activity", "TREATMENT", 94, 117], ["methyl eugenol", "TREATMENT", 134, 148], ["cineole produce sedation", "TREATMENT", 154, 178], ["motor impairment", "PROBLEM", 183, 199], ["essential", "OBSERVATION_MODIFIER", 19, 28], ["oil", "OBSERVATION_MODIFIER", 29, 32]]], ["Essential oil of this leaf also has analgesic and many antiinflammatory activities (Barla et al., 2007) .", [["oil", "ANATOMY", 10, 13], ["leaf", "ANATOMY", 22, 26], ["oil", "ORGANISM_SUBSTANCE", 10, 13], ["leaf", "ORGAN", 22, 26], ["analgesic", "TREATMENT", 36, 45], ["oil", "OBSERVATION_MODIFIER", 10, 13], ["analgesic", "OBSERVATION_MODIFIER", 36, 45], ["antiinflammatory", "OBSERVATION_MODIFIER", 55, 71]]], ["Many polar compounds such as flavones, flavonol, and phenols are present in the methanolic extract of bay leaf and show antioxidative activity.USESTraditionally, it has been used as herbal medicine against number of diseases such as rheumatism, sprains, indigestion, earaches, and to enhance perspiration (Fang et al., 2005) .", [["extract", "ANATOMY", 91, 98], ["leaf", "ANATOMY", 106, 110], ["flavones", "CHEMICAL", 29, 37], ["flavonol", "CHEMICAL", 39, 47], ["phenols", "CHEMICAL", 53, 60], ["rheumatism", "DISEASE", 233, 243], ["sprains", "DISEASE", 245, 252], ["indigestion", "DISEASE", 254, 265], ["earaches", "DISEASE", 267, 275], ["flavones", "CHEMICAL", 29, 37], ["flavonol", "CHEMICAL", 39, 47], ["phenols", "CHEMICAL", 53, 60], ["flavones", "SIMPLE_CHEMICAL", 29, 37], ["flavonol", "SIMPLE_CHEMICAL", 39, 47], ["phenols", "SIMPLE_CHEMICAL", 53, 60], ["leaf", "ORGAN", 106, 110], ["Many polar compounds", "TREATMENT", 0, 20], ["flavones", "TREATMENT", 29, 37], ["flavonol", "TREATMENT", 39, 47], ["phenols", "TREATMENT", 53, 60], ["herbal medicine", "TREATMENT", 182, 197], ["diseases", "PROBLEM", 216, 224], ["rheumatism", "PROBLEM", 233, 243], ["sprains", "PROBLEM", 245, 252], ["indigestion", "PROBLEM", 254, 265], ["earaches", "PROBLEM", 267, 275], ["polar compounds", "OBSERVATION", 5, 20], ["antioxidative activity", "OBSERVATION", 120, 142], ["rheumatism", "OBSERVATION", 233, 243]]], ["It was reported by different researches that bay leaf can also be used to treat diabetes and migraine (Fang et al., 2005) .", [["leaf", "ANATOMY", 49, 53], ["diabetes", "DISEASE", 80, 88], ["migraine", "DISEASE", 93, 101], ["leaf", "ORGAN", 49, 53], ["diabetes", "PROBLEM", 80, 88], ["migraine", "PROBLEM", 93, 101]]], ["It is used with warm water for drinking to treat internal ailments; as a result, excess water is removed by body by urination and acts as an emetic to induce vomiting.", [["body", "ANATOMY", 108, 112], ["internal ailments", "DISEASE", 49, 66], ["vomiting", "DISEASE", 158, 166], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["warm water", "TREATMENT", 16, 26], ["internal ailments", "PROBLEM", 49, 66], ["vomiting", "PROBLEM", 158, 166]]], ["Fresh, mature leaves are used to treat blood dysentery, inflammation, and congestion of kidney.", [["leaves", "ANATOMY", 14, 20], ["blood", "ANATOMY", 39, 44], ["kidney", "ANATOMY", 88, 94], ["blood dysentery", "DISEASE", 39, 54], ["inflammation", "DISEASE", 56, 68], ["leaves", "ORGAN", 14, 20], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["kidney", "ORGAN", 88, 94], ["blood dysentery", "PROBLEM", 39, 54], ["inflammation", "PROBLEM", 56, 68], ["congestion of kidney", "PROBLEM", 74, 94], ["mature", "OBSERVATION_MODIFIER", 7, 13], ["leaves", "OBSERVATION_MODIFIER", 14, 20], ["dysentery", "OBSERVATION", 45, 54], ["inflammation", "OBSERVATION", 56, 68], ["congestion", "OBSERVATION", 74, 84], ["kidney", "ANATOMY", 88, 94]]], ["Bay leaf is also used to treat arthritis, headache, fungal diseases, anorexia, colds, cataracts, diarrhea, colic ulcer, appetizer, neuralgia, and digestive stimulant traditionally (Parthasarathy et al., 2008) .", [["leaf", "ANATOMY", 4, 8], ["colic ulcer", "ANATOMY", 107, 118], ["appetizer", "ANATOMY", 120, 129], ["digestive", "ANATOMY", 146, 155], ["arthritis", "DISEASE", 31, 40], ["headache", "DISEASE", 42, 50], ["fungal diseases", "DISEASE", 52, 67], ["anorexia", "DISEASE", 69, 77], ["colds", "DISEASE", 79, 84], ["cataracts", "DISEASE", 86, 95], ["diarrhea", "DISEASE", 97, 105], ["colic ulcer", "DISEASE", 107, 118], ["appetizer", "DISEASE", 120, 129], ["neuralgia", "DISEASE", 131, 140], ["leaf", "ORGAN", 4, 8], ["digestive", "ORGAN", 146, 155], ["arthritis", "PROBLEM", 31, 40], ["headache", "PROBLEM", 42, 50], ["fungal diseases", "PROBLEM", 52, 67], ["anorexia", "PROBLEM", 69, 77], ["colds", "PROBLEM", 79, 84], ["cataracts", "PROBLEM", 86, 95], ["diarrhea", "PROBLEM", 97, 105], ["colic ulcer", "PROBLEM", 107, 118], ["appetizer", "PROBLEM", 120, 129], ["neuralgia", "PROBLEM", 131, 140], ["digestive stimulant", "PROBLEM", 146, 165], ["arthritis", "OBSERVATION", 31, 40], ["fungal diseases", "OBSERVATION", 52, 67], ["anorexia", "OBSERVATION", 69, 77], ["cataracts", "OBSERVATION", 86, 95], ["diarrhea", "OBSERVATION_MODIFIER", 97, 105], ["colic", "ANATOMY", 107, 112], ["ulcer", "OBSERVATION", 113, 118], ["neuralgia", "OBSERVATION", 131, 140], ["digestive", "ANATOMY", 146, 155]]], ["Bay is found effective against many infections from fungi, viruses, bacteria, and protozoa.", [["infections", "DISEASE", 36, 46], ["many infections", "PROBLEM", 31, 46], ["fungi", "PROBLEM", 52, 57], ["viruses", "PROBLEM", 59, 66], ["bacteria", "PROBLEM", 68, 76], ["protozoa", "PROBLEM", 82, 90], ["infections", "OBSERVATION", 36, 46], ["fungi", "OBSERVATION", 52, 57], ["bacteria", "OBSERVATION_MODIFIER", 68, 76]]], ["Bay is also helpful in inhibiting growth of carcinogenic cells.", [["cells", "ANATOMY", 57, 62], ["cells", "CELL", 57, 62], ["carcinogenic cells", "CELL_TYPE", 44, 62], ["carcinogenic cells", "PROBLEM", 44, 62], ["carcinogenic cells", "OBSERVATION", 44, 62]]], ["The leaves of bay are specific for many fevers, cough, flu, bronchitis, asthma, influenza, cough, cold, lowering blood cholesterol level, chicken pox, diarrhea, and antistress agents.", [["leaves", "ANATOMY", 4, 10], ["blood", "ANATOMY", 113, 118], ["fevers", "DISEASE", 40, 46], ["cough", "DISEASE", 48, 53], ["flu", "DISEASE", 55, 58], ["bronchitis", "DISEASE", 60, 70], ["asthma", "DISEASE", 72, 78], ["influenza", "DISEASE", 80, 89], ["cough", "DISEASE", 91, 96], ["cholesterol", "CHEMICAL", 119, 130], ["chicken pox", "DISEASE", 138, 149], ["diarrhea", "DISEASE", 151, 159], ["cholesterol", "CHEMICAL", 119, 130], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["cholesterol", "SIMPLE_CHEMICAL", 119, 130], ["chicken", "ORGANISM", 138, 145], ["antistress agents", "SIMPLE_CHEMICAL", 165, 182], ["chicken pox", "SPECIES", 138, 149], ["chicken pox", "SPECIES", 138, 149], ["many fevers", "PROBLEM", 35, 46], ["cough", "PROBLEM", 48, 53], ["flu", "PROBLEM", 55, 58], ["bronchitis", "PROBLEM", 60, 70], ["asthma", "PROBLEM", 72, 78], ["influenza", "PROBLEM", 80, 89], ["cough", "PROBLEM", 91, 96], ["cold", "PROBLEM", 98, 102], ["lowering blood cholesterol level", "PROBLEM", 104, 136], ["chicken pox", "PROBLEM", 138, 149], ["diarrhea", "PROBLEM", 151, 159], ["antistress agents", "TREATMENT", 165, 182], ["fevers", "OBSERVATION", 40, 46], ["cough", "OBSERVATION", 48, 53], ["bronchitis", "OBSERVATION", 60, 70], ["asthma", "OBSERVATION", 72, 78], ["influenza", "OBSERVATION", 80, 89], ["cough", "OBSERVATION", 91, 96]]], ["Bay juice is an effective medication for sore eyes and night blindness, which is generally caused by deficit of vitamin A. Bay seeds are mucilaginous and relieve indigestion, sore throat, constipation, and diarrhea.Wound Healing ActivityThe aqueous extract of L. nobilis were compared with the aqueous extract of Allamanda and found to have better wound healing activity.", [["Bay juice", "ANATOMY", 0, 9], ["sore eyes", "ANATOMY", 41, 50], ["Wound", "ANATOMY", 215, 220], ["aqueous extract", "ANATOMY", 241, 256], ["wound", "ANATOMY", 348, 353], ["sore eyes", "DISEASE", 41, 50], ["night blindness", "DISEASE", 55, 70], ["vitamin", "CHEMICAL", 112, 119], ["indigestion", "DISEASE", 162, 173], ["sore throat", "DISEASE", 175, 186], ["constipation", "DISEASE", 188, 200], ["diarrhea", "DISEASE", 206, 214], ["aqueous extract of L. nobilis", "CHEMICAL", 241, 270], ["Allamanda", "CHEMICAL", 313, 322], ["juice", "ORGANISM_SUBSTANCE", 4, 9], ["eyes", "ORGAN", 46, 50], ["vitamin", "SIMPLE_CHEMICAL", 112, 119], ["throat", "ORGANISM_SUBDIVISION", 180, 186], ["Wound", "PATHOLOGICAL_FORMATION", 215, 220], ["aqueous extract", "ORGANISM_SUBSTANCE", 241, 256], ["L. nobilis", "ORGANISM", 260, 270], ["aqueous extract", "ORGANISM_SUBSTANCE", 294, 309], ["Allamanda", "SIMPLE_CHEMICAL", 313, 322], ["wound", "PATHOLOGICAL_FORMATION", 348, 353], ["L. nobilis", "SPECIES", 260, 270], ["L. nobilis", "SPECIES", 260, 270], ["Bay juice", "TREATMENT", 0, 9], ["an effective medication", "TREATMENT", 13, 36], ["sore eyes", "PROBLEM", 41, 50], ["night blindness", "PROBLEM", 55, 70], ["vitamin A.", "TREATMENT", 112, 122], ["mucilaginous", "PROBLEM", 137, 149], ["indigestion", "PROBLEM", 162, 173], ["sore throat", "PROBLEM", 175, 186], ["constipation", "PROBLEM", 188, 200], ["diarrhea", "PROBLEM", 206, 214], ["Wound Healing", "PROBLEM", 215, 228], ["Allamanda", "TREATMENT", 313, 322], ["better wound healing activity", "PROBLEM", 341, 370], ["blindness", "OBSERVATION", 61, 70], ["constipation", "OBSERVATION", 188, 200], ["diarrhea", "OBSERVATION", 206, 214], ["Healing", "OBSERVATION_MODIFIER", 221, 228], ["Activity", "OBSERVATION_MODIFIER", 229, 237], ["aqueous", "OBSERVATION_MODIFIER", 241, 248], ["extract", "OBSERVATION_MODIFIER", 249, 256], ["L. nobilis", "ANATOMY", 260, 270], ["better", "OBSERVATION_MODIFIER", 341, 347], ["wound", "OBSERVATION", 348, 353], ["healing", "OBSERVATION_MODIFIER", 354, 361], ["activity", "OBSERVATION_MODIFIER", 362, 370]]], ["Many excision and incision wound healing models were used to estimate the wound healing activity.", [["wound", "ANATOMY", 27, 32], ["wound", "ANATOMY", 74, 79], ["wound", "PATHOLOGICAL_FORMATION", 27, 32], ["wound", "PATHOLOGICAL_FORMATION", 74, 79], ["Many excision", "TREATMENT", 0, 13], ["incision wound healing models", "TREATMENT", 18, 47], ["the wound healing activity", "PROBLEM", 70, 96], ["excision", "OBSERVATION", 5, 13], ["incision", "OBSERVATION_MODIFIER", 18, 26], ["wound", "OBSERVATION_MODIFIER", 27, 32], ["healing", "OBSERVATION_MODIFIER", 33, 40], ["wound", "ANATOMY", 74, 79], ["healing activity", "OBSERVATION", 80, 96]]], ["Many factors were studied to assess the wound healing activity such as tensile strength, weights of the granulation tissue, rate of wound closure, period of epithelialization, histopathology of the granulation tissue, and hydroxyproline content of the granulation tissue.", [["wound", "ANATOMY", 40, 45], ["granulation tissue", "ANATOMY", 104, 122], ["wound", "ANATOMY", 132, 137], ["granulation tissue", "ANATOMY", 198, 216], ["granulation tissue", "ANATOMY", 252, 270], ["hydroxyproline", "CHEMICAL", 222, 236], ["hydroxyproline", "CHEMICAL", 222, 236], ["wound", "PATHOLOGICAL_FORMATION", 40, 45], ["granulation tissue", "TISSUE", 104, 122], ["wound", "PATHOLOGICAL_FORMATION", 132, 137], ["granulation tissue", "TISSUE", 198, 216], ["hydroxyproline", "SIMPLE_CHEMICAL", 222, 236], ["granulation tissue", "TISSUE", 252, 270], ["Many factors", "PROBLEM", 0, 12], ["the wound healing activity", "PROBLEM", 36, 62], ["the granulation tissue", "PROBLEM", 100, 122], ["wound closure", "TREATMENT", 132, 145], ["epithelialization", "PROBLEM", 157, 174], ["the granulation tissue", "PROBLEM", 194, 216], ["hydroxyproline content", "TREATMENT", 222, 244], ["the granulation tissue", "PROBLEM", 248, 270], ["wound", "ANATOMY", 40, 45], ["healing", "OBSERVATION", 46, 53], ["granulation tissue", "OBSERVATION", 104, 122], ["wound closure", "OBSERVATION", 132, 145], ["epithelialization", "OBSERVATION", 157, 174], ["granulation tissue", "OBSERVATION", 198, 216], ["hydroxyproline content", "OBSERVATION", 222, 244], ["granulation tissue", "OBSERVATION", 252, 270]]], ["Animals treated with bay leaf were found to have a reasonably high rate of wound contraction, hydroxyproline content, and weight of granulation tissue.", [["leaf", "ANATOMY", 25, 29], ["wound", "ANATOMY", 75, 80], ["granulation tissue", "ANATOMY", 132, 150], ["hydroxyproline", "CHEMICAL", 94, 108], ["hydroxyproline", "CHEMICAL", 94, 108], ["Animals", "ORGANISM", 0, 7], ["leaf", "ORGAN", 25, 29], ["wound", "PATHOLOGICAL_FORMATION", 75, 80], ["hydroxyproline", "SIMPLE_CHEMICAL", 94, 108], ["granulation tissue", "TISSUE", 132, 150], ["wound contraction", "PROBLEM", 75, 92], ["hydroxyproline content", "TREATMENT", 94, 116], ["granulation tissue", "PROBLEM", 132, 150], ["wound contraction", "OBSERVATION", 75, 92], ["hydroxyproline content", "OBSERVATION", 94, 116], ["granulation tissue", "OBSERVATION", 132, 150]]], ["Bay leafetreated animals showed a higher number of inflammatory cells and less collagen compared with the animals that were treated with Allamanda cathartica (Nayak et al., 2006) .Antioxidant ActivityEthanol extracts of L. nobilis showed powerful antioxidant activities.", [["inflammatory cells", "ANATOMY", 51, 69], ["extracts", "ANATOMY", 208, 216], ["Ethanol", "CHEMICAL", 200, 207], ["Ethanol", "CHEMICAL", 200, 207], ["inflammatory cells", "CELL", 51, 69], ["collagen", "GENE_OR_GENE_PRODUCT", 79, 87], ["Ethanol extracts", "ORGANISM_SUBSTANCE", 200, 216], ["L. nobilis", "ORGANISM", 220, 230], ["inflammatory cells", "CELL_TYPE", 51, 69], ["collagen", "PROTEIN", 79, 87], ["Allamanda cathartica", "SPECIES", 137, 157], ["L. nobilis", "SPECIES", 220, 230], ["Allamanda cathartica", "SPECIES", 137, 157], ["L. nobilis", "SPECIES", 220, 230], ["inflammatory cells", "PROBLEM", 51, 69], ["Antioxidant", "TREATMENT", 180, 191], ["higher", "OBSERVATION_MODIFIER", 34, 40], ["number", "OBSERVATION_MODIFIER", 41, 47], ["inflammatory cells", "OBSERVATION", 51, 69], ["less collagen", "OBSERVATION_MODIFIER", 74, 87]]], ["The antioxidant activity was determined by evaluating free radical scavenging, hydrogen peroxide scavenging, superoxide anion radical 5.", [["hydrogen peroxide", "CHEMICAL", 79, 96], ["superoxide", "CHEMICAL", 109, 119], ["hydrogen peroxide", "CHEMICAL", 79, 96], ["superoxide", "CHEMICAL", 109, 119], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 79, 96], ["superoxide anion", "SIMPLE_CHEMICAL", 109, 125], ["free radical scavenging", "TREATMENT", 54, 77], ["hydrogen peroxide scavenging", "TREATMENT", 79, 107], ["superoxide anion radical", "TREATMENT", 109, 133]]], ["BAY LEAF scavenging, reducing power, and metal chelating assays.", [["BAY", "CHEMICAL", 0, 3], ["BAY", "CHEMICAL", 0, 3], ["BAY", "SIMPLE_CHEMICAL", 0, 3], ["LEAF", "SIMPLE_CHEMICAL", 4, 8], ["metal chelating assays", "TEST", 41, 63], ["LEAF scavenging", "OBSERVATION", 4, 19]]], ["Strong antioxidant activity of bay leaf was observed in linoleic acid emulsion at a concentration of 20, 40, and 60 mg/mL (94.2%, 97.7%, and 98.6% inhibition of lipid peroxidation, respectively).", [["leaf", "ANATOMY", 35, 39], ["linoleic acid", "CHEMICAL", 56, 69], ["linoleic acid", "CHEMICAL", 56, 69], ["leaf", "ORGAN", 35, 39], ["linoleic acid", "SIMPLE_CHEMICAL", 56, 69], ["lipid", "SIMPLE_CHEMICAL", 161, 166], ["linoleic acid emulsion", "TREATMENT", 56, 78], ["lipid peroxidation", "TEST", 161, 179], ["antioxidant activity", "OBSERVATION", 7, 27]]], ["The antioxidant activity of ethanol extract may be due to phenolic compounds present in the extract (Elmasta\u015f et al., 2006) .Anticonvulsant ActivityL. nobilis leaf essential oil showed anticonvulsant activity in mice.", [["extract", "ANATOMY", 92, 99], ["oil", "ANATOMY", 174, 177], ["ethanol extract", "CHEMICAL", 28, 43], ["ActivityL", "CHEMICAL", 140, 149], ["ethanol", "CHEMICAL", 28, 35], ["ethanol", "SIMPLE_CHEMICAL", 28, 35], ["oil", "ORGANISM_SUBSTANCE", 174, 177], ["mice", "ORGANISM", 212, 216], ["nobilis", "SPECIES", 151, 158], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["ethanol extract", "TREATMENT", 28, 43], ["phenolic compounds", "PROBLEM", 58, 76], ["Anticonvulsant ActivityL", "TREATMENT", 125, 149], ["phenolic compounds", "OBSERVATION", 58, 76], ["oil", "OBSERVATION_MODIFIER", 174, 177], ["anticonvulsant activity", "OBSERVATION", 185, 208]]], ["Essential oil components such as eugenol, pinene, and methyleugenol are responsible for this activity (Sayyah et al., 2002) .Analgesic and AntiinflammatoryL. nobilis essential oil showed analgesic and antiinflammatory activities in mice and rats (Sayyah et al., 2003) .", [["oil", "ANATOMY", 10, 13], ["oil", "ANATOMY", 176, 179], ["eugenol", "CHEMICAL", 33, 40], ["pinene", "CHEMICAL", 42, 48], ["methyleugenol", "CHEMICAL", 54, 67], ["AntiinflammatoryL", "CHEMICAL", 139, 156], ["eugenol", "CHEMICAL", 33, 40], ["pinene", "CHEMICAL", 42, 48], ["methyleugenol", "CHEMICAL", 54, 67], ["oil", "ORGANISM_SUBSTANCE", 10, 13], ["eugenol", "SIMPLE_CHEMICAL", 33, 40], ["pinene", "SIMPLE_CHEMICAL", 42, 48], ["methyleugenol", "SIMPLE_CHEMICAL", 54, 67], ["AntiinflammatoryL", "SIMPLE_CHEMICAL", 139, 156], ["oil", "ORGANISM_SUBSTANCE", 176, 179], ["mice", "ORGANISM", 232, 236], ["rats", "ORGANISM", 241, 245], ["nobilis", "SPECIES", 158, 165], ["mice", "SPECIES", 232, 236], ["rats", "SPECIES", 241, 245], ["mice", "SPECIES", 232, 236], ["methyleugenol", "TREATMENT", 54, 67], ["Analgesic", "TREATMENT", 125, 134], ["AntiinflammatoryL", "TREATMENT", 139, 156], ["analgesic", "TREATMENT", 187, 196], ["antiinflammatory activities", "TREATMENT", 201, 228], ["oil components", "OBSERVATION", 10, 24], ["oil", "OBSERVATION_MODIFIER", 176, 179], ["analgesic", "OBSERVATION_MODIFIER", 187, 196]]], ["Ethanol extract obtained from the leaves and seeds of bay leaf also show the highest antiinflamatory activities by using a carrageenan-induced hind paw edema model (Kozan et al., 2006) .Antimutagenic ActivityEthyl acetate extract of bay leaf has 3-kaempferyl pcoumarate antimutagen, which was identified experimentally and purified chromatographically.", [["leaves", "ANATOMY", 34, 40], ["seeds", "ANATOMY", 45, 50], ["leaf", "ANATOMY", 58, 62], ["hind paw edema", "ANATOMY", 143, 157], ["leaf", "ANATOMY", 237, 241], ["Ethanol", "CHEMICAL", 0, 7], ["carrageenan", "CHEMICAL", 123, 134], ["edema", "DISEASE", 152, 157], ["Ethyl acetate", "CHEMICAL", 208, 221], ["3-kaempferyl pcoumarate", "CHEMICAL", 246, 269], ["Ethanol", "CHEMICAL", 0, 7], ["Ethyl acetate", "CHEMICAL", 208, 221], ["3-kaempferyl pcoumarate", "CHEMICAL", 246, 269], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["leaves", "ORGANISM_SUBDIVISION", 34, 40], ["leaf", "ORGAN", 58, 62], ["carrageenan", "SIMPLE_CHEMICAL", 123, 134], ["hind paw", "ORGANISM_SUBDIVISION", 143, 151], ["edema", "PATHOLOGICAL_FORMATION", 152, 157], ["Ethyl acetate", "SIMPLE_CHEMICAL", 208, 221], ["leaf", "ORGAN", 237, 241], ["3-kaempferyl pcoumarate", "SIMPLE_CHEMICAL", 246, 269], ["Ethanol extract", "TREATMENT", 0, 15], ["a carrageenan-induced hind paw edema model", "TREATMENT", 121, 163], ["Antimutagenic ActivityEthyl acetate extract", "TREATMENT", 186, 229], ["3-kaempferyl pcoumarate antimutagen", "TREATMENT", 246, 281], ["hind paw", "ANATOMY", 143, 151]]], ["The antimutagenicity was due to a desmutagenic action that converted the Trp-P-2 metabolically activated form into its crucial carcinogenic form (Samejima et al., 1998) .Immunostimulant ActivityImmunostimulant effects of powder of bay leaf were shown on rainbow trout by giving them dietary constituents.", [["leaf", "ANATOMY", 235, 239], ["Trp", "CHEMICAL", 73, 76], ["Trp", "CHEMICAL", 73, 76], ["leaf", "ORGAN", 235, 239], ["trout", "ORGANISM", 262, 267], ["Trp-P-2 metabolically activated form", "PROTEIN", 73, 109], ["rainbow trout", "SPECIES", 254, 267], ["rainbow trout", "SPECIES", 254, 267], ["a desmutagenic action", "PROBLEM", 32, 53], ["the Trp", "TEST", 69, 76], ["Immunostimulant", "TREATMENT", 170, 185]]], ["Three groups of rainbow trout were fed with experimental diets.", [["rainbow", "ORGANISM", 16, 23], ["trout", "ORGANISM", 24, 29], ["rainbow trout", "SPECIES", 16, 29], ["rainbow trout", "SPECIES", 16, 29]]], ["After 21 days, nonspecific immune parameters such as phagocytosis in blood leukocytes, extra-or intracellular respiratory burst activities, lysozymes, and protein levels were examined and showed immunostimulant activity (Bilen and Bulut, 2010) .Antiviral ActivityL. nobilis essential oil containing beta-ocimene, 1,8-cineol, alphapinene, and beta-pinene constituents were reported for inhibitory activity in vitro against SARS-CoV and HSV-1 replication.", [["blood leukocytes", "ANATOMY", 69, 85], ["intracellular", "ANATOMY", 96, 109], ["oil", "ANATOMY", 284, 287], ["beta-ocimene", "CHEMICAL", 299, 311], ["1,8-cineol", "CHEMICAL", 313, 323], ["alphapinene", "CHEMICAL", 325, 336], ["beta-pinene", "CHEMICAL", 342, 353], ["beta-ocimene", "CHEMICAL", 299, 311], ["1,8-cineol", "CHEMICAL", 313, 323], ["alphapinene", "CHEMICAL", 325, 336], ["beta-pinene", "CHEMICAL", 342, 353], ["blood leukocytes", "CELL", 69, 85], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["oil", "ORGANISM_SUBSTANCE", 284, 287], ["beta-ocimene", "SIMPLE_CHEMICAL", 299, 311], ["1,8-cineol", "SIMPLE_CHEMICAL", 313, 323], ["alphapinene", "SIMPLE_CHEMICAL", 325, 336], ["beta-pinene", "SIMPLE_CHEMICAL", 342, 353], ["SARS-CoV", "ORGANISM", 422, 430], ["HSV-1", "ORGANISM", 435, 440], ["blood leukocytes", "CELL_TYPE", 69, 85], ["lysozymes", "PROTEIN", 140, 149], ["nobilis", "SPECIES", 266, 273], ["HSV-1", "SPECIES", 435, 440], ["SARS-CoV", "SPECIES", 422, 430], ["HSV-1", "SPECIES", 435, 440], ["nonspecific immune parameters", "TEST", 15, 44], ["phagocytosis", "TEST", 53, 65], ["blood leukocytes", "TEST", 69, 85], ["extra-or intracellular respiratory burst activities", "PROBLEM", 87, 138], ["lysozymes", "TEST", 140, 149], ["protein levels", "TEST", 155, 169], ["immunostimulant activity", "PROBLEM", 195, 219], ["Antiviral ActivityL", "TREATMENT", 245, 264], ["beta-ocimene", "TEST", 299, 311], ["alphapinene", "TREATMENT", 325, 336], ["beta-pinene constituents", "TREATMENT", 342, 366], ["SARS", "PROBLEM", 422, 426], ["CoV", "TEST", 427, 430], ["HSV", "PROBLEM", 435, 438], ["respiratory burst", "OBSERVATION", 110, 127], ["immunostimulant activity", "OBSERVATION", 195, 219]]], ["Essential oil has this activity with an IC 50 value of 120 mg/mL and selectivity index of 4.16 (Bilen and Bulut, 2010) .Anticholinergic ActivityEssential oil, ethanolic extract, and decoction of L. nobilis were reported to have anticholinergic activity toward acetyl cholinesterase (AChE) enzyme and showed good anticholinergic activity.", [["oil", "ANATOMY", 10, 13], ["extract", "ANATOMY", 169, 176], ["ActivityEssential oil, ethanolic extract, and decoction of L. nobilis", "CHEMICAL", 136, 205], ["acetyl", "CHEMICAL", 260, 266], ["acetyl", "CHEMICAL", 260, 266], ["oil", "ORGANISM_SUBSTANCE", 10, 13], ["oil", "ORGANISM_SUBSTANCE", 154, 157], ["L. nobilis", "ORGANISM", 195, 205], ["acetyl cholinesterase", "GENE_OR_GENE_PRODUCT", 260, 281], ["AChE", "SIMPLE_CHEMICAL", 283, 287], ["acetyl cholinesterase (AChE) enzyme", "PROTEIN", 260, 295], ["L. nobilis", "SPECIES", 195, 205], ["L. nobilis", "SPECIES", 195, 205], ["selectivity index", "TEST", 69, 86], ["Anticholinergic ActivityEssential oil", "TREATMENT", 120, 157], ["ethanolic extract", "TREATMENT", 159, 176], ["L. nobilis", "PROBLEM", 195, 205], ["anticholinergic activity", "PROBLEM", 228, 252], ["acetyl cholinesterase", "TEST", 260, 281], ["AChE) enzyme", "TEST", 283, 295], ["oil", "OBSERVATION_MODIFIER", 10, 13], ["L. nobilis", "ANATOMY", 195, 205], ["good", "OBSERVATION_MODIFIER", 307, 311], ["anticholinergic activity", "OBSERVATION", 312, 336]]], ["Ethanolic fraction of about 64% of bay leaf also shown this inhibitory activity (Ferreira et al., 2006) .Insect Repellent ActivityL. nobilis essential oils extracted from seeds were reported to have insect repellant activity against Culex pipiens (Erler et al., 2006) .Antimicrobial ActivityL. nobilis essential oil, methanolic extract of seed oil. and seed oil in vitro showed antibacterial activity.", [["leaf", "ANATOMY", 39, 43], ["oils", "ANATOMY", 151, 155], ["seeds", "ANATOMY", 171, 176], ["oil", "ANATOMY", 312, 315], ["extract", "ANATOMY", 328, 335], ["seed oil", "ANATOMY", 339, 347], ["seed oil", "ANATOMY", 353, 361], ["methanolic extract of seed oil", "CHEMICAL", 317, 347], ["leaf", "ORGAN", 39, 43], ["oils", "ORGANISM_SUBSTANCE", 151, 155], ["Culex pipiens", "ORGANISM", 233, 246], ["oil", "ORGANISM_SUBSTANCE", 312, 315], ["methanolic extract", "ORGANISM_SUBSTANCE", 317, 335], ["seed oil", "ORGANISM_SUBSTANCE", 339, 347], ["seed oil", "ORGANISM_SUBSTANCE", 353, 361], ["nobilis", "SPECIES", 133, 140], ["Culex pipiens", "SPECIES", 233, 246], ["nobilis", "SPECIES", 294, 301], ["Culex pipiens", "SPECIES", 233, 246], ["Ethanolic fraction", "TEST", 0, 18], ["Antimicrobial ActivityL", "TREATMENT", 269, 292], ["methanolic extract of seed oil", "TREATMENT", 317, 347], ["antibacterial activity", "PROBLEM", 378, 400], ["oils", "OBSERVATION_MODIFIER", 151, 155], ["oil", "OBSERVATION_MODIFIER", 312, 315], ["antibacterial activity", "OBSERVATION", 378, 400]]], ["However, methanolic extract of seed oil has more effective antibacterial activity than essential oil and seed oil (Ozcan et al., 2010) .", [["seed oil", "ANATOMY", 31, 39], ["oil", "ANATOMY", 97, 100], ["seed oil", "ANATOMY", 105, 113], ["methanolic extract of seed oil", "CHEMICAL", 9, 39], ["seed oil", "ORGANISM_SUBSTANCE", 31, 39], ["oil", "ORGANISM_SUBSTANCE", 97, 100], ["seed oil", "ORGANISM_SUBSTANCE", 105, 113], ["methanolic extract of seed oil", "TREATMENT", 9, 39], ["more effective", "OBSERVATION_MODIFIER", 44, 58], ["antibacterial activity", "OBSERVATION", 59, 81]]], ["Similarly, in another report the antibacterial activity of L. nobilis essential oil was determined against Staphylococcus aureus, Bacillus subtilis, and Staphylococcus intermedius.", [["oil", "ANATOMY", 80, 83], ["Staphylococcus aureus", "DISEASE", 107, 128], ["L. nobilis", "ORGANISM", 59, 69], ["oil", "ORGANISM_SUBSTANCE", 80, 83], ["Staphylococcus aureus", "ORGANISM", 107, 128], ["Bacillus subtilis", "ORGANISM", 130, 147], ["Staphylococcus intermedius", "ORGANISM", 153, 179], ["L. nobilis", "SPECIES", 59, 69], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Bacillus subtilis", "SPECIES", 130, 147], ["Staphylococcus intermedius", "SPECIES", 153, 179], ["L. nobilis", "SPECIES", 59, 69], ["Staphylococcus aureus", "SPECIES", 107, 128], ["Bacillus subtilis", "SPECIES", 130, 147], ["Staphylococcus intermedius", "SPECIES", 153, 179], ["Staphylococcus aureus", "PROBLEM", 107, 128], ["Bacillus subtilis", "PROBLEM", 130, 147], ["Staphylococcus intermedius", "PROBLEM", 153, 179], ["Staphylococcus intermedius", "OBSERVATION", 153, 179]]], ["The L. nobilis essential oil showed good antibacterial activity with minimal inhibitory concentrations of 0.35 and 0.56 mg/mL, respectively.", [["oil", "ANATOMY", 25, 28], ["L. nobilis", "ORGANISM", 4, 14], ["oil", "ORGANISM_SUBSTANCE", 25, 28], ["L. nobilis", "SPECIES", 4, 14], ["L. nobilis", "SPECIES", 4, 14], ["The L. nobilis essential oil", "TEST", 0, 28], ["L. nobilis", "ANATOMY", 4, 14], ["oil", "OBSERVATION_MODIFIER", 25, 28], ["good", "OBSERVATION_MODIFIER", 36, 40], ["antibacterial activity", "OBSERVATION", 41, 63]]], ["The major constituent of bay leaf, 1,8 cineol, might be responsible for its antibacterial activity (Derwich et al., 2009) .", [["leaf", "ANATOMY", 29, 33], ["1,8 cineol", "CHEMICAL", 35, 45], ["1,8 cineol", "CHEMICAL", 35, 45], ["leaf", "ORGAN", 29, 33], ["1,8 cineol", "SIMPLE_CHEMICAL", 35, 45], ["bay leaf, 1,8 cineol", "TREATMENT", 25, 45], ["bay leaf", "OBSERVATION", 25, 33]]], ["Antifungal activity of L. nobilis was examined on seven strains of plant pathogenic fungi in vitro at different concentrations such as 50, 125, and 250 mg/mL.", [["L. nobilis", "ORGANISM", 23, 33], ["L. nobilis", "SPECIES", 23, 33], ["L. nobilis", "SPECIES", 23, 33], ["L. nobilis", "PROBLEM", 23, 33], ["plant pathogenic fungi", "PROBLEM", 67, 89], ["L. nobilis", "ANATOMY", 23, 33], ["pathogenic fungi", "OBSERVATION", 73, 89]]], ["The greatest antifungal activity was obtained against the fungus Botrytis cinerea at a concentration of 250 mg/mL (Patrakar et al., 2012).Acaricidal ActivityAcaricidal activity of bay leaf oils was observed against Psoroptes cuniculi.", [["leaf oils", "ANATOMY", 184, 193], ["Botrytis cinerea", "ORGANISM", 65, 81], ["leaf oils", "ORGANISM_SUBSTANCE", 184, 193], ["Psoroptes cuniculi", "ORGANISM", 215, 233], ["Botrytis cinerea", "SPECIES", 65, 81], ["Psoroptes cuniculi", "SPECIES", 215, 233], ["Botrytis cinerea", "SPECIES", 65, 81], ["Psoroptes cuniculi", "SPECIES", 215, 233], ["the fungus Botrytis cinerea", "TREATMENT", 54, 81], ["Acaricidal", "TREATMENT", 138, 148], ["bay leaf oils", "TREATMENT", 180, 193], ["Psoroptes cuniculi", "PROBLEM", 215, 233], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["antifungal activity", "OBSERVATION", 13, 32]]], ["Acaricidal activity of bay oil led to a mortality rate of 73% at a concentration of 10% and at 5% average activity was considerably reduced to 51% (Macchioni et al., 2006) .SIDE EFFECTS AND TOXICITYBay leaf and bay leaf oil are likely safe for most people in food amounts.", [["bay oil", "ANATOMY", 23, 30], ["leaf", "ANATOMY", 202, 206], ["leaf oil", "ANATOMY", 215, 223], ["oil", "ORGANISM_SUBSTANCE", 220, 223], ["people", "ORGANISM", 249, 255], ["people", "SPECIES", 249, 255], ["a mortality rate", "TEST", 38, 54], ["TOXICITYBay leaf", "TREATMENT", 190, 206], ["bay leaf oil", "TREATMENT", 211, 223]]], ["There is no choke possibility with ground bay leaf, as does exist with whole leaf.", [["leaf", "ANATOMY", 46, 50], ["leaf", "ANATOMY", 77, 81], ["leaf", "ORGAN", 46, 50], ["leaf", "ORGAN", 77, 81], ["no choke possibility", "UNCERTAINTY", 9, 29]]], ["The whole leaf cannot be digested, so it remains intact while passing through the digestive system.", [["leaf", "ANATOMY", 10, 14], ["digestive system", "ANATOMY", 82, 98], ["leaf", "ORGAN", 10, 14], ["digestive", "ORGAN", 82, 91], ["system", "ANATOMICAL_SYSTEM", 92, 98], ["cannot be", "UNCERTAINTY", 15, 24], ["digested", "OBSERVATION", 25, 33], ["intact", "OBSERVATION", 49, 55], ["digestive system", "ANATOMY", 82, 98]]], ["There is not enough reliable 5.", [["not enough", "UNCERTAINTY", 9, 19]]], ["BAY LEAF information about the safety of taking bay leaf during pregnancy or breastfeeding.", [["leaf", "ANATOMY", 52, 56], ["BAY", "CHEMICAL", 0, 3], ["BAY", "CHEMICAL", 0, 3], ["BAY", "SIMPLE_CHEMICAL", 0, 3], ["leaf", "ORGAN", 52, 56]]], ["Bay leaf might interfere with blood sugar control and may not be safe to use during diabetes.", [["leaf", "ANATOMY", 4, 8], ["blood", "ANATOMY", 30, 35], ["diabetes", "DISEASE", 84, 92], ["sugar", "CHEMICAL", 36, 41], ["leaf", "ORGAN", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["sugar", "SIMPLE_CHEMICAL", 36, 41], ["blood sugar control", "TREATMENT", 30, 49], ["diabetes", "PROBLEM", 84, 92]]], ["Bay leaf might slow down the central nervous system (CNS).", [["leaf", "ANATOMY", 4, 8], ["central nervous system", "ANATOMY", 29, 51], ["CNS", "ANATOMY", 53, 56], ["central nervous system", "ANATOMICAL_SYSTEM", 29, 51], ["CNS", "ANATOMICAL_SYSTEM", 53, 56], ["central", "ANATOMY_MODIFIER", 29, 36], ["nervous system", "ANATOMY", 37, 51], ["CNS", "ANATOMY", 53, 56]]], ["There is a concern that it might slow down the CNS too much when combined with anesthesia and other medications used during and after surgery.", [["CNS", "ANATOMY", 47, 50], ["CNS", "ANATOMICAL_SYSTEM", 47, 50], ["anesthesia", "TREATMENT", 79, 89], ["other medications", "TREATMENT", 94, 111], ["surgery", "TREATMENT", 134, 141]]], ["It is recommended to stop using bay leaf as a medicine at least 2 weeks before a scheduled surgery.", [["leaf", "ANATOMY", 36, 40], ["leaf", "ORGAN", 36, 40], ["a scheduled surgery", "TREATMENT", 79, 98]]]], "a3562127e86eb9d40b7791d5f1ce8a8200b31553": [["In January 2020, a novel virus, the SARS-CoV-2, was identified as the causative agent for a cluster of pneumonia cases initially detected in Wuhan City, Hubei Province, China.", [["pneumonia", "DISEASE", 103, 112], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV-2", "SPECIES", 36, 46], ["a novel virus", "PROBLEM", 17, 30], ["the SARS", "TEST", 32, 40], ["pneumonia cases", "PROBLEM", 103, 118], ["pneumonia", "OBSERVATION", 103, 112]]], ["1 SARS-CoV-2, which causes the disease now named COVID-19, has subsequently spread throughout the globe.", [["COVID-19", "CHEMICAL", 49, 57], ["SARS-CoV-2", "ORGANISM", 2, 12], ["COVID-19", "CELL", 49, 57], ["globe", "ORGAN", 98, 103], ["COVID-19", "DNA", 49, 57], ["the disease", "PROBLEM", 27, 38], ["disease", "OBSERVATION", 31, 38], ["spread", "OBSERVATION_MODIFIER", 76, 82], ["globe", "ANATOMY", 98, 103]]], ["By May 12, 2020, the virus infected more than 4.2 million people and claimed more than 280,000 lives.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["the virus infected", "PROBLEM", 17, 35]]], ["2 Health systems in the world are facing a rapidly increasing demand generated by the COVID-19 pandemic.", [["a rapidly increasing demand", "PROBLEM", 41, 68], ["the COVID", "TEST", 82, 91], ["pandemic", "PROBLEM", 95, 103]]], ["Africa is still in the early stage of the COVID-19 outbreak.", [["the COVID", "TEST", 38, 47]]], ["The Ebola outbreak is a good example of how outbreaks may disrupt programs such as tuberculosis, HIV, and maternal and child health care, increasing mortality from preventable and treatable conditions.", [["Ebola", "DISEASE", 4, 9], ["tuberculosis", "DISEASE", 83, 95], ["HIV", "DISEASE", 97, 100], ["Ebola", "ORGANISM", 4, 9], ["HIV", "SPECIES", 97, 100], ["HIV", "SPECIES", 97, 100], ["tuberculosis", "PROBLEM", 83, 95], ["HIV", "PROBLEM", 97, 100], ["treatable conditions", "PROBLEM", 180, 200], ["Ebola", "OBSERVATION", 4, 9], ["tuberculosis", "OBSERVATION", 83, 95]]], ["[3] [4] [5] [6] [7] [8] To mitigate the impact of COVID-19 on health systems, the WHO prepared a guideline on how to continue essential services during the COVID-19 pandemic.", [["COVID-19", "CHEMICAL", 50, 58], ["[3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 23], ["COVID", "TEST", 50, 55], ["the COVID", "TEST", 152, 161], ["pandemic", "PROBLEM", 165, 173]]], ["The guideline recommends continuation of essential services like vaccination, chronic disease follow-up, and maternal and child health care, taking into consideration the local context and extent of the outbreak.", [["essential services", "TREATMENT", 41, 59], ["vaccination", "TREATMENT", 65, 76], ["chronic disease", "PROBLEM", 78, 93], ["the outbreak", "PROBLEM", 199, 211], ["outbreak", "OBSERVATION", 203, 211]]], ["In areas with a relatively limited number of COVID-19 cases, the health system may have the capacity to maintain routine service delivery in addition to managing COVID-19 cases.", [["COVID", "TEST", 45, 50], ["routine service delivery", "TREATMENT", 113, 137], ["managing COVID", "TREATMENT", 153, 167]]], ["Like other countries, Ethiopia started to practice different prevention strategies after confirming the first case.", [["different prevention strategies", "TREATMENT", 51, 82]]], ["These include partial and selective total lockdown, stopping mass praying, avoiding mass gatherings, and closing schools.", [["partial and selective total lockdown", "TREATMENT", 14, 50], ["stopping mass", "PROBLEM", 52, 65], ["partial", "OBSERVATION_MODIFIER", 14, 21], ["selective", "OBSERVATION_MODIFIER", 26, 35], ["total", "OBSERVATION_MODIFIER", 36, 41]]], ["The Federal Ministry of Health planned to continue essential services during COVID-19 prevention and management.", [["COVID-19 prevention", "TREATMENT", 77, 96], ["management", "TREATMENT", 101, 111]]], ["The Ethiopian essential health service package includes reproductive, maternal, neonatal, child, and adolescent health services; major communicable diseases; noncommunicable diseases; surgical care; and emergency and critical care.", [["communicable diseases", "DISEASE", 135, 156], ["noncommunicable diseases", "DISEASE", 158, 182], ["major communicable diseases", "PROBLEM", 129, 156], ["noncommunicable diseases", "PROBLEM", 158, 182], ["surgical care", "TREATMENT", 184, 197]]], ["10 The Amhara regional state zones passed different preventive decisions, like stopping public transport and different physical distancing rules.", [["public transport", "TREATMENT", 88, 104]]], ["Hospitals across the region stopped elective surgeries and stopped receiving nonemergency and self-referred patients.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["elective surgeries", "TREATMENT", 36, 54]]], ["The hospitals restricted the number of patient attendants and spaced appointments of chronic illnesses.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["chronic illnesses", "PROBLEM", 85, 102], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["illnesses", "OBSERVATION", 93, 102]]], ["Dessie Referral Hospital, one of the facilities in the region serving more than 8 million people of the catchment area (East Amhara, part of Tigray, and Afar region), applied these measures starting from March 23, 2020.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["The transport restriction was lifted on April 16, 2020.", [["The transport restriction", "TREATMENT", 0, 25]]]], "PMC7532351": [["IntroductionPandemic diseases are of global concern in the present era, to cause gigantic morbidity and transience, regardless of, extensive medical facilities.", [["Pandemic diseases", "DISEASE", 12, 29], ["Pandemic diseases", "PROBLEM", 12, 29], ["gigantic morbidity", "PROBLEM", 81, 99], ["gigantic", "OBSERVATION_MODIFIER", 81, 89], ["morbidity", "OBSERVATION", 90, 99]]], ["Particularly, anti-viral therapies have been fraught because of surfacing of mutants competent enough to subdue the drugs targeting viral elements (Ahmad et al., 2020).", [["viral elements", "DNA", 132, 146], ["anti-viral therapies", "TREATMENT", 14, 34], ["surfacing of mutants", "PROBLEM", 64, 84]]], ["Most importantly, enhanced universal travel and swift urbanization has led to contagious outbreak by rising or re-emergence of viruses, posing a serious menace towards communal health and safety, specifically in such unprecedented times where there are no preventive vaccines available.", [["contagious outbreak", "PROBLEM", 78, 97], ["viruses", "PROBLEM", 127, 134], ["preventive vaccines", "TREATMENT", 256, 275], ["contagious", "OBSERVATION_MODIFIER", 78, 88], ["viruses", "OBSERVATION", 127, 134], ["no", "UNCERTAINTY", 253, 255]]], ["With the advent of twenty first century, our planet has observed the incidence of catastrophic viral outbreaks namely, SARS-CoV (Severe Acute Respiratory Syndrome) and MERS-CoV (Middle East Respiratory Syndrome) within human populace (Markoti\u0107 and Kuzman, 2020).", [["SARS-CoV", "DISEASE", 119, 127], ["Acute Respiratory Syndrome", "DISEASE", 136, 162], ["Middle East Respiratory Syndrome", "DISEASE", 178, 210], ["SARS-CoV", "ORGANISM", 119, 127], ["MERS-CoV", "ORGANISM", 168, 176], ["human", "ORGANISM", 219, 224], ["human", "SPECIES", 219, 224], ["SARS-CoV", "SPECIES", 119, 127], ["MERS-CoV", "SPECIES", 168, 176], ["human", "SPECIES", 219, 224], ["catastrophic viral outbreaks", "PROBLEM", 82, 110], ["SARS-CoV (Severe Acute Respiratory Syndrome)", "PROBLEM", 119, 163], ["MERS", "PROBLEM", 168, 172], ["CoV (Middle East Respiratory Syndrome", "PROBLEM", 173, 210], ["catastrophic", "OBSERVATION_MODIFIER", 82, 94], ["viral outbreaks", "OBSERVATION", 95, 110], ["Severe", "OBSERVATION_MODIFIER", 129, 135], ["Acute", "OBSERVATION_MODIFIER", 136, 141], ["Respiratory Syndrome", "OBSERVATION", 142, 162], ["Middle", "ANATOMY_MODIFIER", 178, 184], ["Respiratory Syndrome", "OBSERVATION", 190, 210]]], ["At present, COVID-19 (Coronavirus) is the third most important disease of animal origin, which is prevailing in almost four corners of the world by getting initiated from a single place.", [["COVID-19", "CHEMICAL", 12, 20], ["COVID-19", "ORGANISM", 12, 20], ["Coronavirus", "CANCER", 22, 33], ["COVID-19", "SPECIES", 12, 20], ["COVID", "TEST", 12, 17], ["Coronavirus", "PROBLEM", 22, 33], ["animal origin", "OBSERVATION_MODIFIER", 74, 87]]], ["Nearly, 213 countries of all continents have been affected in less than three months by this pernicious virus (Acharya, 2020).", [["this pernicious virus", "PROBLEM", 88, 109]]], ["After studying its clinical characteristics, experts affirmed that it is quite similar to pneumonia and therefore, named as Novel Coronavirus.", [["pneumonia", "DISEASE", 90, 99], ["pneumonia", "PROBLEM", 90, 99], ["Novel Coronavirus", "PROBLEM", 124, 141], ["pneumonia", "OBSERVATION", 90, 99]]], ["As of August, 24th, 2020, there have been reported 23,584,259 COVID-19 cases with 812,517 deaths globally as depicted by WHO (WHO, 2020).", [["deaths", "DISEASE", 90, 96], ["COVID", "TEST", 62, 67]]], ["The causal agent of COVID-19 is SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) as per officially named by ICTV (International Committee on Taxonomy of Viruses) (Gautret et al., 2020).", [["Acute Respiratory Syndrome", "DISEASE", 51, 77], ["COVID-19", "ORGANISM", 20, 28], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2", "SPECIES", 32, 91], ["COVID", "TEST", 20, 25], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 44, 89], ["Severe", "OBSERVATION_MODIFIER", 44, 50], ["Acute", "OBSERVATION_MODIFIER", 51, 56], ["Respiratory Syndrome", "OBSERVATION", 57, 77]]], ["After incessant investigations, it has been acquired that SARS-CoV resembles sequence homology with bat coronavirus.", [["SARS", "DISEASE", 58, 62], ["SARS-CoV", "ORGANISM", 58, 66], ["bat coronavirus", "ORGANISM", 100, 115], ["bat coronavirus", "SPECIES", 100, 115], ["SARS-CoV", "SPECIES", 58, 66], ["bat coronavirus", "SPECIES", 100, 115], ["incessant investigations", "TEST", 6, 30], ["SARS", "PROBLEM", 58, 62], ["bat coronavirus", "PROBLEM", 100, 115]]], ["Though, its spike glycoproteins have highest affinity for human angiotensin-converting enzyme 2 (ACE2) receptors, that enable them to invade and transmit through human to human (Guo et al., 2020).", [["angiotensin", "CHEMICAL", 64, 75], ["human", "ORGANISM", 58, 63], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 64, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 97, 101], ["human", "ORGANISM", 162, 167], ["human", "ORGANISM", 171, 176], ["spike glycoproteins", "PROTEIN", 12, 31], ["human angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 58, 112], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 171, 176], ["its spike glycoproteins", "PROBLEM", 8, 31], ["human angiotensin", "TREATMENT", 58, 75], ["converting enzyme 2 (ACE2) receptors", "TREATMENT", 76, 112]]], ["Even though it shares resemblance with SARS-CoV, yet its spreading ability and diagnosis is relatively different.", [["SARS", "DISEASE", 39, 43], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["CoV", "PROBLEM", 44, 47], ["relatively", "OBSERVATION_MODIFIER", 92, 102], ["different", "OBSERVATION_MODIFIER", 103, 112]]], ["The distinctive feature is most likely the nucleotide pattern of spike proteins along with its receptor binding domains (Wan et al., 2020).", [["nucleotide", "CHEMICAL", 43, 53], ["spike proteins", "PROTEIN", 65, 79], ["receptor binding domains", "PROTEIN", 95, 119], ["spike proteins", "PROBLEM", 65, 79], ["most likely", "UNCERTAINTY", 27, 38]]], ["Moreover, belonging to the category of \u03b2-coronaviruses, a highly prevalent virus family in nature, it has several hosts, natural, intermediate as well as final.", [["\u03b2-coronaviruses", "GENE_OR_GENE_PRODUCT", 39, 54]]], ["Henceforth, it is a colossal issue to prevent and cure the outbreak of this viral infection owing to its greater transmitting and infecting power.IntroductionLooking into the present scenario, WHO worked really very hard on a plan to battle against this monstrous virus.", [["viral infection", "DISEASE", 76, 91], ["this viral infection", "PROBLEM", 71, 91], ["this monstrous virus", "PROBLEM", 249, 269], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 82, 91]]], ["For instance, they have strategized to minimize physical contact among each other, isolate and screen the infected people during initial stages and recognise and dwindle the spread from the animal sources.", [["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121]]], ["Additionally, focus have been made to address the critical mysteries related to virus in order to conduct awareness among citizens (WHO, 2020).", [["virus", "PROBLEM", 80, 85]]], ["In essence, it has been known to transmit through droplets such assaliva or nose or even through air-borne transmission.", [["nose", "ANATOMY", 76, 80], ["nose", "ORGAN", 76, 80], ["nose", "ANATOMY", 76, 80]]], ["This has vexed the scientists all around the globe to find out best prevention against this pandemic until the suitable vaccine is discovered.", [["this pandemic", "PROBLEM", 87, 100], ["the suitable vaccine", "TREATMENT", 107, 127], ["globe", "ANATOMY", 45, 50]]], ["However, manufacturers are progressively working on manufacturing masks and sanitizers to prevent disease incidence, lucrative for both health professionals as well as common people (Balachandar et al., 2020).", [["people", "ORGANISM", 175, 181], ["people", "SPECIES", 175, 181], ["manufacturing masks", "TREATMENT", 52, 71], ["sanitizers", "TREATMENT", 76, 86], ["disease incidence", "PROBLEM", 98, 115], ["progressively", "OBSERVATION_MODIFIER", 27, 40]]], ["At this point of time, it is immensely imperative to unravel viral pathogenisis to design the drugs or vaccines.", [["viral pathogenisis", "PROBLEM", 61, 79], ["the drugs", "TREATMENT", 90, 99], ["vaccines", "TREATMENT", 103, 111]]], ["It is a gloomy instance that, there is a lack of a verified treatment, however, many drugs are in a pipeline of clinical trials, yet no medically significant results have come out.", [["a verified treatment", "TREATMENT", 49, 69]]], ["Till that time, existing antiviral drugs like Lopinavir, Chloroquine, Nitazoxanide, Ritonavir, Hydroxuchloroquine, Tocilizumab and Azithromycin have been practiced that tend to reduce the replication and viral load (Gautret et al., 2020).", [["Lopinavir", "CHEMICAL", 46, 55], ["Chloroquine", "CHEMICAL", 57, 68], ["Nitazoxanide", "CHEMICAL", 70, 82], ["Ritonavir", "CHEMICAL", 84, 93], ["Hydroxuchloroquine", "CHEMICAL", 95, 113], ["Tocilizumab", "CHEMICAL", 115, 126], ["Azithromycin", "CHEMICAL", 131, 143], ["Lopinavir", "CHEMICAL", 46, 55], ["Chloroquine", "CHEMICAL", 57, 68], ["Nitazoxanide", "CHEMICAL", 70, 82], ["Ritonavir", "CHEMICAL", 84, 93], ["Hydroxuchloroquine", "CHEMICAL", 95, 113], ["Tocilizumab", "CHEMICAL", 115, 126], ["Azithromycin", "CHEMICAL", 131, 143], ["Lopinavir", "SIMPLE_CHEMICAL", 46, 55], ["Chloroquine", "SIMPLE_CHEMICAL", 57, 68], ["Nitazoxanide", "SIMPLE_CHEMICAL", 70, 82], ["Ritonavir", "SIMPLE_CHEMICAL", 84, 93], ["Hydroxuchloroquine", "SIMPLE_CHEMICAL", 95, 113], ["Tocilizumab", "SIMPLE_CHEMICAL", 115, 126], ["Azithromycin", "SIMPLE_CHEMICAL", 131, 143], ["antiviral drugs", "TREATMENT", 25, 40], ["Lopinavir", "TREATMENT", 46, 55], ["Chloroquine", "TREATMENT", 57, 68], ["Nitazoxanide", "TREATMENT", 70, 82], ["Ritonavir", "TREATMENT", 84, 93], ["Hydroxuchloroquine", "TREATMENT", 95, 113], ["Tocilizumab", "TREATMENT", 115, 126], ["Azithromycin", "TREATMENT", 131, 143]]], ["As a research standpoint, scientists are in a quick pace to achieve their targets in order to safeguard the public.", [["a quick pace", "TREATMENT", 44, 56]]], ["Moreover, envisaging steroids, monoclonal antibodies, peptides, interferons, oligonucleotides, enzyme inhibitors are suggested in curbing the disease (Mehta et al., 2020; Li and Clercq, 2020).", [["steroids", "CHEMICAL", 21, 29], ["steroids", "CHEMICAL", 21, 29], ["steroids", "SIMPLE_CHEMICAL", 21, 29], ["monoclonal antibodies", "PROTEIN", 31, 52], ["interferons", "PROTEIN", 64, 75], ["envisaging steroids", "TREATMENT", 10, 29], ["monoclonal antibodies", "TREATMENT", 31, 52], ["peptides", "TREATMENT", 54, 62], ["interferons", "TREATMENT", 64, 75], ["oligonucleotides", "TREATMENT", 77, 93], ["enzyme inhibitors", "TREATMENT", 95, 112]]], ["Hitherto, there are still unproven antiviral drugs, vaccines and other alternatives available that are being tried to target SARS-CoV-2, consequently, accentuation is being imposed on precautionary measures and symptomatic cure (Jean et al., 2020).", [["SARS", "DISEASE", 125, 129], ["SARS-CoV-2", "ORGANISM", 125, 135], ["SARS-CoV", "SPECIES", 125, 133], ["antiviral drugs", "TREATMENT", 35, 50], ["vaccines", "TREATMENT", 52, 60], ["other alternatives", "TREATMENT", 65, 83], ["precautionary measures", "TREATMENT", 184, 206]]], ["Yet, new discoveries require several trials for which few months to years can pass for the development.", [["new", "OBSERVATION_MODIFIER", 5, 8]]], ["Having said that, there is an urgency to beat the COVID-19 outbreak, for which natural products, herbal plants and their formulations should be sent to this battlefield.", [["an urgency", "PROBLEM", 27, 37], ["the COVID", "TEST", 46, 55], ["natural products", "TREATMENT", 79, 95], ["herbal plants", "TREATMENT", 97, 110], ["their formulations", "TREATMENT", 115, 133], ["urgency", "OBSERVATION", 30, 37]]], ["Because of their feasibility, cost-effectiveness, eco-friendliness, efficacious nature and zilch side-effects, they need to be promoted for this warfare.IntroductionIn this milieu, medicinal herbs are 'Gifted Gods' for healing, supporting and rehabilitating patients.", [["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["eco-friendliness", "PROBLEM", 50, 66], ["healing", "PROBLEM", 219, 226]]], ["Even though, no substantiation is present, but different studies on herbal plants are being conducted that have the ability to strengthen immune system and cope up with this virus.", [["immune system", "ANATOMY", 138, 151], ["herbal plants", "TREATMENT", 68, 81], ["this virus", "PROBLEM", 169, 179], ["no", "UNCERTAINTY", 13, 15], ["substantiation", "OBSERVATION", 16, 30]]], ["To expedite, certain phyto-compounds are being recognised to characterise the herbs in mitigating the incidence of infection.", [["infection", "DISEASE", 115, 124], ["certain phyto-compounds", "TREATMENT", 13, 36], ["infection", "PROBLEM", 115, 124], ["infection", "OBSERVATION", 115, 124]]], ["Ayurveda, Unani, Siddhi, Homeopathy, Romanian, Persian, Chinese traditional medicinal plants for example, are being currently exploited to check the effectivenesson this virus (Nikhat and Fazil, 2020; Yang et al., 2020).", [["Homeopathy", "OBSERVATION", 25, 35]]], ["Since decades, herbal plants have been utilised in aboriginal health services as well as conventional medicines to combat diseases.", [["herbal plants", "TREATMENT", 15, 28], ["conventional medicines", "TREATMENT", 89, 111], ["combat diseases", "PROBLEM", 115, 130]]], ["The natural products provide an ancillary steer to unlock different mysteries behind the sickness.", [["sickness", "DISEASE", 89, 97], ["the sickness", "PROBLEM", 85, 97], ["sickness", "OBSERVATION", 89, 97]]], ["The exploitation of antiviral mechanisms of these natural compounds could shed light on their modes of action towards viral life-cycle, invasion, penetration, replication, assemblage and release.", [["antiviral mechanisms", "TREATMENT", 20, 40], ["invasion", "PROBLEM", 136, 144], ["penetration", "PROBLEM", 146, 157], ["antiviral", "OBSERVATION", 20, 29]]], ["There have been more than 25,000 herbal formulations used in folk remedies in Ayurveda alone (Pundarikakshudu and Kanaki, 2019).", [["herbal formulations", "TREATMENT", 33, 52]]], ["Generally, these medications are disregarded and underrated in research and development due to contemporary medicines.", [["these medications", "TREATMENT", 11, 28], ["contemporary medicines", "TREATMENT", 95, 117]]], ["One single herbal species comprises plentiful phyto-constituents that single-handedly or collectively generate a pharmacological effect (Parasurman et al., 2014).", [["herbal species", "OBSERVATION", 11, 25]]], ["Subsequently, these natural constituents are isolated and modulated as drug formulations against different diseases.", [["drug formulations", "TREATMENT", 71, 88], ["different diseases", "PROBLEM", 97, 115]]], ["Medicinal herbs are by far, are the life-saving drugs these days and research is being conducted on them to promote their usage in treatment of COVID-19 patients due to their potential of possessing anti-inflammatory, antioxidant and antiviral properties.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["COVID", "TREATMENT", 144, 149], ["anti-inflammatory, antioxidant", "TREATMENT", 199, 229], ["antiviral properties", "TREATMENT", 234, 254]]], ["Although, clinical trials are conducted to repurpose their value, for innovative treatment to defeat its transmission.", [["innovative treatment", "TREATMENT", 70, 90]]], ["During this period of global fretfulness, it is pertinent to locate long-lasting measures to avert the spread of this pandemic.", [["global fretfulness", "PROBLEM", 22, 40], ["this pandemic", "PROBLEM", 113, 126], ["global", "OBSERVATION_MODIFIER", 22, 28], ["fretfulness", "OBSERVATION", 29, 40]]], ["Hence, its need of the hour to collaborate and counteract against COVID-19 by exercising social distancing along with maintaining hygienic surroundings (Balachander et al., 2020).", [["COVID", "TEST", 66, 71]]], ["The present review discusses the general overview, transmission, clinical approaches and immune-responses of coronavirus along with herbal immune-boosters to combat this infectious and pandemic disease that has created panic all over.", [["coronavirus", "DISEASE", 109, 120], ["infectious and pandemic disease", "DISEASE", 170, 201], ["panic", "DISEASE", 219, 224], ["coronavirus", "ORGANISM", 109, 120], ["coronavirus", "PROBLEM", 109, 120], ["herbal immune-boosters", "TREATMENT", 132, 154], ["this infectious", "PROBLEM", 165, 180], ["pandemic disease", "PROBLEM", 185, 201], ["panic", "PROBLEM", 219, 224]]], ["By this review, we suggest that herbal or medicinal plant formulations could be essential alternative strategy, a step ahead to battle these awful viruses.A General Overview on CoronavirusSARS-CoV-2, provisionally known as 2019-novel coronavirus, is an enveloped positive-sense single-stranded RNA virus that belongs to the subfamily Orthocoronavirinae, and the family Coronaviridae (Huang et al., 2020; Gorbalenya et al., 2020).", [["CoronavirusSARS-CoV-2", "ORGANISM", 177, 198], ["coronavirus", "ORGANISM", 234, 245], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 334, 352], ["herbal", "TREATMENT", 32, 38], ["medicinal plant formulations", "TREATMENT", 42, 70], ["CoronavirusSARS", "TEST", 177, 192], ["CoV", "TEST", 193, 196], ["novel coronavirus", "PROBLEM", 228, 245], ["an enveloped positive-sense single-stranded RNA virus", "PROBLEM", 250, 303], ["coronavirus", "OBSERVATION", 234, 245], ["enveloped", "OBSERVATION_MODIFIER", 253, 262], ["positive", "OBSERVATION", 263, 271]]], ["Subfamily, Orthocoronavirinae, includes four genera, namely alpha-, beta-, delta- and gammacoronavirus.", [["alpha-", "GENE_OR_GENE_PRODUCT", 60, 66], ["beta-", "GENE_OR_GENE_PRODUCT", 68, 73], ["delta", "GENE_OR_GENE_PRODUCT", 75, 80], ["gammacoronavirus", "GENE_OR_GENE_PRODUCT", 86, 102], ["Orthocoronavirinae", "TREATMENT", 11, 29], ["alpha-", "TEST", 60, 66], ["beta-, delta", "TREATMENT", 68, 80], ["gammacoronavirus", "TREATMENT", 86, 102]]], ["Predominantly, alpha-and beta- CoVs infect mammals, whereas the main targets of delta- and gamma-CoVs are avian species (Fan et al., 2019).", [["alpha", "GENE_OR_GENE_PRODUCT", 15, 20], ["beta- CoVs", "GENE_OR_GENE_PRODUCT", 25, 35], ["delta", "GENE_OR_GENE_PRODUCT", 80, 85], ["gamma-CoVs", "GENE_OR_GENE_PRODUCT", 91, 101], ["avian", "ORGANISM", 106, 111], ["alpha", "PROTEIN", 15, 20], ["CoVs", "PROTEIN", 31, 35], ["delta- and gamma-CoVs", "DNA", 80, 101], ["alpha", "TEST", 15, 20], ["beta- CoVs infect mammals", "PROBLEM", 25, 50], ["delta", "TEST", 80, 85], ["avian species", "PROBLEM", 106, 119], ["alpha", "OBSERVATION_MODIFIER", 15, 20], ["CoVs infect mammals", "OBSERVATION", 31, 50], ["main", "OBSERVATION_MODIFIER", 64, 68]]], ["With the outbreak of recent SARS-CoV-2 total of seven human-susceptible CoVs strains have been currently identified that can infect human population.", [["SARS-CoV-2", "ORGANISM", 28, 38], ["human", "ORGANISM", 54, 59], ["CoVs strains", "ORGANISM", 72, 84], ["human", "ORGANISM", 132, 137], ["CoV-", "SPECIES", 33, 37], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 132, 137], ["recent SARS", "PROBLEM", 21, 32], ["CoV", "TEST", 33, 36], ["susceptible CoVs strains", "PROBLEM", 60, 84]]], ["Most of these viruses tend to cause mild infections; however, SARS-CoV identified in 2002, MERS-CoV identified in 2012 and ongoing pandemic caused by SARS-CoV-2 have emerged as fatal CoVs capable of causing severe respiratory tract infections (Guo et al., 2020).", [["respiratory tract", "ANATOMY", 214, 231], ["infections", "DISEASE", 41, 51], ["SARS-CoV", "DISEASE", 62, 70], ["pandemic", "DISEASE", 131, 139], ["SARS", "DISEASE", 150, 154], ["respiratory tract infections", "DISEASE", 214, 242], ["SARS-CoV", "ORGANISM", 62, 70], ["MERS-CoV", "ORGANISM", 91, 99], ["SARS-CoV-2", "ORGANISM", 150, 160], ["CoVs", "CANCER", 183, 187], ["tract", "ORGANISM_SUBDIVISION", 226, 231], ["SARS-CoV-2", "SPECIES", 150, 160], ["SARS-CoV", "SPECIES", 62, 70], ["MERS-CoV", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 150, 158], ["these viruses", "PROBLEM", 8, 21], ["mild infections", "PROBLEM", 36, 51], ["SARS", "PROBLEM", 62, 66], ["SARS", "PROBLEM", 150, 154], ["severe respiratory tract infections", "PROBLEM", 207, 242], ["viruses", "OBSERVATION", 14, 21], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["infections", "OBSERVATION", 41, 51], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["respiratory tract", "ANATOMY", 214, 231]]], ["Genomic sequencing analyses have revealed the close evolutionary relationship of SARS-CoV-2 with other beta-CoVs.", [["SARS", "DISEASE", 81, 85], ["SARS-CoV-2", "ORGANISM", 81, 91], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 103, 112], ["beta-CoVs", "DNA", 103, 112], ["SARS-CoV", "SPECIES", 81, 89], ["Genomic sequencing analyses", "TEST", 0, 27], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89]]], ["It resembles more with Sarbecovirus subgenus that comprises of SARS-CoV than that of MERS-CoVs of Merbecovirus subgenus origin.", [["SARS", "DISEASE", 63, 67], ["SARS-CoV", "ORGANISM", 63, 71], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 85, 94], ["Merbecovirus subgenus", "ORGANISM", 98, 119], ["SARS-CoV", "SPECIES", 63, 71], ["Sarbecovirus subgenus", "PROBLEM", 23, 44], ["SARS", "PROBLEM", 63, 67], ["MERS", "PROBLEM", 85, 89], ["subgenus origin", "OBSERVATION", 111, 126]]], ["At the nucleotide level, SARS-CoV-2 shares 79% homology with SARS-CoV, whereas only 50% with MERS-CoVs (Peng et al., 2020; Zhang and Holmes, 2020).", [["SARS", "DISEASE", 61, 65], ["nucleotide", "CHEMICAL", 7, 17], ["SARS-CoV", "ORGANISM", 61, 69], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 93, 102], ["SARS-CoV-2", "DNA", 25, 35], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 61, 69], ["the nucleotide level", "TEST", 3, 23], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["SARS", "PROBLEM", 61, 65]]], ["Moreover, SARS-CoV-2 just like SARS-CoV utilizes the same ACE2 receptors to infect its hosts (Guo et al., 2020).", [["SARS-CoV-2", "ORGANISM", 10, 20], ["SARS-CoV", "ORGANISM", 31, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["ACE2 receptors", "PROTEIN", 58, 72], ["SARS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 10, 14], ["CoV", "TEST", 15, 18], ["SARS", "PROBLEM", 31, 35], ["CoV", "PROBLEM", 36, 39], ["the same ACE2 receptors", "TREATMENT", 49, 72]]], ["Thus, the sites where ACE2 protein is mainly expressed are the potential target sites for SARS-CoV-2 respectively.", [["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["ACE2", "PROTEIN", 22, 26], ["ACE2 protein", "TREATMENT", 22, 34], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98]]], ["These regions are belong to type II alveolar cells of the lungs and enterocytes of the small intestine (Hamming et al., 2004; Zheng, 2020).", [["alveolar cells", "ANATOMY", 36, 50], ["lungs", "ANATOMY", 58, 63], ["enterocytes", "ANATOMY", 68, 79], ["small intestine", "ANATOMY", 87, 102], ["alveolar cells", "CELL", 36, 50], ["lungs", "ORGAN", 58, 63], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 68, 79], ["intestine", "ORGAN", 93, 102], ["type II alveolar cells", "CELL_TYPE", 28, 50], ["alveolar cells", "OBSERVATION", 36, 50], ["lungs", "ANATOMY", 58, 63], ["enterocytes", "ANATOMY_MODIFIER", 68, 79], ["small intestine", "ANATOMY", 87, 102]]], ["Nevertheless, there are some remarkable biological differences between the SARS-CoV-2 and the other beta-CoVs, which probably make it more infectious.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 100, 109], ["beta-CoVs", "DNA", 100, 109], ["SARS-CoV", "SPECIES", 75, 83], ["the SARS", "TEST", 71, 79], ["CoV", "TEST", 80, 83], ["remarkable", "OBSERVATION_MODIFIER", 29, 39], ["CoVs", "OBSERVATION", 105, 109], ["probably make it", "UNCERTAINTY", 117, 133], ["more", "OBSERVATION_MODIFIER", 134, 138], ["infectious", "OBSERVATION", 139, 149]]], ["Consequently, the epidemiological dynamics of SARS-CoV-2 is different from previous human-CoV outbreaks having striking local and global spread (Zhang and Holmes, 2020; Zheng, 2020).A General Overview on CoronavirusAlthough, SARS-CoV-2 shows greater human-to-human transmission efficiency, its crude fatality rate (0.25% to 5%) is comparatively far less than that of SARS-CoV which is approx.", [["SARS", "DISEASE", 46, 50], ["SARS", "DISEASE", 367, 371], ["SARS-CoV-2", "ORGANISM", 46, 56], ["human", "ORGANISM", 84, 89], ["-CoV", "ORGANISM", 89, 93], ["SARS-CoV-2", "ORGANISM", 225, 235], ["human", "ORGANISM", 250, 255], ["human", "ORGANISM", 259, 264], ["SARS-CoV", "ORGANISM", 367, 375], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 259, 264], ["SARS-CoV", "SPECIES", 46, 54], ["human-CoV", "SPECIES", 84, 93], ["SARS-CoV", "SPECIES", 225, 233], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 259, 264], ["SARS-CoV", "SPECIES", 367, 375], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["CoronavirusAlthough", "TEST", 204, 223], ["SARS", "TEST", 225, 229], ["CoV", "TEST", 230, 233]]], ["Furthermore, SARS-CoV-2 has R0 (basic reproduction number) of 4.7 to 6.6.", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["R0", "PROBLEM", 28, 30]]], ["This highly contagious nature of SARS-CoV-2 is supported by the fact that its spike (S) protein possess 10 to 20 time's greater affinity for ACE2 receptors than SARS-CoV (Zheng, 2020).", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["spike (S)", "GENE_OR_GENE_PRODUCT", 78, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["SARS-CoV", "ORGANISM", 161, 169], ["spike (S) protein", "PROTEIN", 78, 95], ["ACE2 receptors", "PROTEIN", 141, 155], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 161, 169], ["SARS", "PROBLEM", 33, 37], ["its spike (S) protein possess", "PROBLEM", 74, 103], ["ACE2 receptors", "PROBLEM", 141, 155], ["contagious", "OBSERVATION_MODIFIER", 12, 22]]], ["S-protein is the surface glycoprotein that assists the virus in the attachment to the host cells through its receptor-binding domain (RBD).", [["surface", "ANATOMY", 17, 24], ["cells", "ANATOMY", 91, 96], ["S-protein", "GENE_OR_GENE_PRODUCT", 0, 9], ["host cells", "CELL", 86, 96], ["S-protein", "PROTEIN", 0, 9], ["surface glycoprotein", "PROTEIN", 17, 37], ["host cells", "CELL_TYPE", 86, 96], ["receptor-binding domain", "PROTEIN", 109, 132], ["RBD", "PROTEIN", 134, 137], ["the surface glycoprotein", "TREATMENT", 13, 37], ["the virus", "PROBLEM", 51, 60], ["virus", "OBSERVATION", 55, 60], ["host cells", "OBSERVATION", 86, 96]]], ["S-protein has several domains, one of the sections termed as ectodomain has two subunits, S1 and S2, which form a crown-like structure around the virus (Vellingiri et al., 2020).", [["sections", "ANATOMY", 42, 50], ["S-protein", "GENE_OR_GENE_PRODUCT", 0, 9], ["S1", "GENE_OR_GENE_PRODUCT", 90, 92], ["S2", "GENE_OR_GENE_PRODUCT", 97, 99], ["S-protein", "PROTEIN", 0, 9], ["ectodomain", "PROTEIN", 61, 71], ["S1", "PROTEIN", 90, 92], ["S2", "PROTEIN", 97, 99], ["several domains", "PROBLEM", 14, 29], ["a crown-like structure", "PROBLEM", 112, 134], ["S1", "ANATOMY", 90, 92], ["S2", "ANATOMY", 97, 99], ["crown", "OBSERVATION_MODIFIER", 114, 119], ["virus", "OBSERVATION", 146, 151]]], ["Besides, S-protein of SARS-CoV-2 contains a furin-like cleavage site at the S1\u2013S2 junction, missing in other members of its sister clade.", [["\u2013S2 junction", "ANATOMY", 78, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["furin", "GENE_OR_GENE_PRODUCT", 44, 49], ["S-protein", "PROTEIN", 9, 18], ["SARS-CoV-2", "DNA", 22, 32], ["furin-like cleavage site", "DNA", 44, 68], ["S1", "PROTEIN", 76, 78], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "PROBLEM", 22, 26], ["a furin-like cleavage site", "TREATMENT", 42, 68], ["SARS", "OBSERVATION", 22, 26], ["S1", "ANATOMY_MODIFIER", 76, 78], ["\u2013S2 junction", "ANATOMY", 78, 90]]], ["This additional cleavage site might also be responsible for greater pathogenicity of SARS-CoV-2 as it also occurs in highly infectious form of influenza virus but lacking in less pathogenic ones (Coutard et al., 2020; Zhang and Holmes, 2020).Human-to-human Transmission Routes ::: Origin and Transmission of CoronavirusPerson-to-person transmission is primarily reported in families, communities, and hospitals (Guo et al., 2020).", [["SARS", "DISEASE", 85, 89], ["influenza virus", "DISEASE", 143, 158], ["SARS-CoV-2", "ORGANISM", 85, 95], ["influenza virus", "ORGANISM", 143, 158], ["Human", "ORGANISM", 242, 247], ["human", "ORGANISM", 251, 256], ["influenza virus", "SPECIES", 143, 158], ["Human", "SPECIES", 242, 247], ["human", "SPECIES", 251, 256], ["person", "SPECIES", 329, 335], ["SARS-CoV", "SPECIES", 85, 93], ["influenza virus", "SPECIES", 143, 158], ["human", "SPECIES", 251, 256], ["This additional cleavage site", "PROBLEM", 0, 29], ["SARS", "PROBLEM", 85, 89], ["influenza virus", "PROBLEM", 143, 158], ["might also be responsible", "UNCERTAINTY", 30, 55], ["SARS", "OBSERVATION", 85, 89], ["highly", "OBSERVATION_MODIFIER", 117, 123], ["infectious", "OBSERVATION", 124, 134], ["influenza virus", "OBSERVATION", 143, 158]]], ["Droplet transmission is considered as the main route of person-to-person transmission (Han et al., 2020).", [["person", "SPECIES", 56, 62], ["Droplet transmission", "TEST", 0, 20]]], ["The infection also spreads through direct contact and via fomite exposure i.e., direct contact to eyes, nose, and mouth after touching surfaces and objects contaminated by an infected individual (Peng et al., 2020; Morawskaa and Cao, 2020).", [["eyes", "ANATOMY", 98, 102], ["nose", "ANATOMY", 104, 108], ["mouth", "ANATOMY", 114, 119], ["infection", "DISEASE", 4, 13], ["eyes", "ORGAN", 98, 102], ["nose", "ORGAN", 104, 108], ["mouth", "ORGANISM_SUBDIVISION", 114, 119], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["eyes", "ANATOMY", 98, 102], ["nose", "ANATOMY", 104, 108], ["mouth", "ANATOMY", 114, 119]]], ["In general, human-CoVs can remain infectious on some material surfaces for even 9 days (Kampf et al., 2020).", [["human", "ORGANISM", 12, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 18, 22], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["some material surfaces", "TREATMENT", 48, 70], ["infectious", "OBSERVATION", 34, 44]]], ["Besides, SARS-CoV-2 also spreads through contact with asymptomatic carriers (Peng et al., 2020).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 9, 19], ["SARS-CoV", "SPECIES", 9, 17]]], ["Since SARS-CoV-2 infection is spreading at an unprecedented pace, airborne transmission too warrants meticulous determination (Morawskaa and Cao, 2020).", [["infection", "DISEASE", 17, 26], ["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS-CoV-2", "SPECIES", 6, 16], ["SARS", "PROBLEM", 6, 10], ["CoV-2 infection", "PROBLEM", 11, 26], ["CoV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 17, 26], ["spreading", "OBSERVATION_MODIFIER", 30, 39]]], ["In addition, SARS-CoV-2 was found in a stool sample, gastrointestinal tissue even urine and saliva of an infected person, suggests the possibility of intestinal and fecal-oral transmission (Xiao et al., 2020; Guan et al., 2020).", [["stool sample", "ANATOMY", 39, 51], ["gastrointestinal tissue", "ANATOMY", 53, 76], ["urine", "ANATOMY", 82, 87], ["intestinal", "ANATOMY", 150, 160], ["fecal", "ANATOMY", 165, 170], ["oral", "ANATOMY", 171, 175], ["intestinal and fecal-oral transmission", "DISEASE", 150, 188], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["gastrointestinal tissue", "TISSUE", 53, 76], ["urine", "ORGANISM_SUBSTANCE", 82, 87], ["saliva", "ORGANISM_SUBSTANCE", 92, 98], ["intestinal", "ORGAN", 150, 160], ["fecal", "ORGANISM_SUBDIVISION", 165, 170], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["person", "SPECIES", 114, 120], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "TEST", 13, 21], ["a stool sample", "TEST", 37, 51], ["gastrointestinal tissue", "TEST", 53, 76], ["gastrointestinal tissue", "ANATOMY", 53, 76], ["infected", "OBSERVATION", 105, 113], ["suggests the possibility of", "UNCERTAINTY", 122, 149], ["intestinal", "ANATOMY", 150, 160], ["fecal", "ANATOMY", 165, 170]]], ["Although no case of mother to child transmission has been reported yet, infection in two newborns of Wuhan, China raises the question for vertical transmission (Han et al., 2020).", [["infection", "DISEASE", 72, 81], ["infection", "PROBLEM", 72, 81], ["infection", "OBSERVATION", 72, 81]]], ["Apart from this, there are recent studies that reveal that there is a possibility of sexual transmission of COVID-19 infection.", [["COVID-19", "CHEMICAL", 108, 116], ["infection", "DISEASE", 117, 126], ["COVID-19", "ORGANISM", 108, 116], ["COVID-19", "SPECIES", 108, 116], ["recent studies", "TEST", 27, 41], ["COVID-19 infection", "PROBLEM", 108, 126], ["infection", "OBSERVATION", 117, 126]]], ["There are an array of evidences for this transmission such as through faecal-oral route via gastrointestinal infection (Peng et al., 2020).", [["faecal", "ANATOMY", 70, 76], ["oral", "ANATOMY", 77, 81], ["gastrointestinal", "ANATOMY", 92, 108], ["gastrointestinal infection", "DISEASE", 92, 118], ["faecal", "ORGANISM_SUBDIVISION", 70, 76], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["gastrointestinal", "ORGAN", 92, 108], ["this transmission", "PROBLEM", 36, 53], ["gastrointestinal infection", "PROBLEM", 92, 118], ["gastrointestinal", "ANATOMY", 92, 108], ["infection", "OBSERVATION", 109, 118]]], ["This is most probably due to ACE2 that enable virus entry and ACE2 mRNA is overexpressed in gastro-intestinal system as revealed through immunofluorescent analysis of rectal epithelial cells (Hindson, 2020).", [["gastro-intestinal system", "ANATOMY", 92, 116], ["rectal epithelial cells", "ANATOMY", 167, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["intestinal", "ORGAN", 99, 109], ["system", "ANATOMICAL_SYSTEM", 110, 116], ["rectal epithelial cells", "CELL", 167, 190], ["ACE2", "PROTEIN", 29, 33], ["ACE2 mRNA", "RNA", 62, 71], ["rectal epithelial cells", "CELL_TYPE", 167, 190], ["ACE2", "PROBLEM", 29, 33], ["ACE2 mRNA", "TEST", 62, 71], ["immunofluorescent analysis", "TEST", 137, 163], ["most probably due to", "UNCERTAINTY", 8, 28], ["virus", "OBSERVATION", 46, 51], ["gastro", "ANATOMY", 92, 98], ["intestinal system", "ANATOMY", 99, 116], ["rectal", "ANATOMY", 167, 173], ["epithelial cells", "OBSERVATION", 174, 190]]], ["Moreover, RNA analysis of SARS-CoV-2 also revealed that the viral particles can infect these cells therefore, it is quite predictable that sexual intercourse could be the possible way of contagion.", [["cells", "ANATOMY", 93, 98], ["SARS-CoV-2", "ORGANISM", 26, 36], ["cells", "CELL", 93, 98], ["SARS-CoV", "SPECIES", 26, 34], ["RNA analysis", "TEST", 10, 22], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["the viral particles", "PROBLEM", 56, 75], ["viral particles", "OBSERVATION", 60, 75]]], ["There have been cases when person shows negative results on nasopharyngeal swabs, while, positive on rectal swabs, depicting that sexual transmission might be the possibility (Xu et al., 2020).", [["nasopharyngeal swabs", "ANATOMY", 60, 80], ["rectal swabs", "ANATOMY", 101, 113], ["nasopharyngeal swabs", "ORGAN", 60, 80], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 101, 113], ["person", "SPECIES", 27, 33], ["nasopharyngeal swabs", "TEST", 60, 80], ["rectal swabs", "TEST", 101, 113], ["rectal", "ANATOMY", 101, 107]]], ["Henceforth, the physicians as well as doctors in particular recommend a strong message to discourage sexual practices if in any case of COVID-19 infection.", [["infection", "DISEASE", 145, 154], ["COVID-19 infection", "PROBLEM", 136, 154], ["infection", "OBSERVATION", 145, 154]]], ["Hence, comprehensive possible means of SARS-CoV-2 transmission warrants further study.Clinical Attributes of COVID-19A study conducted on 1099 patients (926 non-severe and 173 severe) from 30 provinces of China from December 11, 2019, to January 29, 2020, revealed that dominant clinical manifestations of SARS-CoV-2 infection include fever, cough, fatigue and sputum production.", [["sputum", "ANATOMY", 361, 367], ["SARS", "DISEASE", 39, 43], ["SARS-CoV-2 infection", "DISEASE", 306, 326], ["fever", "DISEASE", 335, 340], ["cough", "DISEASE", 342, 347], ["fatigue", "DISEASE", 349, 356], ["SARS-CoV-2", "ORGANISM", 39, 49], ["patients", "ORGANISM", 143, 151], ["SARS-CoV-2", "ORGANISM", 306, 316], ["sputum", "ORGANISM_SUBSTANCE", 361, 367], ["patients", "SPECIES", 143, 151], ["CoV-2", "SPECIES", 311, 316], ["SARS-CoV", "SPECIES", 306, 314], ["SARS", "PROBLEM", 39, 43], ["further study", "TEST", 72, 85], ["19A study", "TEST", 115, 124], ["SARS", "PROBLEM", 306, 310], ["CoV", "PROBLEM", 311, 314], ["2 infection", "PROBLEM", 315, 326], ["fever", "PROBLEM", 335, 340], ["cough", "PROBLEM", 342, 347], ["fatigue", "PROBLEM", 349, 356], ["sputum production", "PROBLEM", 361, 378], ["dominant", "OBSERVATION_MODIFIER", 270, 278]]], ["While, symptoms such as shortness of breath, myalgia, sore throat, headache, chills, are common, whereas the gastrointestinal symptoms such as vomiting and diarrhea along with anosmia and hypogeusia are rare in pateints (Guan et al., 2020).", [["gastrointestinal", "ANATOMY", 109, 125], ["shortness of breath", "DISEASE", 24, 43], ["myalgia", "DISEASE", 45, 52], ["sore throat", "DISEASE", 54, 65], ["headache", "DISEASE", 67, 75], ["chills", "DISEASE", 77, 83], ["gastrointestinal symptoms", "DISEASE", 109, 134], ["vomiting", "DISEASE", 143, 151], ["diarrhea", "DISEASE", 156, 164], ["anosmia", "DISEASE", 176, 183], ["hypogeusia", "DISEASE", 188, 198], ["gastrointestinal", "ORGAN", 109, 125], ["symptoms", "PROBLEM", 7, 15], ["shortness of breath", "PROBLEM", 24, 43], ["myalgia", "PROBLEM", 45, 52], ["sore throat", "PROBLEM", 54, 65], ["headache", "PROBLEM", 67, 75], ["chills", "PROBLEM", 77, 83], ["the gastrointestinal symptoms", "PROBLEM", 105, 134], ["vomiting", "PROBLEM", 143, 151], ["diarrhea", "PROBLEM", 156, 164], ["anosmia", "PROBLEM", 176, 183], ["hypogeusia", "PROBLEM", 188, 198], ["sore throat", "ANATOMY", 54, 65], ["chills", "OBSERVATION", 77, 83], ["gastrointestinal", "ANATOMY", 109, 125]]], ["Later, meta-analysis of total 43 studies from the period of January 24, 2020, to February 28, 2020, including 3600 patients conducted by Fu and others (2020), ascertains that fever, cough, and fatigue are most frequent, while congestion, sore throat, rhinorrhea, and diarrhea are uncommon clinical manifestations of SARS-CoV-2.", [["fever", "DISEASE", 175, 180], ["cough", "DISEASE", 182, 187], ["fatigue", "DISEASE", 193, 200], ["congestion", "DISEASE", 226, 236], ["sore throat", "DISEASE", 238, 249], ["rhinorrhea", "DISEASE", 251, 261], ["diarrhea", "DISEASE", 267, 275], ["SARS", "DISEASE", 316, 320], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["total 43 studies", "TEST", 24, 40], ["fever", "PROBLEM", 175, 180], ["cough", "PROBLEM", 182, 187], ["fatigue", "PROBLEM", 193, 200], ["congestion", "PROBLEM", 226, 236], ["sore throat", "PROBLEM", 238, 249], ["rhinorrhea", "PROBLEM", 251, 261], ["diarrhea", "PROBLEM", 267, 275], ["SARS", "PROBLEM", 316, 320], ["fever", "OBSERVATION", 175, 180], ["cough", "OBSERVATION", 182, 187], ["congestion", "OBSERVATION", 226, 236], ["sore throat", "ANATOMY", 238, 249], ["rhinorrhea", "OBSERVATION", 251, 261], ["diarrhea", "OBSERVATION", 267, 275]]], ["Moreover, lymphocytopenia, and increased lactate dehydrogenase, C-reactive protein levels and ground-glass opacities are other common abnormalities among patients.", [["lymphocytopenia", "DISEASE", 10, 25], ["lactate", "CHEMICAL", 41, 48], ["lactate", "CHEMICAL", 41, 48], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 41, 62], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 64, 82], ["patients", "ORGANISM", 154, 162], ["lactate dehydrogenase", "PROTEIN", 41, 62], ["C-reactive protein", "PROTEIN", 64, 82], ["patients", "SPECIES", 154, 162], ["lymphocytopenia", "PROBLEM", 10, 25], ["increased lactate dehydrogenase", "PROBLEM", 31, 62], ["C-reactive protein levels", "PROBLEM", 64, 89], ["ground-glass opacities", "PROBLEM", 94, 116], ["other common abnormalities", "PROBLEM", 121, 147], ["lymphocytopenia", "OBSERVATION", 10, 25], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["lactate dehydrogenase", "OBSERVATION", 41, 62], ["reactive protein levels", "OBSERVATION", 66, 89], ["ground-glass opacities", "OBSERVATION", 94, 116], ["common", "OBSERVATION_MODIFIER", 127, 133], ["abnormalities", "OBSERVATION", 134, 147]]], ["Furthermore, the comprehensive study also suggests this novel SARS-CoV-2 affects elderly people with coexisting other medical complications more seriously.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["SARS-CoV", "SPECIES", 62, 70], ["the comprehensive study", "TEST", 13, 36], ["this novel SARS", "PROBLEM", 51, 66], ["coexisting other medical complications", "PROBLEM", 101, 139]]], ["These results are consistent with previous studies conducted on severely ill patients which also advocates high mortality rate in elderly people with acute respiratory distress syndrome (ARDS) and comorbidities such as hypertension, diabetes, chronic obstructive lung disease and coronary heart disease (Yang et al., 2020; Zhou et al., 2020a).", [["respiratory", "ANATOMY", 156, 167], ["lung", "ANATOMY", 263, 267], ["coronary", "ANATOMY", 280, 288], ["heart", "ANATOMY", 289, 294], ["severely ill", "DISEASE", 64, 76], ["acute respiratory distress syndrome", "DISEASE", 150, 185], ["ARDS", "DISEASE", 187, 191], ["hypertension", "DISEASE", 219, 231], ["diabetes", "DISEASE", 233, 241], ["chronic obstructive lung disease", "DISEASE", 243, 275], ["coronary heart disease", "DISEASE", 280, 302], ["patients", "ORGANISM", 77, 85], ["people", "ORGANISM", 138, 144], ["lung", "ORGAN", 263, 267], ["heart", "ORGAN", 289, 294], ["patients", "SPECIES", 77, 85], ["people", "SPECIES", 138, 144], ["previous studies", "TEST", 34, 50], ["acute respiratory distress syndrome", "PROBLEM", 150, 185], ["ARDS)", "PROBLEM", 187, 192], ["comorbidities", "PROBLEM", 197, 210], ["hypertension", "PROBLEM", 219, 231], ["diabetes", "PROBLEM", 233, 241], ["chronic obstructive lung disease", "PROBLEM", 243, 275], ["coronary heart disease", "PROBLEM", 280, 302], ["consistent with", "UNCERTAINTY", 18, 33], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory distress", "OBSERVATION", 156, 176], ["hypertension", "OBSERVATION", 219, 231], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["obstructive", "OBSERVATION_MODIFIER", 251, 262], ["lung", "ANATOMY", 263, 267], ["disease", "OBSERVATION", 268, 275], ["coronary heart", "ANATOMY", 280, 294], ["disease", "OBSERVATION", 295, 302]]], ["The most common complications associated with SARS-CoV-2 infection are sepsis, respiratory and heart failure, ARDS, and septic shock (Zhou et al., 2020a).", [["respiratory", "ANATOMY", 79, 90], ["heart", "ANATOMY", 95, 100], ["SARS-CoV-2 infection", "DISEASE", 46, 66], ["sepsis", "DISEASE", 71, 77], ["respiratory and heart failure", "DISEASE", 79, 108], ["ARDS", "DISEASE", 110, 114], ["septic shock", "DISEASE", 120, 132], ["SARS-CoV-2", "ORGANISM", 46, 56], ["heart", "ORGAN", 95, 100], ["CoV-", "SPECIES", 51, 55], ["The most common complications", "PROBLEM", 0, 29], ["SARS", "PROBLEM", 46, 50], ["CoV-2 infection", "PROBLEM", 51, 66], ["sepsis", "PROBLEM", 71, 77], ["respiratory and heart failure", "PROBLEM", 79, 108], ["ARDS", "PROBLEM", 110, 114], ["septic shock", "PROBLEM", 120, 132], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["complications", "OBSERVATION", 16, 29], ["SARS", "OBSERVATION", 46, 50], ["infection", "OBSERVATION", 57, 66], ["sepsis", "OBSERVATION", 71, 77], ["respiratory", "ANATOMY", 79, 90], ["heart", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108], ["ARDS", "OBSERVATION", 110, 114], ["septic shock", "OBSERVATION", 120, 132]]], ["Even though children of all ages face risk of SARS-CoV infection, the serious progression of infection and morbidity is rare in children and adolescents relative to the adults (Lu et al., 2020a).Perspectives on Immune Responses and ImmunopathologySARS-CoV-2 infection is often categorized into three stages: first, asymptomatic phase; second, non-severe symptomatic phase; and third, severe respiratory symptomatic phase (Shi et al., 2020).", [["respiratory", "ANATOMY", 391, 402], ["SARS-CoV infection", "DISEASE", 46, 64], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 258, 267], ["children", "ORGANISM", 12, 20], ["SARS-CoV", "ORGANISM", 46, 54], ["children", "ORGANISM", 128, 136], ["ImmunopathologySARS-CoV-2", "ORGANISM", 232, 257], ["children", "SPECIES", 12, 20], ["children", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["CoV infection", "PROBLEM", 51, 64], ["infection", "PROBLEM", 93, 102], ["Immune Responses", "TEST", 211, 227], ["ImmunopathologySARS", "TEST", 232, 251], ["CoV", "TEST", 252, 255], ["2 infection", "PROBLEM", 256, 267], ["non-severe symptomatic phase", "PROBLEM", 343, 371], ["third, severe respiratory symptomatic phase", "PROBLEM", 377, 420], ["SARS", "OBSERVATION", 46, 50], ["CoV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64], ["serious", "OBSERVATION_MODIFIER", 70, 77], ["progression", "OBSERVATION_MODIFIER", 78, 89], ["infection", "OBSERVATION", 93, 102], ["severe", "OBSERVATION_MODIFIER", 384, 390], ["respiratory", "ANATOMY", 391, 402]]], ["Usually, a small number of patient's progress to the severe stage and develop ARDS and/or multiorgan failure (Cao et al., 2020).Perspectives on Immune Responses and ImmunopathologyHost's immune responses initiate as soon as SARS-CoV-2 binds to ACE2 receptors and releases viral RNA for replication.", [["multiorgan", "ANATOMY", 90, 100], ["ARDS", "DISEASE", 78, 82], ["multiorgan failure", "DISEASE", 90, 108], ["patient", "ORGANISM", 27, 34], ["multiorgan", "ORGAN", 90, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 224, 234], ["ACE2", "GENE_OR_GENE_PRODUCT", 244, 248], ["ACE2 receptors", "PROTEIN", 244, 258], ["viral RNA", "RNA", 272, 281], ["patient", "SPECIES", 27, 34], ["the severe stage", "PROBLEM", 49, 65], ["ARDS", "PROBLEM", 78, 82], ["multiorgan failure", "PROBLEM", 90, 108], ["ACE2 receptors", "TREATMENT", 244, 258], ["viral RNA", "TREATMENT", 272, 281], ["small", "OBSERVATION_MODIFIER", 11, 16], ["ARDS", "OBSERVATION", 78, 82], ["multiorgan", "ANATOMY", 90, 100], ["failure", "OBSERVATION", 101, 108]]], ["Both the innate and adaptive immune response could be triggered in response to the SARS-CoV-2 infection (Cao et al., 2020).", [["infection", "DISEASE", 94, 103], ["SARS-CoV-2", "ORGANISM", 83, 93], ["SARS-CoV-2", "SPECIES", 83, 93], ["the SARS", "PROBLEM", 79, 87], ["CoV-2 infection", "PROBLEM", 88, 103]]], ["However, immune responses are different between severely and moderately infected persons.", [["persons", "ORGANISM", 81, 88], ["persons", "SPECIES", 81, 88], ["severely and moderately infected persons", "PROBLEM", 48, 88], ["moderately", "OBSERVATION_MODIFIER", 61, 71], ["infected", "OBSERVATION", 72, 80]]], ["In a blood sample of symptomatic hospitalised patients with mild to moderate SARS-CoV-2 infection before resolution of symptoms, immunological changes such as increase in the number of activated CD4+ helper T cells and CD8+ killer T cells, follicular helper T (Tfh) cells, antibody-secreting cells (ASCs) and antibodies particularly IgG (Immunoglobulin G)and IgM (Immunoglobulin M) were detected (Thevarajan, 2020).", [["blood sample", "ANATOMY", 5, 17], ["CD4+ helper T cells", "ANATOMY", 195, 214], ["CD8+ killer T cells", "ANATOMY", 219, 238], ["follicular helper T (Tfh) cells", "ANATOMY", 240, 271], ["cells", "ANATOMY", 292, 297], ["ASCs", "ANATOMY", 299, 303], ["SARS-CoV-2 infection", "DISEASE", 77, 97], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["patients", "ORGANISM", 46, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 195, 198], ["CD8", "GENE_OR_GENE_PRODUCT", 219, 222], ["cells", "CELL", 292, 297], ["ASCs", "CELL", 299, 303], ["IgG (Immunoglobulin G", "GENE_OR_GENE_PRODUCT", 333, 354], ["IgM", "GENE_OR_GENE_PRODUCT", 359, 362], ["Immunoglobulin M", "GENE_OR_GENE_PRODUCT", 364, 380], ["activated CD4+ helper T cells", "CELL_TYPE", 185, 214], ["CD8+ killer T cells", "CELL_TYPE", 219, 238], ["follicular helper T (Tfh) cells", "CELL_TYPE", 240, 271], ["antibody-secreting cells", "CELL_TYPE", 273, 297], ["ASCs", "CELL_TYPE", 299, 303], ["antibodies", "PROTEIN", 309, 319], ["IgG", "PROTEIN", 333, 336], ["Immunoglobulin G", "PROTEIN", 338, 354], ["IgM", "PROTEIN", 359, 362], ["Immunoglobulin M", "PROTEIN", 364, 380], ["patients", "SPECIES", 46, 54], ["mild to moderate SARS", "PROBLEM", 60, 81], ["CoV-2 infection", "PROBLEM", 82, 97], ["symptoms", "PROBLEM", 119, 127], ["immunological changes", "PROBLEM", 129, 150], ["activated CD4", "TEST", 185, 198], ["CD8", "TEST", 219, 222], ["killer T cells", "TEST", 224, 238], ["follicular helper T (Tfh) cells", "TEST", 240, 271], ["antibody", "TEST", 273, 281], ["ASCs", "TEST", 299, 303], ["antibodies", "TEST", 309, 319], ["IgG", "TEST", 333, 336], ["Immunoglobulin G", "TEST", 338, 354], ["IgM", "TEST", 359, 362], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["SARS", "OBSERVATION", 77, 81], ["increase", "OBSERVATION_MODIFIER", 159, 167], ["secreting cells", "OBSERVATION", 282, 297]]], ["On the other hand, in severely infected patients, lymphocytopenia is a common denominator with substantial fall in numbers of natural killer cells, B cells, CD3+ T cells, CD4+ helper T cells, CD8+ killer T cells along with the increase in neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein levels.", [["natural killer cells", "ANATOMY", 126, 146], ["B cells", "ANATOMY", 148, 155], ["CD3+ T cells", "ANATOMY", 157, 169], ["CD4+ helper T cells", "ANATOMY", 171, 190], ["CD8+ killer T cells", "ANATOMY", 192, 211], ["neutrophil", "ANATOMY", 239, 249], ["lymphocytopenia", "DISEASE", 50, 65], ["patients", "ORGANISM", 40, 48], ["natural killer cells", "CELL", 126, 146], ["B cells", "CELL", 148, 155], ["CD3", "GENE_OR_GENE_PRODUCT", 157, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 171, 174], ["CD8", "GENE_OR_GENE_PRODUCT", 192, 195], ["neutrophil", "CELL", 239, 249], ["lymphocyte", "CELL", 253, 263], ["NLR", "GENE_OR_GENE_PRODUCT", 271, 274], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 280, 298], ["natural killer cells", "CELL_TYPE", 126, 146], ["B cells", "CELL_TYPE", 148, 155], ["CD3+ T cells", "CELL_TYPE", 157, 169], ["CD4+ helper T cells", "CELL_TYPE", 171, 190], ["CD8+ killer T cells", "CELL_TYPE", 192, 211], ["neutrophil", "CELL_TYPE", 239, 249], ["NLR", "PROTEIN", 271, 274], ["patients", "SPECIES", 40, 48], ["lymphocytopenia", "PROBLEM", 50, 65], ["substantial fall", "PROBLEM", 95, 111], ["natural killer cells", "PROBLEM", 126, 146], ["B cells", "TEST", 148, 155], ["CD3", "TEST", 157, 160], ["T cells", "PROBLEM", 162, 169], ["CD4", "TEST", 171, 174], ["CD8", "TEST", 192, 195], ["killer T cells", "PROBLEM", 197, 211], ["neutrophil", "TEST", 239, 249], ["lymphocyte ratio", "TEST", 253, 269], ["NLR", "TEST", 271, 274], ["C-reactive protein levels", "PROBLEM", 280, 305], ["severely", "OBSERVATION_MODIFIER", 22, 30], ["infected", "OBSERVATION", 31, 39], ["lymphocytopenia", "OBSERVATION", 50, 65], ["substantial", "OBSERVATION_MODIFIER", 95, 106], ["fall", "OBSERVATION", 107, 111], ["natural killer cells", "OBSERVATION", 126, 146], ["increase", "OBSERVATION_MODIFIER", 227, 235], ["neutrophil", "OBSERVATION", 239, 249], ["reactive protein levels", "OBSERVATION", 282, 305]]], ["Additionally, in comparison to the non-severe patients, pro-inflammatory cytokines and chemokines such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-2, IL-6, IL-7, IL-8, IL-10, Granulocyte-colony stimulating factor (GCSF), monocytechemoattractant protein 1 (MCP1) and macrophage inflammatory protein 1-alpha (MIP1-alpha) are often reported to be elevated in serum levels of critically ill patients (Huang et al., 2020; Qin et al., 2020; Wang et al., 2020a).", [["serum", "ANATOMY", 363, 368], ["tumor necrosis", "DISEASE", 106, 120], ["critically ill", "DISEASE", 379, 393], ["patients", "ORGANISM", 46, 54], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 106, 135], ["interleukin (IL)-2", "GENE_OR_GENE_PRODUCT", 137, 155], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL-7", "GENE_OR_GENE_PRODUCT", 163, 167], ["IL-8", "GENE_OR_GENE_PRODUCT", 169, 173], ["IL-10", "GENE_OR_GENE_PRODUCT", 175, 180], ["Granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 182, 219], ["GCSF", "GENE_OR_GENE_PRODUCT", 221, 225], ["monocytechemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 228, 261], ["MCP1", "GENE_OR_GENE_PRODUCT", 263, 267], ["macrophage inflammatory protein 1-alpha", "GENE_OR_GENE_PRODUCT", 273, 312], ["MIP1-alpha", "GENE_OR_GENE_PRODUCT", 314, 324], ["serum", "ORGANISM_SUBSTANCE", 363, 368], ["patients", "ORGANISM", 394, 402], ["pro-inflammatory cytokines", "PROTEIN", 56, 82], ["chemokines", "PROTEIN", 87, 97], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 106, 135], ["IL-10", "PROTEIN", 175, 180], ["Granulocyte-colony stimulating factor", "PROTEIN", 182, 219], ["GCSF", "PROTEIN", 221, 225], ["monocytechemoattractant protein 1", "PROTEIN", 228, 261], ["MCP1", "PROTEIN", 263, 267], ["macrophage inflammatory protein 1-alpha (MIP1-alpha", "PROTEIN", 273, 324], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 394, 402], ["pro-inflammatory cytokines", "TEST", 56, 82], ["chemokines", "PROBLEM", 87, 97], ["tumor necrosis factor", "PROBLEM", 106, 127], ["TNF", "TEST", 129, 132], ["interleukin (IL)", "TEST", 137, 153], ["IL", "TEST", 157, 159], ["IL", "TEST", 163, 165], ["IL", "TEST", 169, 171], ["IL", "TEST", 175, 177], ["Granulocyte", "TEST", 182, 193], ["GCSF", "TEST", 221, 225], ["monocytechemoattractant protein", "TEST", 228, 259], ["MCP1", "TEST", 263, 267], ["macrophage inflammatory protein", "TEST", 273, 304], ["alpha", "TEST", 307, 312], ["MIP1", "TEST", 314, 318], ["serum levels", "TEST", 363, 375], ["pro-inflammatory cytokines", "OBSERVATION", 56, 82], ["tumor", "OBSERVATION_MODIFIER", 106, 111], ["necrosis", "OBSERVATION", 112, 120], ["Granulocyte", "ANATOMY", 182, 193], ["macrophage", "ANATOMY", 273, 283], ["elevated", "OBSERVATION", 351, 359]]], ["The elevated ratio of NLR, which is a biomarker of systemic inflammatory response syndrome, points to the devastated inflammatory state of ICU patients (Salciccioli et al., 2015).", [["systemic inflammatory response syndrome", "DISEASE", 51, 90], ["NLR", "GENE_OR_GENE_PRODUCT", 22, 25], ["patients", "ORGANISM", 143, 151], ["NLR", "PROTEIN", 22, 25], ["patients", "SPECIES", 143, 151], ["The elevated ratio of NLR", "PROBLEM", 0, 25], ["systemic inflammatory response syndrome", "PROBLEM", 51, 90], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["systemic", "OBSERVATION_MODIFIER", 51, 59], ["inflammatory response syndrome", "OBSERVATION", 60, 90], ["devastated", "OBSERVATION_MODIFIER", 106, 116], ["inflammatory", "OBSERVATION_MODIFIER", 117, 129]]], ["Moreover, uncontrolled levels of cytokines and chemokines cause over-active inflammatory responses or cytokine storm.", [["cytokines", "PROTEIN", 33, 42], ["chemokines", "PROTEIN", 47, 57], ["cytokine", "PROTEIN", 102, 110], ["uncontrolled levels of cytokines", "PROBLEM", 10, 42], ["active inflammatory responses", "PROBLEM", 69, 98], ["cytokine storm", "PROBLEM", 102, 116], ["active", "OBSERVATION_MODIFIER", 69, 75], ["inflammatory", "OBSERVATION", 76, 88], ["cytokine storm", "OBSERVATION", 102, 116]]], ["This hyperactive immune response along with impaired adaptive immune response may trigger pulmonary injury, ARDS, viral sepsis and organ failure like complications, and eventually death in some cases (Prompetchara et al., 2020).Plant Based-Therapeutic Approaches against COVID-19 ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaThe traditional medicines have been in general disregarded in the novel research and expansion of contemporary drugs due to the fact that their translational ability is commonly underrated.", [["pulmonary", "ANATOMY", 90, 99], ["organ", "ANATOMY", 131, 136], ["pulmonary injury", "DISEASE", 90, 106], ["ARDS", "DISEASE", 108, 112], ["viral sepsis", "DISEASE", 114, 126], ["organ failure", "DISEASE", 131, 144], ["death", "DISEASE", 180, 185], ["pulmonary", "ORGAN", 90, 99], ["organ", "ORGAN", 131, 136], ["This hyperactive immune response", "PROBLEM", 0, 32], ["impaired adaptive immune response", "PROBLEM", 44, 77], ["pulmonary injury", "PROBLEM", 90, 106], ["ARDS", "PROBLEM", 108, 112], ["viral sepsis", "PROBLEM", 114, 126], ["organ failure", "PROBLEM", 131, 144], ["complications", "PROBLEM", 150, 163], ["COVID", "TEST", 271, 276], ["Ayurveda", "TREATMENT", 335, 343], ["The traditional medicines", "TREATMENT", 343, 368], ["contemporary drugs", "TREATMENT", 441, 459], ["immune response", "OBSERVATION", 17, 32], ["pulmonary", "ANATOMY", 90, 99], ["injury", "OBSERVATION", 100, 106], ["ARDS", "OBSERVATION", 108, 112], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["sepsis", "OBSERVATION", 120, 126], ["organ", "ANATOMY", 131, 136], ["failure", "OBSERVATION", 137, 144]]], ["These medicines are considered vague in the context of their usage in the non-western medical technologies (Yuan et al., 2016).", [["These medicines", "TREATMENT", 0, 15]]], ["Wide array of phytochemical components is extracted from a single herb that may function unaided or in amalgamation with other components to yield preferred pharmacological effects (Parasuraman et al., 2014).", [["phytochemical components", "PROBLEM", 14, 38], ["a single herb", "TREATMENT", 57, 70], ["phytochemical components", "OBSERVATION", 14, 38]]], ["It has been frequently indicated that 70-80% of the people belonging to the developing countries are directly dependent on the herbal drug for their primary healthcare in comparison to the modern synthetic drugs (Hamilton, 2004).", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["Beneficial impact of the medicinal plants lies in their bioactive constituent's specifically secondary metabolites viz. steroids, alkaloids, diterpenes, triterpenes, aliphatics and glycosides etc. (Chikezie et al., 2015).", [["steroids", "CHEMICAL", 120, 128], ["alkaloids, diterpenes, triterpenes", "CHEMICAL", 130, 164], ["aliphatics", "CHEMICAL", 166, 176], ["steroids", "CHEMICAL", 120, 128], ["diterpenes", "CHEMICAL", 141, 151], ["triterpenes", "CHEMICAL", 153, 164], ["aliphatics", "CHEMICAL", 166, 176], ["glycosides", "CHEMICAL", 181, 191], ["steroids", "SIMPLE_CHEMICAL", 120, 128], ["alkaloids", "SIMPLE_CHEMICAL", 130, 139], ["diterpenes", "SIMPLE_CHEMICAL", 141, 151], ["triterpenes", "SIMPLE_CHEMICAL", 153, 164], ["aliphatics", "SIMPLE_CHEMICAL", 166, 176], ["glycosides etc", "SIMPLE_CHEMICAL", 181, 195], ["the medicinal plants", "TREATMENT", 21, 41], ["secondary metabolites viz", "PROBLEM", 93, 118], ["steroids", "TREATMENT", 120, 128], ["alkaloids", "TREATMENT", 130, 139], ["diterpenes", "TREATMENT", 141, 151], ["triterpenes", "TREATMENT", 153, 164], ["aliphatics", "TREATMENT", 166, 176], ["glycosides", "TREATMENT", 181, 191]]], ["The exploration for innovative phytochemical with antiviral bioactivity has frequently been substandard and inefficient due to adaptive viral resistance accompanied by viral latency and persistent infections in patients with compromised immunity (Sumithira et al., 2012).", [["infections", "DISEASE", 197, 207], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["The exploration", "TEST", 0, 15], ["innovative phytochemical", "TREATMENT", 20, 44], ["antiviral bioactivity", "TREATMENT", 50, 71], ["adaptive viral resistance", "PROBLEM", 127, 152], ["viral latency", "PROBLEM", 168, 181], ["persistent infections", "PROBLEM", 186, 207], ["viral resistance", "OBSERVATION", 136, 152], ["viral latency", "OBSERVATION", 168, 181], ["persistent", "OBSERVATION_MODIFIER", 186, 196], ["infections", "OBSERVATION", 197, 207]]], ["Most of the antiviral therapeutics modules are non-specific in their action towards viruses (Jiang et al. 2015).", [["the antiviral therapeutics modules", "TREATMENT", 8, 42]]], ["The progression in development of novel antiviral mediators is the foremost concern of the medical research at present.", [["novel antiviral mediators", "TREATMENT", 34, 59], ["progression", "OBSERVATION_MODIFIER", 4, 15], ["antiviral mediators", "OBSERVATION", 40, 59]]], ["The antiviral bioactivities of plethora of medicinal plants plays a remarkable role in diverse stages of virus growth (Akram et al., 2018).Plant Based-Therapeutic Approaches against COVID-19 ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaThe traditional Indian medicines network is one of the oldest health modules since the human existence and plays a crucial role in combating and fulfilling the needs of the global healthcare system (Ravishankar and Shukla, 2007).", [["human", "ORGANISM", 341, 346], ["human", "SPECIES", 341, 346], ["human", "SPECIES", 341, 346], ["The antiviral bioactivities", "TREATMENT", 0, 27], ["medicinal plants", "TREATMENT", 43, 59], ["virus growth", "PROBLEM", 105, 117], ["COVID", "TEST", 182, 187], ["Ayurveda", "TREATMENT", 246, 254], ["The traditional Indian medicines", "TREATMENT", 254, 286], ["antiviral bioactivities", "OBSERVATION", 4, 27], ["medicinal plants", "OBSERVATION", 43, 59]]], ["These traditional practices include ayurveda, siddha, yoga and unani, homeopathy and naturopathy and they are lucratively practiced for healing varied infectious disorders (Gomathi et al., 2020).", [["naturopathy", "DISEASE", 85, 96], ["infectious disorders", "DISEASE", 151, 171], ["homeopathy", "PROBLEM", 70, 80], ["naturopathy", "PROBLEM", 85, 96], ["healing varied infectious disorders", "PROBLEM", 136, 171]]], ["These modules employ plants, animal products and minerals for treatment of wide range of diseases (Tabuti et al., 2003).", [["minerals", "SIMPLE_CHEMICAL", 49, 57], ["animal products and minerals", "TREATMENT", 29, 57], ["treatment", "TREATMENT", 62, 71], ["diseases", "PROBLEM", 89, 97]]], ["Approximately, twenty-five thousand plant based formulations and extracts have been used in folk medication in the south Asian subcontinents (Pundarikakshudu and Kanaki, 2019).", [["extracts", "ANATOMY", 65, 73], ["extracts", "ORGANISM_SUBSTANCE", 65, 73], ["plant based formulations", "TREATMENT", 36, 60], ["extracts", "TREATMENT", 65, 73], ["folk medication", "TREATMENT", 92, 107]]], ["Moreover, recently total medicinal plants in India were estimated to be 3000, nevertheless traditional ayurveda practioners use around 8000 varied species of plant for the treatments (Pundarikakshudu and Kanaki, 2019).Plant Based-Therapeutic Approaches against COVID-19 ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaRecently, in India, it was suggested by the Ministry of AYUSH (Ayurvedic, Yoga and Naturopathy, Unani, Siddha and Homeopathy), to drink Kadha as a booster of immunity and lowering the tenderness caused during COVID-19 catastrophe (AYUSH Advisory, 2020).", [["Kadha", "CHEMICAL", 469, 474], ["tenderness", "DISEASE", 517, 527], ["the treatments", "TREATMENT", 168, 182], ["COVID", "TEST", 261, 266], ["Naturopathy", "PROBLEM", 416, 427], ["the tenderness", "PROBLEM", 513, 527]]], ["A Kadha is an extract prepared from less juicy or dry ingredients like spices and herbs.", [["extract", "ANATOMY", 14, 21], ["Kadha", "CHEMICAL", 2, 7], ["Kadha", "SIMPLE_CHEMICAL", 2, 7], ["spices", "ORGANISM_SUBDIVISION", 71, 77]]], ["The Ministry of AYUSH with its conventional acquaintance has an extensive custom of maintenance of nation's health and its participation has augmented manifolds in this COVID-19 pandemic crisis (AYUSH Advisory, 2020).", [["extensive", "OBSERVATION_MODIFIER", 64, 73], ["custom", "OBSERVATION_MODIFIER", 74, 80]]], ["All ayurvedic healthcare professional generally recommend classical ayurveda medicine, however AYUSH-64 a novel formulation prepared by CCRAS provides resistance against malaria and other fevers.", [["AYUSH-64", "CHEMICAL", 95, 103], ["CCRAS", "CHEMICAL", 136, 141], ["malaria", "DISEASE", 170, 177], ["fevers", "DISEASE", 188, 194], ["AYUSH-64", "CHEMICAL", 95, 103], ["AYUSH-64", "SIMPLE_CHEMICAL", 95, 103], ["CCRAS", "SIMPLE_CHEMICAL", 136, 141], ["classical ayurveda medicine", "TREATMENT", 58, 85], ["AYUSH", "TEST", 95, 100], ["a novel formulation", "TREATMENT", 104, 123], ["malaria", "PROBLEM", 170, 177], ["other fevers", "PROBLEM", 182, 194]]], ["The decoction of sunthi (Zingiber officinaleRoscoe.), lavanga (Syzygium aromaticum) and maricha (Piper nigrum) have been recommended to the healthy as well as COVID-19 infected person, as it provides support in the humoral and cell mediated responses and also lowers the air way hyper responsiveness and nasal congestions (Carrasco et al., 2009; Kim et al., 2009; Bui et al., 2019).", [["cell", "ANATOMY", 227, 231], ["nasal", "ANATOMY", 304, 309], ["sunthi", "CHEMICAL", 17, 23], ["nasal congestions", "DISEASE", 304, 321], ["Zingiber officinaleRoscoe.", "ORGANISM", 25, 51], ["lavanga (", "ORGANISM", 54, 63], ["Syzygium aromaticum", "ORGANISM", 63, 82], ["maricha", "ORGANISM", 88, 95], ["Piper nigrum", "ORGANISM", 97, 109], ["COVID-19", "CELL", 159, 167], ["person", "ORGANISM", 177, 183], ["cell", "CELL", 227, 231], ["nasal", "ORGANISM_SUBDIVISION", 304, 309], ["Zingiber officinaleRoscoe", "SPECIES", 25, 50], ["lavanga", "SPECIES", 54, 61], ["Syzygium aromaticum", "SPECIES", 63, 82], ["maricha", "SPECIES", 88, 95], ["Piper nigrum", "SPECIES", 97, 109], ["person", "SPECIES", 177, 183], ["Zingiber officinaleRoscoe", "SPECIES", 25, 50], ["Syzygium aromaticum", "SPECIES", 63, 82], ["Piper nigrum", "SPECIES", 97, 109], ["sunthi (Zingiber officinaleRoscoe", "TREATMENT", 17, 50], ["lavanga (Syzygium aromaticum", "TREATMENT", 54, 82], ["maricha (Piper nigrum", "TREATMENT", 88, 109], ["the air way hyper responsiveness", "PROBLEM", 267, 299], ["nasal congestions", "PROBLEM", 304, 321], ["nasal", "ANATOMY", 304, 309]]], ["Various ayurvedic products and fatty acids in the form of ghee are implicated in the up-regulation of resistance.", [["fatty acids", "CHEMICAL", 31, 42], ["fatty acids", "CHEMICAL", 31, 42], ["ayurvedic products", "SIMPLE_CHEMICAL", 8, 26], ["fatty acids", "SIMPLE_CHEMICAL", 31, 42], ["ghee", "ORGANISM_SUBSTANCE", 58, 62], ["Various ayurvedic products", "TREATMENT", 0, 26], ["fatty acids", "TEST", 31, 42], ["ayurvedic products", "OBSERVATION", 8, 26], ["fatty acids", "OBSERVATION", 31, 42], ["resistance", "OBSERVATION", 102, 112]]], ["The resistance is enhanced in a pleiotropic manner and the bioactive compounds participate in various procedures of adaptive as well as innate immune responses (Shukla et al., 2014).", [["resistance", "OBSERVATION_MODIFIER", 4, 14], ["enhanced", "OBSERVATION_MODIFIER", 18, 26], ["bioactive compounds", "OBSERVATION", 59, 78]]], ["Similarly, the bioactive constituent in Curcuma longa Linn. i.e. curumin, is identified to block cytokine release, specifically interleukin-1, interleukin-6, pro-inflammatory cytokines and tumor necrosis factor-\u03b1 and is directed to be consumed with milk (Omara et al., 2010).", [["milk", "ANATOMY", 249, 253], ["curumin", "CHEMICAL", 65, 72], ["tumor necrosis", "DISEASE", 189, 203], ["curumin", "CHEMICAL", 65, 72], ["Curcuma longa", "ORGANISM", 40, 53], ["Linn", "ORGANISM", 54, 58], ["curumin", "SIMPLE_CHEMICAL", 65, 72], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 128, 141], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 143, 156], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 189, 212], ["milk", "ORGANISM_SUBSTANCE", 249, 253], ["cytokine", "PROTEIN", 97, 105], ["interleukin-1", "PROTEIN", 128, 141], ["interleukin-6", "PROTEIN", 143, 156], ["pro-inflammatory cytokines", "PROTEIN", 158, 184], ["tumor necrosis factor-\u03b1", "PROTEIN", 189, 212], ["Curcuma longa", "SPECIES", 40, 53], ["Curcuma longa Linn", "SPECIES", 40, 58], ["block cytokine release", "TEST", 91, 113], ["interleukin", "TEST", 128, 139], ["interleukin", "TEST", 143, 154], ["pro-inflammatory cytokines", "TREATMENT", 158, 184], ["tumor necrosis factor", "PROBLEM", 189, 210], ["bioactive", "OBSERVATION_MODIFIER", 15, 24], ["constituent", "OBSERVATION_MODIFIER", 25, 36], ["Curcuma longa Linn", "OBSERVATION", 40, 58], ["tumor", "OBSERVATION_MODIFIER", 189, 194], ["necrosis", "OBSERVATION", 195, 203]]], ["Inhibition of the cytokine discharge is one of the prime clinical development associated with experimental modules of flu and other infectious diseases and have also been compared to COVID-19 where similar cytokine storm play an imperative role in transience (Sordillo et al., 2015).", [["flu", "DISEASE", 118, 121], ["infectious diseases", "DISEASE", 132, 151], ["COVID-19", "CELL", 183, 191], ["cytokine", "PROTEIN", 18, 26], ["cytokine", "PROTEIN", 206, 214], ["the cytokine discharge", "TREATMENT", 14, 36], ["flu", "PROBLEM", 118, 121], ["other infectious diseases", "PROBLEM", 126, 151], ["infectious", "OBSERVATION", 132, 142]]], ["Moreover, AYUSH has recommended certain preventive and medicinal plants for prevention and prophylactic of COVID-19 including warm extracts of Tinospora cordifolia (advised for chronic fever), Andrograhis paniculata (advised for fever and cold), Cydonia oblonga, Zizyphus jujube and Cordia myxa (enhancing antioxidant, immune-modulatory, anti-allergic, smooth muscle relaxant, anti-influenza activity) and Arsenicum album 30 (found effective against SARS-CoV-2, immune-modulator).", [["extracts", "ANATOMY", 131, 139], ["smooth muscle", "ANATOMY", 353, 366], ["AYUSH", "CHEMICAL", 10, 15], ["COVID-19", "CHEMICAL", 107, 115], ["Tinospora cordifolia", "CHEMICAL", 143, 163], ["chronic fever", "DISEASE", 177, 190], ["Andrograhis paniculata", "CHEMICAL", 193, 215], ["fever", "DISEASE", 229, 234], ["Arsenicum album 30", "CHEMICAL", 406, 424], ["COVID-19", "CHEMICAL", 107, 115], ["COVID-19", "SIMPLE_CHEMICAL", 107, 115], ["extracts", "ORGANISM_SUBSTANCE", 131, 139], ["Tinospora cordifolia", "ORGANISM", 143, 163], ["Andrograhis paniculata", "ORGANISM", 193, 215], ["Cydonia oblonga", "ORGANISM", 246, 261], ["Zizyphus jujube", "ORGANISM", 263, 278], ["Cordia myxa", "ORGANISM", 283, 294], ["smooth muscle", "TISSUE", 353, 366], ["Arsenicum album 30", "ORGANISM", 406, 424], ["SARS-CoV-2", "ORGANISM", 450, 460], ["Tinospora cordifolia", "SPECIES", 143, 163], ["Andrograhis paniculata", "SPECIES", 193, 215], ["Cydonia oblonga", "SPECIES", 246, 261], ["Zizyphus jujube", "SPECIES", 263, 278], ["Cordia myxa", "SPECIES", 283, 294], ["Arsenicum album", "SPECIES", 406, 421], ["Tinospora cordifolia", "SPECIES", 143, 163], ["Andrograhis paniculata", "SPECIES", 193, 215], ["Cydonia oblonga", "SPECIES", 246, 261], ["Zizyphus jujube", "SPECIES", 263, 278], ["Cordia myxa", "SPECIES", 283, 294], ["Arsenicum album 30", "SPECIES", 406, 424], ["SARS-CoV", "SPECIES", 450, 458], ["medicinal plants", "TREATMENT", 55, 71], ["prevention", "TREATMENT", 76, 86], ["prophylactic of COVID", "TREATMENT", 91, 112], ["warm extracts", "TREATMENT", 126, 139], ["Tinospora cordifolia", "TREATMENT", 143, 163], ["chronic fever", "PROBLEM", 177, 190], ["Andrograhis paniculata", "PROBLEM", 193, 215], ["fever", "PROBLEM", 229, 234], ["cold", "PROBLEM", 239, 243], ["Cydonia oblonga", "PROBLEM", 246, 261], ["Zizyphus jujube", "TREATMENT", 263, 278], ["immune-modulatory", "TREATMENT", 319, 336], ["anti-allergic", "TREATMENT", 338, 351], ["smooth muscle relaxant", "TREATMENT", 353, 375], ["anti-influenza activity", "TREATMENT", 377, 400], ["Arsenicum album", "TEST", 406, 421], ["SARS", "TEST", 450, 454], ["CoV", "TEST", 455, 458], ["immune-modulator", "TREATMENT", 462, 478], ["Tinospora cordifolia", "OBSERVATION", 143, 163]]], ["The symptomatic management of COVID-19 was suggested to be acquired from Agastya Haritaki (prevention of upper respiratory infections and Anuthaila (sesame oil drops) recommended to prevent respiratory infections (Vellingiri et al., 2020).Plant Based-Therapeutic Approaches against COVID-19 ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaTCM clinical trials and studies indicate the amelioration of symptoms of mild to moderate COVID-19 infections.", [["respiratory", "ANATOMY", 111, 122], ["oil", "ANATOMY", 156, 159], ["respiratory", "ANATOMY", 190, 201], ["COVID-19", "CHEMICAL", 30, 38], ["upper respiratory infections", "DISEASE", 105, 133], ["Anuthaila", "CHEMICAL", 138, 147], ["respiratory infections", "DISEASE", 190, 212], ["COVID", "DISEASE", 444, 449], ["infections", "DISEASE", 453, 463], ["COVID-19", "CHEMICAL", 30, 38], ["COVID", "TEST", 30, 35], ["Agastya Haritaki", "TREATMENT", 73, 89], ["upper respiratory infections", "PROBLEM", 105, 133], ["Anuthaila (sesame oil drops", "TREATMENT", 138, 165], ["respiratory infections", "PROBLEM", 190, 212], ["COVID", "TEST", 282, 287], ["AyurvedaTCM clinical trials", "TEST", 346, 373], ["studies", "TEST", 378, 385], ["symptoms", "PROBLEM", 415, 423], ["mild to moderate COVID-19 infections", "PROBLEM", 427, 463], ["symptomatic", "OBSERVATION_MODIFIER", 4, 15], ["upper", "ANATOMY_MODIFIER", 105, 110], ["respiratory", "ANATOMY", 111, 122], ["infections", "OBSERVATION", 123, 133], ["respiratory", "ANATOMY", 190, 201], ["infections", "OBSERVATION", 202, 212], ["mild", "OBSERVATION_MODIFIER", 427, 431], ["moderate", "OBSERVATION_MODIFIER", 435, 443], ["infections", "OBSERVATION", 453, 463]]], ["The seriously infected patients tormented from hypoxia, were competent to ease the symptoms including high fever, breathing problems and coughing (Toots et al., 2019).", [["hypoxia", "DISEASE", 47, 54], ["fever", "DISEASE", 107, 112], ["breathing problems", "DISEASE", 114, 132], ["coughing", "DISEASE", 137, 145], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["hypoxia", "PROBLEM", 47, 54], ["the symptoms", "PROBLEM", 79, 91], ["high fever", "PROBLEM", 102, 112], ["breathing problems", "PROBLEM", 114, 132], ["coughing", "PROBLEM", 137, 145], ["seriously", "OBSERVATION_MODIFIER", 4, 13], ["infected", "OBSERVATION_MODIFIER", 14, 22], ["hypoxia", "OBSERVATION", 47, 54]]], ["Furthermore, a report by Song et al. (2019) revealed the bioactive potential of extracts Sanctellaria baicalensis containing baicalin which is considered as one of the prime TCM herbal constituent as well as hesperetin a bioactive constituent present in tangerine peel, have been employed in curing the symptoms associated with COVID-19 (Panda et al., 2020).", [["extracts", "ANATOMY", 80, 88], ["peel", "ANATOMY", 264, 268], ["Sanctellaria baicalensis", "CHEMICAL", 89, 113], ["baicalin", "CHEMICAL", 125, 133], ["hesperetin", "CHEMICAL", 208, 218], ["COVID-19", "CHEMICAL", 328, 336], ["baicalin", "CHEMICAL", 125, 133], ["hesperetin", "CHEMICAL", 208, 218], ["COVID-19", "CHEMICAL", 328, 336], ["extracts", "ORGANISM_SUBSTANCE", 80, 88], ["Sanctellaria baicalensis", "ORGANISM", 89, 113], ["baicalin", "SIMPLE_CHEMICAL", 125, 133], ["hesperetin", "SIMPLE_CHEMICAL", 208, 218], ["tangerine", "ORGANISM", 254, 263], ["peel", "TISSUE", 264, 268], ["Sanctellaria baicalensis", "SPECIES", 89, 113], ["Sanctellaria baicalensis", "SPECIES", 89, 113], ["extracts Sanctellaria baicalensis", "TREATMENT", 80, 113], ["baicalin", "TREATMENT", 125, 133], ["the symptoms", "PROBLEM", 299, 311], ["Sanctellaria baicalensis", "OBSERVATION", 89, 113]]], ["Another TCM medicine viz.", [["Another TCM medicine", "TREATMENT", 0, 20]]], ["Xuebijing Injections has been widely affirmed to lower the hazards of community-transmission of pneumonia as well as it reduces the time required for ventilating a severe patient (Song et al., 2019).Plant Based-Therapeutic Approaches against COVID-19 ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaOne of the commonly accepted traditional Chinese medicines is Kombucha, which is a concoction prepared from the culture of Acetobacter and yeast.", [["Xuebijing", "CHEMICAL", 0, 9], ["pneumonia", "DISEASE", 96, 105], ["AyurvedaOne", "CHEMICAL", 306, 317], ["Kombucha", "CHEMICAL", 376, 384], ["COVID-19", "CHEMICAL", 242, 250], ["patient", "ORGANISM", 171, 178], ["Kombucha", "SIMPLE_CHEMICAL", 376, 384], ["Acetobacter", "SIMPLE_CHEMICAL", 437, 448], ["patient", "SPECIES", 171, 178], ["yeast", "SPECIES", 453, 458], ["yeast", "SPECIES", 453, 458], ["Xuebijing Injections", "TREATMENT", 0, 20], ["pneumonia", "PROBLEM", 96, 105], ["COVID", "TEST", 242, 247], ["AyurvedaOne", "TREATMENT", 306, 317], ["traditional Chinese medicines", "TREATMENT", 343, 372], ["a concoction", "PROBLEM", 395, 407], ["the culture", "TEST", 422, 433], ["Acetobacter", "PROBLEM", 437, 448], ["yeast", "PROBLEM", 453, 458], ["pneumonia", "OBSERVATION", 96, 105], ["severe", "OBSERVATION_MODIFIER", 164, 170]]], ["This concoction is prepared in black tea and Chinese herbal extract comprised of liquorice, green tea, chrysanthemum and Grosvenor momordia, which acts as an effective probiotic (Greenwatt et al., 2000).", [["extract", "ANATOMY", 60, 67], ["liquorice, green tea", "CHEMICAL", 81, 101], ["chrysanthemum", "CHEMICAL", 103, 116], ["tea", "ORGANISM_SUBDIVISION", 37, 40], ["liquorice", "SIMPLE_CHEMICAL", 81, 90], ["green tea", "ORGANISM", 92, 101], ["chrysanthemum", "SIMPLE_CHEMICAL", 103, 116], ["Grosvenor momordia", "ORGANISM", 121, 139], ["tea", "SPECIES", 98, 101], ["black tea", "SPECIES", 31, 40], ["green tea", "SPECIES", 92, 101], ["black tea", "TREATMENT", 31, 40], ["Chinese herbal extract", "TREATMENT", 45, 67]]], ["Similar extract has been employed in treatment of foot and mouth disease virus.", [["extract", "ANATOMY", 8, 15], ["foot", "ANATOMY", 50, 54], ["foot and mouth disease", "DISEASE", 50, 72], ["foot and mouth disease virus", "ORGANISM", 50, 78], ["foot and mouth disease virus", "SPECIES", 50, 78], ["foot and mouth disease virus", "PROBLEM", 50, 78], ["foot", "ANATOMY", 50, 54], ["mouth", "ANATOMY", 59, 64], ["disease", "OBSERVATION", 65, 72]]], ["Moreover, their exist a wide array of reports suggesting utilization of herbal extracts in TCM such as extracts prepared from Azadirachta indica (Kumar and Navaratnam, 2013; Gupta et al., 2017), Camellia sinensis (Song et al., 2005; Kuzuhara et al., 2009; Li et al., 2015), Ocimum sanctum and Agremone mexicana (Varshney et al., 2013), Zingiber officinale (Shah and Krishnamurthy, 2013), Tinospora cordifolia (Shah and Krishnamurthy, 2013), Alium sativum (Kim et al., 2005; Wang et al., 2006) and Ocimum basilicum (Kubi\u00e7a et al., 2014) etc. for their antimicrobial potential.", [["extracts", "ANATOMY", 79, 87], ["extracts", "ANATOMY", 103, 111], ["TCM", "CHEMICAL", 91, 94], ["extracts", "ORGANISM_SUBSTANCE", 103, 111], ["Azadirachta indica", "ORGANISM", 126, 144], ["Camellia sinensis", "ORGANISM", 195, 212], ["Ocimum sanctum", "ORGANISM", 274, 288], ["Agremone mexicana", "ORGANISM", 293, 310], ["Zingiber officinale", "ORGANISM", 336, 355], ["Tinospora cordifolia", "ORGANISM", 388, 408], ["Alium sativum", "ORGANISM", 441, 454], ["Ocimum basilicum", "ORGANISM", 497, 513], ["Azadirachta indica", "SPECIES", 126, 144], ["Camellia sinensis", "SPECIES", 195, 212], ["Ocimum sanctum", "SPECIES", 274, 288], ["Agremone mexicana", "SPECIES", 293, 310], ["Zingiber officinale", "SPECIES", 336, 355], ["Tinospora cordifolia", "SPECIES", 388, 408], ["Alium sativum", "SPECIES", 441, 454], ["Ocimum basilicum", "SPECIES", 497, 513], ["Azadirachta indica", "SPECIES", 126, 144], ["Camellia sinensis", "SPECIES", 195, 212], ["Ocimum sanctum", "SPECIES", 274, 288], ["Agremone mexicana", "SPECIES", 293, 310], ["Zingiber officinale", "SPECIES", 336, 355], ["Tinospora cordifolia", "SPECIES", 388, 408], ["Alium sativum", "SPECIES", 441, 454], ["Ocimum basilicum", "SPECIES", 497, 513], ["herbal extracts", "PROBLEM", 72, 87], ["Tinospora cordifolia", "TREATMENT", 388, 408], ["herbal extracts", "OBSERVATION", 72, 87], ["antimicrobial potential", "OBSERVATION_MODIFIER", 551, 574]]], ["A corroborative suggestion was made by Su et al. (2020), that traditional Chinese herb i.e. Exocarpium Citri grandis was found to be effective in preventing and treating COVID-19 pandemic.", [["Exocarpium Citri grandis", "CHEMICAL", 92, 116], ["Exocarpium Citri grandis", "ORGANISM", 92, 116], ["Exocarpium Citri grandis", "SPECIES", 92, 116], ["Exocarpium Citri grandis", "SPECIES", 92, 116], ["traditional Chinese herb", "TREATMENT", 62, 86], ["Exocarpium Citri grandis", "TREATMENT", 92, 116], ["COVID", "TEST", 170, 175], ["pandemic", "PROBLEM", 179, 187]]], ["A novel approach to TCM is combination therapy in which the old traditional practices are mixed together to develop an effective formulation for treating various diseases.", [["TCM", "CHEMICAL", 20, 23], ["A novel approach", "TREATMENT", 0, 16], ["TCM", "TREATMENT", 20, 23], ["combination therapy", "TREATMENT", 27, 46], ["an effective formulation", "TREATMENT", 116, 140], ["various diseases", "PROBLEM", 154, 170]]], ["Combination treatment has been employed in suppression of viral hepatisis.", [["Combination treatment", "TREATMENT", 0, 21], ["viral hepatisis", "PROBLEM", 58, 73], ["viral hepatisis", "OBSERVATION", 58, 73]]], ["Also liquid fermented broth of Ganoderma lucidum in combination with extract of Radix Sophorae flavescentis, was affirmed to be effective against hepatitis B virus.", [["extract", "ANATOMY", 69, 76], ["Ganoderma lucidum", "CHEMICAL", 31, 48], ["extract of Radix Sophorae flavescentis", "CHEMICAL", 69, 107], ["hepatitis B", "DISEASE", 146, 157], ["Ganoderma lucidum", "ORGANISM", 31, 48], ["Radix Sophorae flavescentis", "ORGANISM", 80, 107], ["hepatitis B virus", "ORGANISM", 146, 163], ["Ganoderma lucidum", "SPECIES", 31, 48], ["Radix Sophorae flavescentis", "SPECIES", 80, 107], ["hepatitis B virus", "SPECIES", 146, 163], ["Ganoderma lucidum", "SPECIES", 31, 48], ["Radix Sophorae flavescentis", "SPECIES", 80, 107], ["hepatitis B virus", "SPECIES", 146, 163], ["Ganoderma lucidum", "TREATMENT", 31, 48], ["Radix Sophorae flavescentis", "TREATMENT", 80, 107], ["hepatitis B virus", "PROBLEM", 146, 163], ["Ganoderma lucidum", "OBSERVATION_MODIFIER", 31, 48]]], ["Another vital example is glycyrrhizin a bioactive compound isolated from Lycoris radiata shows a strong potential against anti-SARS-CoV activity (Li et al,.", [["glycyrrhizin", "CHEMICAL", 25, 37], ["glycyrrhizin", "CHEMICAL", 25, 37], ["glycyrrhizin", "SIMPLE_CHEMICAL", 25, 37], ["Lycoris radiata", "ORGANISM", 73, 88], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 122, 135], ["Lycoris radiata", "SPECIES", 73, 88], ["Lycoris radiata", "SPECIES", 73, 88], ["anti-SARS-CoV", "SPECIES", 122, 135], ["glycyrrhizin", "TREATMENT", 25, 37], ["Lycoris radiata", "TREATMENT", 73, 88]]], ["2005 a,b).Terpenoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaThe triterpenes are composed of 6 isoprene units and with squalene as a prototype and are diversely occurrence in plant species (Petr et al., 2006).", [["squalene", "CHEMICAL", 197, 205], ["Terpenoids", "CHEMICAL", 10, 20], ["triterpenes", "CHEMICAL", 143, 154], ["isoprene", "CHEMICAL", 173, 181], ["squalene", "CHEMICAL", 197, 205], ["Terpenoids", "SIMPLE_CHEMICAL", 10, 20], ["COVID-19 Virus", "ORGANISM", 61, 75], ["triterpenes", "SIMPLE_CHEMICAL", 143, 154], ["squalene", "SIMPLE_CHEMICAL", 197, 205], ["Secondary Plant Metabolites", "TEST", 25, 52], ["COVID", "TEST", 61, 66], ["Ayurveda", "TREATMENT", 131, 139], ["The triterpenes", "TREATMENT", 139, 154], ["6 isoprene units", "TREATMENT", 171, 187], ["squalene", "TREATMENT", 197, 205], ["plant species", "OBSERVATION", 253, 266]]], ["They play a vital role in modulation of cellular metabolism, specifically the biosynthesis of sterols and have a significant level of antiviral activity (Malinowska et al., 2013).", [["cellular", "ANATOMY", 40, 48], ["sterols", "CHEMICAL", 94, 101], ["cellular", "CELL", 40, 48], ["sterols", "SIMPLE_CHEMICAL", 94, 101], ["cellular metabolism", "PROBLEM", 40, 59], ["the biosynthesis of sterols", "TREATMENT", 74, 101], ["cellular metabolism", "OBSERVATION", 40, 59], ["antiviral activity", "OBSERVATION", 134, 152]]], ["Various triterpenes have been reported to have effect against HSV1 and HSV2 these include dammaradienol, dammarenediol-II, dammarenolic acid, hydroxyhopanone, hydroxydammarenone-I, shoreic acid, ursonic acid, hydroxyoleanonic lactone and eichlerianic acid (Poehland et al., 1987).", [["dammaradienol", "CHEMICAL", 90, 103], ["dammarenediol-II, dammarenolic acid", "CHEMICAL", 105, 140], ["hydroxyhopanone", "CHEMICAL", 142, 157], ["hydroxydammarenone-I, shoreic acid, ursonic acid", "CHEMICAL", 159, 207], ["hydroxyoleanonic lactone", "CHEMICAL", 209, 233], ["eichlerianic acid", "CHEMICAL", 238, 255], ["triterpenes", "CHEMICAL", 8, 19], ["dammaradienol", "CHEMICAL", 90, 103], ["dammarenediol-II", "CHEMICAL", 105, 121], ["dammarenolic acid", "CHEMICAL", 123, 140], ["hydroxyhopanone", "CHEMICAL", 142, 157], ["hydroxydammarenone-I", "CHEMICAL", 159, 179], ["shoreic acid", "CHEMICAL", 181, 193], ["ursonic acid", "CHEMICAL", 195, 207], ["hydroxyoleanonic lactone", "CHEMICAL", 209, 233], ["eichlerianic acid", "CHEMICAL", 238, 255], ["triterpenes", "SIMPLE_CHEMICAL", 8, 19], ["HSV1", "ORGANISM", 62, 66], ["HSV2", "SIMPLE_CHEMICAL", 71, 75], ["dammaradienol", "SIMPLE_CHEMICAL", 90, 103], ["dammarenediol-II", "SIMPLE_CHEMICAL", 105, 121], ["dammarenolic acid", "SIMPLE_CHEMICAL", 123, 140], ["hydroxyhopanone", "SIMPLE_CHEMICAL", 142, 157], ["hydroxydammarenone-I", "SIMPLE_CHEMICAL", 159, 179], ["shoreic acid", "SIMPLE_CHEMICAL", 181, 193], ["ursonic acid", "SIMPLE_CHEMICAL", 195, 207], ["hydroxyoleanonic lactone", "SIMPLE_CHEMICAL", 209, 233], ["eichlerianic acid", "SIMPLE_CHEMICAL", 238, 255], ["HSV1", "SPECIES", 62, 66], ["HSV2", "SPECIES", 71, 75], ["Various triterpenes", "TREATMENT", 0, 19], ["HSV1", "PROBLEM", 62, 66], ["HSV2", "PROBLEM", 71, 75], ["dammaradienol", "TREATMENT", 90, 103], ["dammarenediol", "TREATMENT", 105, 118], ["dammarenolic acid", "TREATMENT", 123, 140], ["hydroxyhopanone", "TREATMENT", 142, 157], ["hydroxydammarenone", "TREATMENT", 159, 177], ["shoreic acid", "TREATMENT", 181, 193], ["ursonic acid", "TREATMENT", 195, 207], ["hydroxyoleanonic lactone", "TREATMENT", 209, 233], ["eichlerianic acid", "TREATMENT", 238, 255], ["triterpenes", "OBSERVATION", 8, 19]]], ["Structurally coronavirus is composed of single stranded RNA, reported to be one of the longest RNA virus.", [["single stranded RNA", "RNA", 40, 59], ["Structurally coronavirus", "PROBLEM", 0, 24], ["single stranded RNA", "PROBLEM", 40, 59], ["the longest RNA virus", "PROBLEM", 83, 104], ["coronavirus", "OBSERVATION", 13, 24], ["stranded RNA", "OBSERVATION", 47, 59]]], ["This RNA strand acts as an RNA messenger, when it transmits into a cell it stimulates the synthesis of two polyproteins which are further composed of a novel replication and transmission complexes that regulate the synthesis of RNA, structural proteins and enhance the activity of protease enzyme.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["protease enzyme", "GENE_OR_GENE_PRODUCT", 281, 296], ["RNA strand", "RNA", 5, 15], ["RNA messenger", "RNA", 27, 40], ["novel replication and transmission complexes", "PROTEIN", 152, 196], ["RNA", "RNA", 228, 231], ["structural proteins", "PROTEIN", 233, 252], ["protease enzyme", "PROTEIN", 281, 296], ["two polyproteins", "PROBLEM", 103, 119], ["a novel replication and transmission complexes", "PROBLEM", 150, 196], ["the synthesis of RNA", "PROBLEM", 211, 231], ["structural proteins", "PROBLEM", 233, 252], ["protease enzyme", "TEST", 281, 296]]], ["Here protease enzyme has a significant participation in fragmentation of the polyprotein (Cui et al., 2019, John et al., 2015).", [["protease enzyme", "PROTEIN", 5, 20], ["protease enzyme", "TEST", 5, 20], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["fragmentation", "OBSERVATION", 56, 69]]], ["Apart from designing and chemical synthesizing of protease inhibitor, one of the most recent therapeutic strategies to cure viral infection is to identify the inhibitors of these enzymes in natural products and compounds.", [["viral infection", "DISEASE", 124, 139], ["enzymes", "PROTEIN", 179, 186], ["chemical synthesizing of protease inhibitor", "TREATMENT", 25, 68], ["cure viral infection", "PROBLEM", 119, 139], ["these enzymes", "TEST", 173, 186]]], ["Amongst these, terpenoids have a specific significance due to fact of diverse availability in plants and microorganism and low inhibitory concentration i.e. IC50.", [["terpenoids", "CHEMICAL", 15, 25], ["microorganism", "TREATMENT", 105, 118], ["low inhibitory concentration", "TREATMENT", 123, 151]]], ["The terpenoids are the chief secondary metabolites present in more than 36,000 species accounted so far (Augustin et al., 2011).", [["terpenoids", "CHEMICAL", 4, 14], ["terpenoids", "OBSERVATION_MODIFIER", 4, 14]]], ["These secondary metabolites have multifaceted therapeutic application viz. anti-cancerous (Topcu et al., 2007), anti-inflammatory and antiviral (Nosrati and Behbahani et al., 2015), antioxidant (del Cerman et al., 1995) and antibacterial (Angeh et al., 2007).Terpenoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaIn a recent report by Shaghaghi (2020) the structure of terpinoid constituents and COVID-19 protease was elucidated from the different databases such as PubChem and Protein Data Bank (PDB).", [["Terpenoids", "CHEMICAL", 259, 269], ["terpinoid", "CHEMICAL", 444, 453], ["Nosrati", "SIMPLE_CHEMICAL", 145, 152], ["Terpenoids", "SIMPLE_CHEMICAL", 259, 269], ["COVID-19 Virus", "ORGANISM", 310, 324], ["terpinoid constituents", "SIMPLE_CHEMICAL", 444, 466], ["COVID-19 protease", "GENE_OR_GENE_PRODUCT", 471, 488], ["COVID-19 protease", "PROTEIN", 471, 488], ["multifaceted therapeutic application viz", "TREATMENT", 33, 73], ["anti-inflammatory", "TREATMENT", 112, 129], ["antibacterial", "TREATMENT", 224, 237], ["Secondary Plant Metabolites", "TEST", 274, 301], ["COVID", "TEST", 310, 315], ["terpinoid constituents", "PROBLEM", 444, 466], ["COVID", "TEST", 471, 476], ["protease", "TREATMENT", 480, 488], ["multifaceted", "OBSERVATION_MODIFIER", 33, 45], ["therapeutic", "OBSERVATION_MODIFIER", 46, 57]]], ["Followed by this, the sophisticated technique of molecular docking was utilized by employing MVD (molegro virtual docker) software.", [["molecular docking", "TREATMENT", 49, 66]]], ["9 and different terpenes were analyzed for their inhibitory effects.", [["terpenes", "CHEMICAL", 16, 24], ["terpenes", "SIMPLE_CHEMICAL", 16, 24], ["different terpenes", "TREATMENT", 6, 24]]], ["These included thymoquinone extracted from Nigella sativa.", [["thymoquinone", "CHEMICAL", 15, 27], ["thymoquinone", "CHEMICAL", 15, 27], ["thymoquinone", "SIMPLE_CHEMICAL", 15, 27], ["Nigella sativa", "ORGANISM", 43, 57], ["Nigella sativa", "SPECIES", 43, 57], ["Nigella sativa", "SPECIES", 43, 57], ["thymoquinone", "TREATMENT", 15, 27], ["Nigella sativa", "PROBLEM", 43, 57], ["Nigella sativa", "OBSERVATION", 43, 57]]], ["Molecular dynamic simulations have also shown that thymoquinone can interact with the attachment of SARS-CoV-2 to the HSPA5 substrate-binding domain b (SBDb) to stress cells and thus reduce the possibility of infection (Elfiky, 2020).", [["stress cells", "ANATOMY", 161, 173], ["thymoquinone", "CHEMICAL", 51, 63], ["infection", "DISEASE", 209, 218], ["thymoquinone", "CHEMICAL", 51, 63], ["thymoquinone", "SIMPLE_CHEMICAL", 51, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["HSPA5 substrate-binding domain b", "GENE_OR_GENE_PRODUCT", 118, 150], ["cells", "CELL", 168, 173], ["HSPA5 substrate-binding domain b", "PROTEIN", 118, 150], ["SBDb", "PROTEIN", 152, 156], ["stress cells", "CELL_TYPE", 161, 173], ["Molecular dynamic simulations", "TEST", 0, 29], ["thymoquinone", "TREATMENT", 51, 63], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["the HSPA5 substrate", "TEST", 114, 133], ["stress cells", "PROBLEM", 161, 173], ["infection", "PROBLEM", 209, 218], ["infection", "OBSERVATION", 209, 218]]], ["Nevertheless, it is potentially time to switch thymoquinone from experiments on the bench to clinical trials for the Covid-19 pandemic (Ahmad et al., 2020).", [["thymoquinone", "CHEMICAL", 47, 59], ["thymoquinone", "CHEMICAL", 47, 59], ["thymoquinone", "SIMPLE_CHEMICAL", 47, 59], ["thymoquinone", "TREATMENT", 47, 59]]], ["Salvinorin A derived from Salvia divinorum, Bilobalide and Ginkgolide A extracted from Gingko biloba, citral from Backhousia citriodora, menthol from Mentha, Noscapine extracted from Papaveraceae family, Forscolin from Plectranthus barbatus and Beta Selinene from Apium graveolens.", [["Salvinorin A", "CHEMICAL", 0, 12], ["Bilobalide", "CHEMICAL", 44, 54], ["Ginkgolide A", "CHEMICAL", 59, 71], ["Gingko biloba", "CHEMICAL", 87, 100], ["citral", "CHEMICAL", 102, 108], ["menthol", "CHEMICAL", 137, 144], ["Noscapine", "CHEMICAL", 158, 167], ["Forscolin", "CHEMICAL", 204, 213], ["Apium graveolens", "CHEMICAL", 264, 280], ["Salvinorin A", "CHEMICAL", 0, 12], ["Ginkgolide A", "CHEMICAL", 59, 71], ["citral", "CHEMICAL", 102, 108], ["menthol", "CHEMICAL", 137, 144], ["Salvinorin A", "SIMPLE_CHEMICAL", 0, 12], ["Salvia divinorum", "ORGANISM", 26, 42], ["Bilobalide", "SIMPLE_CHEMICAL", 44, 54], ["Ginkgolide A", "SIMPLE_CHEMICAL", 59, 71], ["Gingko biloba", "ORGANISM", 87, 100], ["citral", "SIMPLE_CHEMICAL", 102, 108], ["Backhousia citriodora", "ORGANISM", 114, 135], ["menthol", "SIMPLE_CHEMICAL", 137, 144], ["Noscapine", "SIMPLE_CHEMICAL", 158, 167], ["Papaveraceae", "ORGANISM", 183, 195], ["Forscolin", "SIMPLE_CHEMICAL", 204, 213], ["Plectranthus barbatus", "ORGANISM", 219, 240], ["Beta Selinene", "SIMPLE_CHEMICAL", 245, 258], ["Apium graveolens", "ORGANISM", 264, 280], ["Salvia divinorum", "SPECIES", 26, 42], ["Gingko biloba", "SPECIES", 87, 100], ["Backhousia citriodora", "SPECIES", 114, 135], ["Plectranthus barbatus", "SPECIES", 219, 240], ["Apium graveolens", "SPECIES", 264, 280], ["Salvia divinorum", "SPECIES", 26, 42], ["Gingko biloba", "SPECIES", 87, 100], ["Backhousia citriodora", "SPECIES", 114, 135], ["Plectranthus barbatus", "SPECIES", 219, 240], ["Apium graveolens", "SPECIES", 264, 280], ["Salvinorin", "TREATMENT", 0, 10], ["Salvia divinorum", "TREATMENT", 26, 42], ["Bilobalide", "TREATMENT", 44, 54], ["Ginkgolide", "TREATMENT", 59, 69], ["Gingko biloba", "TREATMENT", 87, 100], ["citral", "TREATMENT", 102, 108], ["Noscapine", "TREATMENT", 158, 167], ["Forscolin", "TREATMENT", 204, 213], ["Plectranthus barbatus", "TREATMENT", 219, 240]]], ["The fallout of this experiment illustrated the strapping interactions of terpenoids in the two enzymatically secluded regions.", [["terpenoids", "CHEMICAL", 73, 83], ["terpenoids", "TREATMENT", 73, 83], ["fallout", "OBSERVATION", 4, 11], ["terpenoids", "OBSERVATION_MODIFIER", 73, 83], ["enzymatically", "OBSERVATION_MODIFIER", 95, 108], ["secluded", "OBSERVATION", 109, 117]]], ["The fastening of varied amino acids as they were present in the secluded regions of the active site in all the 9 compounds was observed and plays a significant function in enzymatic catalysis.", [["amino acids", "CHEMICAL", 24, 35], ["amino acids", "CHEMICAL", 24, 35], ["amino acids", "AMINO_ACID", 24, 35], ["varied amino acids", "TREATMENT", 17, 35], ["enzymatic catalysis", "TREATMENT", 172, 191], ["active", "OBSERVATION_MODIFIER", 88, 94], ["site", "OBSERVATION_MODIFIER", 95, 99], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["enzymatic catalysis", "OBSERVATION", 172, 191]]], ["It was further revealed in the study that terpenoids were able to successfully suppress the virus protease enzyme activity.", [["terpenoids", "CHEMICAL", 42, 52], ["terpenoids", "SIMPLE_CHEMICAL", 42, 52], ["virus protease enzyme", "PROTEIN", 92, 113], ["the study", "TEST", 27, 36], ["terpenoids", "TREATMENT", 42, 52], ["the virus protease enzyme activity", "TREATMENT", 88, 122]]], ["Another report by Chowdhary et al. (2003), suggested antiretroviral and anticancer activities of Betulinic acid a pentacyclic triterpenoid which was extracted from the bark of white Betula alba var. pubescens tree.", [["anticancer", "ANATOMY", 72, 82], ["bark", "ANATOMY", 168, 172], ["Betulinic acid", "CHEMICAL", 97, 111], ["pentacyclic triterpenoid", "CHEMICAL", 114, 138], ["Betulinic acid", "CHEMICAL", 97, 111], ["pentacyclic triterpenoid", "CHEMICAL", 114, 138], ["anticancer", "CANCER", 72, 82], ["Betulinic acid", "SIMPLE_CHEMICAL", 97, 111], ["pentacyclic triterpenoid", "SIMPLE_CHEMICAL", 114, 138], ["bark", "ORGANISM_SUBDIVISION", 168, 172], ["white", "ORGANISM", 176, 181], ["Betula alba", "ORGANISM", 182, 193], ["pubescens tree", "ORGANISM", 199, 213], ["Betula alba", "SPECIES", 182, 193], ["pubescens", "SPECIES", 199, 208], ["Betula alba var", "SPECIES", 182, 197], ["pubescens", "SPECIES", 199, 208], ["antiretroviral and anticancer activities", "TREATMENT", 53, 93], ["Betulinic acid a pentacyclic triterpenoid", "TREATMENT", 97, 138], ["pentacyclic triterpenoid", "OBSERVATION", 114, 138], ["tree", "ANATOMY_MODIFIER", 209, 213]]], ["The betulinic acid was observed to cause apoptosis by modulation of mitogen activated protein kinases (MAPK) cascade and subsequently resulted in activation of caspase enzyme, changes in mitochondrial membrane and DNA fragmentation (Thurnher et al., 2003).Polyphenols/Flavonoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaAmongst many groups of substances polyphenols display a wide range of biological activities.", [["mitochondrial membrane", "ANATOMY", 187, 209], ["betulinic acid", "CHEMICAL", 4, 18], ["betulinic acid", "CHEMICAL", 4, 18], ["Polyphenols", "CHEMICAL", 256, 267], ["Flavonoids", "CHEMICAL", 268, 278], ["polyphenols", "CHEMICAL", 431, 442], ["betulinic acid", "SIMPLE_CHEMICAL", 4, 18], ["mitogen activated protein kinases", "GENE_OR_GENE_PRODUCT", 68, 101], ["MAPK", "GENE_OR_GENE_PRODUCT", 103, 107], ["caspase enzyme", "GENE_OR_GENE_PRODUCT", 160, 174], ["mitochondrial membrane", "CELLULAR_COMPONENT", 187, 209], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["Polyphenols", "SIMPLE_CHEMICAL", 256, 267], ["Flavonoids", "SIMPLE_CHEMICAL", 268, 278], ["COVID-19 Virus", "ORGANISM", 319, 333], ["polyphenols", "SIMPLE_CHEMICAL", 431, 442], ["mitogen activated protein kinases", "PROTEIN", 68, 101], ["MAPK", "PROTEIN", 103, 107], ["caspase enzyme", "PROTEIN", 160, 174], ["The betulinic acid", "TEST", 0, 18], ["apoptosis", "PROBLEM", 41, 50], ["mitogen activated protein kinases", "TREATMENT", 68, 101], ["caspase enzyme", "TEST", 160, 174], ["changes in mitochondrial membrane", "PROBLEM", 176, 209], ["DNA fragmentation", "PROBLEM", 214, 231], ["Polyphenols", "TREATMENT", 256, 267], ["Flavonoids", "TREATMENT", 268, 278], ["Secondary Plant Metabolites", "TEST", 283, 310], ["COVID", "TEST", 319, 324], ["AyurvedaAmongst", "TREATMENT", 389, 404], ["substances polyphenols", "TREATMENT", 420, 442], ["betulinic acid", "OBSERVATION", 4, 18], ["mitochondrial membrane", "OBSERVATION", 187, 209], ["DNA fragmentation", "OBSERVATION", 214, 231], ["Flavonoids", "OBSERVATION", 268, 278]]], ["Polyphenols are known to increase the immune to cells to foreign infestations and in response permits cellular accumulation of different types of polyphenols through varied receptors.", [["cells", "ANATOMY", 48, 53], ["cellular", "ANATOMY", 102, 110], ["Polyphenols", "CHEMICAL", 0, 11], ["Polyphenols", "CHEMICAL", 0, 11], ["polyphenols", "CHEMICAL", 146, 157], ["Polyphenols", "SIMPLE_CHEMICAL", 0, 11], ["cells", "CELL", 48, 53], ["cellular", "CELL", 102, 110], ["polyphenols", "SIMPLE_CHEMICAL", 146, 157], ["Polyphenols", "TREATMENT", 0, 11], ["foreign infestations", "PROBLEM", 57, 77], ["cellular accumulation", "PROBLEM", 102, 123], ["polyphenols through varied receptors", "TREATMENT", 146, 182], ["foreign infestations", "OBSERVATION", 57, 77], ["cellular accumulation", "OBSERVATION", 102, 123], ["different types", "OBSERVATION_MODIFIER", 127, 142]]], ["This subsequently triggers signaling pathways and initiate immune responses (Ding et al., 2018).", [["signaling pathways", "PROBLEM", 27, 45]]], ["The natural polyphenols were identified as potent COVID-19 protease (Mpro) inhibitors in an in-silico study conducted by Adem et al. (2020).", [["polyphenols", "CHEMICAL", 12, 23], ["polyphenols", "SIMPLE_CHEMICAL", 12, 23], ["COVID-19 protease", "GENE_OR_GENE_PRODUCT", 50, 67], ["Mpro", "SIMPLE_CHEMICAL", 69, 73], ["The natural polyphenols", "TREATMENT", 0, 23], ["potent COVID-19 protease (Mpro) inhibitors", "TREATMENT", 43, 85]]], ["In this study, efficiency of medicinal plants based on bioactive constituent's viz. flavonoids was analyzed against COVID-19 Mpro and was carried by using molecular docking technique.", [["flavonoids", "CHEMICAL", 84, 94], ["COVID-19 Mpro", "CHEMICAL", 116, 129], ["flavonoids", "CHEMICAL", 84, 94], ["flavonoids", "SIMPLE_CHEMICAL", 84, 94], ["COVID", "PROTEIN", 116, 121], ["this study", "TEST", 3, 13], ["medicinal plants", "TREATMENT", 29, 45], ["bioactive constituent's viz", "TREATMENT", 55, 82], ["flavonoids", "TREATMENT", 84, 94], ["COVID", "TEST", 116, 121], ["medicinal plants", "OBSERVATION", 29, 45]]], ["The COVID-19 virus was docked with 80 different flavonoids and the results indicated that compound such as rutin, apiin, hesperidin, diosmin and diacetylcurcumin etc. had an effective inhibitory effect on protease enzyme and they might have a role in lowering the symptoms of COVID-19 infection.Polyphenols/Flavonoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaAn imperative class of plant secondary metabolites is flavonoids with antiviral therapeutic potential with more than 5000 different compounds identified and described (Ververidis et al., 2007).", [["rutin", "CHEMICAL", 107, 112], ["apiin", "CHEMICAL", 114, 119], ["hesperidin", "CHEMICAL", 121, 131], ["diosmin", "CHEMICAL", 133, 140], ["diacetylcurcumin", "CHEMICAL", 145, 161], ["COVID-19", "CHEMICAL", 276, 284], ["infection", "DISEASE", 285, 294], ["flavonoids", "CHEMICAL", 490, 500], ["flavonoids", "CHEMICAL", 48, 58], ["rutin", "CHEMICAL", 107, 112], ["apiin", "CHEMICAL", 114, 119], ["hesperidin", "CHEMICAL", 121, 131], ["diosmin", "CHEMICAL", 133, 140], ["diacetylcurcumin", "CHEMICAL", 145, 161], ["Polyphenols", "CHEMICAL", 295, 306], ["Flavonoids", "CHEMICAL", 307, 317], ["flavonoids", "CHEMICAL", 490, 500], ["COVID-19 virus", "ORGANISM", 4, 18], ["flavonoids", "SIMPLE_CHEMICAL", 48, 58], ["rutin", "SIMPLE_CHEMICAL", 107, 112], ["apiin", "SIMPLE_CHEMICAL", 114, 119], ["hesperidin", "SIMPLE_CHEMICAL", 121, 131], ["diosmin", "SIMPLE_CHEMICAL", 133, 140], ["diacetylcurcumin", "SIMPLE_CHEMICAL", 145, 161], ["COVID-19", "GENE_OR_GENE_PRODUCT", 276, 284], ["Polyphenols", "SIMPLE_CHEMICAL", 295, 306], ["Flavonoids", "SIMPLE_CHEMICAL", 307, 317], ["COVID-19 Virus", "ORGANISM", 358, 372], ["flavonoids", "SIMPLE_CHEMICAL", 490, 500], ["protease enzyme", "PROTEIN", 205, 220], ["COVID-19 virus", "SPECIES", 4, 18], ["The COVID-19 virus", "TREATMENT", 0, 18], ["rutin", "TREATMENT", 107, 112], ["apiin", "TREATMENT", 114, 119], ["hesperidin", "TREATMENT", 121, 131], ["diosmin", "TREATMENT", 133, 140], ["diacetylcurcumin etc", "TREATMENT", 145, 165], ["protease enzyme", "TREATMENT", 205, 220], ["the symptoms", "PROBLEM", 260, 272], ["COVID-19 infection", "PROBLEM", 276, 294], ["Polyphenols", "TREATMENT", 295, 306], ["Flavonoids", "TREATMENT", 307, 317], ["Secondary Plant Metabolites", "TEST", 322, 349], ["COVID", "TEST", 358, 363], ["flavonoids", "PROBLEM", 490, 500], ["antiviral therapeutic potential", "TREATMENT", 506, 537], ["infection", "OBSERVATION", 285, 294], ["Flavonoids", "OBSERVATION", 307, 317], ["secondary metabolites", "OBSERVATION", 465, 486]]], ["These secondary metabolites are considered one of the most profusely present polyphenols in the human diet and are generally found as glycosides and acylglycosides in vegetables and fruits.", [["vegetables", "ANATOMY", 167, 177], ["fruits", "ANATOMY", 182, 188], ["acylglycosides", "CHEMICAL", 149, 163], ["polyphenols", "CHEMICAL", 77, 88], ["acylglycosides", "CHEMICAL", 149, 163], ["polyphenols", "SIMPLE_CHEMICAL", 77, 88], ["human", "ORGANISM", 96, 101], ["acylglycosides", "SIMPLE_CHEMICAL", 149, 163], ["vegetables", "ORGANISM_SUBDIVISION", 167, 177], ["fruits", "ORGANISM_SUBDIVISION", 182, 188], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["glycosides", "TREATMENT", 134, 144], ["acylglycosides", "TREATMENT", 149, 163], ["polyphenols", "OBSERVATION", 77, 88], ["human", "ANATOMY", 96, 101]]], ["There are wide array of flavonoids present naturally in plants including quercetin, naringin, hesperetin and catechin and they have been analyzed for their activity against plethora of animal viruses such as HSV-1, respiratory syncytial virus, parainfluenza virus type 3 and polio-virus type 1 (Kaul et al., 1985).", [["quercetin", "CHEMICAL", 73, 82], ["naringin", "CHEMICAL", 84, 92], ["hesperetin", "CHEMICAL", 94, 104], ["catechin", "CHEMICAL", 109, 117], ["respiratory syncytial virus", "DISEASE", 215, 242], ["parainfluenza virus", "DISEASE", 244, 263], ["flavonoids", "CHEMICAL", 24, 34], ["quercetin", "CHEMICAL", 73, 82], ["naringin", "CHEMICAL", 84, 92], ["hesperetin", "CHEMICAL", 94, 104], ["catechin", "CHEMICAL", 109, 117], ["flavonoids", "SIMPLE_CHEMICAL", 24, 34], ["quercetin", "SIMPLE_CHEMICAL", 73, 82], ["naringin", "SIMPLE_CHEMICAL", 84, 92], ["hesperetin", "SIMPLE_CHEMICAL", 94, 104], ["catechin", "SIMPLE_CHEMICAL", 109, 117], ["HSV-1", "ORGANISM", 208, 213], ["respiratory syncytial virus", "ORGANISM", 215, 242], ["parainfluenza virus type 3", "ORGANISM", 244, 270], ["polio-virus type 1", "ORGANISM", 275, 293], ["HSV-1", "SPECIES", 208, 213], ["respiratory syncytial virus", "SPECIES", 215, 242], ["parainfluenza virus type", "SPECIES", 244, 268], ["polio-virus", "SPECIES", 275, 286], ["HSV-1", "SPECIES", 208, 213], ["respiratory syncytial virus", "SPECIES", 215, 242], ["polio-virus type 1", "SPECIES", 275, 293], ["wide array of flavonoids", "PROBLEM", 10, 34], ["quercetin", "TREATMENT", 73, 82], ["naringin", "TREATMENT", 84, 92], ["hesperetin", "TREATMENT", 94, 104], ["catechin", "TREATMENT", 109, 117], ["animal viruses", "PROBLEM", 185, 199], ["HSV", "TEST", 208, 211], ["respiratory syncytial virus", "PROBLEM", 215, 242], ["parainfluenza virus type", "PROBLEM", 244, 268], ["polio-virus type", "PROBLEM", 275, 291], ["wide", "OBSERVATION_MODIFIER", 10, 14], ["array", "OBSERVATION_MODIFIER", 15, 20], ["flavonoids", "OBSERVATION", 24, 34], ["respiratory syncytial", "ANATOMY", 215, 236], ["parainfluenza virus", "OBSERVATION", 244, 263]]], ["The anti-viral activity of flavonoids was reported earlier, against Rous sarcoma, pseudorabies, adenoviruses and Sindbis (Chiang et al., 2003), and also against severe acute respiratory syndrome coronavirus (SARS-CoV) (Yi et al. 2004).", [["flavonoids", "CHEMICAL", 27, 37], ["Rous sarcoma", "DISEASE", 68, 80], ["pseudorabies, adenoviruses", "DISEASE", 82, 108], ["acute respiratory syndrome coronavirus", "DISEASE", 168, 206], ["SARS-CoV)", "DISEASE", 208, 217], ["flavonoids", "CHEMICAL", 27, 37], ["flavonoids", "SIMPLE_CHEMICAL", 27, 37], ["Rous sarcoma", "ORGANISM", 68, 80], ["pseudorabies", "ORGANISM", 82, 94], ["adenoviruses", "ORGANISM", 96, 108], ["Sindbis", "ORGANISM", 113, 120], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 161, 206], ["SARS-CoV", "ORGANISM", 208, 216], ["Rous", "SPECIES", 68, 72], ["pseudorabies", "SPECIES", 82, 94], ["Rous sarcoma", "SPECIES", 68, 80], ["pseudorabies", "SPECIES", 82, 94], ["severe acute respiratory syndrome coronavirus", "SPECIES", 161, 206], ["SARS-CoV", "SPECIES", 208, 216], ["The anti-viral activity of flavonoids", "TREATMENT", 0, 37], ["Rous sarcoma", "PROBLEM", 68, 80], ["pseudorabies", "PROBLEM", 82, 94], ["adenoviruses", "PROBLEM", 96, 108], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 161, 206], ["anti-viral activity", "OBSERVATION", 4, 23], ["sarcoma", "OBSERVATION", 73, 80], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory syndrome coronavirus", "OBSERVATION", 174, 206]]], ["The main mechanism by which they suppress the viral infection is by inhibition of cellular receptor kinases including MAPKs, the serine/threonine-specific protein kinase (Akt) and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K) and as consequence interferes with the cellular signal transduction cascades (Villa et al., 2017).Polyphenols/Flavonoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaGlycyrrhizin is the chief constituent of Glycyrrhiza glabra root and are rich in flavonoids, \u03b2-sitosterol, hydroxyl coumarins and glycyrrhetinic acid.", [["cellular", "ANATOMY", 82, 90], ["cellular", "ANATOMY", 278, 286], ["root", "ANATOMY", 538, 542], ["viral infection", "DISEASE", 46, 61], ["phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 184, 221], ["AyurvedaGlycyrrhizin", "CHEMICAL", 470, 490], ["\u03b2-sitosterol", "CHEMICAL", 571, 583], ["hydroxyl coumarins", "CHEMICAL", 585, 603], ["glycyrrhetinic acid", "CHEMICAL", 608, 627], ["serine", "CHEMICAL", 129, 135], ["threonine", "CHEMICAL", 136, 145], ["phosphatidylinositol-4,5-bisphosphate", "CHEMICAL", 184, 221], ["Polyphenols", "CHEMICAL", 337, 348], ["Flavonoids", "CHEMICAL", 349, 359], ["AyurvedaGlycyrrhizin", "CHEMICAL", 470, 490], ["flavonoids", "CHEMICAL", 559, 569], ["\u03b2-sitosterol", "CHEMICAL", 571, 583], ["hydroxyl coumarins", "CHEMICAL", 585, 603], ["glycyrrhetinic acid", "CHEMICAL", 608, 627], ["cellular", "CELL", 82, 90], ["MAPKs", "GENE_OR_GENE_PRODUCT", 118, 123], ["serine/threonine-specific protein kinase", "GENE_OR_GENE_PRODUCT", 129, 169], ["Akt", "GENE_OR_GENE_PRODUCT", 171, 174], ["phosphatidylinositol-4,5-bisphosphate 3-kinase", "GENE_OR_GENE_PRODUCT", 184, 230], ["PI3-K", "GENE_OR_GENE_PRODUCT", 232, 237], ["cellular", "CELL", 278, 286], ["Polyphenols", "SIMPLE_CHEMICAL", 337, 348], ["Flavonoids", "SIMPLE_CHEMICAL", 349, 359], ["COVID-19 Virus", "ORGANISM", 400, 414], ["AyurvedaGlycyrrhizin", "SIMPLE_CHEMICAL", 470, 490], ["Glycyrrhiza glabra", "ORGANISM", 519, 537], ["root", "ORGAN", 538, 542], ["flavonoids", "SIMPLE_CHEMICAL", 559, 569], ["\u03b2-sitosterol", "SIMPLE_CHEMICAL", 571, 583], ["hydroxyl coumarins", "SIMPLE_CHEMICAL", 585, 603], ["glycyrrhetinic acid", "SIMPLE_CHEMICAL", 608, 627], ["cellular receptor kinases", "PROTEIN", 82, 107], ["MAPKs", "PROTEIN", 118, 123], ["serine/threonine-specific protein kinase", "PROTEIN", 129, 169], ["Akt", "PROTEIN", 171, 174], ["phosphatidylinositol-4,5-bisphosphate 3-kinase", "PROTEIN", 184, 230], ["PI3-K", "PROTEIN", 232, 237], ["Glycyrrhiza glabra", "SPECIES", 519, 537], ["Glycyrrhiza glabra", "SPECIES", 519, 537], ["the viral infection", "PROBLEM", 42, 61], ["cellular receptor kinases", "TREATMENT", 82, 107], ["MAPKs", "TEST", 118, 123], ["the serine/threonine", "TEST", 125, 145], ["Akt", "TEST", 171, 174], ["the phosphatidylinositol", "TEST", 180, 204], ["bisphosphate", "TEST", 209, 221], ["Polyphenols", "TREATMENT", 337, 348], ["Flavonoids", "TREATMENT", 349, 359], ["Secondary Plant Metabolites", "TEST", 364, 391], ["COVID", "TEST", 400, 405], ["AyurvedaGlycyrrhizin", "TREATMENT", 470, 490], ["Glycyrrhiza glabra root", "TREATMENT", 519, 542], ["flavonoids", "TREATMENT", 559, 569], ["\u03b2-sitosterol", "TREATMENT", 571, 583], ["hydroxyl coumarins", "TREATMENT", 585, 603], ["glycyrrhetinic acid", "TREATMENT", 608, 627], ["main", "OBSERVATION_MODIFIER", 4, 8], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["Flavonoids", "OBSERVATION", 349, 359], ["Glycyrrhiza glabra root", "OBSERVATION", 519, 542]]], ["Glycyrrhizin, since the ancient times have been employed in treatment of various ailments including bronchitis, gastritis and jaundice.", [["Glycyrrhizin", "CHEMICAL", 0, 12], ["bronchitis", "DISEASE", 100, 110], ["gastritis", "DISEASE", 112, 121], ["jaundice", "DISEASE", 126, 134], ["Glycyrrhizin", "CHEMICAL", 0, 12], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 0, 12], ["Glycyrrhizin", "TREATMENT", 0, 12], ["various ailments", "PROBLEM", 73, 89], ["bronchitis", "PROBLEM", 100, 110], ["gastritis", "PROBLEM", 112, 121], ["jaundice", "PROBLEM", 126, 134], ["bronchitis", "OBSERVATION", 100, 110], ["gastritis", "OBSERVATION", 112, 121], ["jaundice", "OBSERVATION", 126, 134]]], ["Furthermore, they have been affirmed to have anti-inflammatory and antioxidant potential that induce the formation of interferons in human body (Ramos-Tovar and Muriel, 2019).", [["body", "ANATOMY", 139, 143], ["interferons", "GENE_OR_GENE_PRODUCT", 118, 129], ["human", "ORGANISM", 133, 138], ["body", "ORGANISM_SUBDIVISION", 139, 143], ["interferons", "PROTEIN", 118, 129], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["anti-inflammatory", "TREATMENT", 45, 62], ["interferons in human body", "TREATMENT", 118, 143]]], ["It was observed by Pilcher (2003) that Glycyrrhizin lowers the ability of SARS-Cov agents to attach to the cell particularly in the early stages of viral infestation.", [["cell", "ANATOMY", 107, 111], ["Glycyrrhizin", "CHEMICAL", 39, 51], ["viral infestation", "DISEASE", 148, 165], ["Glycyrrhizin", "CHEMICAL", 39, 51], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 39, 51], ["cell", "CELL", 107, 111], ["Glycyrrhizin", "TREATMENT", 39, 51], ["SARS", "PROBLEM", 74, 78], ["Cov agents", "TREATMENT", 79, 89], ["viral infestation", "PROBLEM", 148, 165], ["early stages", "OBSERVATION_MODIFIER", 132, 144], ["viral infestation", "OBSERVATION", 148, 165]]], ["Similar, observation of imperative anti-SARS-CoV activity as shown by Glycyrrhizin was made by Cinatl et al. (2003).", [["Glycyrrhizin", "CHEMICAL", 70, 82], ["Glycyrrhizin", "CHEMICAL", 70, 82], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 35, 48], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 70, 82], ["Glycyrrhizin", "TREATMENT", 70, 82]]], ["The anti-SARS-CoV activity of Glycyrrhizin was further confirmed by other studies (Yeh et al. 2013).", [["Glycyrrhizin", "CHEMICAL", 30, 42], ["Glycyrrhizin", "CHEMICAL", 30, 42], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 17], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 30, 42], ["The anti-SARS", "TEST", 0, 13], ["Glycyrrhizin", "TREATMENT", 30, 42], ["other studies", "TEST", 68, 81]]], ["More recently, the in-silico experimentation revealed that Glycyrrhizin has similar behaviour against COVID-19 disease and acts as a potential inhibitor (Mohammadi and Shaghaghi, 2020).Polyphenols/Flavonoids ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaBaicalin, another significant flavones glucuronide extracted from Scutellaria genus has been reported to have antioxidative and anti-apoptotic activity and it has been employed in treatment of diseases like pulmonary atrial hypertension.", [["pulmonary atrial", "ANATOMY", 533, 549], ["Glycyrrhizin", "CHEMICAL", 59, 71], ["COVID-19 disease", "DISEASE", 102, 118], ["AyurvedaBaicalin", "CHEMICAL", 318, 334], ["glucuronide", "CHEMICAL", 365, 376], ["Scutellaria genus", "CHEMICAL", 392, 409], ["pulmonary atrial hypertension", "DISEASE", 533, 562], ["Glycyrrhizin", "CHEMICAL", 59, 71], ["Polyphenols", "CHEMICAL", 185, 196], ["Flavonoids", "CHEMICAL", 197, 207], ["AyurvedaBaicalin", "CHEMICAL", 318, 334], ["flavones glucuronide", "CHEMICAL", 356, 376], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 59, 71], ["Polyphenols", "SIMPLE_CHEMICAL", 185, 196], ["Flavonoids", "SIMPLE_CHEMICAL", 197, 207], ["COVID-19 Virus", "ORGANISM", 248, 262], ["AyurvedaBaicalin", "SIMPLE_CHEMICAL", 318, 334], ["flavones glucuronide", "SIMPLE_CHEMICAL", 356, 376], ["Scutellaria genus", "ORGANISM", 392, 409], ["pulmonary atrial", "MULTI-TISSUE_STRUCTURE", 533, 549], ["Scutellaria genus", "SPECIES", 392, 409], ["COVID-19", "SPECIES", 102, 110], ["Glycyrrhizin", "TREATMENT", 59, 71], ["COVID-19 disease", "PROBLEM", 102, 118], ["Polyphenols", "TREATMENT", 185, 196], ["Flavonoids", "TREATMENT", 197, 207], ["Secondary Plant Metabolites", "TEST", 212, 239], ["COVID", "TEST", 248, 253], ["AyurvedaBaicalin", "TREATMENT", 318, 334], ["another significant flavones glucuronide", "TREATMENT", 336, 376], ["Scutellaria genus", "PROBLEM", 392, 409], ["antioxidative", "TREATMENT", 436, 449], ["diseases", "PROBLEM", 519, 527], ["pulmonary atrial hypertension", "PROBLEM", 533, 562], ["Flavonoids", "OBSERVATION", 197, 207], ["Scutellaria genus", "OBSERVATION", 392, 409], ["diseases", "OBSERVATION", 519, 527], ["pulmonary atrial", "ANATOMY", 533, 549], ["hypertension", "OBSERVATION", 550, 562]]], ["The anti-SARS-CoV potential of baicalin was initially observed by Chen et al. (2004), who suggested strong inhibitory effect and considerably lower toxic implications on the plant cell lines in-vitro.", [["cell lines", "ANATOMY", 180, 190], ["baicalin", "CHEMICAL", 31, 39], ["baicalin", "CHEMICAL", 31, 39], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 17], ["baicalin", "SIMPLE_CHEMICAL", 31, 39], ["plant cell lines", "CELL", 174, 190], ["plant cell lines", "CELL_LINE", 174, 190], ["baicalin", "TREATMENT", 31, 39], ["considerably lower toxic implications", "PROBLEM", 129, 166], ["the plant cell lines", "TREATMENT", 170, 190], ["toxic", "OBSERVATION_MODIFIER", 148, 153], ["plant cell lines", "OBSERVATION", 174, 190]]], ["The in-silico experimentation with baicalin resulted in stimulation of certain compounds that suppressed the COVID-19 infection as a consequence of ACE2 enzyme activation (Liu et al., 2020).", [["baicalin", "CHEMICAL", 35, 43], ["infection", "DISEASE", 118, 127], ["baicalin", "CHEMICAL", 35, 43], ["baicalin", "SIMPLE_CHEMICAL", 35, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 109, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["ACE2", "PROTEIN", 148, 152], ["baicalin", "TREATMENT", 35, 43], ["certain compounds", "PROBLEM", 71, 88], ["the COVID-19 infection", "PROBLEM", 105, 127], ["ACE2 enzyme activation", "PROBLEM", 148, 170], ["infection", "OBSERVATION", 118, 127]]], ["A flavanone glycoside isolated from citrus fruits is Hesperidin, which has been reported to work against COVID-19.", [["fruits", "ANATOMY", 43, 49], ["flavanone glycoside", "CHEMICAL", 2, 21], ["Hesperidin", "CHEMICAL", 53, 63], ["flavanone glycoside", "CHEMICAL", 2, 21], ["flavanone glycoside", "SIMPLE_CHEMICAL", 2, 21], ["citrus", "ORGANISM", 36, 42], ["fruits", "ORGANISM_SUBDIVISION", 43, 49], ["Hesperidin", "SIMPLE_CHEMICAL", 53, 63], ["citrus", "SPECIES", 36, 42], ["A flavanone glycoside", "TREATMENT", 0, 21], ["citrus fruits", "TREATMENT", 36, 49], ["Hesperidin", "TREATMENT", 53, 63], ["COVID", "TEST", 105, 110], ["flavanone glycoside", "OBSERVATION", 2, 21], ["citrus fruits", "OBSERVATION", 36, 49]]], ["Hesperidin rich citrus peel from the waste were used in the study which underwent hydrodynamic cavitation-based speedy expansion and act as antiviral agent against COVID-19 (Meneguzzo et al., 2020).", [["peel", "ANATOMY", 23, 27], ["Hesperidin", "CHEMICAL", 0, 10], ["citrus peel", "CHEMICAL", 16, 27], ["COVID-19", "CHEMICAL", 164, 172], ["Hesperidin", "CHEMICAL", 0, 10], ["Hesperidin", "SIMPLE_CHEMICAL", 0, 10], ["citrus peel", "TISSUE", 16, 27], ["Hesperidin rich citrus peel", "TREATMENT", 0, 27], ["the study", "TEST", 56, 65], ["hydrodynamic cavitation", "PROBLEM", 82, 105], ["antiviral agent", "TREATMENT", 140, 155], ["COVID", "TEST", 164, 169], ["rich", "OBSERVATION_MODIFIER", 11, 15], ["citrus peel", "OBSERVATION", 16, 27], ["hydrodynamic cavitation", "OBSERVATION", 82, 105]]], ["Fig. 2elucidates prospects of augmentation in immuno-modulatory responses against COVID-19 by polyphneols/flavonoids and terpenoids.Dipeptides ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaChymotrypsin a bioactive compound with activity similar to protease is an approved target in novel designing of inhibitors of coronavirus.", [["COVID-19 by polyphneols/flavonoids and terpenoids", "CHEMICAL", 82, 131], ["Dipeptides", "CHEMICAL", 132, 142], ["AyurvedaChymotrypsin", "CHEMICAL", 253, 273], ["coronavirus", "DISEASE", 387, 398], ["COVID-19", "CHEMICAL", 82, 90], ["polyphneols", "CHEMICAL", 94, 105], ["flavonoids", "CHEMICAL", 106, 116], ["terpenoids", "CHEMICAL", 121, 131], ["Dipeptides", "CHEMICAL", 132, 142], ["COVID-19", "SIMPLE_CHEMICAL", 82, 90], ["polyphneols", "SIMPLE_CHEMICAL", 94, 105], ["flavonoids", "SIMPLE_CHEMICAL", 106, 116], ["terpenoids", "SIMPLE_CHEMICAL", 121, 131], ["Dipeptides", "SIMPLE_CHEMICAL", 132, 142], ["COVID-19 Virus", "ORGANISM", 183, 197], ["AyurvedaChymotrypsin", "SIMPLE_CHEMICAL", 253, 273], ["coronavirus", "ORGANISM", 387, 398], ["protease", "PROTEIN", 320, 328], ["augmentation", "TREATMENT", 30, 42], ["immuno", "TEST", 46, 52], ["COVID", "TEST", 82, 87], ["polyphneols/flavonoids", "TREATMENT", 94, 116], ["terpenoids", "TREATMENT", 121, 131], ["Dipeptides", "TEST", 132, 142], ["Secondary Plant Metabolites", "TEST", 147, 174], ["COVID", "TEST", 183, 188], ["AyurvedaChymotrypsin", "TREATMENT", 253, 273], ["protease", "TREATMENT", 320, 328], ["inhibitors", "TREATMENT", 373, 383], ["coronavirus", "PROBLEM", 387, 398], ["augmentation", "OBSERVATION_MODIFIER", 30, 42], ["flavonoids", "ANATOMY", 106, 116]]], ["TCS, India conducted a recent survey on 31 molecules out of a total of 1600000 molecules identified which act as efficient protease inhibitors against COVID-19.", [["COVID-19", "CHEMICAL", 151, 159], ["TCS", "CHEMICAL", 0, 3], ["efficient protease inhibitors", "TREATMENT", 113, 142], ["COVID", "TEST", 151, 156]]], ["One such imperative bioactive dipeptite is Aurantiamide, a plant derivative extracted from Piper aurantiacum, widely distributed in India, Nepal, Thialand, Vietnam and other Asian countries.", [["dipeptite", "CHEMICAL", 30, 39], ["Aurantiamide", "CHEMICAL", 43, 55], ["dipeptite", "CHEMICAL", 30, 39], ["Aurantiamide", "CHEMICAL", 43, 55], ["dipeptite", "SIMPLE_CHEMICAL", 30, 39], ["Aurantiamide", "SIMPLE_CHEMICAL", 43, 55], ["Piper aurantiacum", "ORGANISM", 91, 108], ["Piper aurantiacum", "SPECIES", 91, 108], ["Piper aurantiacum", "SPECIES", 91, 108], ["Aurantiamide", "TREATMENT", 43, 55], ["a plant derivative", "TREATMENT", 57, 75], ["bioactive dipeptite", "OBSERVATION", 20, 39], ["Piper aurantiacum", "OBSERVATION", 91, 108], ["widely", "OBSERVATION_MODIFIER", 110, 116], ["distributed", "OBSERVATION_MODIFIER", 117, 128]]], ["Aurantiamide acetate is proposed to have diverse bioactivitity and therapeutic potential viz. anti-cancerous and anti-inflammatory (Sengupta et al., 2020).", [["Aurantiamide acetate", "CHEMICAL", 0, 20], ["Aurantiamide acetate", "CHEMICAL", 0, 20], ["Aurantiamide acetate", "SIMPLE_CHEMICAL", 0, 20], ["Aurantiamide acetate", "TREATMENT", 0, 20], ["diverse bioactivitity", "TREATMENT", 41, 62], ["therapeutic potential viz", "TREATMENT", 67, 92], ["anti-inflammatory", "OBSERVATION_MODIFIER", 113, 130]]], ["Co-application of Hydroxychloroquinine and azithromycin has been widely reported to be used as treatment for COVID-19 till present time.", [["Hydroxychloroquinine", "CHEMICAL", 18, 38], ["azithromycin", "CHEMICAL", 43, 55], ["Hydroxychloroquinine", "CHEMICAL", 18, 38], ["azithromycin", "CHEMICAL", 43, 55], ["Hydroxychloroquinine", "SIMPLE_CHEMICAL", 18, 38], ["azithromycin", "SIMPLE_CHEMICAL", 43, 55], ["Hydroxychloroquinine", "TREATMENT", 18, 38], ["azithromycin", "TREATMENT", 43, 55], ["COVID", "TEST", 109, 114]]], ["Apart from aurantiamide, other potential peptide that has role in combating COVID-19 is peptide EK1 (Lu et al., 2020c).Sulphated Polysaccharides ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaThe polysaccharides are a structurally multifaceted class of biomolecules that have diverse physiochemical characteristics which forms the foundation of its varied application in the field of medicine and pharmaceutical sciences (Olafsdottir et al., 2001).", [["aurantiamide", "CHEMICAL", 11, 23], ["aurantiamide", "CHEMICAL", 11, 23], ["COVID-19", "CHEMICAL", 76, 84], ["aurantiamide", "SIMPLE_CHEMICAL", 11, 23], ["COVID-19", "GENE_OR_GENE_PRODUCT", 76, 84], ["COVID-19 Virus", "ORGANISM", 185, 199], ["aurantiamide", "TREATMENT", 11, 23], ["COVID", "TEST", 76, 81], ["Sulphated Polysaccharides", "TEST", 119, 144], ["Secondary Plant Metabolites", "TEST", 149, 176], ["COVID", "TEST", 185, 190], ["Ayurveda", "TREATMENT", 255, 263], ["structurally", "OBSERVATION_MODIFIER", 289, 301], ["multifaceted", "OBSERVATION_MODIFIER", 302, 314], ["biomolecules", "OBSERVATION", 324, 336], ["diverse", "OBSERVATION_MODIFIER", 347, 354], ["physiochemical characteristics", "OBSERVATION", 355, 385], ["varied", "OBSERVATION_MODIFIER", 420, 426]]], ["The polysaccharides are isolated from plants sources including tree exudates, roots, cell walls and seeds as well as animal sources including chitin, chondroitin sulfate and hyaluronan).", [["exudates", "ANATOMY", 68, 76], ["roots", "ANATOMY", 78, 83], ["cell walls", "ANATOMY", 85, 95], ["seeds", "ANATOMY", 100, 105], ["chondroitin sulfate", "CHEMICAL", 150, 169], ["hyaluronan", "CHEMICAL", 174, 184], ["tree exudates", "MULTI-TISSUE_STRUCTURE", 63, 76], ["roots", "TISSUE", 78, 83], ["cell walls", "TISSUE", 85, 95], ["chitin", "SIMPLE_CHEMICAL", 142, 148], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 150, 169], ["hyaluronan", "SIMPLE_CHEMICAL", 174, 184], ["chitin", "PROTEIN", 142, 148], ["The polysaccharides", "PROBLEM", 0, 19], ["tree exudates", "PROBLEM", 63, 76], ["roots, cell walls and seeds", "PROBLEM", 78, 105], ["chitin, chondroitin sulfate", "TREATMENT", 142, 169], ["hyaluronan", "TREATMENT", 174, 184], ["tree", "OBSERVATION_MODIFIER", 63, 67], ["exudates", "OBSERVATION", 68, 76], ["roots", "OBSERVATION_MODIFIER", 78, 83], ["cell walls", "OBSERVATION", 85, 95]]], ["In addition to this, several bacterial and fungal sources such as hydrocolloids including xanthan, wellan and gellan are the major sources of natural polysaccharides (Gaikwad et al., 2009).", [["xanthan", "CHEMICAL", 90, 97], ["wellan", "CHEMICAL", 99, 105], ["gellan", "CHEMICAL", 110, 116], ["xanthan", "SIMPLE_CHEMICAL", 90, 97], ["wellan", "SIMPLE_CHEMICAL", 99, 105], ["gellan", "SIMPLE_CHEMICAL", 110, 116], ["several bacterial and fungal sources", "PROBLEM", 21, 57], ["hydrocolloids", "TREATMENT", 66, 79], ["xanthan", "TREATMENT", 90, 97], ["wellan", "TREATMENT", 99, 105], ["gellan", "TREATMENT", 110, 116], ["bacterial", "OBSERVATION_MODIFIER", 29, 38], ["fungal sources", "OBSERVATION", 43, 57]]], ["Another significant resource of polysaccharides is algae i.e. mucopolysaccharides and storage polysaccharides have been largely extracted from them.", [["algae", "SIMPLE_CHEMICAL", 51, 56], ["mucopolysaccharides", "SIMPLE_CHEMICAL", 62, 81], ["polysaccharides", "TREATMENT", 32, 47], ["mucopolysaccharides", "PROBLEM", 62, 81], ["storage polysaccharides", "PROBLEM", 86, 109], ["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["Macroalagae in the form of seed weeds are the major reservoirs of these polysaccharides (Gaikwad et al., 2009).Sulphated Polysaccharides ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaHundreds of naturally occurring polysaccharides are presently identified and they bestow richest and most traditional pool of structurally and functionally assorted biopolymers.", [["Macroalagae", "CHEMICAL", 0, 11], ["COVID-19 Virus", "ORGANISM", 177, 191], ["Macroalagae", "TREATMENT", 0, 11], ["Sulphated Polysaccharides", "TEST", 111, 136], ["Secondary Plant Metabolites", "TEST", 141, 168], ["COVID", "TEST", 177, 182], ["naturally occurring polysaccharides", "PROBLEM", 267, 302], ["seed weeds", "OBSERVATION", 27, 37]]], ["Apart from its earlier application in the industrial field, recent developments have been made in its employment in the pharmaceutical sector and are considered as pharmacologically active polymers.", [["pharmacologically active polymers", "TREATMENT", 164, 197], ["earlier", "OBSERVATION_MODIFIER", 15, 22]]], ["They have long been recognized for their anti-tumor, anti-coagulant, antiviral and immunomodulatory etc. bioactivities (Martinez et al., 2005).", [["anti-tumor", "CANCER", 41, 51], ["anti-coagulant", "TREATMENT", 53, 67], ["antiviral", "TREATMENT", 69, 78], ["immunomodulatory etc", "TREATMENT", 83, 103]]], ["Synthetic and natural polymers of carbohydrate biomolecules have been affirmed to be selective inhibitors or suppressors of enveloped viruses for example HSV, HIV, human cytomegalovirus, respiratory syncytical and influenza virus.", [["HSV, HIV, human cytomegalovirus, respiratory syncytical and influenza virus", "DISEASE", 154, 229], ["carbohydrate", "CHEMICAL", 34, 46], ["carbohydrate biomolecules", "SIMPLE_CHEMICAL", 34, 59], ["enveloped viruses", "ORGANISM", 124, 141], ["HSV", "ORGANISM", 154, 157], ["HIV", "ORGANISM", 159, 162], ["human", "ORGANISM", 164, 169], ["cytomegalovirus", "ORGANISM", 170, 185], ["respiratory syncytical", "ORGANISM", 187, 209], ["influenza virus", "ORGANISM", 214, 229], ["HIV", "SPECIES", 159, 162], ["human", "SPECIES", 164, 169], ["influenza virus", "SPECIES", 214, 229], ["HSV", "SPECIES", 154, 157], ["HIV", "SPECIES", 159, 162], ["human cytomegalovirus", "SPECIES", 164, 185], ["Synthetic and natural polymers of carbohydrate biomolecules", "TREATMENT", 0, 59], ["selective inhibitors", "TREATMENT", 85, 105], ["suppressors", "TREATMENT", 109, 120], ["enveloped viruses", "PROBLEM", 124, 141], ["HSV", "PROBLEM", 154, 157], ["HIV", "PROBLEM", 159, 162], ["human cytomegalovirus", "PROBLEM", 164, 185], ["respiratory syncytical and influenza virus", "PROBLEM", 187, 229], ["influenza virus", "OBSERVATION", 214, 229]]], ["Moreover, efforts have been made in advancement in development of polysachharide molecules as specific inhibitors of varied classes of viruses (De Clercq, 1990, 1995).", [["polysachharide", "CHEMICAL", 66, 80], ["polysachharide molecules", "SIMPLE_CHEMICAL", 66, 90], ["polysachharide molecules", "PROBLEM", 66, 90]]], ["Guduchi or Giloy herb is suggested to contain various diterpene compound and polysaccharides including arabinogalactan polysaccharide (Subhose et al., 2005).", [["Guduchi", "CHEMICAL", 0, 7], ["arabinogalactan polysaccharide", "CHEMICAL", 103, 133], ["diterpene", "CHEMICAL", 54, 63], ["Guduchi", "SIMPLE_CHEMICAL", 0, 7], ["Giloy herb", "ORGANISM", 11, 21], ["diterpene compound", "SIMPLE_CHEMICAL", 54, 72], ["polysaccharides", "SIMPLE_CHEMICAL", 77, 92], ["arabinogalactan polysaccharide", "SIMPLE_CHEMICAL", 103, 133], ["Giloy herb", "TREATMENT", 11, 21], ["various diterpene compound and polysaccharides", "TREATMENT", 46, 92], ["arabinogalactan polysaccharide", "TREATMENT", 103, 133], ["diterpene compound", "OBSERVATION", 54, 72]]], ["These polysaccharides and terpenoids are immunomodulating and adaptogenic in nature.", [["terpenoids", "CHEMICAL", 26, 36], ["terpenoids", "SIMPLE_CHEMICAL", 26, 36], ["These polysaccharides", "TEST", 0, 21], ["terpenoids", "TREATMENT", 26, 36], ["terpenoids", "OBSERVATION_MODIFIER", 26, 36], ["immunomodulating", "OBSERVATION_MODIFIER", 41, 57]]], ["Various studies on Giloy herbal extract revealed that it could cause imperative enhancement in IgG antibodies in the serum and activation of macrophages (Fortunatov, 1952), induction of cell regulated immunity and humoral immunity (Winston and Maimes, 2007).", [["serum", "ANATOMY", 117, 122], ["macrophages", "ANATOMY", 141, 152], ["cell", "ANATOMY", 186, 190], ["Giloy herbal extract", "CHEMICAL", 19, 39], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 95, 109], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["macrophages", "CELL", 141, 152], ["cell", "CELL", 186, 190], ["IgG antibodies", "PROTEIN", 95, 109], ["macrophages", "CELL_TYPE", 141, 152], ["Various studies", "TEST", 0, 15], ["Giloy herbal extract", "TEST", 19, 39], ["imperative enhancement in IgG antibodies", "PROBLEM", 69, 109], ["the serum", "TEST", 113, 122], ["cell regulated immunity", "TREATMENT", 186, 209], ["IgG antibodies", "OBSERVATION", 95, 109]]], ["These plants have been widely reported for their potential antiviral activity against H1N1 flu and an immunostimulator.Sulphated Polysaccharides ::: Secondary Plant Metabolites against COVID-19 Virus ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaIn, Porphyridium another imperative unicellular microalga, each cell is encapsulated in a sulphated polysaccharides.", [["cell", "ANATOMY", 327, 331], ["H1N1 flu", "DISEASE", 86, 94], ["Porphyridium", "CHEMICAL", 267, 279], ["H1N1 flu", "ORGANISM", 86, 94], ["COVID-19 Virus", "ORGANISM", 185, 199], ["Porphyridium", "SIMPLE_CHEMICAL", 267, 279], ["cell", "CELL", 327, 331], ["sulphated polysaccharides", "SIMPLE_CHEMICAL", 353, 378], ["H1N1 flu", "SPECIES", 86, 94], ["H1N1 flu", "SPECIES", 86, 94], ["H1N1 flu", "PROBLEM", 86, 94], ["an immunostimulator", "TREATMENT", 99, 118], ["Sulphated Polysaccharides", "TEST", 119, 144], ["Secondary Plant Metabolites", "TEST", 149, 176], ["COVID", "TEST", 185, 190], ["AyurvedaIn", "TREATMENT", 255, 265], ["Porphyridium", "TREATMENT", 267, 279], ["a sulphated polysaccharides", "TREATMENT", 351, 378], ["unicellular microalga", "OBSERVATION", 299, 320], ["sulphated polysaccharides", "OBSERVATION_MODIFIER", 353, 378]]], ["The capsule outside the cell is dissolved in a growth medium to form exopolysaccharides.", [["capsule", "ANATOMY", 4, 11], ["cell", "ANATOMY", 24, 28], ["capsule", "CANCER", 4, 11], ["cell", "CELL", 24, 28], ["capsule", "OBSERVATION_MODIFIER", 4, 11], ["cell", "ANATOMY", 24, 28], ["dissolved", "OBSERVATION_MODIFIER", 32, 41], ["growth medium", "OBSERVATION_MODIFIER", 47, 60]]], ["These complex sugars are composed of glucuronic acid (10%), galactose (22%), glucose (24%), xylose (38%) and other saccharides such as rhamnose, mannose and arabinose in minute concentration (Geresh et al., 2002).", [["glucuronic acid", "CHEMICAL", 37, 52], ["galactose", "CHEMICAL", 60, 69], ["glucose", "CHEMICAL", 77, 84], ["xylose", "CHEMICAL", 92, 98], ["rhamnose", "CHEMICAL", 135, 143], ["mannose", "CHEMICAL", 145, 152], ["arabinose", "CHEMICAL", 157, 166], ["sugars", "CHEMICAL", 14, 20], ["glucuronic acid", "CHEMICAL", 37, 52], ["galactose", "CHEMICAL", 60, 69], ["glucose", "CHEMICAL", 77, 84], ["xylose", "CHEMICAL", 92, 98], ["rhamnose", "CHEMICAL", 135, 143], ["mannose", "CHEMICAL", 145, 152], ["arabinose", "CHEMICAL", 157, 166], ["glucuronic acid", "SIMPLE_CHEMICAL", 37, 52], ["galactose", "SIMPLE_CHEMICAL", 60, 69], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["xylose", "SIMPLE_CHEMICAL", 92, 98], ["saccharides", "SIMPLE_CHEMICAL", 115, 126], ["rhamnose", "SIMPLE_CHEMICAL", 135, 143], ["mannose", "SIMPLE_CHEMICAL", 145, 152], ["arabinose", "SIMPLE_CHEMICAL", 157, 166], ["These complex sugars", "TEST", 0, 20], ["glucuronic acid", "TEST", 37, 52], ["galactose", "TEST", 60, 69], ["glucose", "TEST", 77, 84], ["xylose", "TEST", 92, 98], ["other saccharides", "TEST", 109, 126]]], ["The exopolysaccharides are compatible with the human body and are biodegradable and plays vital role in manufacturing of various medicines, cosmetics and food derivatives.", [["body", "ANATOMY", 53, 57], ["human", "ORGANISM", 47, 52], ["body", "ORGANISM_SUBDIVISION", 53, 57], ["food derivatives", "SIMPLE_CHEMICAL", 154, 170], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["various medicines", "TREATMENT", 121, 138], ["cosmetics", "TREATMENT", 140, 149], ["food derivatives", "TREATMENT", 154, 170], ["compatible with", "UNCERTAINTY", 27, 42]]], ["A study carried out by Pujol et al. (2002), revealed identification of various sulfated polysachharides from marine algae and animal resorviors and act as potential inhibitors of human and animal viral infections.", [["viral infections", "DISEASE", 196, 212], ["sulfated polysachharides", "CHEMICAL", 79, 103], ["polysachharides", "SIMPLE_CHEMICAL", 88, 103], ["human", "ORGANISM", 179, 184], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["A study", "TEST", 0, 7], ["various sulfated polysachharides", "TREATMENT", 71, 103], ["marine algae", "TREATMENT", 109, 121], ["animal resorviors", "TREATMENT", 126, 143], ["potential inhibitors of human", "PROBLEM", 155, 184], ["animal viral infections", "PROBLEM", 189, 212], ["viral infections", "OBSERVATION", 196, 212]]], ["A study by Nagle et al. (2020), suggested strong antiviral bioactivity of sulfated polysaccharides isolated from marine red algae.", [["sulfated polysaccharides", "SIMPLE_CHEMICAL", 74, 98], ["red algae", "ORGANISM", 120, 129], ["A study", "TEST", 0, 7], ["strong antiviral bioactivity of sulfated polysaccharides", "TREATMENT", 42, 98], ["marine red algae", "TREATMENT", 113, 129], ["marine red algae", "OBSERVATION", 113, 129]]], ["Sulfated polysaccharides are multifarious class of macromolecules and have diverse clinical relevance (Seedevi et al., 2013).", [["Sulfated polysaccharides", "SIMPLE_CHEMICAL", 0, 24], ["Sulfated polysaccharides", "TREATMENT", 0, 24]]], ["They have been found to be broadly distributed in animals, plants and algae found in the saline soil.", [["algae", "CELL", 70, 75], ["algae", "TREATMENT", 70, 75], ["the saline soil", "TREATMENT", 85, 100], ["broadly", "OBSERVATION_MODIFIER", 27, 34], ["distributed", "OBSERVATION_MODIFIER", 35, 46]]], ["A report by Karthik et al. (2014), revealed their presence in the marine saline soil is an indication of an adaptation process which might have established during application.", [["the marine saline soil", "TREATMENT", 62, 84], ["an adaptation process", "PROBLEM", 105, 126], ["adaptation", "OBSERVATION", 108, 118]]], ["The two chief constituents responsible for the antiviral bioactivity of sulfated polysaccharides are chondroitin sulfate and heparin (Ghosh et al., 2009).", [["chondroitin sulfate", "CHEMICAL", 101, 120], ["heparin", "CHEMICAL", 125, 132], ["chondroitin sulfate", "CHEMICAL", 101, 120], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 72, 96], ["chondroitin sulfate", "SIMPLE_CHEMICAL", 101, 120], ["heparin", "SIMPLE_CHEMICAL", 125, 132], ["the antiviral bioactivity", "TREATMENT", 43, 68], ["sulfated polysaccharides", "TREATMENT", 72, 96], ["chondroitin sulfate", "TREATMENT", 101, 120], ["heparin", "TREATMENT", 125, 132]]], ["The exopolysaccharides of Porphyridium have been elucidated to be potent against several virus viz. retrovirus (Talyshinsky, 2002), and HSV-1 and HSV-2 (Nagle et al., 2020) etc. Therefore, these biocompatible compounds were suggested to be employed in coating materials of various sanitary items for COVID-19 deterrence.Potential Role of Medicinal Plants as Antiviral Warriors ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaThe naturally occurring products and phytomedicines are coming to the fore all around the world, owing to the orientation of the social fabric to such remedies in different health care centres all across the globe (WHO, 2004).", [["Porphyridium", "CHEMICAL", 26, 38], ["Porphyridium", "SIMPLE_CHEMICAL", 26, 38], ["retrovirus", "ORGANISM", 100, 110], ["HSV-1", "ORGANISM", 136, 141], ["HSV-2", "ORGANISM", 146, 151], ["HSV-1", "SPECIES", 136, 141], ["HSV-1", "SPECIES", 136, 141], ["The exopolysaccharides of Porphyridium", "PROBLEM", 0, 38], ["several virus viz", "PROBLEM", 81, 98], ["retrovirus", "PROBLEM", 100, 110], ["HSV", "TEST", 136, 139], ["HSV", "TEST", 146, 149], ["these biocompatible compounds", "TREATMENT", 189, 218], ["Ayurveda", "TREATMENT", 432, 440], ["phytomedicines", "TREATMENT", 477, 491], ["globe", "ANATOMY", 648, 653]]], ["The global outlook for drug formulation is showing a paradigm shift as individuals are facing chronic as well as lifestyle-related disorders, due to which they are turning their stance towards improving life-styles and disease deterrence.", [["drug formulation", "TREATMENT", 23, 39], ["related disorders", "PROBLEM", 123, 140], ["disease deterrence", "PROBLEM", 219, 237]]], ["However, during ancient period herbal phyto-constituents were the only alternatives for healing the illness as antibiotics were not discovered.", [["illness", "DISEASE", 100, 107], ["healing the illness", "PROBLEM", 88, 107], ["antibiotics", "TREATMENT", 111, 122]]], ["Particularly, herbal formulations endow us with toolbox to concoct novel antiviral products.", [["herbal formulations", "TREATMENT", 14, 33], ["toolbox", "TREATMENT", 48, 55], ["novel antiviral products", "TREATMENT", 67, 91], ["antiviral products", "OBSERVATION", 73, 91]]], ["This pragmatically involves the understanding of antiviral mechanisms of natural products and their role in heckling virus life-cycle, replication, assembly and its release.", [["antiviral mechanisms", "TREATMENT", 49, 69], ["natural products", "TREATMENT", 73, 89]]], ["Ever since, the safety and clinical characteristics of traditional medicines have come out, their consumption have been gradually elevating after approval by scientific communities (Mohammadi and Shaghaghi, 2020).", [["traditional medicines", "TREATMENT", 55, 76]]], ["Attributable to the side-effects of chemical compounds onto human bodies, it has believed to utilize the herbal therapies with much more effectiveness and nil side-effects.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["the herbal therapies", "TREATMENT", 101, 121], ["chemical compounds", "OBSERVATION", 36, 54]]], ["Undeniably, traditional drugs are long in the tooth since primordial times and play a significant role to meet global health needs.", [["tooth", "ANATOMY", 46, 51], ["tooth", "ORGAN", 46, 51], ["traditional drugs", "TREATMENT", 12, 29]]], ["Usually, Ayurveda, Naturopathy, Siddha, Homopathy, Yoga, Persian medicines, Unani, Romanian, and Chinese conventional medicines have been known since ancient times (Gomathi et al., 2020; Heidary et al., 2020; Yang et al., 2020; Ling, 2020).", [["Naturopathy", "DISEASE", 19, 30]]], ["Usage of these systems in medical field is quite lucrative to suppress viral infections in respiratory systems and modulating inflammatory reactions within immune systems.", [["respiratory", "ANATOMY", 91, 102], ["infections", "DISEASE", 77, 87], ["viral infections in respiratory systems", "PROBLEM", 71, 110], ["modulating inflammatory reactions", "PROBLEM", 115, 148], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infections", "OBSERVATION", 77, 87], ["respiratory systems", "ANATOMY", 91, 110], ["inflammatory", "OBSERVATION", 126, 138]]], ["As depicted earlier, AYUSH has initiated a holistic perspective of medicine to cure presently prevailing anti-viral infections via self remedial processes (AYUSH, 2020).Potential Role of Medicinal Plants as Antiviral Warriors ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaA wide spectrum of studies is being conducted to design a formulation against coronavirus with the aid of medicinal plants.", [["AYUSH", "CHEMICAL", 21, 26], ["infections", "DISEASE", 116, 126], ["coronavirus", "DISEASE", 367, 378], ["coronavirus", "ORGANISM", 367, 378], ["medicine", "TREATMENT", 67, 75], ["anti-viral infections", "PROBLEM", 105, 126], ["studies", "TEST", 308, 315], ["a formulation", "TREATMENT", 345, 358], ["coronavirus", "PROBLEM", 367, 378], ["medicinal plants", "TREATMENT", 395, 411], ["medicinal plants", "OBSERVATION", 395, 411]]], ["The pages of history stand testimony to the fact that diversity of medicinal plants such as Indigofera tinctoria, Evolvulus alsinoides, Vitex trifolia, Pergularia daemi, Gymnema sylvestre, Clerodendrumineme, Abutilon indicum, Clitoria tematea, Leucas Aspera, Sphaeranthus indicus, Allium sativum, Cassia alata showed an anti-mice coronavirus activity (SARS-CoV) (Vimalanathan et al., 2009).", [["Indigofera tinctoria", "ORGANISM", 92, 112], ["Evolvulus alsinoides", "ORGANISM", 114, 134], ["Vitex trifolia", "ORGANISM", 136, 150], ["Pergularia daemi", "ORGANISM", 152, 168], ["Gymnema sylvestre", "ORGANISM", 170, 187], ["Clerodendrumineme", "ORGANISM", 189, 206], ["Abutilon indicum", "ORGANISM", 208, 224], ["Clitoria tematea", "ORGANISM", 226, 242], ["Leucas Aspera", "ORGANISM", 244, 257], ["Sphaeranthus indicus", "ORGANISM", 259, 279], ["Allium sativum", "ORGANISM", 281, 295], ["Cassia alata", "ORGANISM", 297, 309], ["anti-mice coronavirus", "ORGANISM", 320, 341], ["Indigofera tinctoria", "SPECIES", 92, 112], ["Evolvulus alsinoides", "SPECIES", 114, 134], ["Vitex trifolia", "SPECIES", 136, 150], ["Pergularia daemi", "SPECIES", 152, 168], ["Gymnema sylvestre", "SPECIES", 170, 187], ["Abutilon indicum", "SPECIES", 208, 224], ["Clitoria tematea", "SPECIES", 226, 242], ["Leucas Aspera", "SPECIES", 244, 257], ["Sphaeranthus indicus", "SPECIES", 259, 279], ["Allium sativum", "SPECIES", 281, 295], ["Cassia alata", "SPECIES", 297, 309], ["Indigofera tinctoria", "SPECIES", 92, 112], ["Evolvulus alsinoides", "SPECIES", 114, 134], ["Vitex trifolia", "SPECIES", 136, 150], ["Pergularia daemi", "SPECIES", 152, 168], ["Gymnema sylvestre", "SPECIES", 170, 187], ["Abutilon indicum", "SPECIES", 208, 224], ["Clitoria tematea", "SPECIES", 226, 242], ["Sphaeranthus indicus", "SPECIES", 259, 279], ["Allium sativum", "SPECIES", 281, 295], ["Cassia alata", "SPECIES", 297, 309], ["anti-mice coronavirus", "SPECIES", 320, 341], ["SARS-CoV", "SPECIES", 352, 360], ["medicinal plants", "TREATMENT", 67, 83], ["Indigofera tinctoria", "PROBLEM", 92, 112], ["Evolvulus alsinoides", "PROBLEM", 114, 134], ["Vitex trifolia", "TREATMENT", 136, 150], ["Pergularia daemi", "TREATMENT", 152, 168], ["Gymnema sylvestre", "TREATMENT", 170, 187], ["Clerodendrumineme", "TREATMENT", 189, 206], ["Abutilon indicum", "TREATMENT", 208, 224], ["Clitoria tematea", "TREATMENT", 226, 242], ["Leucas Aspera", "TREATMENT", 244, 257], ["Sphaeranthus indicus", "TREATMENT", 259, 279], ["Allium sativum", "TREATMENT", 281, 295], ["Cassia alata", "TEST", 297, 309], ["an anti-mice coronavirus activity", "TREATMENT", 317, 350], ["medicinal plants", "OBSERVATION", 67, 83], ["Vitex trifolia", "OBSERVATION", 136, 150]]], ["Amid them, V. trifolia and S. indicus plummeted inflammatory cytokines via NF-\u03baB pathway, insinuated for respiratory discomfort in SARS-CoV (Srivastava et al., 2015).", [["respiratory", "ANATOMY", 105, 116], ["respiratory discomfort", "DISEASE", 105, 127], ["SARS", "DISEASE", 131, 135], ["V. trifolia", "ORGANISM", 11, 22], ["S. indicus", "ORGANISM", 27, 37], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["inflammatory cytokines", "PROTEIN", 48, 70], ["NF-\u03baB", "PROTEIN", 75, 80], ["V. trifolia", "SPECIES", 11, 22], ["S. indicus", "SPECIES", 27, 37], ["V. trifolia", "SPECIES", 11, 22], ["S. indicus", "SPECIES", 27, 37], ["SARS-CoV", "SPECIES", 131, 139], ["inflammatory cytokines", "PROBLEM", 48, 70], ["B pathway", "TREATMENT", 79, 88], ["respiratory discomfort", "PROBLEM", 105, 127], ["inflammatory", "OBSERVATION_MODIFIER", 48, 60], ["respiratory", "ANATOMY", 105, 116], ["discomfort", "OBSERVATION", 117, 127]]], ["In addition, C. tematea was recognised as MT (Metalloprotease) inhibitor, ADAM17, which is linked with shredding ACE-2 enzyme, often associated with virus replication (Maity et al., 2012).", [["C. tematea", "ORGANISM", 13, 23], ["MT", "GENE_OR_GENE_PRODUCT", 42, 44], ["Metalloprotease", "GENE_OR_GENE_PRODUCT", 46, 61], ["ADAM17", "GENE_OR_GENE_PRODUCT", 74, 80], ["ACE-2", "GENE_OR_GENE_PRODUCT", 113, 118], ["MT (Metalloprotease) inhibitor", "PROTEIN", 42, 72], ["ADAM17", "PROTEIN", 74, 80], ["shredding ACE-2 enzyme", "PROTEIN", 103, 125], ["C. tematea", "SPECIES", 13, 23], ["C. tematea", "SPECIES", 13, 23], ["C. tematea", "TREATMENT", 13, 23], ["MT (Metalloprotease) inhibitor", "TREATMENT", 42, 72], ["virus replication", "PROBLEM", 149, 166]]], ["Further, Glycyrrhiza glabra and A. sativum have also been found to impede viral replication against SARS-CoV, while C. ineme was potentially observed to deactivate viral ribosome machinery, revealing its utility against testing SARS-CoV-2-protein translation and protein synthesis (Nourazarian, 2015; Keyaerts et al., 2007).", [["ribosome", "ANATOMY", 170, 178], ["SARS", "DISEASE", 100, 104], ["Glycyrrhiza glabra", "ORGANISM", 9, 27], ["A. sativum", "ORGANISM", 32, 42], ["SARS-CoV", "ORGANISM", 100, 108], ["C. ineme", "ORGANISM", 116, 124], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 228, 238], ["Glycyrrhiza glabra", "SPECIES", 9, 27], ["A. sativum", "SPECIES", 32, 42], ["C. ineme", "SPECIES", 116, 124], ["Glycyrrhiza glabra", "SPECIES", 9, 27], ["A. sativum", "SPECIES", 32, 42], ["SARS-CoV", "SPECIES", 100, 108], ["C. ineme", "SPECIES", 116, 124], ["Glycyrrhiza glabra", "TREATMENT", 9, 27], ["A. sativum", "TEST", 32, 42], ["SARS", "PROBLEM", 100, 104], ["testing SARS", "TEST", 220, 232], ["CoV", "TEST", 233, 236], ["protein synthesis", "TEST", 263, 280]]], ["Likewise, Strobilanthes cusia also blocked the RNA synthesis of viral species and mediated papain like proteases activities in order to target HCoV (Tsai et al., 2020).", [["Strobilanthes cusia", "CHEMICAL", 10, 29], ["Strobilanthes cusia", "ORGANISM", 10, 29], ["papain", "GENE_OR_GENE_PRODUCT", 91, 97], ["HCoV", "GENE_OR_GENE_PRODUCT", 143, 147], ["papain", "PROTEIN", 91, 97], ["proteases", "PROTEIN", 103, 112], ["Strobilanthes cusia", "SPECIES", 10, 29], ["HCoV", "SPECIES", 143, 147], ["viral species", "PROBLEM", 64, 77], ["mediated papain", "TREATMENT", 82, 97], ["viral species", "OBSERVATION", 64, 77]]], ["In Asia, mountainous zones are lavishly flourished with plants with medicinal value against various respiratory disorders (Amber et al., 2017).", [["respiratory", "ANATOMY", 100, 111], ["respiratory disorders", "DISEASE", 100, 121], ["various respiratory disorders", "PROBLEM", 92, 121]]], ["For instance, Hyoscyamus niger, Verbascum thapsus, Cynara scolymus, Justicia adhatoda were found to attack the molecules bulging among SARS-CoV-2 and influenza virus and found to inhinit Ca2+ channels (Gilani et al., 2008).", [["Ca2", "CHEMICAL", 187, 190], ["Ca2+", "CHEMICAL", 187, 191], ["Hyoscyamus niger", "ORGANISM", 14, 30], ["Verbascum thapsus", "ORGANISM", 32, 49], ["Cynara scolymus", "ORGANISM", 51, 66], ["Justicia adhatoda", "ORGANISM", 68, 85], ["SARS-CoV-2", "ORGANISM", 135, 145], ["influenza virus", "ORGANISM", 150, 165], ["Ca2+", "SIMPLE_CHEMICAL", 187, 191], ["Ca2", "PROTEIN", 187, 190], ["Hyoscyamus niger", "SPECIES", 14, 30], ["Verbascum thapsus", "SPECIES", 32, 49], ["Cynara scolymus", "SPECIES", 51, 66], ["Justicia adhatoda", "SPECIES", 68, 85], ["CoV-2", "SPECIES", 140, 145], ["influenza virus", "SPECIES", 150, 165], ["Hyoscyamus niger", "SPECIES", 14, 30], ["Verbascum thapsus", "SPECIES", 32, 49], ["Cynara scolymus", "SPECIES", 51, 66], ["Justicia adhatoda", "SPECIES", 68, 85], ["SARS-CoV-2", "SPECIES", 135, 145], ["influenza virus", "SPECIES", 150, 165], ["Hyoscyamus niger", "TEST", 14, 30], ["Cynara scolymus", "PROBLEM", 51, 66], ["Justicia adhatoda", "PROBLEM", 68, 85], ["the molecules bulging", "PROBLEM", 107, 128], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["influenza virus", "PROBLEM", 150, 165]]], ["Consequently, it could earmark orf3 (Ca2+ channel), stimulating other downstream pathways against viral attack.", [["Ca2", "CHEMICAL", 37, 40], ["Ca2+", "CHEMICAL", 37, 41], ["orf3", "GENE_OR_GENE_PRODUCT", 31, 35], ["Ca2+ channel", "GENE_OR_GENE_PRODUCT", 37, 49], ["orf3", "PROTEIN", 31, 35], ["Ca2+ channel", "PROTEIN", 37, 49], ["viral attack", "PROBLEM", 98, 110], ["viral attack", "OBSERVATION", 98, 110]]], ["Notably, various herbal plants showed restraining affects against ACE, for example, Coriandrum sativum, Punica granatum, Boerhaavia diffusa, Cassia occidentalis, Coscinium fenestratum, Embeliaribes etc. (Hussain et al., 2018; Khan and Kumar, 2019).", [["ACE", "GENE_OR_GENE_PRODUCT", 66, 69], ["Coriandrum sativum", "ORGANISM", 84, 102], ["Punica granatum", "ORGANISM", 104, 119], ["Boerhaavia diffusa", "ORGANISM", 121, 139], ["Cassia occidentalis", "ORGANISM", 141, 160], ["Coscinium fenestratum", "ORGANISM", 162, 183], ["Embeliaribes etc", "ORGANISM", 185, 201], ["Coriandrum sativum", "SPECIES", 84, 102], ["Punica granatum", "SPECIES", 104, 119], ["Boerhaavia diffusa", "SPECIES", 121, 139], ["Cassia occidentalis", "SPECIES", 141, 160], ["Coscinium fenestratum", "SPECIES", 162, 183], ["Coriandrum sativum", "SPECIES", 84, 102], ["Punica granatum", "SPECIES", 104, 119], ["Boerhaavia diffusa", "SPECIES", 121, 139], ["Cassia occidentalis", "SPECIES", 141, 160], ["Coscinium fenestratum", "SPECIES", 162, 183], ["various herbal plants", "TREATMENT", 9, 30], ["ACE", "TREATMENT", 66, 69], ["Coriandrum sativum", "TEST", 84, 102], ["Punica granatum", "PROBLEM", 104, 119], ["Boerhaavia diffusa", "PROBLEM", 121, 139], ["Cassia occidentalis", "PROBLEM", 141, 160], ["herbal plants", "OBSERVATION", 17, 30], ["Punica granatum", "ANATOMY", 104, 119], ["Cassia occidentalis", "OBSERVATION", 141, 160]]], ["Research is currently being focussed on these plants to scrutinize their effects on COVID-19.", [["COVID", "TEST", 84, 89]]], ["Another tropical species Andrographis paniculatain South Asia depicted sturdy competence against viral infections (Yarnell, 2018).", [["viral infections", "DISEASE", 97, 113], ["Another tropical species", "TEST", 0, 24], ["viral infections", "PROBLEM", 97, 113]]], ["More recently, Liu et al. (2020), found that A. paniculata repressed NOD-like receptor Proteins (NLRP3), IL-1\u03b2, C-1 (Caspase-1) molecules, comprehensively associated with SARS-CoV and SARS-CoV-2 pathogenesis.", [["A. paniculata", "ORGANISM", 45, 58], ["NOD-like receptor Proteins", "GENE_OR_GENE_PRODUCT", 69, 95], ["NLRP3", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["C-1", "GENE_OR_GENE_PRODUCT", 112, 115], ["Caspase-1", "GENE_OR_GENE_PRODUCT", 117, 126], ["SARS-CoV", "ORGANISM", 171, 179], ["SARS-CoV-2", "ORGANISM", 184, 194], ["NOD-like receptor Proteins", "PROTEIN", 69, 95], ["NLRP3", "PROTEIN", 97, 102], ["IL-1\u03b2", "PROTEIN", 105, 110], ["C-1 (Caspase-1) molecules", "PROTEIN", 112, 137], ["A. paniculata", "SPECIES", 45, 58], ["A. paniculata", "SPECIES", 45, 58], ["SARS-CoV", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 184, 192], ["NOD", "TEST", 69, 72], ["receptor Proteins", "TEST", 78, 95], ["NLRP3", "TEST", 97, 102], ["IL", "TEST", 105, 107], ["C", "TEST", 112, 113], ["Caspase", "TEST", 117, 124], ["SARS", "PROBLEM", 171, 175], ["CoV", "PROBLEM", 176, 179], ["SARS", "PROBLEM", 184, 188], ["CoV", "PROBLEM", 189, 192], ["2 pathogenesis", "PROBLEM", 193, 207]]], ["Also, Salacia oblonga reflected inhibitory effects on angiotensin II having direct link with bronchitis and lung damage (He et al., 2011).", [["lung", "ANATOMY", 108, 112], ["angiotensin II", "CHEMICAL", 54, 68], ["bronchitis", "DISEASE", 93, 103], ["lung damage", "DISEASE", 108, 119], ["Salacia oblonga", "ORGANISM", 6, 21], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 54, 68], ["lung", "ORGAN", 108, 112], ["angiotensin II", "PROTEIN", 54, 68], ["Salacia oblonga", "SPECIES", 6, 21], ["Salacia oblonga", "SPECIES", 6, 21], ["Salacia oblonga", "PROBLEM", 6, 21], ["inhibitory effects", "PROBLEM", 32, 50], ["angiotensin II", "TREATMENT", 54, 68], ["bronchitis", "PROBLEM", 93, 103], ["lung damage", "PROBLEM", 108, 119], ["inhibitory effects", "OBSERVATION", 32, 50], ["bronchitis", "OBSERVATION", 93, 103], ["lung", "ANATOMY", 108, 112], ["damage", "OBSERVATION", 113, 119]]], ["Strikingly, many herbal plants used to treat HIV proteases can also be a suitable candidate for COVID-19.", [["COVID-19", "CHEMICAL", 96, 104], ["HIV", "ORGANISM", 45, 48], ["HIV proteases", "PROTEIN", 45, 58], ["HIV", "SPECIES", 45, 48], ["many herbal plants", "TREATMENT", 12, 30], ["HIV proteases", "PROBLEM", 45, 58], ["COVID", "TEST", 96, 101], ["herbal plants", "OBSERVATION", 17, 30]]], ["To expedite, Acacia nilotica, Ocimum sanctum, Eugenia jambolana, Vitex negundo, Euphorbia granulate, Ocimum kikim, Ocimum scharicum, Solanum nigrum etc. were effective against HIV-reverse transcriptase activityand can be potent for SARS-CoV-2 too (Mishra et al., 2014; Rege and Chowdhary, 2014; NAIR, 2012; Thayil Seema and Thyagarajan, 2016).", [["Vitex negundo, Euphorbia granulate, Ocimum kikim, Ocimum scharicum, Solanum nigrum", "CHEMICAL", 65, 147], ["Acacia nilotica", "ORGANISM", 13, 28], ["Ocimum sanctum", "ORGANISM", 30, 44], ["Eugenia jambolana", "ORGANISM", 46, 63], ["Vitex negundo", "ORGANISM", 65, 78], ["Euphorbia granulate", "ORGANISM", 80, 99], ["Ocimum kikim", "ORGANISM", 101, 113], ["Ocimum scharicum", "ORGANISM", 115, 131], ["Solanum nigrum", "ORGANISM", 133, 147], ["etc", "ORGANISM", 148, 151], ["HIV", "ORGANISM", 176, 179], ["HIV-reverse transcriptase", "PROTEIN", 176, 201], ["Acacia nilotica", "SPECIES", 13, 28], ["Ocimum sanctum", "SPECIES", 30, 44], ["Eugenia jambolana", "SPECIES", 46, 63], ["Vitex negundo", "SPECIES", 65, 78], ["Euphorbia granulate", "SPECIES", 80, 99], ["Ocimum kikim", "SPECIES", 101, 113], ["Ocimum scharicum", "SPECIES", 115, 131], ["Solanum nigrum", "SPECIES", 133, 147], ["HIV", "SPECIES", 176, 179], ["Acacia nilotica", "SPECIES", 13, 28], ["Ocimum sanctum", "SPECIES", 30, 44], ["Eugenia jambolana", "SPECIES", 46, 63], ["Vitex negundo", "SPECIES", 65, 78], ["Euphorbia granulate", "SPECIES", 80, 99], ["Ocimum kikim", "SPECIES", 101, 113], ["Ocimum scharicum", "SPECIES", 115, 131], ["Solanum nigrum", "SPECIES", 133, 147], ["HIV", "SPECIES", 176, 179], ["SARS-CoV", "SPECIES", 232, 240], ["Acacia nilotica", "TREATMENT", 13, 28], ["Ocimum sanctum", "TREATMENT", 30, 44], ["Eugenia jambolana", "TREATMENT", 46, 63], ["Vitex", "TREATMENT", 65, 70], ["Euphorbia granulate", "TREATMENT", 80, 99], ["HIV", "PROBLEM", 176, 179], ["reverse transcriptase activityand", "TREATMENT", 180, 213], ["SARS", "PROBLEM", 232, 236], ["CoV", "TEST", 237, 240], ["Eugenia jambolana", "ANATOMY", 46, 63], ["Euphorbia granulate", "OBSERVATION", 80, 99], ["Solanum nigrum", "OBSERVATION", 133, 147]]], ["Further, Sambucus ebulus also attack the enveloped viruses, thereby, should be tested to study its target action against this virus (Ganjhu et al., 2015).Potential Role of Medicinal Plants as Antiviral Warriors ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaAdding to the above mentioned reports, Cheng et al. (2006) investigated the role of triterpene glycosides screened from Heteromorpha, Bupleurum and Scrophularia scordonia against coronavirus 229E by averting the attachment and invasion into the host.", [["triterpene glycosides", "CHEMICAL", 358, 379], ["Heteromorpha", "CHEMICAL", 394, 406], ["229E", "CHEMICAL", 465, 469], ["triterpene glycosides", "CHEMICAL", 358, 379], ["Sambucus ebulus", "ORGANISM", 9, 24], ["triterpene glycosides", "SIMPLE_CHEMICAL", 358, 379], ["Heteromorpha", "SIMPLE_CHEMICAL", 394, 406], ["Bupleurum", "ORGANISM", 408, 417], ["Scrophularia scordonia", "ORGANISM", 422, 444], ["coronavirus 229E", "ORGANISM", 453, 469], ["Sambucus ebulus", "SPECIES", 9, 24], ["Scrophularia scordonia", "SPECIES", 422, 444], ["coronavirus", "SPECIES", 453, 464], ["Sambucus ebulus", "SPECIES", 9, 24], ["Scrophularia scordonia", "SPECIES", 422, 444], ["coronavirus 229E", "SPECIES", 453, 469], ["Sambucus ebulus", "PROBLEM", 9, 24], ["the enveloped viruses", "PROBLEM", 37, 58], ["triterpene glycosides", "TREATMENT", 358, 379], ["Heteromorpha", "TREATMENT", 394, 406], ["Bupleurum", "TREATMENT", 408, 417], ["Scrophularia scordonia", "PROBLEM", 422, 444], ["coronavirus", "PROBLEM", 453, 464], ["Sambucus ebulus", "OBSERVATION", 9, 24], ["enveloped", "OBSERVATION_MODIFIER", 41, 50], ["viruses", "OBSERVATION", 51, 58], ["Bupleurum", "ANATOMY", 408, 417]]], ["Moreover, Artemisia annua, Lindera aggregata, Lycoris radiate, Isatis indigoticahave been known to exhibit anti-SARS-CoV effects (Li et al., 2005).", [["Artemisia annua", "CHEMICAL", 10, 25], ["Artemisia annua", "ORGANISM", 10, 25], ["Lindera aggregata", "ORGANISM", 27, 44], ["Lycoris radiate", "ORGANISM", 46, 61], ["Isatis indigoticahave", "ORGANISM", 63, 84], ["Artemisia annua", "SPECIES", 10, 25], ["Lindera aggregata", "SPECIES", 27, 44], ["Isatis indigoticahave", "SPECIES", 63, 84], ["Artemisia annua", "SPECIES", 10, 25], ["Lindera aggregata", "SPECIES", 27, 44], ["Isatis indigoticahave", "SPECIES", 63, 84]]], ["Similarly, naturally occurring repressors have been recognised such as scutellarein, phenolics, myricetin etc. from Isatis indigotica and Torreya nucifera respectively against SARS-CoV enzymes.", [["scutellarein", "CHEMICAL", 71, 83], ["myricetin", "CHEMICAL", 96, 105], ["SARS", "DISEASE", 176, 180], ["scutellarein", "CHEMICAL", 71, 83], ["phenolics", "CHEMICAL", 85, 94], ["myricetin", "CHEMICAL", 96, 105], ["scutellarein", "SIMPLE_CHEMICAL", 71, 83], ["phenolics", "SIMPLE_CHEMICAL", 85, 94], ["myricetin", "SIMPLE_CHEMICAL", 96, 105], ["Isatis indigotica", "ORGANISM", 116, 133], ["Torreya nucifera", "ORGANISM", 138, 154], ["SARS-CoV enzymes", "GENE_OR_GENE_PRODUCT", 176, 192], ["SARS-CoV enzymes", "PROTEIN", 176, 192], ["Isatis indigotica", "SPECIES", 116, 133], ["Torreya nucifera", "SPECIES", 138, 154], ["Isatis indigotica", "SPECIES", 116, 133], ["Torreya nucifera", "SPECIES", 138, 154], ["SARS-CoV", "SPECIES", 176, 184], ["phenolics", "TREATMENT", 85, 94], ["myricetin", "TREATMENT", 96, 105], ["SARS", "PROBLEM", 176, 180], ["CoV enzymes", "TEST", 181, 192]]], ["Another study was reported in Houttuynia cordata against SARS-CoV through inhibition of 3CL-proteases and RNA-polymerases (Yu et al., 2012).", [["SARS", "DISEASE", 57, 61], ["Houttuynia cordata", "ORGANISM", 30, 48], ["SARS-CoV", "ORGANISM", 57, 65], ["3CL-proteases", "GENE_OR_GENE_PRODUCT", 88, 101], ["3CL", "PROTEIN", 88, 91], ["proteases", "PROTEIN", 92, 101], ["RNA-polymerases", "PROTEIN", 106, 121], ["Houttuynia cordata", "SPECIES", 30, 48], ["Houttuynia cordata", "SPECIES", 30, 48], ["SARS-CoV", "SPECIES", 57, 65], ["Another study", "TEST", 0, 13], ["SARS", "PROBLEM", 57, 61], ["3CL-proteases", "TREATMENT", 88, 101], ["RNA-polymerases", "TREATMENT", 106, 121]]], ["Further, Nigella sativa have also been demonstrated to possess multifaceted properties due to the presence of thymoquinone against H9N2 and cytomegaloviral diseases (Tavakkoli et al., 2017).", [["thymoquinone", "CHEMICAL", 110, 122], ["H9N2", "DISEASE", 131, 135], ["cytomegaloviral diseases", "DISEASE", 140, 164], ["thymoquinone", "CHEMICAL", 110, 122], ["Nigella sativa", "ORGANISM", 9, 23], ["thymoquinone", "SIMPLE_CHEMICAL", 110, 122], ["H9N2", "ORGANISM", 131, 135], ["Nigella sativa", "SPECIES", 9, 23], ["H9N2", "SPECIES", 131, 135], ["Nigella sativa", "SPECIES", 9, 23], ["Nigella sativa", "TREATMENT", 9, 23], ["thymoquinone", "TREATMENT", 110, 122], ["H9N2", "PROBLEM", 131, 135], ["cytomegaloviral diseases", "PROBLEM", 140, 164]]], ["More recently, the role of Piper Betel in combating COVID-19 infections have also been explored (Sengupta, 2020).", [["Piper Betel", "CHEMICAL", 27, 38], ["infections", "DISEASE", 61, 71], ["Piper Betel", "ORGANISM", 27, 38], ["COVID-19", "ORGANISM", 52, 60], ["infections", "PROBLEM", 61, 71]]], ["According to their study, 'Aurantiamide', an active metabolite from Piper aurantiacum has chymotrypsin like-proteases like activities that is a ratified agent for inhibiting coronavirus.", [["Aurantiamide", "CHEMICAL", 27, 39], ["Piper aurantiacum", "CHEMICAL", 68, 85], ["Aurantiamide", "CHEMICAL", 27, 39], ["Aurantiamide", "SIMPLE_CHEMICAL", 27, 39], ["Piper aurantiacum", "ORGANISM", 68, 85], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 90, 102], ["coronavirus", "ORGANISM", 174, 185], ["chymotrypsin like-proteases", "PROTEIN", 90, 117], ["Piper aurantiacum", "SPECIES", 68, 85], ["Piper aurantiacum", "SPECIES", 68, 85], ["their study", "TEST", 13, 24], ["'Aurantiamide'", "TREATMENT", 26, 40], ["an active metabolite", "PROBLEM", 42, 62], ["chymotrypsin", "PROBLEM", 90, 102], ["proteases like activities", "PROBLEM", 108, 133], ["a ratified agent", "TREATMENT", 142, 158], ["inhibiting coronavirus", "PROBLEM", 163, 185]]], ["In addition to this, it also encompassespiperol, eugenol, catechol, caryophyllene, etragol, chavibetol, betlol, quercetin etc. that also grows body's self-defense mechanism either through reception of viruses or in waning off the viral load within the infected hosts (Sengupta, 2020).Alongside, studies have been depicted the role of herbal drug Gene-Eden-VIR/Novirin against many noxious viruses and this drug is mainly comprised of quercetin, green tea, cinnamon, licorice and selenium (Polansky and Lori, 2020).", [["body", "ANATOMY", 143, 147], ["encompassespiperol", "CHEMICAL", 29, 47], ["eugenol", "CHEMICAL", 49, 56], ["catechol", "CHEMICAL", 58, 66], ["caryophyllene", "CHEMICAL", 68, 81], ["etragol", "CHEMICAL", 83, 90], ["chavibetol", "CHEMICAL", 92, 102], ["betlol", "CHEMICAL", 104, 110], ["quercetin", "CHEMICAL", 112, 121], ["Gene-Eden-VIR", "CHEMICAL", 346, 359], ["Novirin", "CHEMICAL", 360, 367], ["quercetin", "CHEMICAL", 434, 443], ["green tea, cinnamon, licorice", "CHEMICAL", 445, 474], ["selenium", "CHEMICAL", 479, 487], ["encompassespiperol", "CHEMICAL", 29, 47], ["eugenol", "CHEMICAL", 49, 56], ["catechol", "CHEMICAL", 58, 66], ["caryophyllene", "CHEMICAL", 68, 81], ["etragol", "CHEMICAL", 83, 90], ["chavibetol", "CHEMICAL", 92, 102], ["betlol", "CHEMICAL", 104, 110], ["quercetin", "CHEMICAL", 112, 121], ["quercetin", "CHEMICAL", 434, 443], ["selenium", "CHEMICAL", 479, 487], ["encompassespiperol", "SIMPLE_CHEMICAL", 29, 47], ["eugenol", "SIMPLE_CHEMICAL", 49, 56], ["catechol", "SIMPLE_CHEMICAL", 58, 66], ["caryophyllene", "SIMPLE_CHEMICAL", 68, 81], ["etragol", "SIMPLE_CHEMICAL", 83, 90], ["chavibetol", "SIMPLE_CHEMICAL", 92, 102], ["betlol", "SIMPLE_CHEMICAL", 104, 110], ["quercetin", "SIMPLE_CHEMICAL", 112, 121], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["Gene-Eden-VIR", "SIMPLE_CHEMICAL", 346, 359], ["Novirin", "SIMPLE_CHEMICAL", 360, 367], ["quercetin", "SIMPLE_CHEMICAL", 434, 443], ["green tea", "SIMPLE_CHEMICAL", 445, 454], ["cinnamon", "SIMPLE_CHEMICAL", 456, 464], ["licorice", "SIMPLE_CHEMICAL", 466, 474], ["selenium", "SIMPLE_CHEMICAL", 479, 487], ["eugenol", "TREATMENT", 49, 56], ["catechol", "TREATMENT", 58, 66], ["caryophyllene", "TREATMENT", 68, 81], ["etragol", "TREATMENT", 83, 90], ["chavibetol", "TREATMENT", 92, 102], ["betlol", "TREATMENT", 104, 110], ["quercetin", "TREATMENT", 112, 121], ["viruses", "PROBLEM", 201, 208], ["the viral load", "PROBLEM", 226, 240], ["herbal drug Gene-Eden", "TREATMENT", 334, 355], ["VIR", "TREATMENT", 356, 359], ["Novirin", "TREATMENT", 360, 367], ["many noxious viruses", "PROBLEM", 376, 396], ["this drug", "TREATMENT", 401, 410], ["quercetin", "TREATMENT", 434, 443], ["green tea", "TREATMENT", 445, 454], ["cinnamon", "TREATMENT", 456, 464], ["viruses", "OBSERVATION", 201, 208], ["viral load", "OBSERVATION", 230, 240]]], ["They found that it disrupts the viral entry, infection, replication, viral proteases, viral quasi-speciesand triggers the immunity, thereby, can be evidently utilised against SARS-CoV-2 respectively (Polansky and Lori, 2020).Potential Role of Medicinal Plants as Antiviral Warriors ::: Traditional Cure for COVID-19: A Possible Room for AyurvedaInterestingly, the role of tulsi for scientific evidence against COVID-19 has also been elucidated (Goothy et al., 2020).", [["infection", "DISEASE", 45, 54], ["COVID-19", "CHEMICAL", 410, 418], ["COVID-19", "CHEMICAL", 410, 418], ["SARS-CoV-2", "ORGANISM", 175, 185], ["viral proteases", "PROTEIN", 69, 84], ["SARS-CoV", "SPECIES", 175, 183], ["the viral entry", "PROBLEM", 28, 43], ["infection", "PROBLEM", 45, 54], ["viral proteases", "PROBLEM", 69, 84], ["SARS", "PROBLEM", 175, 179], ["CoV", "TEST", 180, 183], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infection", "OBSERVATION", 45, 54]]], ["As, it is well known herbal plant for antiviral effects in inhibiting many deadly viruses like vaccinia, dengue, hepatitis, encephalitis etc. by enhancing their survival and defense ability.", [["vaccinia", "DISEASE", 95, 103], ["dengue", "DISEASE", 105, 111], ["hepatitis", "DISEASE", 113, 122], ["encephalitis", "DISEASE", 124, 136], ["vaccinia", "ORGANISM", 95, 103], ["antiviral effects", "TREATMENT", 38, 55], ["vaccinia", "PROBLEM", 95, 103], ["dengue", "PROBLEM", 105, 111], ["hepatitis", "PROBLEM", 113, 122], ["encephalitis", "PROBLEM", 124, 136], ["vaccinia", "OBSERVATION", 95, 103], ["hepatitis", "OBSERVATION", 113, 122], ["encephalitis", "OBSERVATION", 124, 136]]], ["Moreover, it also reinstate the physiological functions of body through its phenolic and antioxidative property that in turns shields the body from toxic substances (Shivananjappa and Joshi, 2012).", [["body", "ANATOMY", 59, 63], ["body", "ANATOMY", 138, 142], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["phenolic", "SIMPLE_CHEMICAL", 76, 84], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["antioxidative property", "TREATMENT", 89, 111], ["body", "ANATOMY", 138, 142], ["toxic substances", "OBSERVATION", 148, 164]]], ["The most possible mechanism underlying its immunity boosters lies in triggering humoral and cellular immunity responses (Vaghasiya et al., 2010).", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100], ["most possible", "UNCERTAINTY", 4, 17], ["cellular immunity", "OBSERVATION", 92, 109]]], ["Apart from this, modulatory actions of GABA pathway also encompass their multi-modal therapeutic properties, therefore, we can conjecture that it could be efficient in cure of COVID-19.", [["GABA", "CHEMICAL", 39, 43], ["GABA", "CHEMICAL", 39, 43], ["COVID-19", "CHEMICAL", 176, 184], ["GABA", "SIMPLE_CHEMICAL", 39, 43], ["COVID-19", "CELL", 176, 184], ["COVID", "TEST", 176, 181]]], ["Nevertheless, the role of Persian herbs have also been untangled against COVID-19 via inhibitory action against ACE2 enzyme that enables viral entry into the host cells.", [["cells", "ANATOMY", 163, 168], ["COVID-19", "CHEMICAL", 73, 81], ["COVID-19", "CHEMICAL", 73, 81], ["COVID-19", "GENE_OR_GENE_PRODUCT", 73, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["cells", "CELL", 163, 168], ["ACE2 enzyme", "PROTEIN", 112, 123], ["host cells", "CELL_TYPE", 158, 168], ["COVID", "TEST", 73, 78], ["ACE2 enzyme", "TEST", 112, 123], ["host cells", "OBSERVATION", 158, 168]]], ["Various species like, Allium sativum, Cerasus avium, Berberis integerrima, Alcea digitata, Rubia tinctorum, Peganum harmala etc. were illuminated as ACE2 inhibitors, therefore, could be considered for COVID-19 prevention after proper evaluation (Hiedary et al., 2020).Henceforth, herbal plants could be possibly used to mitigate the emergence of COVID-19 (Table 1).", [["COVID-19", "CHEMICAL", 346, 354], ["Allium sativum", "ORGANISM", 22, 36], ["Cerasus avium", "ORGANISM", 38, 51], ["Berberis integerrima", "ORGANISM", 53, 73], ["Alcea digitata", "ORGANISM", 75, 89], ["Rubia tinctorum", "ORGANISM", 91, 106], ["Peganum harmala", "ORGANISM", 108, 123], ["etc", "ORGANISM", 124, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 149, 153], ["ACE2", "PROTEIN", 149, 153], ["Allium sativum", "SPECIES", 22, 36], ["Cerasus avium", "SPECIES", 38, 51], ["Berberis integerrima", "SPECIES", 53, 73], ["Alcea digitata", "SPECIES", 75, 89], ["Rubia tinctorum", "SPECIES", 91, 106], ["Peganum harmala", "SPECIES", 108, 123], ["Allium sativum", "SPECIES", 22, 36], ["Cerasus avium", "SPECIES", 38, 51], ["Berberis integerrima", "SPECIES", 53, 73], ["Alcea digitata", "SPECIES", 75, 89], ["Rubia tinctorum", "SPECIES", 91, 106], ["Peganum harmala", "SPECIES", 108, 123], ["Various species", "PROBLEM", 0, 15], ["Allium sativum", "TEST", 22, 36], ["Cerasus avium", "TEST", 38, 51], ["Berberis integerrima", "TEST", 53, 73], ["Alcea digitata", "TEST", 75, 89], ["ACE2 inhibitors", "TREATMENT", 149, 164], ["COVID", "TEST", 201, 206], ["proper evaluation", "TEST", 227, 244], ["herbal plants", "TREATMENT", 280, 293], ["COVID", "TEST", 346, 351], ["Berberis integerrima", "OBSERVATION", 53, 73], ["Rubia", "ANATOMY", 91, 96], ["tinctorum", "ANATOMY_MODIFIER", 97, 106], ["Peganum", "ANATOMY", 108, 115]]], ["Despite the fact that, a lot many medicinal plants have been propagated for this purpose, a lot more research is being carried to formulate the drug specifically for this.Immune System Rebooting ::: Ancillary Armours to Combat COVID-19 Viral InfectionThe upliftment of immune responses of body is the cutting edge in thwarting the viruses to stay healthy.", [["body", "ANATOMY", 289, 293], ["Viral Infection", "DISEASE", 236, 251], ["body", "ORGANISM_SUBDIVISION", 289, 293], ["COVID", "TEST", 227, 232], ["Viral Infection", "PROBLEM", 236, 251], ["Infection", "OBSERVATION", 242, 251], ["viruses", "OBSERVATION", 331, 338]]], ["For this purpose, it is rudimentary to amend the current lifestyle by adding smarter works in 'to do's' list so as to make inner immune/defense competitive against viruses such as COVID-19.", [["inner", "TISSUE", 123, 128], ["COVID", "TEST", 180, 185]]], ["This would naturally heal the antiviral effects within the body by dissolution of the avidity of the disease and infection.", [["body", "ANATOMY", 59, 63], ["infection", "DISEASE", 113, 122], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["the disease", "PROBLEM", 97, 108], ["infection", "PROBLEM", 113, 122], ["antiviral effects", "OBSERVATION", 30, 47], ["disease", "OBSERVATION", 101, 108], ["infection", "OBSERVATION", 113, 122]]], ["Majority of these attributes are linked to reboot the functions associated with improved immunity via mediating anti-inflammatory activities, enhancing cell-mediated immune functions, modulated APC (Antigen Presenting Cell) activities and suppressing pro-inflammatory mediators.", [["cell", "ANATOMY", 152, 156], ["Cell", "ANATOMY", 218, 222], ["cell", "CELL", 152, 156], ["APC", "GENE_OR_GENE_PRODUCT", 194, 197], ["Cell", "CELL", 218, 222], ["APC", "CELL_TYPE", 194, 197], ["pro-inflammatory mediators", "PROTEIN", 251, 277], ["modulated APC", "PROBLEM", 184, 197], ["suppressing pro-inflammatory mediators", "TREATMENT", 239, 277]]], ["In addition, they also mediate effective cell-cell communication during innate as well as adaptive immune responses (Sarfraz et al., 2020).", [["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 46, 50], ["cell", "CELL", 41, 45], ["cell", "CELL", 46, 50]]], ["Hence, a scientific expedition of escalating immune system through appropriate sleep, judicious exercise, stress-free environment, proper nutritive foods, water intake and consumption of fresh and healthy fruits and vegetables would anticipate the citizenry to cope with coronavirus battle via naturally vaccinating their systems (Jayawardena et al., 2020).Immune System Rebooting ::: Ancillary Armours to Combat COVID-19 Viral InfectionThe scientific picturespeculates that different stressors, sleep dispossession and sparkling beverages subdue the immune systemby the release of ACTH (Adrenocorticotrophic Hormones) namely, adrenaline, non-adrenaline and glucocorticoids.", [["immune system", "ANATOMY", 45, 58], ["fruits", "ANATOMY", 205, 211], ["vegetables", "ANATOMY", 216, 226], ["Viral Infection", "DISEASE", 422, 437], ["adrenaline", "CHEMICAL", 627, 637], ["non-adrenaline", "CHEMICAL", 639, 653], ["glucocorticoids", "CHEMICAL", 658, 673], ["adrenaline", "CHEMICAL", 627, 637], ["non-adrenaline", "CHEMICAL", 639, 653], ["fruits", "ORGANISM_SUBDIVISION", 205, 211], ["vegetables", "ORGANISM_SUBDIVISION", 216, 226], ["coronavirus", "ORGANISM", 271, 282], ["ACTH", "GENE_OR_GENE_PRODUCT", 582, 586], ["Adrenocorticotrophic Hormones", "SIMPLE_CHEMICAL", 588, 617], ["adrenaline", "SIMPLE_CHEMICAL", 627, 637], ["non-adrenaline", "SIMPLE_CHEMICAL", 639, 653], ["glucocorticoids", "SIMPLE_CHEMICAL", 658, 673], ["escalating immune system", "TREATMENT", 34, 58], ["stress-free environment", "TREATMENT", 106, 129], ["coronavirus battle", "TREATMENT", 271, 289], ["COVID", "TEST", 413, 418], ["Viral Infection", "PROBLEM", 422, 437], ["sleep dispossession", "PROBLEM", 496, 515], ["ACTH (Adrenocorticotrophic Hormones", "TREATMENT", 582, 617], ["adrenaline", "TREATMENT", 627, 637], ["non-adrenaline and glucocorticoids", "TREATMENT", 639, 673], ["Infection", "OBSERVATION", 428, 437], ["glucocorticoids", "ANATOMY", 658, 673]]], ["This in turn makes a person susceptible to pathogenic infections by weakening the immune system of the body.", [["immune system", "ANATOMY", 82, 95], ["body", "ANATOMY", 103, 107], ["infections", "DISEASE", 54, 64], ["immune system", "ANATOMICAL_SYSTEM", 82, 95], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["person", "SPECIES", 21, 27], ["pathogenic infections", "PROBLEM", 43, 64], ["pathogenic", "OBSERVATION_MODIFIER", 43, 53], ["infections", "OBSERVATION", 54, 64], ["immune system", "OBSERVATION", 82, 95], ["body", "ANATOMY", 103, 107]]], ["For instance, immune system mediators like NK (Natural Killer) cells, Helper-T-cells, lymphocytes, antibodies, interleukins (IL4, 5, 10, 13), cytokines are impaired that leads to increased chances of infection along with the reactivation of the latent viruses (Calder et al., 2020).", [["immune system", "ANATOMY", 14, 27], ["NK", "ANATOMY", 43, 45], ["Natural Killer) cells", "ANATOMY", 47, 68], ["Helper-T-cells", "ANATOMY", 70, 84], ["lymphocytes", "ANATOMY", 86, 97], ["infection", "DISEASE", 200, 209], ["NK", "CELL", 43, 45], ["Natural Killer) cells", "CELL", 47, 68], ["Helper-T-cells", "CELL", 70, 84], ["lymphocytes", "CELL", 86, 97], ["interleukins", "GENE_OR_GENE_PRODUCT", 111, 123], ["IL4", "GENE_OR_GENE_PRODUCT", 125, 128], ["5", "GENE_OR_GENE_PRODUCT", 130, 131], ["10", "GENE_OR_GENE_PRODUCT", 133, 135], ["13", "GENE_OR_GENE_PRODUCT", 137, 139], ["NK (Natural Killer) cells", "CELL_TYPE", 43, 68], ["Helper-T-cells", "CELL_TYPE", 70, 84], ["lymphocytes", "CELL_TYPE", 86, 97], ["antibodies", "PROTEIN", 99, 109], ["interleukins", "PROTEIN", 111, 123], ["IL4, 5, 10, 13", "PROTEIN", 125, 139], ["cytokines", "PROTEIN", 142, 151], ["immune system mediators", "TEST", 14, 37], ["NK", "TEST", 43, 45], ["Helper", "TEST", 70, 76], ["lymphocytes", "TEST", 86, 97], ["antibodies", "TEST", 99, 109], ["interleukins", "TEST", 111, 123], ["IL4", "TEST", 125, 128], ["cytokines", "TEST", 142, 151], ["infection", "PROBLEM", 200, 209], ["the latent viruses", "PROBLEM", 241, 259], ["lymphocytes", "ANATOMY", 86, 97], ["increased", "OBSERVATION_MODIFIER", 179, 188], ["infection", "OBSERVATION", 200, 209], ["latent", "OBSERVATION_MODIFIER", 245, 251], ["viruses", "OBSERVATION", 252, 259]]], ["In addition, scarcity of sleep may also hinder the immune pathways within the individual through ACTH-curbed persistent activation of NF-\u03baB that elevates the threat of infections due to plummeted microbial gene expression levels.", [["infections", "DISEASE", 168, 178], ["ACTH", "GENE_OR_GENE_PRODUCT", 97, 101], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["NF-\u03baB", "PROTEIN", 134, 139], ["ACTH", "TEST", 97, 101], ["persistent activation of NF", "PROBLEM", 109, 136], ["infections", "PROBLEM", 168, 178], ["plummeted microbial gene expression levels", "PROBLEM", 186, 228], ["infections", "OBSERVATION", 168, 178]]], ["Meanwhile, the proper sleep balances the hormonal responses within the body to ensure the reorganisation of T-cells towards lymph nodes to boost their immunogenic memory response (Calder et al., 2020).", [["body", "ANATOMY", 71, 75], ["T-cells", "ANATOMY", 108, 115], ["lymph nodes", "ANATOMY", 124, 135], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["T-cells", "CELL", 108, 115], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 124, 135], ["T-cells", "CELL_TYPE", 108, 115], ["lymph nodes", "PROBLEM", 124, 135], ["lymph nodes", "OBSERVATION", 124, 135]]], ["Moreover, consumption of fizzy drinks or alcohol based beverages causes high glucose or CO2 within blood that in turn causes hypercapnia so as to inhibit macrophage activity and pathogen clearance.", [["blood", "ANATOMY", 99, 104], ["macrophage", "ANATOMY", 154, 164], ["fizzy drinks", "CHEMICAL", 25, 37], ["alcohol", "CHEMICAL", 41, 48], ["glucose", "CHEMICAL", 77, 84], ["CO2", "CHEMICAL", 88, 91], ["alcohol", "CHEMICAL", 41, 48], ["glucose", "CHEMICAL", 77, 84], ["CO2", "CHEMICAL", 88, 91], ["alcohol", "SIMPLE_CHEMICAL", 41, 48], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["CO2", "SIMPLE_CHEMICAL", 88, 91], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["macrophage", "CELL", 154, 164], ["high glucose", "PROBLEM", 72, 84], ["CO2 within blood", "PROBLEM", 88, 104], ["hypercapnia", "PROBLEM", 125, 136], ["macrophage activity", "PROBLEM", 154, 173], ["pathogen clearance", "TEST", 178, 196], ["hypercapnia", "OBSERVATION", 125, 136]]], ["It also hampers the immuno-modulators, thereby loss of control on invading pathogens.", [["the immuno-modulators", "PROBLEM", 16, 37], ["loss of control on invading pathogens", "PROBLEM", 47, 84], ["immuno-modulators", "OBSERVATION", 20, 37], ["loss", "OBSERVATION_MODIFIER", 47, 51]]], ["Whilst, proper sleep, active daily routine, exercise etc. augments the immune-surveillance in the form of NK cells, monocytes, neutrophils, T-cells, Immunoglobulin's etc. to counteract adverse health components (Nieman and Wentz, 2019).", [["NK cells", "ANATOMY", 106, 114], ["monocytes", "ANATOMY", 116, 125], ["neutrophils", "ANATOMY", 127, 138], ["T-cells", "ANATOMY", 140, 147], ["NK cells", "CELL", 106, 114], ["monocytes", "CELL", 116, 125], ["neutrophils", "CELL", 127, 138], ["T-cells", "CELL", 140, 147], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 149, 163], ["NK cells", "CELL_TYPE", 106, 114], ["monocytes", "CELL_TYPE", 116, 125], ["neutrophils", "CELL_TYPE", 127, 138], ["T-cells", "CELL_TYPE", 140, 147], ["Immunoglobulin's etc", "PROTEIN", 149, 169], ["the immune", "TEST", 67, 77], ["NK cells", "TEST", 106, 114], ["monocytes", "TEST", 116, 125], ["neutrophils", "TEST", 127, 138], ["T", "TEST", 140, 141], ["Immunoglobulin", "TEST", 149, 163]]], ["Apart from this, muti-vitamins intake within human body can wash away the sickness forces through recruiting the immune soldiers (Combs and McClung, 2016).", [["body", "ANATOMY", 51, 55], ["muti-vitamins", "CHEMICAL", 17, 30], ["sickness", "DISEASE", 74, 82], ["muti-vitamins", "CHEMICAL", 17, 30], ["muti-vitamins", "SIMPLE_CHEMICAL", 17, 30], ["human", "ORGANISM", 45, 50], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["this, muti-vitamins intake", "TREATMENT", 11, 37], ["the sickness forces", "PROBLEM", 70, 89]]], ["Diet comprising of multi-vitamins wield immune-modulatory possessions on numerous immune cells such as monocytes, neutrophils, lymphocytes, NK cells, dendritic cells that bump up the immunity against pathogens (Lewis et al., 2019; Petric, 2020).", [["immune cells", "ANATOMY", 82, 94], ["monocytes", "ANATOMY", 103, 112], ["neutrophils", "ANATOMY", 114, 125], ["lymphocytes", "ANATOMY", 127, 138], ["NK cells", "ANATOMY", 140, 148], ["dendritic cells", "ANATOMY", 150, 165], ["multi-vitamins", "SIMPLE_CHEMICAL", 19, 33], ["immune cells", "CELL", 82, 94], ["monocytes", "CELL", 103, 112], ["neutrophils", "CELL", 114, 125], ["lymphocytes", "CELL", 127, 138], ["NK cells", "CELL", 140, 148], ["dendritic cells", "CELL", 150, 165], ["immune cells", "CELL_TYPE", 82, 94], ["monocytes", "CELL_TYPE", 103, 112], ["neutrophils", "CELL_TYPE", 114, 125], ["lymphocytes", "CELL_TYPE", 127, 138], ["NK cells", "CELL_TYPE", 140, 148], ["dendritic cells", "CELL_TYPE", 150, 165], ["multi-vitamins", "TREATMENT", 19, 33], ["numerous immune cells", "PROBLEM", 73, 94], ["monocytes", "TEST", 103, 112], ["neutrophils", "TEST", 114, 125], ["lymphocytes", "TEST", 127, 138], ["NK cells", "PROBLEM", 140, 148], ["dendritic cells", "PROBLEM", 150, 165], ["pathogens", "PROBLEM", 200, 209], ["immune cells", "OBSERVATION", 82, 94], ["lymphocytes", "ANATOMY", 127, 138], ["NK cells", "OBSERVATION", 140, 148], ["dendritic cells", "OBSERVATION", 150, 165]]], ["Perhaps, these immune cells would trigger the anti-pathogenic responses against coronaviruses via exasperating the levels of Cathelicidin, Defensin \u03b2, antimicrobial peptides, phagocytosis, neutrophil migration and chemotaxis, oxidant generation, NK-activation (CD69, CD25), IF-\u03b3, antibodies synthesis, cytokine synthesis and T-cell proliferation respectively.Immune System Rebooting ::: Ancillary Armours to Combat COVID-19 Viral InfectionInevitably, assorted dietary minerals that are essential immunity mediators should be incorporated into the diet, for example, different fruits, spices and vegetables are abundant with immuno-stimulators that in turn fortifies the innate as well as adaptive immune responses against viral elements (Sarfraz et al., 2020).", [["immune cells", "ANATOMY", 15, 27], ["neutrophil", "ANATOMY", 189, 199], ["NK", "ANATOMY", 246, 248], ["T-cell", "ANATOMY", 325, 331], ["fruits", "ANATOMY", 576, 582], ["spices", "ANATOMY", 584, 590], ["vegetables", "ANATOMY", 595, 605], ["immune cells", "CELL", 15, 27], ["coronaviruses", "ORGANISM", 80, 93], ["Cathelicidin", "GENE_OR_GENE_PRODUCT", 125, 137], ["Defensin \u03b2", "GENE_OR_GENE_PRODUCT", 139, 149], ["antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 151, 173], ["neutrophil", "CELL", 189, 199], ["NK", "CELL", 246, 248], ["CD69", "GENE_OR_GENE_PRODUCT", 261, 265], ["CD25", "GENE_OR_GENE_PRODUCT", 267, 271], ["IF-\u03b3", "GENE_OR_GENE_PRODUCT", 274, 278], ["T-cell", "CELL", 325, 331], ["fruits", "ORGANISM_SUBDIVISION", 576, 582], ["spices", "ORGANISM_SUBDIVISION", 584, 590], ["vegetables", "ORGANISM_SUBDIVISION", 595, 605], ["immune cells", "CELL_TYPE", 15, 27], ["Cathelicidin", "PROTEIN", 125, 137], ["Defensin \u03b2", "PROTEIN", 139, 149], ["CD69", "PROTEIN", 261, 265], ["CD25", "PROTEIN", 267, 271], ["IF", "PROTEIN", 274, 276], ["\u03b3", "PROTEIN", 277, 278], ["antibodies", "PROTEIN", 280, 290], ["cytokine", "PROTEIN", 302, 310], ["viral elements", "DNA", 722, 736], ["these immune cells", "PROBLEM", 9, 27], ["coronaviruses", "PROBLEM", 80, 93], ["Cathelicidin", "TREATMENT", 125, 137], ["Defensin", "TREATMENT", 139, 147], ["antimicrobial peptides", "TREATMENT", 151, 173], ["phagocytosis", "PROBLEM", 175, 187], ["neutrophil migration", "PROBLEM", 189, 209], ["chemotaxis", "TEST", 214, 224], ["oxidant generation", "TEST", 226, 244], ["CD69", "TEST", 261, 265], ["CD25", "TEST", 267, 271], ["IF", "TEST", 274, 276], ["antibodies synthesis", "TEST", 280, 300], ["cytokine synthesis", "TEST", 302, 320], ["Combat COVID", "TEST", 408, 420], ["Viral InfectionInevitably", "PROBLEM", 424, 449], ["essential immunity mediators", "TREATMENT", 486, 514], ["immuno-stimulators", "TREATMENT", 624, 642], ["adaptive immune responses", "TREATMENT", 688, 713], ["neutrophil migration", "OBSERVATION", 189, 209]]], ["To elucidate, these foods contain allicin, cucumins, papain, ginsenoside, mangoosteen, chloroquine etc. that has a direct effect on dendritic cells, NK cells, lymphocytes, antibodies in imparting shield against foreign particles invading human body.", [["dendritic cells", "ANATOMY", 132, 147], ["NK cells", "ANATOMY", 149, 157], ["lymphocytes", "ANATOMY", 159, 170], ["body", "ANATOMY", 244, 248], ["allicin", "CHEMICAL", 34, 41], ["cucumins, papain, ginsenoside, mangoosteen", "CHEMICAL", 43, 85], ["chloroquine", "CHEMICAL", 87, 98], ["allicin", "CHEMICAL", 34, 41], ["cucumins", "CHEMICAL", 43, 51], ["ginsenoside", "CHEMICAL", 61, 72], ["mangoosteen", "CHEMICAL", 74, 85], ["chloroquine", "CHEMICAL", 87, 98], ["allicin", "SIMPLE_CHEMICAL", 34, 41], ["cucumins", "SIMPLE_CHEMICAL", 43, 51], ["papain", "SIMPLE_CHEMICAL", 53, 59], ["ginsenoside", "SIMPLE_CHEMICAL", 61, 72], ["mangoosteen", "SIMPLE_CHEMICAL", 74, 85], ["chloroquine", "SIMPLE_CHEMICAL", 87, 98], ["dendritic cells", "CELL", 132, 147], ["NK cells", "CELL", 149, 157], ["lymphocytes", "CELL", 159, 170], ["human", "ORGANISM", 238, 243], ["body", "ORGANISM_SUBDIVISION", 244, 248], ["dendritic cells", "CELL_TYPE", 132, 147], ["NK cells", "CELL_TYPE", 149, 157], ["lymphocytes", "CELL_TYPE", 159, 170], ["antibodies", "PROTEIN", 172, 182], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 238, 243], ["allicin", "TREATMENT", 34, 41], ["cucumins", "TREATMENT", 43, 51], ["papain", "TREATMENT", 53, 59], ["ginsenoside", "TREATMENT", 61, 72], ["mangoosteen", "TREATMENT", 74, 85], ["chloroquine", "TREATMENT", 87, 98], ["dendritic cells", "PROBLEM", 132, 147], ["NK cells", "TEST", 149, 157], ["lymphocytes", "TEST", 159, 170], ["antibodies", "TEST", 172, 182], ["foreign particles", "PROBLEM", 211, 228], ["dendritic cells", "OBSERVATION", 132, 147], ["NK cells", "OBSERVATION", 149, 157], ["lymphocytes", "ANATOMY", 159, 170], ["foreign particles", "OBSERVATION", 211, 228], ["body", "ANATOMY_MODIFIER", 244, 248]]], ["As the diet is a summation of trace elements, mineral supplements, vitamins (A, D, C, E, K), zinc etc, it can fulfil all the repercussions such as hypovitaminosis caused due to viral attack respectively (Gunville et al., 2013; Petric, 2020).", [["vitamins", "CHEMICAL", 67, 75], ["A, D, C, E, K", "CHEMICAL", 77, 90], ["zinc", "CHEMICAL", 93, 97], ["hypovitaminosis", "DISEASE", 147, 162], ["vitamins (A, D, C, E, K", "CHEMICAL", 67, 90], ["zinc", "CHEMICAL", 93, 97], ["vitamins", "SIMPLE_CHEMICAL", 67, 75], ["A", "SIMPLE_CHEMICAL", 77, 78], ["D", "SIMPLE_CHEMICAL", 80, 81], ["C", "SIMPLE_CHEMICAL", 83, 84], ["E, K", "SIMPLE_CHEMICAL", 86, 90], ["zinc", "SIMPLE_CHEMICAL", 93, 97], ["a summation of trace elements", "TREATMENT", 15, 44], ["mineral supplements", "TREATMENT", 46, 65], ["vitamins (A, D, C, E, K)", "TREATMENT", 67, 91], ["zinc etc", "TREATMENT", 93, 101], ["hypovitaminosis", "PROBLEM", 147, 162], ["viral attack", "PROBLEM", 177, 189]]], ["Additionally, regular physical activities is adjuvant for boosting immunity and metabolic health specifically, if it's sunny, as ultra-violet and infra-red rays are natural virucidal elements (Lytle et al., 2005; Martin et al., 2009).", [["ultra-violet and infra-red rays", "TREATMENT", 129, 160], ["natural virucidal elements", "PROBLEM", 165, 191]]], ["However, the biological activities can also be improved by ingesting high levels of naturally existing polyphenols that not only elicit immunity against viruses but they are also comprised of receptors that identifies and permit their cellular uptake for activating signaling cascade underlying innate immunity (Nieman and Wentz, 2019).", [["cellular", "ANATOMY", 235, 243], ["polyphenols", "CHEMICAL", 103, 114], ["polyphenols", "SIMPLE_CHEMICAL", 103, 114], ["cellular", "CELL", 235, 243], ["naturally existing polyphenols", "TREATMENT", 84, 114], ["viruses", "PROBLEM", 153, 160]]], ["To exemplify, curcumin and epigallocatechin gallate causes epigenetic alterations within cells, curb gasto-intestinal immunity and allergic responses (Ding et al., 2018).", [["cells", "ANATOMY", 89, 94], ["gasto-intestinal", "ANATOMY", 101, 117], ["curcumin", "CHEMICAL", 14, 22], ["epigallocatechin gallate", "CHEMICAL", 27, 51], ["allergic", "DISEASE", 131, 139], ["curcumin", "CHEMICAL", 14, 22], ["epigallocatechin gallate", "CHEMICAL", 27, 51], ["curcumin", "SIMPLE_CHEMICAL", 14, 22], ["epigallocatechin gallate", "SIMPLE_CHEMICAL", 27, 51], ["cells", "CELL", 89, 94], ["intestinal", "ORGAN", 107, 117], ["curcumin and epigallocatechin gallate", "TREATMENT", 14, 51], ["epigenetic alterations within cells", "PROBLEM", 59, 94], ["allergic responses", "PROBLEM", 131, 149], ["intestinal", "ANATOMY", 107, 117]]], ["These compounds predominantly include flavonoids, phenols, stilbenoids that are abundantly present in plants in the form of aglycones or glucose esters (Ma et al., 2014).", [["phenols", "CHEMICAL", 50, 57], ["stilbenoids", "CHEMICAL", 59, 70], ["glucose esters", "CHEMICAL", 137, 151], ["flavonoids", "CHEMICAL", 38, 48], ["phenols", "CHEMICAL", 50, 57], ["stilbenoids", "CHEMICAL", 59, 70], ["glucose esters", "CHEMICAL", 137, 151], ["flavonoids", "SIMPLE_CHEMICAL", 38, 48], ["phenols", "SIMPLE_CHEMICAL", 50, 57], ["stilbenoids", "SIMPLE_CHEMICAL", 59, 70], ["aglycones", "SIMPLE_CHEMICAL", 124, 133], ["glucose esters", "SIMPLE_CHEMICAL", 137, 151], ["flavonoids", "PROBLEM", 38, 48], ["glucose esters", "TEST", 137, 151], ["flavonoids", "OBSERVATION", 38, 48]]], ["An in vitro study reported by Lin et al. (2017), depicted the role of resveratrol from grape seeds against coronaviruses.", [["resveratrol", "CHEMICAL", 70, 81], ["resveratrol", "CHEMICAL", 70, 81], ["resveratrol", "SIMPLE_CHEMICAL", 70, 81], ["grape seeds", "ORGANISM", 87, 98], ["coronaviruses", "ORGANISM", 107, 120], ["An in vitro study", "TEST", 0, 17], ["resveratrol", "TREATMENT", 70, 81], ["coronaviruses", "PROBLEM", 107, 120]]], ["Likewise, other antiviral components like glycyrrhizin from liquorice have been known to show some activity against coronaviruses and SARS, revealing the significance of glycyrrhizin to be used as trial drug in COVID-19 affected patients, in order to develop it as a potent cure drug (Chen et al., 2004; Cinatl et al., 2003; Brush et al., 2006).", [["glycyrrhizin", "CHEMICAL", 42, 54], ["liquorice", "CHEMICAL", 60, 69], ["SARS", "DISEASE", 134, 138], ["glycyrrhizin", "CHEMICAL", 170, 182], ["glycyrrhizin", "CHEMICAL", 42, 54], ["glycyrrhizin", "CHEMICAL", 170, 182], ["glycyrrhizin", "SIMPLE_CHEMICAL", 42, 54], ["liquorice", "SIMPLE_CHEMICAL", 60, 69], ["coronaviruses", "ORGANISM", 116, 129], ["glycyrrhizin", "SIMPLE_CHEMICAL", 170, 182], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["other antiviral components", "TREATMENT", 10, 36], ["glycyrrhizin from liquorice", "TREATMENT", 42, 69], ["coronaviruses", "PROBLEM", 116, 129], ["SARS", "PROBLEM", 134, 138], ["glycyrrhizin", "TREATMENT", 170, 182]]], ["Nevertheless, other plants like oregano, garlic, ginger, lemon, broccoli, mint, tulsi, fennel, thyme, cinnamon, star anise etc. should be tested in the different forms so as to form an effective drug to fight against COVID-19 (Yasmin et al., 2020).", [["tulsi", "ANATOMY", 80, 85], ["oregano, garlic, ginger, lemon, broccoli, mint, tulsi, fennel, thyme, cinnamon, star anise", "CHEMICAL", 32, 122], ["COVID-19", "CHEMICAL", 217, 225], ["oregano", "ORGANISM_SUBDIVISION", 32, 39], ["garlic", "SIMPLE_CHEMICAL", 41, 47], ["ginger", "ORGANISM_SUBDIVISION", 49, 55], ["lemon", "ORGANISM_SUBDIVISION", 57, 62], ["broccoli", "ORGANISM_SUBDIVISION", 64, 72], ["mint", "ORGANISM_SUBDIVISION", 74, 78], ["tulsi", "ORGANISM_SUBDIVISION", 80, 85], ["fennel", "ORGANISM_SUBDIVISION", 87, 93], ["thyme", "ORGANISM_SUBDIVISION", 95, 100], ["cinnamon", "ORGANISM_SUBDIVISION", 102, 110], ["oregano", "SPECIES", 32, 39], ["garlic", "SPECIES", 41, 47], ["ginger", "SPECIES", 49, 55], ["lemon", "SPECIES", 57, 62], ["broccoli", "SPECIES", 64, 72], ["thyme", "SPECIES", 95, 100], ["oregano", "SPECIES", 32, 39], ["broccoli", "SPECIES", 64, 72], ["COVID", "TEST", 217, 222], ["broccoli", "ANATOMY", 64, 72]]], ["Above all, smoking has a direct impact on immune responses through escalating pathogen immunity and dwindling the defense responses within hosts.", [["smoking", "CHEMICAL", 11, 18], ["immune responses", "TREATMENT", 42, 58], ["escalating pathogen immunity", "TREATMENT", 67, 95]]], ["Moreover, T-helper cells, CD4, CD25, CD8+ T-cells, memory cells, B and T cells, NK cells, macrophages etc. are also hindered by smoke.Therefore, these steps can reboot the immune system and reinforce the inner forces to battle against severe viral infections COVID-19 respectively.Vitamins ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionVitamin A is an essential fat-soluble vitamin which has a major involvement in regulating vision, growth and maturity as well as protection of the mucosal and epithelium integrity of the human body (Huang et al., 2018).", [["T-helper cells", "ANATOMY", 10, 24], ["T-cells", "ANATOMY", 42, 49], ["memory cells", "ANATOMY", 51, 63], ["B", "ANATOMY", 65, 66], ["T cells", "ANATOMY", 71, 78], ["NK cells", "ANATOMY", 80, 88], ["macrophages", "ANATOMY", 90, 101], ["immune system", "ANATOMY", 172, 185], ["mucosal", "ANATOMY", 518, 525], ["epithelium", "ANATOMY", 530, 540], ["body", "ANATOMY", 564, 568], ["viral infections", "DISEASE", 242, 258], ["InfectionVitamin", "CHEMICAL", 362, 378], ["vitamin", "CHEMICAL", 409, 416], ["Vitamins", "CHEMICAL", 281, 289], ["InfectionVitamin", "CHEMICAL", 362, 378], ["vitamin", "CHEMICAL", 409, 416], ["T-helper cells", "CELL", 10, 24], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD25", "GENE_OR_GENE_PRODUCT", 31, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["T-cells", "CELL", 42, 49], ["memory cells", "CELL", 51, 63], ["B", "CELL", 65, 66], ["T cells", "CELL", 71, 78], ["NK cells", "CELL", 80, 88], ["macrophages", "CELL", 90, 101], ["Vitamins", "SIMPLE_CHEMICAL", 281, 289], ["fat", "TISSUE", 397, 400], ["vitamin", "SIMPLE_CHEMICAL", 409, 416], ["mucosal", "TISSUE", 518, 525], ["epithelium", "TISSUE", 530, 540], ["human", "ORGANISM", 558, 563], ["body", "ORGANISM_SUBDIVISION", 564, 568], ["T-helper cells", "CELL_TYPE", 10, 24], ["CD4", "PROTEIN", 26, 29], ["CD25", "PROTEIN", 31, 35], ["CD8", "PROTEIN", 37, 40], ["T-cells", "CELL_TYPE", 42, 49], ["memory cells", "CELL_TYPE", 51, 63], ["B and T cells", "CELL_TYPE", 65, 78], ["NK cells", "CELL_TYPE", 80, 88], ["macrophages", "CELL_TYPE", 90, 101], ["human", "SPECIES", 558, 563], ["human", "SPECIES", 558, 563], ["CD4", "TEST", 26, 29], ["CD25", "TEST", 31, 35], ["CD8", "TEST", 37, 40], ["T-cells", "TEST", 42, 49], ["memory cells", "TEST", 51, 63], ["the immune system", "TREATMENT", 168, 185], ["the inner forces", "TREATMENT", 200, 216], ["severe viral infections COVID", "PROBLEM", 235, 264], ["COVID", "TEST", 347, 352], ["Viral InfectionVitamin", "TREATMENT", 356, 378], ["an essential fat-soluble vitamin", "TREATMENT", 384, 416], ["CD25", "ANATOMY", 31, 35], ["NK cells", "OBSERVATION", 80, 88], ["infections", "OBSERVATION", 248, 258], ["regulating vision", "OBSERVATION", 450, 467], ["mucosal", "ANATOMY", 518, 525], ["epithelium integrity", "OBSERVATION", 530, 550], ["human body", "ANATOMY", 558, 568]]], ["It has a crucial participation in elevating the immunomodulatory responses and dogmatic functions in humoral as well as cellular responses.", [["cellular", "ANATOMY", 120, 128], ["cellular", "CELL", 120, 128], ["crucial", "OBSERVATION_MODIFIER", 9, 16]]], ["The Vitamin A supplements given to the infants with measles and rabies showed impending improvement (2.1 times) in antibiotic response in association with the vaccinations (Siddiqui et al., 2001).", [["Vitamin A", "CHEMICAL", 4, 13], ["measles", "DISEASE", 52, 59], ["rabies", "DISEASE", 64, 70], ["Vitamin A", "CHEMICAL", 4, 13], ["Vitamin A", "SIMPLE_CHEMICAL", 4, 13], ["infants", "ORGANISM", 39, 46], ["infants", "SPECIES", 39, 46], ["rabies", "SPECIES", 64, 70], ["The Vitamin A supplements", "TREATMENT", 0, 25], ["measles", "PROBLEM", 52, 59], ["antibiotic response", "TREATMENT", 115, 134]]], ["Vitamin D another fat-soluble vitamin and has a vital role in regulating the adaptive and innate immune responses (Rosen et al., 2016).", [["Vitamin D", "CHEMICAL", 0, 9], ["vitamin", "CHEMICAL", 30, 37], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin", "CHEMICAL", 30, 37], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["fat", "TISSUE", 18, 21], ["vitamin", "SIMPLE_CHEMICAL", 30, 37], ["Vitamin D another fat-soluble vitamin", "TREATMENT", 0, 37]]], ["More recently, a study carried out by Aglipay et al. (2017), revealed that supplementation with high dose of vitamin D (2000 IU/day) in contrast to a standard dose (400 IU/day) had no significant effect on the viral infection in the upper respiratory track, however the one third of the population was found to have vitamin D levels less than 30 ng/ml.", [["respiratory", "ANATOMY", 239, 250], ["vitamin D", "CHEMICAL", 109, 118], ["viral infection", "DISEASE", 210, 225], ["vitamin D", "CHEMICAL", 316, 325], ["vitamin D", "CHEMICAL", 109, 118], ["vitamin D", "CHEMICAL", 316, 325], ["vitamin D", "SIMPLE_CHEMICAL", 109, 118], ["vitamin D", "SIMPLE_CHEMICAL", 316, 325], ["a study", "TEST", 15, 22], ["vitamin D", "TREATMENT", 109, 118], ["the viral infection", "PROBLEM", 206, 225], ["vitamin D levels", "TEST", 316, 332], ["no", "UNCERTAINTY", 181, 183], ["significant", "OBSERVATION_MODIFIER", 184, 195], ["viral", "OBSERVATION_MODIFIER", 210, 215], ["infection", "OBSERVATION", 216, 225], ["upper", "ANATOMY_MODIFIER", 233, 238], ["respiratory track", "OBSERVATION", 239, 256]]], ["Similarly, another study suggests vitamin D supplementation with influenza vaccine resulted in enhancement in the levels of TGF-\u03b2 in the plasma which further indicated that vitamin D directs the lymphocytes polarization towards the tolerogenic immune response (Goncalves-Mendes et al., 2019).", [["plasma", "ANATOMY", 137, 143], ["lymphocytes", "ANATOMY", 195, 206], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin D", "CHEMICAL", 173, 182], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin D", "CHEMICAL", 173, 182], ["vitamin D", "SIMPLE_CHEMICAL", 34, 43], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 124, 129], ["plasma", "ORGANISM_SUBSTANCE", 137, 143], ["vitamin D", "SIMPLE_CHEMICAL", 173, 182], ["lymphocytes", "CELL", 195, 206], ["TGF-\u03b2", "PROTEIN", 124, 129], ["lymphocytes", "CELL_TYPE", 195, 206], ["another study", "TEST", 11, 24], ["vitamin D supplementation", "TREATMENT", 34, 59], ["influenza vaccine", "TREATMENT", 65, 82], ["enhancement", "PROBLEM", 95, 106], ["TGF", "TEST", 124, 127], ["the plasma", "TEST", 133, 143], ["vitamin D", "TREATMENT", 173, 182], ["the lymphocytes polarization", "TREATMENT", 191, 219], ["Goncalves", "TEST", 261, 270]]], ["Vitamin D has also been affirmed to demonstrate beneficial effect against other viruses including HCV genotype infection (Abu-Mouch et al., 2011) and HCV genotype 2-3 (Nimer and Mouch, 2012).", [["Vitamin D", "CHEMICAL", 0, 9], ["HCV genotype infection", "DISEASE", 98, 120], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["HCV", "ORGANISM", 98, 101], ["HCV", "SPECIES", 98, 101], ["HCV", "SPECIES", 150, 153], ["Vitamin D", "TREATMENT", 0, 9], ["other viruses", "PROBLEM", 74, 87], ["HCV genotype infection", "PROBLEM", 98, 120], ["HCV genotype", "TEST", 150, 162]]], ["Another report which suggests antiviral capability of Vitamin D was elucidated by Grant et al. (2020).", [["Vitamin D", "CHEMICAL", 54, 63], ["Vitamin D", "CHEMICAL", 54, 63], ["Vitamin D", "SIMPLE_CHEMICAL", 54, 63], ["Vitamin D", "TREATMENT", 54, 63], ["antiviral capability", "OBSERVATION", 30, 50]]], ["It was further affirmed that Vitamin D was potent in reducing the hazards associated with viral pandemics.", [["Vitamin D", "CHEMICAL", 29, 38], ["viral pandemics", "DISEASE", 90, 105], ["Vitamin D", "CHEMICAL", 29, 38], ["Vitamin D", "SIMPLE_CHEMICAL", 29, 38], ["Vitamin D", "TREATMENT", 29, 38], ["viral pandemics", "PROBLEM", 90, 105], ["viral pandemics", "OBSERVATION", 90, 105]]], ["The high dose of Vitamin D reduced the hazard of several chronic ailments such as cardiovascular diseases, diabetes mellitus, hypertension, cancers and respiratory tract infection.", [["cardiovascular", "ANATOMY", 82, 96], ["cancers", "ANATOMY", 140, 147], ["respiratory tract", "ANATOMY", 152, 169], ["Vitamin D", "CHEMICAL", 17, 26], ["cardiovascular diseases", "DISEASE", 82, 105], ["diabetes mellitus", "DISEASE", 107, 124], ["hypertension", "DISEASE", 126, 138], ["cancers", "DISEASE", 140, 147], ["respiratory tract infection", "DISEASE", 152, 179], ["Vitamin D", "CHEMICAL", 17, 26], ["Vitamin D", "SIMPLE_CHEMICAL", 17, 26], ["cancers", "CANCER", 140, 147], ["tract", "ORGANISM_SUBDIVISION", 164, 169], ["Vitamin D", "TREATMENT", 17, 26], ["several chronic ailments", "PROBLEM", 49, 73], ["cardiovascular diseases", "PROBLEM", 82, 105], ["diabetes mellitus", "PROBLEM", 107, 124], ["hypertension", "PROBLEM", 126, 138], ["cancers", "PROBLEM", 140, 147], ["respiratory tract infection", "PROBLEM", 152, 179], ["high", "OBSERVATION_MODIFIER", 4, 8], ["several", "OBSERVATION_MODIFIER", 49, 56], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["ailments", "OBSERVATION", 65, 73], ["cardiovascular", "ANATOMY", 82, 96], ["diseases", "OBSERVATION", 97, 105], ["hypertension", "OBSERVATION", 126, 138], ["cancers", "OBSERVATION", 140, 147], ["respiratory tract", "ANATOMY", 152, 169], ["infection", "OBSERVATION", 170, 179]]], ["Grant and co-workers, additional revealed that vitamin D lowers the risk to respiratory tract infection by sustaining tight junction, decline in the synthesis of pro-inflammatory cytokines and killing the envelope of virus via induction of defensins and cathelicidin.", [["respiratory tract", "ANATOMY", 76, 93], ["tight junction", "ANATOMY", 118, 132], ["vitamin D", "CHEMICAL", 47, 56], ["respiratory tract infection", "DISEASE", 76, 103], ["vitamin D", "CHEMICAL", 47, 56], ["vitamin D", "SIMPLE_CHEMICAL", 47, 56], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["tight junction", "CELLULAR_COMPONENT", 118, 132], ["defensins", "GENE_OR_GENE_PRODUCT", 240, 249], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 254, 266], ["pro-inflammatory cytokines", "PROTEIN", 162, 188], ["defensins", "PROTEIN", 240, 249], ["cathelicidin", "PROTEIN", 254, 266], ["vitamin D", "PROBLEM", 47, 56], ["respiratory tract infection", "PROBLEM", 76, 103], ["pro-inflammatory cytokines", "TREATMENT", 162, 188], ["defensins", "TREATMENT", 240, 249], ["cathelicidin", "TREATMENT", 254, 266], ["respiratory tract", "ANATOMY", 76, 93], ["infection", "OBSERVATION", 94, 103], ["tight junction", "OBSERVATION", 118, 132], ["pro-inflammatory cytokines", "OBSERVATION", 162, 188]]], ["Consequently, the risk of cytokine storm is lowered which prevents pneumonia.Vitamins ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionVitamin E is also a fat soluble vital and has an antioxidative potential and regulates the host's immune responses (I Eze et al., 2016).", [["fat", "ANATOMY", 187, 190], ["pneumonia", "DISEASE", 67, 76], ["InfectionVitamin", "CHEMICAL", 158, 174], ["Vitamins", "CHEMICAL", 77, 85], ["InfectionVitamin", "CHEMICAL", 158, 174], ["Vitamins", "SIMPLE_CHEMICAL", 77, 85], ["fat", "TISSUE", 187, 190], ["cytokine", "PROTEIN", 26, 34], ["cytokine storm", "PROBLEM", 26, 40], ["pneumonia", "PROBLEM", 67, 76], ["COVID", "TEST", 143, 148], ["Viral InfectionVitamin", "TREATMENT", 152, 174], ["cytokine storm", "OBSERVATION", 26, 40], ["pneumonia", "OBSERVATION", 67, 76]]], ["The positive effect of vitamin E against chronic hepatitis was reported by Andreone et al. (2001).", [["vitamin E", "CHEMICAL", 23, 32], ["chronic hepatitis", "DISEASE", 41, 58], ["vitamin E", "CHEMICAL", 23, 32], ["vitamin E", "SIMPLE_CHEMICAL", 23, 32], ["vitamin E", "TREATMENT", 23, 32], ["chronic hepatitis", "PROBLEM", 41, 58], ["positive effect", "OBSERVATION_MODIFIER", 4, 19], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["hepatitis", "OBSERVATION", 49, 58]]], ["They suggested appreciable elevation in normalization of liver enzyme activity and HBV-DNA negativitization.", [["liver", "ANATOMY", 57, 62], ["liver", "ORGAN", 57, 62], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["liver enzyme", "PROTEIN", 57, 69], ["HBV", "SPECIES", 83, 86], ["appreciable elevation", "PROBLEM", 15, 36], ["liver enzyme activity", "TEST", 57, 78], ["HBV", "PROBLEM", 83, 86], ["DNA negativitization", "PROBLEM", 87, 107], ["appreciable", "OBSERVATION_MODIFIER", 15, 26], ["elevation", "OBSERVATION", 27, 36], ["liver", "ANATOMY", 57, 62]]], ["Another vitamin that acts as an important antioxidant and enzymatic co-factor is Vitamin C. It acts as a co-factor in varied physiological processes such as hormone synthesis, immune potentiation and collagen synthesis (Kim et al., 2013).", [["vitamin", "CHEMICAL", 8, 15], ["Vitamin C.", "CHEMICAL", 81, 91], ["vitamin", "CHEMICAL", 8, 15], ["Vitamin C.", "CHEMICAL", 81, 91], ["vitamin", "SIMPLE_CHEMICAL", 8, 15], ["Vitamin C.", "SIMPLE_CHEMICAL", 81, 91], ["collagen", "GENE_OR_GENE_PRODUCT", 200, 208], ["collagen", "PROTEIN", 200, 208], ["Another vitamin", "TREATMENT", 0, 15], ["enzymatic co-factor", "TREATMENT", 58, 77], ["Vitamin C.", "TREATMENT", 81, 91], ["a co-factor in varied physiological processes", "PROBLEM", 103, 148], ["hormone synthesis", "TREATMENT", 157, 174], ["immune potentiation", "TREATMENT", 176, 195], ["collagen synthesis", "PROBLEM", 200, 218]]], ["The meta-analysis role of vitamin C in treatment and preventions of common cold was carried out by Hemil\u00e4 and Chalker (2013).", [["vitamin C", "CHEMICAL", 26, 35], ["vitamin C", "CHEMICAL", 26, 35], ["vitamin C", "SIMPLE_CHEMICAL", 26, 35], ["vitamin C", "TREATMENT", 26, 35], ["treatment", "TREATMENT", 39, 48], ["common cold", "PROBLEM", 68, 79]]], ["It was concluded in the view of evidences that vitamin C mega dose showed reduction in the frequency of common cold in the community.", [["vitamin C", "CHEMICAL", 47, 56], ["vitamin C", "CHEMICAL", 47, 56], ["vitamin C", "SIMPLE_CHEMICAL", 47, 56], ["vitamin C mega dose", "TREATMENT", 47, 66]]], ["A study conducted by Utomo et al. (2020) was aimed at elucidating the potential of Curcuma sp., Citrus sp., Alpinia galanga, and Caesalpinia sappan as an anti SARS-CoV-2 agent via its binding to 3 protein receptors.", [["Caesalpinia sappan", "CHEMICAL", 129, 147], ["Curcuma sp.", "ORGANISM", 83, 94], ["Citrus sp.", "ORGANISM", 96, 106], ["Alpinia galanga", "ORGANISM", 108, 123], ["Caesalpinia sappan", "ORGANISM", 129, 147], ["protein receptors", "PROTEIN", 197, 214], ["Curcuma sp.", "SPECIES", 83, 94], ["Citrus sp.", "SPECIES", 96, 106], ["Alpinia galanga", "SPECIES", 108, 123], ["Curcuma sp.", "SPECIES", 83, 94], ["Citrus sp.", "SPECIES", 96, 106], ["Alpinia galanga", "SPECIES", 108, 123], ["Caesalpinia sappan", "SPECIES", 129, 147], ["A study", "TEST", 0, 7], ["Curcuma sp.", "TREATMENT", 83, 94], ["Citrus sp.", "TREATMENT", 96, 106], ["Alpinia galanga", "TREATMENT", 108, 123], ["Caesalpinia sappan", "TREATMENT", 129, 147], ["an anti SARS", "TREATMENT", 151, 163], ["CoV-2 agent", "TREATMENT", 164, 175]]], ["The protein targets identified were Receptor Binding Domain of spike glycol proteins (RBDS), protease domain of Angiotensin Converting Enzyme-2 PD-ACE2 and SARS-CoV-2 protease by employing molecular docking technique.", [["Angiotensin", "CHEMICAL", 112, 123], ["glycol", "CHEMICAL", 69, 75], ["Receptor Binding Domain of spike glycol proteins", "GENE_OR_GENE_PRODUCT", 36, 84], ["RBDS", "GENE_OR_GENE_PRODUCT", 86, 90], ["Angiotensin Converting Enzyme-2 PD-ACE2", "GENE_OR_GENE_PRODUCT", 112, 151], ["SARS-CoV-2 protease", "GENE_OR_GENE_PRODUCT", 156, 175], ["Receptor Binding Domain of spike glycol proteins", "PROTEIN", 36, 84], ["RBDS", "PROTEIN", 86, 90], ["protease domain", "PROTEIN", 93, 108], ["Angiotensin Converting Enzyme-2 PD-ACE2 and SARS-CoV-2 protease", "PROTEIN", 112, 175], ["The protein targets", "TEST", 0, 19], ["spike glycol proteins", "TREATMENT", 63, 84], ["RBDS", "TEST", 86, 90], ["protease domain", "TREATMENT", 93, 108], ["Angiotensin", "TREATMENT", 112, 123], ["Enzyme", "TEST", 135, 141], ["PD", "TEST", 144, 146], ["ACE2", "TEST", 147, 151], ["SARS", "PROBLEM", 156, 160], ["CoV-2 protease", "TREATMENT", 161, 175]]], ["The result of the study revealed that Citrus sp. had the highest inhibitory potential against SARS-CoV-2, followed by galangal, sappan wood and curcuma species and it was further suggested that they might have antiviral potency against COVID-19.", [["wood", "ANATOMY", 135, 139], ["Citrus sp", "ORGANISM", 38, 47], ["SARS-CoV-2", "ORGANISM", 94, 104], ["galangal", "SIMPLE_CHEMICAL", 118, 126], ["sappan wood", "ORGANISM", 128, 139], ["curcuma species", "SIMPLE_CHEMICAL", 144, 159], ["SARS-CoV", "SPECIES", 94, 102], ["the study", "TEST", 14, 23], ["SARS", "PROBLEM", 94, 98], ["CoV", "TEST", 99, 102], ["curcuma species", "PROBLEM", 144, 159], ["antiviral potency", "TREATMENT", 210, 227], ["COVID", "TEST", 236, 241], ["Citrus sp", "OBSERVATION", 38, 47], ["curcuma species", "OBSERVATION", 144, 159]]], ["Additionally, different plant based sources of vitamins include, mushrooms, carrots, broccoli, almonds, citrus, guava, amla, avocados etc. Fig. 3describes the role of Vitamins (A, C, E and D) in combating COVID-19.Minerals ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionZinc is one of the indispensible elements which has significant role in modulation of growth and development and the regulation of the immunomodulatory responses (Lindenmayer et al., 2014; Read et al., 2019).", [["almonds", "ANATOMY", 95, 102], ["vitamins include, mushrooms, carrots, broccoli, almonds, citrus, guava", "CHEMICAL", 47, 117], ["vitamins", "CHEMICAL", 47, 55], ["Vitamins (A, C, E and D", "CHEMICAL", 167, 190], ["COVID-19", "CHEMICAL", 205, 213], ["vitamins", "SIMPLE_CHEMICAL", 47, 55], ["carrots", "ORGANISM_SUBDIVISION", 76, 83], ["broccoli", "ORGANISM_SUBDIVISION", 85, 93], ["almonds", "ORGANISM_SUBDIVISION", 95, 102], ["citrus", "ORGANISM_SUBDIVISION", 104, 110], ["guava", "ORGANISM_SUBDIVISION", 112, 117], ["amla", "SIMPLE_CHEMICAL", 119, 123], ["Vitamins", "SIMPLE_CHEMICAL", 167, 175], ["C", "SIMPLE_CHEMICAL", 180, 181], ["E", "SIMPLE_CHEMICAL", 183, 184], ["D", "SIMPLE_CHEMICAL", 189, 190], ["carrots", "SPECIES", 76, 83], ["broccoli", "SPECIES", 85, 93], ["almonds", "SPECIES", 95, 102], ["broccoli", "SPECIES", 85, 93], ["vitamins", "TREATMENT", 47, 55], ["mushrooms", "TREATMENT", 65, 74], ["guava", "TREATMENT", 112, 117], ["amla", "TREATMENT", 119, 123], ["Vitamins (A, C, E and D)", "TREATMENT", 167, 191], ["COVID", "TEST", 205, 210], ["Nutrient Supplements", "TREATMENT", 227, 247], ["Combat COVID", "TEST", 273, 285], ["Viral InfectionZinc", "PROBLEM", 289, 308], ["broccoli", "ANATOMY", 85, 93], ["significant", "OBSERVATION_MODIFIER", 356, 367], ["growth", "OBSERVATION_MODIFIER", 390, 396]]], ["Deficiency in the Zn, results in enhanced vulnerability to microbial infections specifically viral.", [["Zn", "CHEMICAL", 18, 20], ["infections", "DISEASE", 69, 79], ["Zn", "CHEMICAL", 18, 20], ["Zn", "SIMPLE_CHEMICAL", 18, 20], ["Deficiency in the Zn", "PROBLEM", 0, 20], ["microbial infections", "PROBLEM", 59, 79], ["viral", "PROBLEM", 93, 98], ["infections", "OBSERVATION", 69, 79]]], ["Large number of studies reveal that zinc levels in an individual is a vital factor that regulates the immunity against any kind of viral infection and the Zn-deficient population is found to be more vulnerable to acquiring infections such as HIV and HCV (Read et al., 2019).", [["zinc", "CHEMICAL", 36, 40], ["viral infection", "DISEASE", 131, 146], ["Zn-", "CHEMICAL", 155, 158], ["infections", "DISEASE", 223, 233], ["HIV and HCV", "DISEASE", 242, 253], ["zinc", "CHEMICAL", 36, 40], ["zinc", "SIMPLE_CHEMICAL", 36, 40], ["Zn-", "GENE_OR_GENE_PRODUCT", 155, 158], ["HIV", "ORGANISM", 242, 245], ["HCV", "ORGANISM", 250, 253], ["HIV", "SPECIES", 242, 245], ["HIV", "SPECIES", 242, 245], ["HCV", "SPECIES", 250, 253], ["studies", "TEST", 16, 23], ["zinc levels", "PROBLEM", 36, 47], ["a vital factor", "PROBLEM", 68, 82], ["viral infection", "PROBLEM", 131, 146], ["the Zn-deficient population", "PROBLEM", 151, 178], ["acquiring infections", "PROBLEM", 213, 233], ["HIV", "PROBLEM", 242, 245], ["HCV", "PROBLEM", 250, 253], ["zinc", "OBSERVATION_MODIFIER", 36, 40], ["levels", "OBSERVATION_MODIFIER", 41, 47], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146], ["infections", "OBSERVATION", 223, 233]]], ["A study by Acevedo-Murillo et al. (2019), in which 103 children with pneumonia symptoms were observed to show clinical improvement in terms of oxygen saturation, duration of illness and rate of respiration in the Zn supplemented children in comparison to control.", [["pneumonia", "DISEASE", 69, 78], ["oxygen", "CHEMICAL", 143, 149], ["illness", "DISEASE", 174, 181], ["Zn", "CHEMICAL", 213, 215], ["oxygen", "CHEMICAL", 143, 149], ["Zn", "CHEMICAL", 213, 215], ["children", "ORGANISM", 55, 63], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["children", "ORGANISM", 229, 237], ["children", "SPECIES", 55, 63], ["children", "SPECIES", 229, 237], ["A study", "TEST", 0, 7], ["pneumonia symptoms", "PROBLEM", 69, 87], ["oxygen saturation", "TEST", 143, 160], ["illness", "PROBLEM", 174, 181], ["pneumonia", "OBSERVATION", 69, 78], ["oxygen saturation", "OBSERVATION", 143, 160]]], ["They further revealed elevation in the cytokine response in the zinc group.Minerals ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionAnother crucial trace element Copper has also been reported to have a key role in growth and differentiation of immune cells (Li et al., 2019).", [["immune cells", "ANATOMY", 277, 289], ["zinc", "CHEMICAL", 64, 68], ["Copper", "CHEMICAL", 195, 201], ["zinc", "CHEMICAL", 64, 68], ["Copper", "CHEMICAL", 195, 201], ["zinc", "SIMPLE_CHEMICAL", 64, 68], ["Copper", "SIMPLE_CHEMICAL", 195, 201], ["immune cells", "CELL", 277, 289], ["cytokine", "PROTEIN", 39, 47], ["immune cells", "CELL_TYPE", 277, 289], ["elevation", "PROBLEM", 22, 31], ["the cytokine response", "TEST", 35, 56], ["Nutrient Supplements", "TREATMENT", 88, 108], ["Combat COVID", "TEST", 134, 146], ["Viral InfectionAnother crucial trace element", "PROBLEM", 150, 194], ["elevation", "OBSERVATION_MODIFIER", 22, 31], ["cytokine response", "OBSERVATION", 39, 56], ["trace element", "OBSERVATION", 181, 194], ["immune cells", "OBSERVATION", 277, 289]]], ["The intracellular concentration of copper modulates the influenza virus life cycle and a thujaplicin-copper chelate suppresses the multiplication of human influenza virus (Rupp et al., 2017; Miyamoto et al., 1998).", [["intracellular", "ANATOMY", 4, 17], ["copper", "CHEMICAL", 35, 41], ["thujaplicin", "CHEMICAL", 89, 100], ["copper", "CHEMICAL", 101, 107], ["influenza virus", "DISEASE", 155, 170], ["copper", "CHEMICAL", 35, 41], ["thujaplicin", "CHEMICAL", 89, 100], ["copper", "CHEMICAL", 101, 107], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["copper", "SIMPLE_CHEMICAL", 35, 41], ["influenza virus", "ORGANISM", 56, 71], ["thujaplicin", "SIMPLE_CHEMICAL", 89, 100], ["copper chelate", "SIMPLE_CHEMICAL", 101, 115], ["human", "ORGANISM", 149, 154], ["influenza virus", "ORGANISM", 155, 170], ["human", "SPECIES", 149, 154], ["influenza virus", "SPECIES", 155, 170], ["human influenza virus", "SPECIES", 149, 170], ["the influenza virus life cycle", "TREATMENT", 52, 82], ["a thujaplicin-copper chelate", "TREATMENT", 87, 115], ["human influenza virus", "PROBLEM", 149, 170], ["concentration", "OBSERVATION_MODIFIER", 18, 31]]], ["Another observation made by Turnlund et al. (2004) was that there was an elevation in activity of SOD, plasma ceruloplasmin ad benzykamine oxidase activity in response to higher doses of copper i.e. 7.8 mg/day in comparison to 1.6 mg/day.", [["plasma", "ANATOMY", 103, 109], ["benzykamine", "CHEMICAL", 127, 138], ["copper", "CHEMICAL", 187, 193], ["benzykamine", "CHEMICAL", 127, 138], ["copper", "CHEMICAL", 187, 193], ["SOD", "SIMPLE_CHEMICAL", 98, 101], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["ceruloplasmin", "GENE_OR_GENE_PRODUCT", 110, 123], ["benzykamine oxidase", "GENE_OR_GENE_PRODUCT", 127, 146], ["copper", "SIMPLE_CHEMICAL", 187, 193], ["SOD", "PROTEIN", 98, 101], ["plasma ceruloplasmin", "PROTEIN", 103, 123], ["benzykamine oxidase", "PROTEIN", 127, 146], ["an elevation in activity of SOD", "PROBLEM", 70, 101], ["plasma ceruloplasmin ad benzykamine oxidase activity", "TREATMENT", 103, 155], ["higher doses of copper", "TREATMENT", 171, 193], ["elevation", "OBSERVATION_MODIFIER", 73, 82]]], ["It was further elucidated that there was a considerable reduction in circulation of neutrophils, antibiotic titers and serum IL-2R against the Beijing strain influenza infestation.", [["neutrophils", "ANATOMY", 84, 95], ["serum", "ANATOMY", 119, 124], ["influenza infestation", "DISEASE", 158, 179], ["neutrophils", "CELL", 84, 95], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["IL-2R", "GENE_OR_GENE_PRODUCT", 125, 130], ["Beijing strain influenza", "ORGANISM", 143, 167], ["neutrophils", "CELL_TYPE", 84, 95], ["serum IL-2R", "PROTEIN", 119, 130], ["a considerable reduction in circulation of neutrophils", "PROBLEM", 41, 95], ["antibiotic titers", "TEST", 97, 114], ["serum IL", "TEST", 119, 127], ["the Beijing strain influenza infestation", "PROBLEM", 139, 179], ["considerable", "OBSERVATION_MODIFIER", 43, 55], ["reduction", "OBSERVATION_MODIFIER", 56, 65], ["circulation", "OBSERVATION_MODIFIER", 69, 80], ["influenza infestation", "OBSERVATION", 158, 179]]], ["Magnesium also has an imperative participation in scheming immune functions in infected cell via affecting immunoglobin biosynthesis, cytolysis dependent upon the antibodies, macrophage response to lymphokines, enhanced adherence of the cells and T and helper cells-B adherence (Liang et al., 2012).", [["cell", "ANATOMY", 88, 92], ["macrophage", "ANATOMY", 175, 185], ["cells", "ANATOMY", 237, 242], ["helper cells", "ANATOMY", 253, 265], ["Magnesium", "CHEMICAL", 0, 9], ["Magnesium", "CHEMICAL", 0, 9], ["Magnesium", "SIMPLE_CHEMICAL", 0, 9], ["cell", "CELL", 88, 92], ["immunoglobin", "GENE_OR_GENE_PRODUCT", 107, 119], ["macrophage", "CELL", 175, 185], ["cells", "CELL", 237, 242], ["T", "CELL", 247, 248], ["helper cells-B", "CELL", 253, 267], ["antibodies", "PROTEIN", 163, 173], ["lymphokines", "PROTEIN", 198, 209], ["T and helper cells", "CELL_TYPE", 247, 265], ["Magnesium", "TREATMENT", 0, 9], ["scheming immune functions", "PROBLEM", 50, 75], ["infected cell", "PROBLEM", 79, 92], ["immunoglobin biosynthesis", "PROBLEM", 107, 132], ["cytolysis dependent", "PROBLEM", 134, 153], ["the antibodies", "TEST", 159, 173], ["lymphokines", "TREATMENT", 198, 209], ["infected cell", "OBSERVATION", 79, 92], ["immunoglobin biosynthesis", "OBSERVATION", 107, 132]]], ["There are a few reports which suggest participation of Mg in immunomodulatory responses against viral infestations (Chaigne-Delalande et al., 2013).Minerals ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionIn addition to this, another trace element that has been reported to have wide range of pleiotropic effects ranges from anti-inflammatory to antioxidative is Selenium (Se) (Rayman, 2012).", [["Mg", "CHEMICAL", 55, 57], ["viral infestations", "DISEASE", 96, 114], ["Selenium", "CHEMICAL", 396, 404], ["Se", "CHEMICAL", 406, 408], ["Mg", "CHEMICAL", 55, 57], ["Selenium", "CHEMICAL", 396, 404], ["Se", "CHEMICAL", 406, 408], ["Mg", "SIMPLE_CHEMICAL", 55, 57], ["Selenium", "SIMPLE_CHEMICAL", 396, 404], ["Se", "SIMPLE_CHEMICAL", 406, 408], ["Mg", "TREATMENT", 55, 57], ["viral infestations", "PROBLEM", 96, 114], ["Combat COVID", "TREATMENT", 207, 219], ["Viral InfectionIn", "PROBLEM", 223, 240], ["another trace element", "PROBLEM", 259, 280], ["pleiotropic effects", "PROBLEM", 326, 345]]], ["Comparatively, the lower concentrations of Se are related to enhancement in the jeopardy of mortality, meager immune responses and cognitive reduction, whereas the higher doses are affirmed to show antiviral activity (Rayman, 2012).", [["Se", "CHEMICAL", 43, 45], ["cognitive reduction", "DISEASE", 131, 150], ["Se", "CHEMICAL", 43, 45], ["Se", "SIMPLE_CHEMICAL", 43, 45], ["cognitive reduction", "TREATMENT", 131, 150], ["lower concentrations", "OBSERVATION_MODIFIER", 19, 39], ["enhancement", "OBSERVATION", 61, 72], ["antiviral activity", "OBSERVATION", 198, 216]]], ["Supplementation of Se results in elevation in concentration of Se in the plasma, up-regulation of lymphocyte phospholipid levels and activity of GPOX in the cell, subsequently leading elevation in cellular immune response.", [["plasma", "ANATOMY", 73, 79], ["lymphocyte", "ANATOMY", 98, 108], ["cell", "ANATOMY", 157, 161], ["cellular", "ANATOMY", 197, 205], ["Se", "CHEMICAL", 19, 21], ["Se", "CHEMICAL", 63, 65], ["Se", "CHEMICAL", 19, 21], ["Se", "CHEMICAL", 63, 65], ["Se", "SIMPLE_CHEMICAL", 19, 21], ["Se", "SIMPLE_CHEMICAL", 63, 65], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["lymphocyte", "CELL", 98, 108], ["GPOX", "GENE_OR_GENE_PRODUCT", 145, 149], ["cell", "CELL", 157, 161], ["cellular", "CELL", 197, 205], ["GPOX", "PROTEIN", 145, 149], ["elevation in concentration", "PROBLEM", 33, 59], ["the plasma", "TEST", 69, 79], ["lymphocyte phospholipid levels", "TEST", 98, 128], ["GPOX in the cell", "PROBLEM", 145, 161], ["elevation in cellular immune response", "PROBLEM", 184, 221], ["elevation", "OBSERVATION_MODIFIER", 33, 42], ["cell", "ANATOMY", 157, 161], ["elevation", "OBSERVATION_MODIFIER", 184, 193], ["cellular immune response", "OBSERVATION", 197, 221]]], ["Similar reports of hasty clearance of poliovirus were also reported by Se supplementation (Ivory et al., 2017).", [["Se", "CHEMICAL", 71, 73], ["Se", "CHEMICAL", 71, 73], ["poliovirus", "ORGANISM", 38, 48], ["Se", "SIMPLE_CHEMICAL", 71, 73], ["poliovirus", "SPECIES", 38, 48], ["hasty clearance of poliovirus", "PROBLEM", 19, 48], ["poliovirus", "OBSERVATION", 38, 48]]], ["Various plants namely, beans, nuts, peanuts, grains, mushrooms, cereals, lentils, garlic, grains, etc. have been wide sources of minerals and must be included in diet.Nutraceuticals supplements and Probiotics ::: Nutrient Supplements ::: Ancillary Armours to Combat COVID-19 Viral InfectionNutraceuticals are the products which are argued to provide physiological assistance and protection against varied persistent diseases.", [["beans", "ANATOMY", 23, 28], ["nuts", "ANATOMY", 30, 34], ["peanuts", "ANATOMY", 36, 43], ["grains", "ANATOMY", 45, 51], ["mushrooms", "ANATOMY", 53, 62], ["lentils", "ANATOMY", 73, 80], ["garlic", "ANATOMY", 82, 88], ["grains", "ANATOMY", 90, 96], [", beans, nuts, peanuts, grains, mushrooms, cereals, lentils, garlic", "CHEMICAL", 21, 88], ["beans", "ORGANISM_SUBDIVISION", 23, 28], ["nuts", "ORGANISM_SUBDIVISION", 30, 34], ["peanuts", "TISSUE", 36, 43], ["grains", "ORGANISM_SUBDIVISION", 45, 51], ["mushrooms", "ORGANISM_SUBDIVISION", 53, 62], ["cereals", "ORGANISM_SUBDIVISION", 64, 71], ["lentils", "SIMPLE_CHEMICAL", 73, 80], ["garlic", "SIMPLE_CHEMICAL", 82, 88], ["grains", "ORGANISM_SUBDIVISION", 90, 96], ["beans", "SPECIES", 23, 28], ["peanuts", "SPECIES", 36, 43], ["garlic", "SPECIES", 82, 88], ["minerals", "TREATMENT", 129, 137], ["Nutraceuticals supplements", "TREATMENT", 167, 193], ["Nutrient Supplements", "TREATMENT", 213, 233], ["Combat COVID", "TEST", 259, 271], ["Viral InfectionNutraceuticals", "PROBLEM", 275, 304], ["physiological assistance", "TREATMENT", 350, 374], ["protection", "TREATMENT", 379, 389], ["varied persistent diseases", "PROBLEM", 398, 424], ["mushrooms", "ANATOMY", 53, 62], ["garlic", "ANATOMY", 82, 88], ["persistent", "OBSERVATION_MODIFIER", 405, 415], ["diseases", "OBSERVATION", 416, 424]]], ["Wide range of nutraceutical products have been isolated herbal products, dietary supplements, isolated nutrients, genetically engineered foods and processed cereals, beverages and soups (Kalra, 2003).", [["nutraceutical products", "TREATMENT", 14, 36], ["herbal products", "TREATMENT", 56, 71], ["dietary supplements", "TREATMENT", 73, 92], ["isolated nutrients", "TREATMENT", 94, 112], ["nutraceutical products", "OBSERVATION", 14, 36], ["isolated", "OBSERVATION_MODIFIER", 47, 55], ["herbal products", "OBSERVATION", 56, 71]]], ["Certain nutraceuticals have been shown earlier to enhance the immune function.", [["Certain nutraceuticals", "TREATMENT", 0, 22]]], ["McCarty and DiNicolantonio (2020) elucidated that, a few nutraceuticals were able to lower the degree of symptoms and provide respite to the patients infected from coronavirus and influenza.", [["coronavirus", "DISEASE", 164, 175], ["influenza", "DISEASE", 180, 189], ["patients", "ORGANISM", 141, 149], ["coronavirus", "ORGANISM", 164, 175], ["patients", "SPECIES", 141, 149], ["coronavirus", "SPECIES", 164, 175], ["DiNicolantonio", "TREATMENT", 12, 26], ["a few nutraceuticals", "TREATMENT", 51, 71], ["symptoms", "PROBLEM", 105, 113], ["coronavirus", "PROBLEM", 164, 175], ["influenza", "PROBLEM", 180, 189], ["coronavirus", "OBSERVATION", 164, 175]]], ["Another significant product is probiotic, they are defined as live micro-organisms which bestow varied health benefits such as improvement in gastrointestinal activity (Sanders, 2008).", [["gastrointestinal", "ANATOMY", 142, 158], ["gastrointestinal", "ORGAN", 142, 158], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["probiotic", "OBSERVATION_MODIFIER", 31, 40], ["gastrointestinal", "ANATOMY", 142, 158]]], ["They also induce certain specific immune responses by augmenting antibody synthesis (Kanauchi et al., 2018).", [["augmenting antibody synthesis", "TREATMENT", 54, 83]]], ["A report by Bunout et al. (2002) suggested the role of probiotics in the improvement in immune response to vaccination in the elderly people.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["probiotics", "TREATMENT", 55, 65], ["vaccination", "TREATMENT", 107, 118]]], ["Antibody production against influenza B was elevated significantly against influenza and there was no effect of probiotics on IL-4 and INF secretion by cultured monocytes.", [["monocytes", "ANATOMY", 161, 170], ["influenza B", "DISEASE", 28, 39], ["influenza", "DISEASE", 75, 84], ["influenza B", "ORGANISM", 28, 39], ["IL-4", "GENE_OR_GENE_PRODUCT", 126, 130], ["INF", "GENE_OR_GENE_PRODUCT", 135, 138], ["monocytes", "CELL", 161, 170], ["INF", "PROTEIN", 135, 138], ["cultured monocytes", "CELL_LINE", 152, 170], ["Antibody production", "TEST", 0, 19], ["influenza B", "PROBLEM", 28, 39], ["elevated", "PROBLEM", 44, 52], ["influenza", "PROBLEM", 75, 84], ["probiotics", "TREATMENT", 112, 122], ["IL", "TEST", 126, 128], ["INF secretion", "PROBLEM", 135, 148], ["cultured monocytes", "TEST", 152, 170]]], ["Moreover, an observation made by Akatsu et al. (2013) revealed positive effects of supplementation with Bifidobacterium longum on the immunomodulatory responses and intestinal microbiota in elderly people.", [["intestinal microbiota", "ANATOMY", 165, 186], ["Bifidobacterium longum", "CHEMICAL", 104, 126], ["Bifidobacterium longum", "ORGANISM", 104, 126], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 165, 186], ["people", "ORGANISM", 198, 204], ["Bifidobacterium longum", "SPECIES", 104, 126], ["people", "SPECIES", 198, 204], ["Bifidobacterium longum", "SPECIES", 104, 126], ["supplementation with Bifidobacterium longum", "TREATMENT", 83, 126], ["intestinal microbiota", "ANATOMY", 165, 186]]], ["A significant augmentation in the number of bifidobacteria was recorded in the faecal matter.", [["faecal matter", "ANATOMY", 79, 92], ["bifidobacteria", "SIMPLE_CHEMICAL", 44, 58], ["faecal", "ORGANISM_SUBDIVISION", 79, 85], ["A significant augmentation", "TREATMENT", 0, 26], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["augmentation", "OBSERVATION", 14, 26], ["bifidobacteria", "OBSERVATION", 44, 58], ["faecal matter", "ANATOMY", 79, 92]]], ["Furthermore, it was suggested that there was an increase in serum IgA levels.", [["serum", "ANATOMY", 60, 65], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["IgA", "GENE_OR_GENE_PRODUCT", 66, 69], ["IgA", "PROTEIN", 66, 69], ["an increase in serum IgA levels", "PROBLEM", 45, 76], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["An investigation was carried out to elucidate whether consumption of probiotics such as lactobacilli has an effect on acquired cold symptoms.", [["lactobacilli", "CHEMICAL", 88, 100], ["lactobacilli", "SIMPLE_CHEMICAL", 88, 100], ["An investigation", "TEST", 0, 16], ["probiotics", "TREATMENT", 69, 79], ["lactobacilli", "TREATMENT", 88, 100], ["acquired cold symptoms", "PROBLEM", 118, 140]]], ["Reduction in pharyngeal symptoms was significant was observed.Impact of PAK-1 Blockers: Budding Therapeutics against CoronavirusPAKs belong to mammalian kinases family also known as RAC/CDC42-activated kinases that have been came into existence since decades.", [["pharyngeal", "ANATOMY", 13, 23], ["pharyngeal", "ORGAN", 13, 23], ["PAK-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["CoronavirusPAKs", "GENE_OR_GENE_PRODUCT", 117, 132], ["RAC", "GENE_OR_GENE_PRODUCT", 182, 185], ["CDC42", "GENE_OR_GENE_PRODUCT", 186, 191], ["PAK", "PROTEIN", 72, 75], ["CoronavirusPAKs", "PROTEIN", 117, 132], ["mammalian kinases family", "PROTEIN", 143, 167], ["RAC", "PROTEIN", 182, 185], ["CDC42", "PROTEIN", 186, 191], ["activated kinases", "PROTEIN", 192, 209], ["pharyngeal symptoms", "PROBLEM", 13, 32], ["PAK-1 Blockers", "TREATMENT", 72, 86], ["Budding Therapeutics", "TREATMENT", 88, 108], ["CoronavirusPAKs", "TREATMENT", 117, 132], ["RAC/CDC42-activated kinases", "TREATMENT", 182, 209], ["pharyngeal", "ANATOMY", 13, 23], ["symptoms", "OBSERVATION", 24, 32]]], ["Amid, these classes PAK1 is most prominent category of \"pathogenic kinases\" that can cause a plethora of diseases like cancer, inflammation, malaria, dengue, immuno-suppression and many antiviral diseases, if behave abnormally (Maruta, 2020).", [["cancer", "ANATOMY", 119, 125], ["cancer", "DISEASE", 119, 125], ["inflammation", "DISEASE", 127, 139], ["malaria", "DISEASE", 141, 148], ["dengue", "DISEASE", 150, 156], ["immuno-suppression", "DISEASE", 158, 176], ["PAK1", "GENE_OR_GENE_PRODUCT", 20, 24], ["cancer", "CANCER", 119, 125], ["PAK1", "PROTEIN", 20, 24], ["pathogenic kinases", "PROTEIN", 56, 74], ["\"pathogenic kinases", "PROBLEM", 55, 74], ["diseases like cancer", "PROBLEM", 105, 125], ["inflammation", "PROBLEM", 127, 139], ["malaria", "PROBLEM", 141, 148], ["dengue", "PROBLEM", 150, 156], ["immuno-suppression", "PROBLEM", 158, 176], ["many antiviral diseases", "PROBLEM", 181, 204], ["most prominent", "OBSERVATION_MODIFIER", 28, 42], ["pathogenic kinases", "OBSERVATION", 56, 74], ["plethora", "OBSERVATION_MODIFIER", 93, 101], ["diseases", "OBSERVATION", 105, 113], ["cancer", "OBSERVATION", 119, 125], ["inflammation", "OBSERVATION", 127, 139], ["malaria", "OBSERVATION_MODIFIER", 141, 148], ["antiviral diseases", "OBSERVATION", 186, 204]]], ["Strikingly, PAK1-blockers (naturally existing) such as caffeic acid, its esters, bee-product propolis have been observed to inhibit RAC that directly activates PAK1 (Xu et al., 2005).", [["caffeic acid", "CHEMICAL", 55, 67], ["bee-product propolis", "CHEMICAL", 81, 101], ["caffeic acid", "CHEMICAL", 55, 67], ["esters", "CHEMICAL", 73, 79], ["PAK1", "GENE_OR_GENE_PRODUCT", 12, 16], ["caffeic acid", "SIMPLE_CHEMICAL", 55, 67], ["esters", "SIMPLE_CHEMICAL", 73, 79], ["bee-", "SIMPLE_CHEMICAL", 81, 85], ["propolis", "SIMPLE_CHEMICAL", 93, 101], ["RAC", "GENE_OR_GENE_PRODUCT", 132, 135], ["PAK1", "GENE_OR_GENE_PRODUCT", 160, 164], ["PAK1", "PROTEIN", 12, 16], ["RAC", "PROTEIN", 132, 135], ["PAK1", "PROTEIN", 160, 164], ["PAK1-blockers", "TREATMENT", 12, 25], ["caffeic acid", "TREATMENT", 55, 67], ["bee-product propolis", "TREATMENT", 81, 101]]], ["However, previous studies reported that chloroquine a drug active against malaria also suppressed the incidence of SARS/Coronavirus infection, but its mode of action still remains unknown (Vinecent, 2005).", [["chloroquine", "CHEMICAL", 40, 51], ["malaria", "DISEASE", 74, 81], ["SARS", "DISEASE", 115, 119], ["Coronavirus infection", "DISEASE", 120, 141], ["chloroquine", "CHEMICAL", 40, 51], ["chloroquine", "SIMPLE_CHEMICAL", 40, 51], ["previous studies", "TEST", 9, 25], ["chloroquine", "TREATMENT", 40, 51], ["malaria", "PROBLEM", 74, 81], ["SARS", "PROBLEM", 115, 119], ["Coronavirus infection", "PROBLEM", 120, 141], ["Coronavirus", "OBSERVATION_MODIFIER", 120, 131], ["infection", "OBSERVATION", 132, 141]]], ["Later, it was reported that this drug induced CDK inhibitor (p21) to inhibit PAK1 activity (Maruta, 2014).", [["CDK", "GENE_OR_GENE_PRODUCT", 46, 49], ["p21", "GENE_OR_GENE_PRODUCT", 61, 64], ["PAK1", "GENE_OR_GENE_PRODUCT", 77, 81], ["CDK inhibitor", "PROTEIN", 46, 59], ["p21", "PROTEIN", 61, 64], ["PAK1", "PROTEIN", 77, 81], ["this drug induced CDK inhibitor", "TREATMENT", 28, 59], ["PAK1 activity", "TEST", 77, 90]]], ["In line of forging argument, a recent study depicted that tumor-repressed phosphatase PTEN, mainly involved in impeding PAK1 also inhibited the coronavirus-curbed LLC2-linked fibrosis (Lu, 2020).", [["tumor", "ANATOMY", 58, 63], ["tumor", "DISEASE", 58, 63], ["fibrosis", "DISEASE", 175, 183], ["tumor", "CANCER", 58, 63], ["PTEN", "GENE_OR_GENE_PRODUCT", 86, 90], ["PAK1", "GENE_OR_GENE_PRODUCT", 120, 124], ["coronavirus", "ORGANISM", 144, 155], ["LLC2", "GENE_OR_GENE_PRODUCT", 163, 167], ["tumor-repressed phosphatase", "PROTEIN", 58, 85], ["PTEN", "PROTEIN", 86, 90], ["PAK1", "PROTEIN", 120, 124], ["LLC2", "PROTEIN", 163, 167], ["a recent study", "TEST", 29, 43], ["tumor", "PROBLEM", 58, 63], ["repressed phosphatase PTEN", "PROBLEM", 64, 90], ["the coronavirus", "PROBLEM", 140, 155], ["linked fibrosis", "PROBLEM", 168, 183], ["tumor", "OBSERVATION", 58, 63], ["fibrosis", "OBSERVATION", 175, 183]]], ["Moreover, LLC2 expression has been observed to correlate with ACE2, a coronavirus receptor and CK2/RAS-PAK1-AP1 signaling cascade (Chen et al., 2010).", [["LLC2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["CK2", "GENE_OR_GENE_PRODUCT", 95, 98], ["RAS", "GENE_OR_GENE_PRODUCT", 99, 102], ["PAK1", "GENE_OR_GENE_PRODUCT", 103, 107], ["AP1", "GENE_OR_GENE_PRODUCT", 108, 111], ["LLC2", "PROTEIN", 10, 14], ["ACE2", "PROTEIN", 62, 66], ["coronavirus receptor", "PROTEIN", 70, 90], ["CK2", "PROTEIN", 95, 98], ["RAS", "PROTEIN", 99, 102], ["PAK1", "PROTEIN", 103, 107], ["AP1", "PROTEIN", 108, 111], ["ACE2", "TEST", 62, 66], ["a coronavirus receptor", "TEST", 68, 90], ["CK2", "TEST", 95, 98], ["RAS", "TEST", 99, 102], ["PAK1", "TEST", 103, 107]]], ["Henceforth, through all these assumptions we can deduce the PAK1-reliance of corona pathogenesis and a suggestion of using PAK1-blockers for treating pandemic COVID-19 outbreak (Fig. 4).", [["COVID", "DISEASE", 159, 164], ["PAK1", "GENE_OR_GENE_PRODUCT", 60, 64], ["PAK1", "GENE_OR_GENE_PRODUCT", 123, 127], ["PAK1", "PROTEIN", 60, 64], ["PAK1", "PROTEIN", 123, 127], ["corona pathogenesis", "PROBLEM", 77, 96], ["PAK1-blockers", "TREATMENT", 123, 136], ["pandemic COVID", "TREATMENT", 150, 164]]], ["Albeit, PAK-1 have a direct link with suppressing the immune system of the hosts, yet, PAK-1 blockers behave as antiviral vaccines in elevating the immune responses (Huynh et al., 2017).", [["immune system", "ANATOMY", 54, 67], ["PAK-1", "GENE_OR_GENE_PRODUCT", 8, 13], ["PAK-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["PAK", "PROTEIN", 8, 11], ["PAK", "PROTEIN", 87, 90], ["PAK", "TEST", 8, 11], ["PAK-1 blockers", "TREATMENT", 87, 101], ["antiviral vaccines", "TREATMENT", 112, 130]]], ["Peeping into the previous studies, it was found that rabies vaccine developed in 1885 was active against myriad of viral diseases but it usually took 12-18 months for actual resistance development.", [["rabies", "DISEASE", 53, 59], ["viral diseases", "DISEASE", 115, 129], ["rabies", "ORGANISM", 53, 59], ["rabies", "SPECIES", 53, 59], ["the previous studies", "TEST", 13, 33], ["rabies vaccine", "TREATMENT", 53, 67], ["viral diseases", "PROBLEM", 115, 129], ["actual resistance development", "PROBLEM", 167, 196], ["viral diseases", "OBSERVATION", 115, 129]]], ["Apparently, a fast-track approach of therapeutics in the form of natural PAK-1 blockers are predominantly making its position nowadays to act against prevailing viral diseases like coronavirus.Impact of PAK-1 Blockers: Budding Therapeutics against CoronavirusInevitably, the conventional and recently accepted product propolis, obtained from bees have been known since ancient times.", [["viral diseases", "DISEASE", 161, 175], ["coronavirus", "DISEASE", 181, 192], ["PAK-1", "GENE_OR_GENE_PRODUCT", 73, 78], ["coronavirus", "ORGANISM", 181, 192], ["PAK-1", "GENE_OR_GENE_PRODUCT", 203, 208], ["PAK", "PROTEIN", 73, 76], ["PAK", "PROTEIN", 203, 206], ["a fast-track approach", "TREATMENT", 12, 33], ["therapeutics", "TREATMENT", 37, 49], ["natural PAK-1 blockers", "TREATMENT", 65, 87], ["prevailing viral diseases", "PROBLEM", 150, 175], ["coronavirus", "PROBLEM", 181, 192], ["PAK-1 Blockers", "TREATMENT", 203, 217], ["Budding Therapeutics", "TREATMENT", 219, 239], ["Coronavirus", "PROBLEM", 248, 259], ["product propolis", "TREATMENT", 310, 326], ["coronavirus", "OBSERVATION", 181, 192]]], ["It is formerly obtained from honey-bee extract via honey-bees feeding the buds of poplar and willow trees, thereby, mixing their saliva into it to form hexagonal bee-hives in order to protect their larval species against many pathogenic organisms.", [["extract", "ANATOMY", 39, 46], ["buds", "ANATOMY", 74, 78], ["honey-bee extract", "CHEMICAL", 29, 46], ["bee", "ORGANISM", 35, 38], ["extract", "ORGANISM_SUBSTANCE", 39, 46], ["buds", "ORGANISM_SUBDIVISION", 74, 78], ["poplar", "ORGANISM_SUBDIVISION", 82, 88], ["saliva", "ORGANISM_SUBSTANCE", 129, 135], ["poplar and willow trees", "TREATMENT", 82, 105], ["hexagonal bee", "PROBLEM", 152, 165], ["hives", "PROBLEM", 166, 171], ["many pathogenic organisms", "PROBLEM", 221, 246]]], ["This product synthesised is called as propolis and is regarded as herbal medicine with anti-viral properties.", [["propolis", "TREATMENT", 38, 46], ["herbal medicine", "TREATMENT", 66, 81], ["anti-viral properties", "TREATMENT", 87, 108]]], ["In contemporary world, propolis is identified in possessing anti-cancer characteristics due to the presence of an ingredient CAPE (Caffeic Acid Phenyl Ester) involved in down-regulation of RAC for PAK1 inhibition respectively (Xu et al., 2005).", [["propolis", "CHEMICAL", 23, 31], ["CAPE", "CHEMICAL", 125, 129], ["Caffeic Acid Phenyl Ester", "CHEMICAL", 131, 156], ["CAPE", "CHEMICAL", 125, 129], ["Caffeic Acid Phenyl Ester", "CHEMICAL", 131, 156], ["propolis", "ORGANISM", 23, 31], ["anti-cancer", "CANCER", 60, 71], ["CAPE", "SIMPLE_CHEMICAL", 125, 129], ["Caffeic Acid Phenyl Ester", "SIMPLE_CHEMICAL", 131, 156], ["RAC", "GENE_OR_GENE_PRODUCT", 189, 192], ["PAK1", "GENE_OR_GENE_PRODUCT", 197, 201], ["RAC", "PROTEIN", 189, 192], ["PAK1", "PROTEIN", 197, 201], ["propolis", "TREATMENT", 23, 31], ["an ingredient CAPE (Caffeic Acid Phenyl Ester)", "TREATMENT", 111, 157], ["PAK1 inhibition", "TREATMENT", 197, 212]]], ["Although, the anticancer constituents in propolis varies from product to product according to harvesting property of bee extracts.", [["anticancer", "ANATOMY", 14, 24], ["extracts", "ANATOMY", 121, 129], ["propolis", "CHEMICAL", 41, 49], ["anticancer", "CANCER", 14, 24], ["propolis", "SIMPLE_CHEMICAL", 41, 49], ["bee", "ORGANISM", 117, 120], ["extracts", "ORGANISM_SUBSTANCE", 121, 129], ["the anticancer constituents in propolis", "PROBLEM", 10, 49], ["anticancer", "OBSERVATION_MODIFIER", 14, 24], ["constituents", "OBSERVATION_MODIFIER", 25, 37]]], ["For instance, the anti-cancer element in Brazilian propolis is Artepillin C (ARC), while in sub-tropical regions of Taiwan and Okinawa, polyphenols namely, Nymphaeols act as direct inhibitors of PAK1 (Nguyen et al., 2017).In view of the fact that, familiar thing among all categories is that they are comprised of PAK1-blockers.", [["Artepillin C", "CHEMICAL", 63, 75], ["Nymphaeols", "CHEMICAL", 156, 166], ["polyphenols", "CHEMICAL", 136, 147], ["Nymphaeols", "CHEMICAL", 156, 166], ["Artepillin C", "SIMPLE_CHEMICAL", 63, 75], ["ARC", "SIMPLE_CHEMICAL", 77, 80], ["polyphenols", "SIMPLE_CHEMICAL", 136, 147], ["Nymphaeols", "SIMPLE_CHEMICAL", 156, 166], ["PAK1", "GENE_OR_GENE_PRODUCT", 195, 199], ["PAK1", "GENE_OR_GENE_PRODUCT", 314, 318], ["anti-cancer element", "DNA", 18, 37], ["PAK1", "PROTEIN", 195, 199], ["PAK1", "PROTEIN", 314, 318], ["the anti-cancer element", "TREATMENT", 14, 37], ["Brazilian propolis", "TREATMENT", 41, 59], ["Artepillin C (ARC)", "TREATMENT", 63, 81], ["polyphenols", "TREATMENT", 136, 147], ["Nymphaeols", "TREATMENT", 156, 166], ["PAK1-blockers", "TREATMENT", 314, 327]]], ["Ever since, has been elucidated that, PAK1 tends to cause cancers, viral diseases like HIV, Hepatitis, pappiloma, influenza, ebola, SARS and corona virus along with immune system suppression of hosts, henceforth, propolis would be quintessential in blocking COVID/coronavirus curbed fibrosis in respiratory tract and boosting the immunity of an individual (Maruta, 2014).", [["cancers", "ANATOMY", 58, 65], ["immune system", "ANATOMY", 165, 178], ["respiratory tract", "ANATOMY", 295, 312], ["cancers", "DISEASE", 58, 65], ["viral diseases", "DISEASE", 67, 81], ["HIV, Hepatitis, pappiloma", "DISEASE", 87, 112], ["influenza", "DISEASE", 114, 123], ["SARS", "DISEASE", 132, 136], ["fibrosis", "DISEASE", 283, 291], ["PAK1", "GENE_OR_GENE_PRODUCT", 38, 42], ["cancers", "CANCER", 58, 65], ["HIV", "ORGANISM", 87, 90], ["ebola", "CANCER", 125, 130], ["corona virus", "ORGANISM", 141, 153], ["COVID", "GENE_OR_GENE_PRODUCT", 258, 263], ["coronavirus", "ORGANISM", 264, 275], ["respiratory tract", "ORGANISM_SUBDIVISION", 295, 312], ["PAK1", "PROTEIN", 38, 42], ["HIV", "SPECIES", 87, 90], ["coronavirus", "SPECIES", 264, 275], ["HIV", "SPECIES", 87, 90], ["corona virus", "SPECIES", 141, 153], ["cancers", "PROBLEM", 58, 65], ["viral diseases", "PROBLEM", 67, 81], ["HIV", "PROBLEM", 87, 90], ["Hepatitis", "PROBLEM", 92, 101], ["pappiloma", "PROBLEM", 103, 112], ["influenza", "PROBLEM", 114, 123], ["ebola", "PROBLEM", 125, 130], ["SARS", "PROBLEM", 132, 136], ["corona virus", "PROBLEM", 141, 153], ["immune system suppression of hosts", "TREATMENT", 165, 199], ["propolis", "TREATMENT", 213, 221], ["coronavirus curbed fibrosis in respiratory tract", "PROBLEM", 264, 312], ["cancers", "OBSERVATION", 58, 65], ["viral diseases", "OBSERVATION", 67, 81], ["Hepatitis", "OBSERVATION", 92, 101], ["coronavirus", "OBSERVATION", 264, 275], ["fibrosis", "OBSERVATION", 283, 291], ["respiratory tract", "ANATOMY", 295, 312]]], ["The effectiveness of propolis also depends on the product, its chemical nature and action.", [["propolis", "CHEMICAL", 21, 29], ["propolis", "ORGANISM", 21, 29], ["propolis", "TREATMENT", 21, 29]]], ["To expedite, CAPE-containing propolis named 'Bio 30\u2032, commercialised by New Zealand is found to be highly active (Maruta, 2014).", [["CAPE", "CHEMICAL", 13, 17], ["CAPE", "CHEMICAL", 13, 17], ["CAPE", "SIMPLE_CHEMICAL", 13, 17], ["propolis", "TREATMENT", 29, 37]]], ["The optimal doses are 1 ml/10 Kg of the body weight.", [["body", "ANATOMY", 40, 44], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["the body weight", "TEST", 36, 51]]], ["Regardless of this pre-formed formulation in the market, it could not be used against COVID-19 eruption, due to paucity of its stock in market place.", [["eruption", "DISEASE", 95, 103], ["COVID-19 eruption", "PROBLEM", 86, 103]]], ["Moreover, the available stocks are being predominantly used for treating patients with deadly cancers and prolonged treatment of genetic brain disorder, NF tumers (Neuro Fibromatosis Type 1, 2) (Maruta and He, 2020).", [["cancers", "ANATOMY", 94, 101], ["brain", "ANATOMY", 137, 142], ["cancers", "DISEASE", 94, 101], ["brain disorder", "DISEASE", 137, 151], ["patients", "ORGANISM", 73, 81], ["cancers", "CANCER", 94, 101], ["brain", "ORGAN", 137, 142], ["patients", "SPECIES", 73, 81], ["deadly cancers", "PROBLEM", 87, 101], ["prolonged treatment", "TREATMENT", 106, 125], ["genetic brain disorder", "PROBLEM", 129, 151], ["NF tumers", "PROBLEM", 153, 162], ["brain", "ANATOMY", 137, 142]]], ["In addition to this, the cell membrane permeability of caffeic acid and ARC is relatively weak, owing to its -COOH moiety.", [["cell membrane", "ANATOMY", 25, 38], ["caffeic acid", "CHEMICAL", 55, 67], ["ARC", "CHEMICAL", 72, 75], ["caffeic acid", "CHEMICAL", 55, 67], ["COOH", "CHEMICAL", 110, 114], ["cell membrane", "CELLULAR_COMPONENT", 25, 38], ["caffeic acid", "SIMPLE_CHEMICAL", 55, 67], ["ARC", "SIMPLE_CHEMICAL", 72, 75], ["the cell membrane permeability", "TEST", 21, 51], ["caffeic acid", "TEST", 55, 67], ["caffeic acid", "OBSERVATION", 55, 67], ["weak", "OBSERVATION", 90, 94]]], ["Nonetheless, this feature could be surmounted by triggering the cell membrane permeability via conversion their esters into 1, 2, 3-triazolyl esters that are thousand times more powerful than ARC or caffeine esters (Maruta and Ahn, 2017).", [["cell membrane", "ANATOMY", 64, 77], ["1, 2, 3-triazolyl esters", "CHEMICAL", 124, 148], ["caffeine esters", "CHEMICAL", 199, 214], ["esters", "CHEMICAL", 112, 118], ["1, 2, 3-triazolyl esters", "CHEMICAL", 124, 148], ["caffeine esters", "CHEMICAL", 199, 214], ["cell membrane", "CELLULAR_COMPONENT", 64, 77], ["esters", "SIMPLE_CHEMICAL", 112, 118], ["1, 2, 3-triazolyl esters", "SIMPLE_CHEMICAL", 124, 148], ["ARC", "SIMPLE_CHEMICAL", 192, 195], ["caffeine esters", "SIMPLE_CHEMICAL", 199, 214], ["the cell membrane permeability", "PROBLEM", 60, 90], ["cell membrane", "OBSERVATION", 64, 77]]], ["Along with this, melatonin hormone (pineal gland hormone) is a serotonin and possess anti-melanogenic activity that is a primitive factor as melanogenesis is directly correlated to PAK1 (Be et al., 2017).", [["pineal gland", "ANATOMY", 36, 48], ["melatonin", "CHEMICAL", 17, 26], ["serotonin", "CHEMICAL", 63, 72], ["melatonin", "CHEMICAL", 17, 26], ["serotonin", "CHEMICAL", 63, 72], ["melatonin hormone", "GENE_OR_GENE_PRODUCT", 17, 34], ["pineal gland", "ORGAN", 36, 48], ["serotonin", "SIMPLE_CHEMICAL", 63, 72], ["PAK1", "GENE_OR_GENE_PRODUCT", 181, 185], ["PAK1", "PROTEIN", 181, 185], ["melatonin hormone (pineal gland hormone", "TREATMENT", 17, 56], ["a serotonin and possess anti-melanogenic activity", "PROBLEM", 61, 110]]], ["Further, it also owns similarity with other anti-PAK1 actions like anti-cancer, antiviral, anti-inflammatory, immuno-boosters etc. Therefore, it is pertinent to mention here that melatonin, a commonly available sleeping pill could be utilized against coronaviral infections.", [["coronaviral", "ANATOMY", 251, 262], ["melatonin", "CHEMICAL", 179, 188], ["coronaviral infections", "DISEASE", 251, 273], ["melatonin", "CHEMICAL", 179, 188], ["anti-PAK1", "GENE_OR_GENE_PRODUCT", 44, 53], ["anti-cancer", "CANCER", 67, 78], ["melatonin", "SIMPLE_CHEMICAL", 179, 188], ["other anti-PAK1 actions", "TREATMENT", 38, 61], ["anti-cancer", "TREATMENT", 67, 78], ["antiviral", "TREATMENT", 80, 89], ["anti-inflammatory", "TREATMENT", 91, 108], ["melatonin", "TREATMENT", 179, 188], ["a commonly available sleeping pill", "TREATMENT", 190, 224], ["coronaviral infections", "PROBLEM", 251, 273], ["anti-inflammatory", "OBSERVATION_MODIFIER", 91, 108], ["infections", "OBSERVATION", 263, 273]]], ["Currently, many investigations are being carried out to high-light the significance of melatonin as another therapeutic resort or COVID-19 adjuvant (Zhang et al., 2020b).", [["melatonin", "CHEMICAL", 87, 96], ["COVID-19", "CHEMICAL", 130, 138], ["melatonin", "CHEMICAL", 87, 96], ["COVID-19", "CHEMICAL", 130, 138], ["melatonin", "SIMPLE_CHEMICAL", 87, 96], ["COVID-19", "SIMPLE_CHEMICAL", 130, 138], ["many investigations", "TEST", 11, 30], ["melatonin", "TREATMENT", 87, 96], ["COVID", "TREATMENT", 130, 135]]], ["Furthermore, glucocorticoid hormone 'ciclesonide' is another choice to cure different inflammatory disorders and it has been widely commercialised under the brand name of Alvesco.", [["ciclesonide", "CHEMICAL", 37, 48], ["inflammatory disorders", "DISEASE", 86, 108], ["ciclesonide", "CHEMICAL", 37, 48], ["glucocorticoid hormone", "GENE_OR_GENE_PRODUCT", 13, 35], ["ciclesonide", "SIMPLE_CHEMICAL", 37, 48], ["glucocorticoid hormone 'ciclesonide'", "TREATMENT", 13, 49], ["different inflammatory disorders", "PROBLEM", 76, 108], ["inflammatory", "OBSERVATION", 86, 98]]], ["It has been officially approved since 1990 and been widely associated with treating adults as well as children.", [["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110]]], ["The molecular mechanism forming the basis for anti-inflammatory action is based on the potential of PAK1-blockers that lays the foundation for its pathway.", [["PAK1", "GENE_OR_GENE_PRODUCT", 100, 104], ["PAK1", "PROTEIN", 100, 104], ["anti-inflammatory action", "TREATMENT", 46, 70], ["PAK1-blockers", "TREATMENT", 100, 113]]], ["Majorly, it works according to two basic reasons, firstly, inflammation is not possible without PAK1 and PAK1-null mutant in mice depicted no inflammation (Allen et al., 2009).", [["inflammation", "DISEASE", 59, 71], ["inflammation", "DISEASE", 142, 154], ["PAK1", "GENE_OR_GENE_PRODUCT", 96, 100], ["PAK1", "GENE_OR_GENE_PRODUCT", 105, 109], ["mice", "ORGANISM", 125, 129], ["PAK1", "PROTEIN", 96, 100], ["PAK1", "PROTEIN", 105, 109], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 125, 129], ["inflammation", "PROBLEM", 59, 71], ["PAK1", "TEST", 96, 100], ["PAK1", "TEST", 105, 109], ["inflammation", "PROBLEM", 142, 154], ["inflammation", "OBSERVATION", 59, 71], ["not possible", "UNCERTAINTY", 75, 87], ["no", "UNCERTAINTY", 139, 141], ["inflammation", "OBSERVATION", 142, 154]]], ["Secondly, ciclesonide inhibited PAK-1 regulated proliferation of lung cancer in A541 cell lines as well as in immuno-deficient mice (Choi et al., 2020).", [["lung cancer", "ANATOMY", 65, 76], ["A541 cell lines", "ANATOMY", 80, 95], ["ciclesonide", "CHEMICAL", 10, 21], ["lung cancer", "DISEASE", 65, 76], ["ciclesonide", "CHEMICAL", 10, 21], ["ciclesonide", "SIMPLE_CHEMICAL", 10, 21], ["PAK-1", "GENE_OR_GENE_PRODUCT", 32, 37], ["lung cancer", "CANCER", 65, 76], ["A541 cell lines", "CELL", 80, 95], ["mice", "ORGANISM", 127, 131], ["PAK", "PROTEIN", 32, 35], ["A541 cell lines", "CELL_LINE", 80, 95], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["ciclesonide", "TREATMENT", 10, 21], ["PAK", "TEST", 32, 35], ["lung cancer", "PROBLEM", 65, 76], ["A541 cell lines", "TREATMENT", 80, 95], ["proliferation", "OBSERVATION_MODIFIER", 48, 61], ["lung", "ANATOMY", 65, 69], ["cancer", "OBSERVATION", 70, 76], ["A541 cell lines", "OBSERVATION", 80, 95]]], ["Thus, this hormone was clinically reported to block PAK1 replication and pathogenesis (lung fibrosis) caused by COVID-19 respectively (Sharp and Dange, 2020).Impact of PAK-1 Blockers: Budding Therapeutics against CoronavirusApart from this, a herbal formulation mainly triterpenes or steroid named 'triptolide' derived from thunder god vine also inhibited RAC followed by blocking PAK1 route (Maruta and Ahn, 2017).", [["lung", "ANATOMY", 87, 91], ["lung fibrosis", "DISEASE", 87, 100], ["steroid", "CHEMICAL", 284, 291], ["triptolide", "CHEMICAL", 299, 309], ["RAC", "CHEMICAL", 356, 359], ["COVID-19", "CHEMICAL", 112, 120], ["triterpenes", "CHEMICAL", 269, 280], ["steroid", "CHEMICAL", 284, 291], ["triptolide", "CHEMICAL", 299, 309], ["PAK1", "GENE_OR_GENE_PRODUCT", 52, 56], ["lung", "ORGAN", 87, 91], ["PAK-1", "GENE_OR_GENE_PRODUCT", 168, 173], ["Coronavirus", "ORGANISM", 213, 224], ["triterpenes", "SIMPLE_CHEMICAL", 269, 280], ["steroid", "SIMPLE_CHEMICAL", 284, 291], ["triptolide", "SIMPLE_CHEMICAL", 299, 309], ["RAC", "SIMPLE_CHEMICAL", 356, 359], ["PAK1", "GENE_OR_GENE_PRODUCT", 381, 385], ["PAK1", "PROTEIN", 52, 56], ["PAK", "PROTEIN", 168, 171], ["RAC", "PROTEIN", 356, 359], ["PAK1", "PROTEIN", 381, 385], ["PAK1 replication", "TREATMENT", 52, 68], ["pathogenesis (lung fibrosis", "PROBLEM", 73, 100], ["COVID", "TEST", 112, 117], ["PAK-1 Blockers", "TREATMENT", 168, 182], ["Budding Therapeutics", "TREATMENT", 184, 204], ["Coronavirus", "PROBLEM", 213, 224], ["a herbal formulation mainly triterpenes", "TREATMENT", 241, 280], ["steroid named 'triptolide'", "TREATMENT", 284, 310], ["lung", "ANATOMY", 87, 91], ["fibrosis", "OBSERVATION", 92, 100]]], ["This medicine was previously treating the patients infected with dengue virus in restricting the proliferation of virus in lungs by blocking PAK1 signaling cascade (Liou et al., 2008).", [["lungs", "ANATOMY", 123, 128], ["dengue", "DISEASE", 65, 71], ["patients", "ORGANISM", 42, 50], ["dengue virus", "ORGANISM", 65, 77], ["lungs", "ORGAN", 123, 128], ["PAK1", "GENE_OR_GENE_PRODUCT", 141, 145], ["PAK1", "PROTEIN", 141, 145], ["patients", "SPECIES", 42, 50], ["dengue virus", "SPECIES", 65, 77], ["This medicine", "TREATMENT", 0, 13], ["dengue virus", "PROBLEM", 65, 77], ["the proliferation of virus in lungs", "PROBLEM", 93, 128], ["dengue virus", "OBSERVATION", 65, 77], ["proliferation", "OBSERVATION_MODIFIER", 97, 110], ["virus", "OBSERVATION", 114, 119], ["lungs", "ANATOMY", 123, 128]]], ["Conversely, due to its lower water solubility, few years back, its -OH group was phosphorylated to enhance its solubility (Patil et al., 2015).", [["OH", "CHEMICAL", 68, 70], ["its lower water solubility", "PROBLEM", 19, 45]]], ["Resultantly, phosphotase-receptive pro-drug of triptolide 'Minnelide' is currently under clinical trials to cure COVID-19 infections as well.", [["triptolide", "CHEMICAL", 47, 57], ["Minnelide", "CHEMICAL", 59, 68], ["infections", "DISEASE", 122, 132], ["triptolide", "CHEMICAL", 47, 57], ["phosphotase", "SIMPLE_CHEMICAL", 13, 24], ["triptolide", "SIMPLE_CHEMICAL", 47, 57], ["Minnelide", "SIMPLE_CHEMICAL", 59, 68], ["phosphotase", "TREATMENT", 13, 24], ["triptolide 'Minnelide'", "TREATMENT", 47, 69], ["cure COVID", "TREATMENT", 108, 118], ["infections", "PROBLEM", 122, 132]]], ["Another compound ivermectin has been screened from bacteria but with some lethal effects.", [["ivermectin", "CHEMICAL", 17, 27], ["ivermectin", "CHEMICAL", 17, 27], ["ivermectin", "SIMPLE_CHEMICAL", 17, 27], ["Another compound ivermectin", "PROBLEM", 0, 27], ["bacteria", "PROBLEM", 51, 59], ["some lethal effects", "PROBLEM", 69, 88], ["ivermectin", "OBSERVATION", 17, 27]]], ["Interestingly, these ill-effects were removed later by chemically re-designing the compound.", [["ill", "OBSERVATION_MODIFIER", 21, 24]]], ["Further, it was pragmatically involved to impede various parasitic infections, cancers etc. eventually causing the impairment of PAK1, which encompasses its anti-cancerous properties (Hashimoto et al., 2009).", [["cancers", "ANATOMY", 79, 86], ["parasitic infections", "DISEASE", 57, 77], ["cancers", "DISEASE", 79, 86], ["cancers", "CANCER", 79, 86], ["PAK1", "GENE_OR_GENE_PRODUCT", 129, 133], ["PAK1", "PROTEIN", 129, 133], ["various parasitic infections", "PROBLEM", 49, 77], ["cancers", "PROBLEM", 79, 86], ["the impairment of PAK1", "PROBLEM", 111, 133], ["parasitic", "OBSERVATION_MODIFIER", 57, 66], ["infections", "OBSERVATION", 67, 77], ["cancers", "OBSERVATION", 79, 86], ["impairment", "OBSERVATION_MODIFIER", 115, 125]]], ["As a consequence, it could be a good option to counteract coronaviral infection, however, a recent study found the role of Ivermectin to occlude COVID-19 incidence in Vero cell cultures (Caly et al., 2020).", [["coronaviral", "ANATOMY", 58, 69], ["Vero cell cultures", "ANATOMY", 167, 185], ["coronaviral infection", "DISEASE", 58, 79], ["Ivermectin", "CHEMICAL", 123, 133], ["COVID-19", "CHEMICAL", 145, 153], ["Ivermectin", "CHEMICAL", 123, 133], ["Ivermectin", "SIMPLE_CHEMICAL", 123, 133], ["Vero cell cultures", "CELL", 167, 185], ["Vero cell cultures", "CELL_LINE", 167, 185], ["coronaviral infection", "PROBLEM", 58, 79], ["a recent study", "TEST", 90, 104], ["Ivermectin", "TREATMENT", 123, 133], ["COVID", "TEST", 145, 150], ["Vero cell cultures", "TEST", 167, 185], ["infection", "OBSERVATION", 70, 79], ["Vero cell", "OBSERVATION_MODIFIER", 167, 176]]], ["Meanwhile, 'Artemisinin', an anti-malarial component originated from plant herb Artemisia annua also showed its active property against malaria and other viral diseases (Sicard et al., 2011).", [["Artemisinin", "CHEMICAL", 12, 23], ["plant herb Artemisia annua", "CHEMICAL", 69, 95], ["malaria", "DISEASE", 136, 143], ["viral diseases", "DISEASE", 154, 168], ["Artemisinin", "CHEMICAL", 12, 23], ["Artemisinin", "SIMPLE_CHEMICAL", 12, 23], ["Artemisia annua", "ORGANISM", 80, 95], ["Artemisia annua", "SPECIES", 80, 95], ["Artemisia annua", "SPECIES", 80, 95], ["an anti-malarial component", "PROBLEM", 26, 52], ["plant herb Artemisia annua", "TEST", 69, 95], ["malaria", "PROBLEM", 136, 143], ["other viral diseases", "PROBLEM", 148, 168], ["herb Artemisia", "OBSERVATION", 75, 89], ["active", "OBSERVATION_MODIFIER", 112, 118], ["viral diseases", "OBSERVATION", 154, 168]]], ["This is however, concerned with the host cells rather than pathogen itself.", [["cells", "ANATOMY", 41, 46], ["host cells", "CELL", 36, 46], ["the host cells", "PROBLEM", 32, 46], ["host cells", "OBSERVATION", 36, 46]]], ["To illustrate, PAK1 upregulation has been observed on the basis of AM-RAS mediated suppression (PAK1-upstream) and RAF in T-cells (PAK1-RAS downstream) (Maruta, 2014).", [["T-cells", "ANATOMY", 122, 129], ["PAK1", "GENE_OR_GENE_PRODUCT", 15, 19], ["AM", "GENE_OR_GENE_PRODUCT", 67, 69], ["RAS", "GENE_OR_GENE_PRODUCT", 70, 73], ["PAK1", "GENE_OR_GENE_PRODUCT", 96, 100], ["RAF", "GENE_OR_GENE_PRODUCT", 115, 118], ["T-cells", "CELL", 122, 129], ["PAK1-RAS", "GENE_OR_GENE_PRODUCT", 131, 139], ["PAK1", "PROTEIN", 15, 19], ["RAS", "PROTEIN", 70, 73], ["PAK1", "PROTEIN", 96, 100], ["RAF", "DNA", 115, 118], ["T-cells", "CELL_TYPE", 122, 129], ["PAK1", "PROTEIN", 131, 135], ["RAS downstream", "DNA", 136, 150], ["PAK1 upregulation", "TEST", 15, 32], ["RAS mediated suppression", "PROBLEM", 70, 94], ["PAK1", "TEST", 96, 100], ["RAF in T-cells", "TEST", 115, 129], ["PAK1", "TEST", 131, 135]]], ["The dihydro derivatives of AM deactivates the virak infection through upregulation of CKD inhibitor p21 respectively (Maruta, 2014).", [["dihydro", "CHEMICAL", 4, 11], ["AM", "CHEMICAL", 27, 29], ["infection", "DISEASE", 52, 61], ["CKD", "DISEASE", 86, 89], ["dihydro", "CHEMICAL", 4, 11], ["dihydro derivatives", "SIMPLE_CHEMICAL", 4, 23], ["AM", "SIMPLE_CHEMICAL", 27, 29], ["p21", "GENE_OR_GENE_PRODUCT", 100, 103], ["CKD inhibitor", "PROTEIN", 86, 99], ["p21", "PROTEIN", 100, 103], ["The dihydro derivatives", "TREATMENT", 0, 23], ["the virak infection", "PROBLEM", 42, 61], ["CKD inhibitor p21", "TREATMENT", 86, 103]]], ["Additionally, reddish peppercorns (ethanol-water extract) was also found active against PAK1 and cyclin D1 in NF1-deprived negative breast cancer cell line (MDA-MB231).", [["reddish peppercorns", "ANATOMY", 14, 33], ["breast cancer cell line", "ANATOMY", 132, 155], ["MDA-MB231", "ANATOMY", 157, 166], ["peppercorns", "CHEMICAL", 22, 33], ["ethanol-water extract", "CHEMICAL", 35, 56], ["breast cancer", "DISEASE", 132, 145], ["peppercorns", "CHEMICAL", 22, 33], ["ethanol", "CHEMICAL", 35, 42], ["peppercorns", "SIMPLE_CHEMICAL", 22, 33], ["ethanol", "SIMPLE_CHEMICAL", 35, 42], ["PAK1", "GENE_OR_GENE_PRODUCT", 88, 92], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 97, 106], ["NF1", "GENE_OR_GENE_PRODUCT", 110, 113], ["breast cancer cell line", "CELL", 132, 155], ["MDA-MB231", "CELL", 157, 166], ["PAK1", "PROTEIN", 88, 92], ["cyclin D1", "PROTEIN", 97, 106], ["NF1-deprived negative breast cancer cell line", "CELL_LINE", 110, 155], ["MDA-MB231", "CELL_LINE", 157, 166], ["reddish peppercorns (ethanol-water extract", "TREATMENT", 14, 56], ["PAK1", "TEST", 88, 92], ["cyclin D1 in NF1", "PROBLEM", 97, 113], ["MDA", "TEST", 157, 160], ["reddish", "OBSERVATION_MODIFIER", 14, 21], ["breast", "ANATOMY", 132, 138], ["cancer cell line", "OBSERVATION", 139, 155]]], ["It was also found to suppress MPNST-cell lines where PAK1 was peculiarly initiated (Hirokawa et al., 2006).", [["MPNST-cell lines", "ANATOMY", 30, 46], ["MPNST-cell lines", "CELL", 30, 46], ["PAK1", "GENE_OR_GENE_PRODUCT", 53, 57], ["MPNST-cell lines", "CELL_LINE", 30, 46], ["PAK1", "PROTEIN", 53, 57], ["MPNST-cell lines", "TREATMENT", 30, 46], ["PAK1", "TEST", 53, 57], ["cell lines", "OBSERVATION", 36, 46]]], ["Concurrently, this extract in the form of tea would enable prevention and cure of COVID-19 incidence owing to its contribution in PAK1 blocking.", [["extract", "ANATOMY", 19, 26], ["tea", "ANATOMY", 42, 45], ["tea", "ORGANISM_SUBDIVISION", 42, 45], ["PAK1", "GENE_OR_GENE_PRODUCT", 130, 134], ["PAK1", "PROTEIN", 130, 134], ["tea", "TREATMENT", 42, 45], ["COVID", "TREATMENT", 82, 87], ["PAK1 blocking", "TREATMENT", 130, 143]]], ["The basic formulations of these peppercorns in boosting immune system and impeding inflammation during viral infections have also been investigated (Jie et al., 2019).", [["immune system", "ANATOMY", 56, 69], ["peppercorns", "CHEMICAL", 32, 43], ["inflammation", "DISEASE", 83, 95], ["viral infections", "DISEASE", 103, 119], ["peppercorns", "SIMPLE_CHEMICAL", 32, 43], ["immune system", "ANATOMICAL_SYSTEM", 56, 69], ["The basic formulations", "TREATMENT", 0, 22], ["these peppercorns", "TREATMENT", 26, 43], ["boosting immune system", "TREATMENT", 47, 69], ["impeding inflammation", "PROBLEM", 74, 95], ["viral infections", "PROBLEM", 103, 119], ["inflammation", "OBSERVATION", 83, 95]]], ["Above all, a peptide namely FK228, identified from soil microbe has been found to restrict the expansion of RAS (pancreatic/colon cancer) carrying oncogenic mutant (K-RAS) respectively (Nakajima et al., 1998).", [["pancreatic", "ANATOMY", 113, 123], ["colon cancer", "ANATOMY", 124, 136], ["FK228", "CHEMICAL", 28, 33], ["pancreatic/colon cancer", "DISEASE", 113, 136], ["FK228", "GENE_OR_GENE_PRODUCT", 28, 33], ["RAS", "GENE_OR_GENE_PRODUCT", 108, 111], ["pancreatic/colon cancer", "CANCER", 113, 136], ["K-RAS", "GENE_OR_GENE_PRODUCT", 165, 170], ["RAS", "PROTEIN", 108, 111], ["oncogenic mutant", "PROTEIN", 147, 163], ["RAS", "PROTEIN", 167, 170], ["a peptide namely FK228", "TREATMENT", 11, 33], ["RAS (pancreatic/colon cancer", "PROBLEM", 108, 136], ["expansion", "OBSERVATION_MODIFIER", 95, 104], ["pancreatic", "ANATOMY", 113, 123], ["colon", "ANATOMY", 124, 129], ["cancer", "OBSERVATION", 130, 136]]], ["Later, it was also reported to deactivate histone deacetylases and PAK1 in different cancer cell lines.", [["cancer cell lines", "ANATOMY", 85, 102], ["cancer", "DISEASE", 85, 91], ["histone deacetylases", "GENE_OR_GENE_PRODUCT", 42, 62], ["PAK1", "GENE_OR_GENE_PRODUCT", 67, 71], ["cancer cell lines", "CELL", 85, 102], ["histone deacetylases", "PROTEIN", 42, 62], ["PAK1", "PROTEIN", 67, 71], ["cancer cell lines", "CELL_LINE", 85, 102], ["histone deacetylases", "TREATMENT", 42, 62], ["PAK1 in different cancer cell lines", "TREATMENT", 67, 102], ["cancer cell lines", "OBSERVATION", 85, 102]]], ["This mainly comprise of breast cancer cell lines as well as NF1-deprived Malignant Peripheral Nerve Sheath Tumor (MPNST) to restrain their proliferation in xenografts of mice (Hirokawa et al., 2005).", [["breast cancer cell lines", "ANATOMY", 24, 48], ["Malignant Peripheral Nerve Sheath Tumor", "ANATOMY", 73, 112], ["MPNST", "ANATOMY", 114, 119], ["xenografts", "ANATOMY", 156, 166], ["breast cancer", "DISEASE", 24, 37], ["MPNST", "DISEASE", 114, 119], ["breast cancer cell lines", "CELL", 24, 48], ["NF1", "GENE_OR_GENE_PRODUCT", 60, 63], ["Malignant Peripheral Nerve Sheath Tumor", "CANCER", 73, 112], ["MPNST", "CANCER", 114, 119], ["xenografts", "CANCER", 156, 166], ["mice", "ORGANISM", 170, 174], ["breast cancer cell lines", "CELL_LINE", 24, 48], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 170, 174], ["breast cancer cell lines", "PROBLEM", 24, 48], ["NF1", "TEST", 60, 63], ["Malignant Peripheral Nerve Sheath Tumor (MPNST)", "TREATMENT", 73, 120], ["breast", "ANATOMY", 24, 30], ["cancer", "OBSERVATION", 31, 37], ["cell lines", "OBSERVATION", 38, 48], ["deprived", "OBSERVATION_MODIFIER", 64, 72], ["Malignant", "OBSERVATION_MODIFIER", 73, 82], ["Peripheral", "ANATOMY_MODIFIER", 83, 93], ["Nerve", "ANATOMY", 94, 99], ["Sheath", "ANATOMY_MODIFIER", 100, 106], ["Tumor", "OBSERVATION", 107, 112], ["proliferation", "OBSERVATION_MODIFIER", 139, 152]]], ["Therefore, possessing all these features it was approved to cure rare cancer disease cutaneous lymphoma and commercialised as 'Isodax' in market.", [["cancer", "ANATOMY", 70, 76], ["cutaneous lymphoma", "ANATOMY", 85, 103], ["cancer disease cutaneous lymphoma", "DISEASE", 70, 103], ["rare cancer", "CANCER", 65, 76], ["cutaneous lymphoma", "CANCER", 85, 103], ["rare cancer disease cutaneous lymphoma", "PROBLEM", 65, 103], ["cancer", "OBSERVATION", 70, 76], ["cutaneous lymphoma", "OBSERVATION", 85, 103]]], ["However, research is being conducted with the belief that it could be most probably utilized for COVID-19 therapy.", [["COVID-19", "CHEMICAL", 97, 105], ["COVID-19 therapy", "TREATMENT", 97, 113]]], ["It is need of an hour to clinically test various PAK1-blockers against blocking virus replication to develop anti-COVID-19 therapy for patients suffering worldwide.ConclusionsStrata of mankind has been marred with the onset of the unexpected pandemics, leading to the atrocious effects on their entire communities.", [["anti-COVID-19", "CHEMICAL", 109, 122], ["PAK1", "GENE_OR_GENE_PRODUCT", 49, 53], ["anti-COVID-19", "SIMPLE_CHEMICAL", 109, 122], ["patients", "ORGANISM", 135, 143], ["PAK1", "PROTEIN", 49, 53], ["patients", "SPECIES", 135, 143], ["PAK1-blockers", "TREATMENT", 49, 62], ["blocking virus replication", "TREATMENT", 71, 97], ["anti-COVID-19 therapy", "TREATMENT", 109, 130], ["the unexpected pandemics", "PROBLEM", 227, 251], ["the atrocious effects", "PROBLEM", 264, 285], ["pandemics", "OBSERVATION", 242, 251]]], ["Unfortunately, SARS-CoV-2 has led the global population on their toes due to its highly infectious nature and susceptibility towards humans in causing higher mortalities among them.", [["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "ORGANISM", 15, 25], ["toes", "ORGANISM_SUBDIVISION", 65, 69], ["humans", "ORGANISM", 133, 139], ["humans", "SPECIES", 133, 139], ["SARS-CoV", "SPECIES", 15, 23], ["humans", "SPECIES", 133, 139], ["SARS", "PROBLEM", 15, 19], ["global", "OBSERVATION_MODIFIER", 38, 44], ["population", "OBSERVATION", 45, 55], ["highly", "OBSERVATION_MODIFIER", 81, 87], ["infectious", "OBSERVATION", 88, 98]]], ["We can also introspect that about a lot many cases of COVID-19 have been undetected and by looking into the ongoing trends, the cases are doing to inflate in the coming future.", [["COVID", "TEST", 54, 59]]], ["Besides, WHO has advised the world to take preventive measures, owing to which government has facilitated nationwide shutdowns, self-quarantine, physical distancing to ensure public safety.", [["preventive measures", "TREATMENT", 43, 62]]], ["Thus far, the prevailing drugs and vaccines for antiviral diseases have been used as clinical trials to fight against coronavirus.", [["antiviral diseases", "DISEASE", 48, 66], ["coronavirus", "DISEASE", 118, 129], ["coronavirus", "ORGANISM", 118, 129], ["the prevailing drugs", "TREATMENT", 10, 30], ["vaccines", "TREATMENT", 35, 43], ["antiviral diseases", "PROBLEM", 48, 66], ["coronavirus", "PROBLEM", 118, 129]]], ["Furthermore, by studying the gene pool of SARS-CoV-2, researchers would be able to invent the vaccine for this petrified virus.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "SPECIES", 42, 50], ["the vaccine", "TREATMENT", 90, 101], ["this petrified virus", "PROBLEM", 106, 126]]], ["Our review projected the possible role of herbal plants and their sources in the treatment of COVID-19 infections due to its bioactive ingredients acting as substantial warriors in this battle.", [["COVID-19", "CHEMICAL", 94, 102], ["infections", "DISEASE", 103, 113], ["COVID-19", "ORGANISM", 94, 102], ["COVID-19", "SPECIES", 94, 102], ["herbal plants", "TREATMENT", 42, 55], ["COVID-19 infections", "PROBLEM", 94, 113], ["its bioactive ingredients", "TREATMENT", 121, 146], ["possible", "UNCERTAINTY", 25, 33]]], ["Intriguingly, pro-active devotions in this research would definitely enable us to develop vaccines or drugs to cure COVID-19, for which it is pre-requisite to unlock this treasure of information pertaining to traditional medicines.", [["vaccines", "TREATMENT", 90, 98], ["drugs", "TREATMENT", 102, 107], ["traditional medicines", "TREATMENT", 209, 230]]], ["However, there is an urgent need to invest time on these studies for acquiring about appropriate doses and formulations for discovering drugs or vaccines from these formulations.", [["these studies", "TEST", 51, 64], ["formulations", "TREATMENT", 107, 119], ["discovering drugs", "TREATMENT", 124, 141], ["vaccines", "TREATMENT", 145, 153], ["these formulations", "TREATMENT", 159, 177]]], ["For this purpose, scientific evidences and comprehensive pharmaco-dynamic knowledge related to medicinal plants should be made available to scientists to design clinical trials.", [["medicinal plants", "TREATMENT", 95, 111]]], ["Integration of this concept would certainly develop the drug therapy in the near future.", [["the drug therapy", "TREATMENT", 52, 68]]], ["All what we can do is wait for the hope of radiance at the terminating point of the tunnel, in solitude.Future Perspectives and ConclusionsDue to the ongoing disaster of COVID-19, there is a pressing need for the discovery of alternative remedial measures.", [["radiance", "TREATMENT", 43, 51], ["COVID", "TEST", 170, 175], ["alternative remedial measures", "TREATMENT", 226, 255], ["tunnel", "OBSERVATION", 84, 90]]], ["There is a wide scope of herbal medicines that have been used since traditional times.", [["herbal medicines", "TREATMENT", 25, 41], ["wide", "OBSERVATION_MODIFIER", 11, 15]]], ["They have been considered as potent clinical agents against wide array of viral diseases due to their anti-viral properties.", [["viral diseases", "DISEASE", 74, 88], ["potent clinical agents", "TREATMENT", 29, 51], ["viral diseases", "PROBLEM", 74, 88], ["their anti-viral properties", "TREATMENT", 96, 123], ["viral diseases", "OBSERVATION", 74, 88]]], ["These natural products of Ayurveda are being tested for treating COVID-19.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID", "TEST", 65, 70]]], ["Basically, these formulations are comprised of huge number of phytochemicals such as terpenoids, alkaloids, flavonoids, phenols, tannins, polyphenols, saponins, polysaccharides, proteins, lipids and peptides that possess myriad of functions against viral invasion, penetration, replication, expression, assembly and release.", [["terpenoids, alkaloids, flavonoids, phenols, tannins, polyphenols, saponins, polysaccharides", "CHEMICAL", 85, 176], ["terpenoids", "CHEMICAL", 85, 95], ["flavonoids", "CHEMICAL", 108, 118], ["phenols", "CHEMICAL", 120, 127], ["tannins", "CHEMICAL", 129, 136], ["polyphenols", "CHEMICAL", 138, 149], ["saponins", "CHEMICAL", 151, 159], ["terpenoids", "SIMPLE_CHEMICAL", 85, 95], ["alkaloids", "SIMPLE_CHEMICAL", 97, 106], ["flavonoids", "SIMPLE_CHEMICAL", 108, 118], ["phenols", "SIMPLE_CHEMICAL", 120, 127], ["tannins", "SIMPLE_CHEMICAL", 129, 136], ["polyphenols", "SIMPLE_CHEMICAL", 138, 149], ["saponins", "SIMPLE_CHEMICAL", 151, 159], ["polysaccharides", "SIMPLE_CHEMICAL", 161, 176], ["lipids", "SIMPLE_CHEMICAL", 188, 194], ["terpenoids", "PROBLEM", 85, 95], ["alkaloids", "TREATMENT", 97, 106], ["flavonoids", "TREATMENT", 108, 118], ["phenols", "TREATMENT", 120, 127], ["tannins", "TREATMENT", 129, 136], ["polyphenols", "TREATMENT", 138, 149], ["saponins", "TREATMENT", 151, 159], ["polysaccharides", "TREATMENT", 161, 176], ["proteins", "TREATMENT", 178, 186], ["lipids", "TREATMENT", 188, 194], ["peptides", "TREATMENT", 199, 207], ["viral invasion", "PROBLEM", 249, 263], ["huge", "OBSERVATION_MODIFIER", 47, 51], ["invasion", "OBSERVATION", 255, 263]]], ["Moreover, medicinal plants and their natural ingredients proved to be the most promising alternatives to prevent or cure the infection and spread of this disease since its outbreak.", [["infection", "DISEASE", 125, 134], ["medicinal plants", "TREATMENT", 10, 26], ["the infection", "PROBLEM", 121, 134], ["this disease", "PROBLEM", 149, 161], ["infection", "OBSERVATION", 125, 134]]], ["However, they are still being tested under in vitro conditions to get the direct evidence on the positive health of COVID-19 patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["COVID", "TEST", 116, 121]]], ["In the present review, we have elaborated the potential role of herbal formulations to treat COVID-19 through summarising the ongoing trials of plants and their products against this deadly virus.", [["COVID-19", "CHEMICAL", 93, 101], ["COVID-19", "CHEMICAL", 93, 101], ["herbal formulations", "TREATMENT", 64, 83], ["COVID", "TREATMENT", 93, 98], ["plants", "TREATMENT", 144, 150], ["their products", "TREATMENT", 155, 169], ["this deadly virus", "PROBLEM", 178, 195]]], ["Although, the investigations for evaluation of different plant genera as anti SARS-CoV-2 agents, are insufficient.", [["the investigations", "TEST", 10, 28], ["evaluation", "TEST", 33, 43], ["different plant genera", "TREATMENT", 47, 69], ["anti SARS", "TREATMENT", 73, 82], ["CoV-2 agents", "TREATMENT", 83, 95]]], ["But research is in the pipeline to untangle their potential positive aspect and we expect these studies to be conducted in a more elaborated manner in future.", [["these studies", "TEST", 90, 103]]], ["Yet, many scientists are still engaged in these studies to develop a suitable antidode for this virus.", [["antidode", "CANCER", 78, 86], ["these studies", "TEST", 42, 55], ["a suitable antidode", "TREATMENT", 67, 86], ["this virus", "PROBLEM", 91, 101]]], ["The future possibilities upholds the fact that by combining these studies with effective technology and testing we can demonstrate their role in blocking the life-cycle of this virus, protein denaturation of receptor proteins and role of certain proteases enzymes could be studied.FundingThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author contributionsRB, PA, KK: Conceptualization; SKK, RK AB, VB Data curation; AS, AA, KK, RK: Methodology; KK, SKK, AS, AB, PO: Resources; PO, AS, AB: Software; RB, PA, KK: Supervision; RB, KK, PA, VB, PO, AS, Roles/Writing - original draft; RB, PA, AA, KK: Writing - review & editing.Uncited References:", [["receptor proteins", "PROTEIN", 208, 225], ["proteases enzymes", "PROTEIN", 246, 263], ["these studies", "TEST", 60, 73], ["testing", "TEST", 104, 111], ["this virus", "PROBLEM", 172, 182], ["protein denaturation of receptor proteins", "PROBLEM", 184, 225], ["certain proteases enzymes", "PROBLEM", 238, 263]]]], "2393a9c4acfb8c7c975931063f8b10ea39760fd0": [["IntroductionMany people use the internet to seek information that will help them understand their body and their health [1] [2] [3] .", [["body", "ANATOMY", 98, 102], ["people", "ORGANISM", 17, 23], ["body", "ORGANISM_SUBDIVISION", 98, 102], ["people", "SPECIES", 17, 23]]], ["For example, users may wish to figure out a medical condition by searching for symptoms they experience.", [["a medical condition", "PROBLEM", 42, 61], ["symptoms", "PROBLEM", 79, 87]]], ["With the ubiquitous availability of the internet, searching and finding relevant information is easier than ever before and a widespread phenomenon.", [["a widespread phenomenon", "PROBLEM", 124, 147], ["widespread", "OBSERVATION_MODIFIER", 126, 136], ["phenomenon", "OBSERVATION", 137, 147]]], ["Likewise, two out of five internet users in Germany search the internet for health information before their doctor's appointment, and around half of internet users after their appointment [6] .PLOS ONEIn addition, the rise of health applications (apps) on mobile devices such as smartphones and tablets, as well as accompanying health and fitness trackers (\"wearables\"), make it possible for people to track their health and fitness without the help of medical professionals and at lower costs.", [["people", "ORGANISM", 392, 398], ["people", "SPECIES", 392, 398], ["mobile devices", "TREATMENT", 256, 270], ["tablets", "TREATMENT", 295, 302]]], ["Just like researching health information online, the use of health apps on mobile devices is spreading rapidly.", [["mobile devices", "TREATMENT", 75, 89]]], ["Moreover, the number of health apps in Apple's App Store is estimated to be about 90,000 [9] .PLOS ONEUnderstanding who uses health apps on mobile devices and searches and consumes what kind of health information on the internet is crucial for several reasons.", [["mobile devices", "TREATMENT", 140, 154]]], ["Health apps and mobile devices are used to improve self-reflection [10] , change behaviors [11] and track physical activity [12] .", [["mobile devices", "TREATMENT", 16, 30]]], ["Likewise, health information collected from the internet influences users' decisions about their own health and decisions they make for others (e.g., their children) [13] .", [["children", "ORGANISM", 156, 164], ["children", "SPECIES", 156, 164]]], ["Online health information may also influence how users treat conditions or symptoms they experience.", [["symptoms", "PROBLEM", 75, 83]]], ["For some of these users, browsing behavior as well as app use was in addition monitored on smartphones and tablets during the same time period.", [["smartphones", "TREATMENT", 91, 102], ["tablets", "TREATMENT", 107, 114]]], ["The data were collected by a commercial vendor who keeps a pool of participants who are occasionally invited to answer short surveys for money.", [["participants", "SPECIES", 67, 79]]], ["Previous work mostly relied on self-reported measures of online behavior through questionnaires, which is often inaccurate due to recall error, and previous research often used samples small in size.", [["small", "OBSERVATION_MODIFIER", 185, 190], ["size", "OBSERVATION_MODIFIER", 194, 198]]], ["Our approach of passively tracking browsing behavior addresses these limitations and allows more accurate and detailed insights into how people use the internet.", [["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143]]], ["In addition to the tracking data, participants also provided socio-demographic information, information on health issues and information on other lifestyle behaviors that may influence their health (e.g., exercising and smoking).", [["participants", "SPECIES", 34, 46]]], ["This combination of web logs and survey data creates a unique data source for studying individuals' health activities in the online world, going far beyond previous research.", [["survey data", "TEST", 33, 44]]], ["Results indicate that women, young users and users who have a university degree are more likely to engage in health-related internet/app use.", [["women", "ORGANISM", 22, 27], ["women", "SPECIES", 22, 27]]], ["We find limited evidence that health-related internet/app use is related to health conditions, but that it is related with lifestyle behaviors such as smoking.", [["smoking", "CHEMICAL", 151, 158]]], ["Regarding topics that users engage in the most, we classify participants' visits to health-related internet domains and apps into broader categories.", [["participants", "SPECIES", 60, 72]]], ["Our results indicate that users are particularly interested in exercising and weight loss as well as nutrition and alternative medicine.", [["weight loss", "DISEASE", 78, 89], ["weight loss", "PROBLEM", 78, 89], ["nutrition and alternative medicine", "TREATMENT", 101, 135]]], ["Analysis of health-related search queries made to search engines reveals that users are most interested in finding pharmacies, symptoms of medical conditions, various forms of pain and remedies for health problems.Related workIn this section, we review two streams of previous work that are relevant for our study: Correlates of health-related internet and app use and health information search through search engines.Correlates of health-related internet and app useInternet use for health information seeking is associated with a variety of socio-demographic characteristics.", [["pain", "DISEASE", 176, 180], ["useInternet", "CHEMICAL", 464, 475], ["symptoms of medical conditions", "PROBLEM", 127, 157], ["pain", "PROBLEM", 176, 180], ["health problems", "PROBLEM", 198, 213]]], ["Consistent findings are reported regarding education (users with lower education are less likely to seek health information online) [4, [19] [20] [21] [21] [22] [23] [24] and gender (women more likely) [4, 17, 19, 20, 21, 21, 22, 25] .", [["women", "ORGANISM", 183, 188], ["women", "SPECIES", 183, 188]]], ["Some studies also report effects regarding income (users with higher income more likely) [4, 21, 22] and race/ethnicity (non-white users less likely) [4, 25] .Correlates of health-related internet and app useLess is known regarding associations between users' health behavior and health-related internet use.", [["Some studies", "TEST", 0, 12]]], ["Several studies report that users with \"fair\" or \"poor\" health are more likely to use the internet for health purposes [22, 26] .", [["Several studies", "TEST", 0, 15]]], ["Users who already have a chronic health condition are more likely to seek information online [27] , while those who are at risk of getting a medical condition (for example, cancer) rely more often on information obtained from health professionals [23] .", [["cancer", "ANATOMY", 173, 179], ["cancer", "DISEASE", 173, 179], ["cancer", "CANCER", 173, 179], ["a chronic health condition", "PROBLEM", 23, 49], ["cancer", "PROBLEM", 173, 179]]], ["Furthermore, there seems to be a positive association between obesity and healthrelated internet use [28] .Correlates of health-related internet and app useRegarding determinants of health-related app use, socio-demographic relationships similar to those mentioned above are reported (e.g., age, education, gender, income) [7, [29] [30] [31] [32] .", [["obesity", "DISEASE", 62, 69], ["obesity", "PROBLEM", 62, 69], ["obesity", "OBSERVATION", 62, 69]]], ["In addition, having a history of chronic medical conditions [33] , being obese [31] and engaging in physical activity are all positively associated with health-related app use [30, 33] .", [["chronic medical conditions", "PROBLEM", 33, 59], ["chronic", "OBSERVATION_MODIFIER", 33, 40]]], ["Overall, however, regular use of health apps and other digital health solutions is not widespread, even among users with a high digital affinity (see, for example, [34] ).Correlates of health-related internet and app useTo sum up, previous work identified several socio-demographic correlates of health-related internet and app use, such as age, gender and education.", [["a high digital affinity", "PROBLEM", 121, 144]]], ["Moreover, a few studies find relationships between users' health and their online and app activities.", [["a few studies", "TEST", 10, 23]]], ["One major drawback of all of the studies mentioned here, however, is that they rely on survey data.", [["the studies", "TEST", 29, 40], ["survey data", "TEST", 87, 98]]], ["Analyzing web logs and records of mobile device use such as those used in our study offers a more complete and fine-grained picture of users' online and app activities.Correlates of health-related internet and app useMoreover, they allow us to study not only who engages in health-related internet and app use, but also how users obtain their information.Health information search through search enginesBesides literature regarding the question of who uses the internet and apps for health-related purposes, previous work studying health-related search queries is relevant for our study.", [["mobile device", "TREATMENT", 34, 47], ["our study", "TEST", 74, 83], ["our study", "TEST", 577, 586]]], ["Most of the studies in this domain rely on the analysis of search query data.Health information search through search enginesCartright et al. identify health-related search queries (about 20% out of all queries) made to three major search engines in the U.S. over a period of six months [36] .", [["the studies", "TEST", 8, 19], ["the analysis", "TEST", 43, 55], ["search query data", "TEST", 59, 76]]], ["The resulting queries are classified into different foci (symptom, cause or remedy).", [["foci", "ANATOMY", 52, 56], ["different foci (symptom", "PROBLEM", 42, 65], ["different", "OBSERVATION_MODIFIER", 42, 51], ["foci", "OBSERVATION", 52, 56]]], ["Using similar data, White et al. show that users who start a session searching for simple symptoms easily end up searching for serious diseases [13] .", [["simple symptoms", "PROBLEM", 83, 98], ["serious diseases", "PROBLEM", 127, 143]]], ["Thereby, the authors show that likely innocuous health searches can quickly lead users to seek information about serious, but rare disease with similar symptoms.", [["rare disease", "PROBLEM", 126, 138], ["similar symptoms", "PROBLEM", 144, 160]]], ["Using Google search queries, Ginsberg et al. demonstrate that (for some time) search activity for influenza-like symptoms was an accurate predictor of actual influenza epidemics [37] .", [["influenza-like symptoms", "DISEASE", 98, 121], ["influenza", "DISEASE", 158, 167], ["influenza", "PROBLEM", 98, 107], ["symptoms", "PROBLEM", 113, 121], ["actual influenza epidemics", "PROBLEM", 151, 177]]], ["A few years later, however, the performance of their algorithms decreased rapidly due to changes in Google's search algorithms and in the ways people used the search engine [38] .Health information search through search enginesAbebe et al. study health information needs related to HIV/AIDS, malaria and tuberculosis in 54 African countries [39] .", [["HIV/AIDS", "DISEASE", 282, 290], ["malaria", "DISEASE", 292, 299], ["tuberculosis", "DISEASE", 304, 316], ["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["HIV", "SPECIES", 282, 285], ["HIV", "SPECIES", 282, 285], ["HIV/AIDS", "PROBLEM", 282, 290], ["malaria", "PROBLEM", 292, 299], ["tuberculosis", "PROBLEM", 304, 316], ["few", "OBSERVATION_MODIFIER", 2, 5], ["tuberculosis", "OBSERVATION", 304, 316]]], ["Using Bing search data from those countries, the authors show that users are mostly interested in gathering information about symptoms, testing and treatment, but also stigma, discrimination and natural cures.", [["symptoms", "PROBLEM", 126, 134], ["testing", "TEST", 136, 143], ["treatment", "TREATMENT", 148, 157]]], ["Using 18 months and billions of search queries posted to Bing's web search engine, Fourney et al. show how concerns about pregnancy and childbirth change over the course of pregnancy [40] .Health information search through search enginesFurthermore, Yahoo! search activity for cancer correlates with estimated cancer incidence, mortality and, especially, news coverage [41] .", [["cancer", "ANATOMY", 277, 283], ["cancer", "ANATOMY", 310, 316], ["cancer", "DISEASE", 277, 283], ["cancer", "DISEASE", 310, 316], ["cancer", "CANCER", 277, 283], ["cancer", "CANCER", 310, 316], ["pregnancy", "PROBLEM", 122, 131], ["childbirth change", "PROBLEM", 136, 153], ["cancer", "PROBLEM", 277, 283], ["estimated cancer incidence", "PROBLEM", 300, 326]]], ["Similarly, search activity for information about cancer in the U.K. and the U.S. increased from 2008 to 2010, with almost half of all searches dealing with breast cancer, followed by lung and prostate cancer [42] .", [["cancer", "ANATOMY", 49, 55], ["breast cancer", "ANATOMY", 156, 169], ["lung", "ANATOMY", 183, 187], ["prostate cancer", "ANATOMY", 192, 207], ["cancer", "DISEASE", 49, 55], ["breast cancer", "DISEASE", 156, 169], ["lung and prostate cancer", "DISEASE", 183, 207], ["cancer", "CANCER", 49, 55], ["breast cancer", "CANCER", 156, 169], ["lung", "ORGAN", 183, 187], ["prostate cancer", "CANCER", 192, 207], ["cancer", "PROBLEM", 49, 55], ["breast cancer", "PROBLEM", 156, 169], ["lung and prostate cancer", "PROBLEM", 183, 207], ["breast", "ANATOMY", 156, 162], ["cancer", "OBSERVATION", 163, 169], ["lung", "ANATOMY", 183, 187], ["prostate", "ANATOMY", 192, 200], ["cancer", "OBSERVATION", 201, 207]]], ["Most common topics include different treatment forms, diagnosis and screening.Health information search through search enginesGoogle Trends, a tool allowing the estimation of aggregated Google search activity for specific queries, is popular for studying health-related search activity [43] [44] [45] .", [["different treatment forms", "TREATMENT", 27, 52], ["screening", "TEST", 68, 77]]], ["For example, research found that queries about breast cancer screening made to Google correlate with changes in legislature and news coverage [44] .", [["breast cancer", "ANATOMY", 47, 60], ["breast cancer", "DISEASE", 47, 60], ["breast cancer", "CANCER", 47, 60], ["breast cancer screening", "TEST", 47, 70], ["breast", "ANATOMY", 47, 53], ["cancer", "OBSERVATION", 54, 60]]], ["Likewise, Google Trends shows that consistent seasonal patterns in search activity exist and that breast, pancreatic and ovarian cancer are among the most searched for forms of cancer [43, 45] .Health information search through search enginesAnother approach to obtain information about users' online search behavior is used in [46] .", [["breast", "ANATOMY", 98, 104], ["pancreatic", "ANATOMY", 106, 116], ["ovarian cancer", "ANATOMY", 121, 135], ["cancer", "ANATOMY", 177, 183], ["breast, pancreatic and ovarian cancer", "DISEASE", 98, 135], ["cancer", "DISEASE", 177, 183], ["breast", "CANCER", 98, 104], ["pancreatic", "CANCER", 106, 116], ["ovarian cancer", "CANCER", 121, 135], ["cancer", "CANCER", 177, 183], ["Google Trends", "TEST", 10, 23], ["breast, pancreatic and ovarian cancer", "PROBLEM", 98, 135], ["cancer", "PROBLEM", 177, 183], ["breast", "ANATOMY", 98, 104], ["pancreatic", "ANATOMY", 106, 116], ["ovarian", "ANATOMY", 121, 128], ["cancer", "OBSERVATION", 129, 135], ["cancer", "OBSERVATION", 177, 183]]], ["56 women were recruited from a commercial vendor in market research.", [["women", "ORGANISM", 3, 8], ["women", "SPECIES", 3, 8]]], ["Women answered an online survey and were then instructed to search information online about a hypothetical body change.", [["body", "ANATOMY", 107, 111], ["Women", "ORGANISM", 0, 5], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["Women", "SPECIES", 0, 5], ["a hypothetical body change", "PROBLEM", 92, 118]]], ["Monitoring the online searching behavior of the participants through a browser plugin, the authors find that seeking information about unfamiliar symptoms online does not necessarily help women understand their condition.Health information search through search enginesTo sum up, previous work mainly relied on search query data obtained from various search engines or tools built on top of them (Google Trends).", [["women", "ORGANISM", 188, 193], ["participants", "SPECIES", 48, 60], ["women", "SPECIES", 188, 193], ["unfamiliar symptoms", "PROBLEM", 135, 154], ["query data", "TEST", 318, 328]]], ["Moreover, query data is often difficult to obtain [40] or relies on small samples with specific foci [46] .Data and methodologyWe analyze four months (July-October 2017) of web log and mobile device use data for a sample of 1,959 German internet users.", [["samples", "ANATOMY", 74, 81], ["query data", "TEST", 10, 20], ["small samples with specific foci", "PROBLEM", 68, 100], ["mobile device", "TREATMENT", 185, 198], ["foci", "OBSERVATION", 96, 100]]], ["Data were collected by a commercial vendor (respondi AG [47] in market research for a third-party (SINUS Markt-und Sozialforschung GmbH [48] ) not involved in this study for market research purposes.", [["SINUS Markt", "TEST", 99, 110], ["this study", "TEST", 159, 169], ["SINUS", "ANATOMY", 99, 104]]], ["The vendor keeps an opt-in panel of participants for marketing and social research.", [["participants", "SPECIES", 36, 48]]], ["Participants of the panel are occasionally invited to answer surveys in exchange for small cash incentives.", [["Participants", "SPECIES", 0, 12]]], ["In addition, participants can agree to the monitoring of their browsing behavior and mobile device use for additional incentives, after giving informed consent that their survey, web log and app use data will be used for academic and market research purposes.", [["participants", "SPECIES", 13, 25], ["the monitoring", "TEST", 39, 53], ["mobile device", "TREATMENT", 85, 98]]], ["Details on the panel, the vendor's recruitment process as well as the privacy policy can be found at [47] .Data and methodologyTo ask participants questions, researchers provide them to the vendor who then implements them in its online survey platform.", [["participants", "SPECIES", 134, 146], ["the panel", "TEST", 11, 20]]], ["At no times is there contact between researchers and participants of the vendor's panel.", [["participants", "SPECIES", 53, 65]]], ["That is, all data accessible to us are striped of users' names, addresses or birth dates and cannot be linked back.Data and methodologyGiven these circumstances (pseudonymized data provided by a survey platform from users of the platform who gave informed consent in combination with no possibility for us to deidentify individuals), this study was exempted from an approval by the Ethics Committee of the University of Mannheim (Ethics Committee of the University of Mannheim, Decision \"EK Mannheim 15/2020\").Data and methodologyThe vendor gathers web logs from participants' personal computers and mobile devices (smartphones and tablets) through a tool based on software provided by Wakoopa [49] .", [["participants", "SPECIES", 563, 575], ["this study", "TEST", 334, 344], ["mobile devices (smartphones and tablets", "TREATMENT", 600, 639]]], ["In addition, they download an app on their mobile devices (smartphones and tablets, Android and iOS devices only).", [["their mobile devices", "TREATMENT", 37, 57], ["tablets", "TREATMENT", 75, 82], ["Android and iOS devices", "TREATMENT", 84, 107]]], ["This app collects web logs from the native browsers (i.e., Safari on iOS devices and Chrome on Android devices) as well as information about the apps participants use.Data and methodologyEach time a participant navigates to a website, the complete URL of the website (e.g., https://en.wikipedia.org/wiki/URL), the domain (wikipedia.org), the current date and time as well as the time spent on the website are recorded (both on personal computers and mobile devices).", [["participants", "SPECIES", 150, 162], ["participant", "SPECIES", 199, 210], ["iOS devices", "TREATMENT", 69, 80], ["Android devices", "TREATMENT", 95, 110], ["mobile devices", "TREATMENT", 450, 464]]], ["In addition, on mobile devices, information about the apps that participants use are recorded.", [["participants", "SPECIES", 64, 76], ["mobile devices", "TREATMENT", 16, 30]]], ["Every time a participant opens an app on a device, the name of the app, the duration of use and information about the device are logged.", [["participant", "SPECIES", 13, 24], ["a device", "TREATMENT", 41, 49], ["the device", "TREATMENT", 114, 124]]], ["At any time, participants can turn off data collection temporarily or stop data collection completely.Data and methodologyThe vendor also provides background information about the users, including socio-demographics and information on various health issues, which were collected through a web survey.", [["participants", "SPECIES", 13, 25], ["data collection", "TEST", 39, 54]]], ["Table 1 shows characteristics of the participants in our study.", [["participants", "SPECIES", 37, 49], ["our study", "TEST", 53, 62]]], ["Overall, about half of all participants are female (54.72%), and the mean age is about 42 years.", [["participants", "ORGANISM", 27, 39], ["participants", "SPECIES", 27, 39]]], ["58.96% of participants work full-or half-time.", [["participants", "ORGANISM", 10, 22], ["participants", "SPECIES", 10, 22]]], ["More than 80% have some education beyond basic secondary school and most of the participants have a personal net monthly income between \u20ac1,000 and \u20ac2,000.", [["participants", "ORGANISM", 80, 92], ["participants", "SPECIES", 80, 92]]], ["Besides socio-demographic information, Table 1 lists also the most common health issues reported by the participants.", [["participants", "SPECIES", 104, 116]]], ["32.06%% of all participants indicated back problems and about 26.08% of having (any) allergies.", [["allergies", "DISEASE", 85, 94], ["participants", "SPECIES", 15, 27], ["back problems", "PROBLEM", 38, 51], ["any) allergies", "PROBLEM", 80, 94], ["back", "ANATOMY", 38, 42]]], ["20.93% reported having high blood pressure, 18.07% problems with sleeplessness, 16.23% depression and 11.84% reported obesity.", [["blood", "ANATOMY", 28, 33], ["high blood pressure", "DISEASE", 23, 42], ["sleeplessness", "DISEASE", 65, 78], ["depression", "DISEASE", 87, 97], ["obesity", "DISEASE", 118, 125], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["high blood pressure", "PROBLEM", 23, 42], ["sleeplessness", "PROBLEM", 65, 78], ["depression", "PROBLEM", 87, 97], ["obesity", "PROBLEM", 118, 125], ["obesity", "OBSERVATION", 118, 125]]], ["Regarding other lifestyle behaviors, 41.45% indicated smoking and 76.88% participating in any physical activity (such as running, swimming and playing football).", [["smoking", "CHEMICAL", 54, 61]]], ["Thus, we find that some participants in the sample do have to cope with several health problems and engage in healthrelated lifestyle behaviors.Data and methodologyWe create three datasets from the data described above.", [["participants", "SPECIES", 24, 36]]], ["The first one contains web logs from both personal computers and mobile devices (28,524,036 total logs from 1,959 participants).", [["participants", "SPECIES", 114, 126], ["mobile devices", "TREATMENT", 65, 79], ["web logs", "OBSERVATION", 23, 31]]], ["Overall, participants visited 194,389 unique domains.", [["participants", "SPECIES", 9, 21]]], ["To identify web logs that refer to domains with health content, we used Webshrinker [50], an online service offering domain categorization.", [["domain categorization", "TREATMENT", 117, 138]]], ["If available, Webshrinker also included the appropriate subcategory (for example, chronic pain, dental care or alternative medicine).", [["pain", "DISEASE", 90, 94], ["chronic pain", "PROBLEM", 82, 94], ["dental care", "TREATMENT", 96, 107], ["alternative medicine", "TREATMENT", 111, 131]]], ["Table 2 shows the number of health-related domains per subcategory.Data and methodologyThe second dataset contains records of app use (8,957,760 total records from 1,328 participants).", [["participants", "SPECIES", 170, 182]]], ["The remaining 631 participants either used a personal computer only or did not use apps on their mobile devices.", [["participants", "SPECIES", 18, 30]]], ["Therefore, the number of participants in this dataset is smaller than the total number of participants in our study.", [["participants", "SPECIES", 25, 37], ["participants", "SPECIES", 90, 102], ["our study", "TEST", 106, 115], ["smaller", "OBSERVATION_MODIFIER", 57, 64]]], ["Overall, participants used 10,123 unique apps.", [["participants", "SPECIES", 9, 21]]], ["Limiting app use records to apps that were used for at least thirty minutes by at least one user (during the four months of data collection), the number of apps decreases to 157.", [["data collection", "TEST", 124, 139]]], ["Regarding apps that users actually use, we find that tracking one's health and fitness, as well as exercising and weight loss and women's health are the popular categories.", [["weight loss", "DISEASE", 114, 125], ["women", "ORGANISM", 130, 135], ["women", "SPECIES", 130, 135], ["weight loss and women's health", "PROBLEM", 114, 144]]], ["It contains search queries sent to the 19 most common search engines in the web logs dataset (for example, Google, Bing, Yahoo and Duck-DuckGo).", [["search queries", "TEST", 12, 26]]], ["We extract the search queries from these URLs (for example, the search queries extracted from the URL https://www.google.com/search?q=high+blood+pressure are \"high blood pressure\").", [["blood", "ANATOMY", 164, 169], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["high blood pressure\"", "PROBLEM", 159, 179]]], ["1,656 (84.53%) participants used one of the search engines at least once.", [["participants", "SPECIES", 15, 27]]], ["We chose websites that listed diseases and organs and other parts of the human body, technical medical terms, medical disciplines, symptoms of diseases and medical encyclopedia.", [["organs", "ANATOMY", 43, 49], ["body", "ANATOMY", 79, 83], ["organs", "ORGAN", 43, 49], ["human", "ORGANISM", 73, 78], ["body", "ORGANISM_SUBDIVISION", 79, 83], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["symptoms of diseases", "PROBLEM", 131, 151]]], ["Prior to scraping the terms from the websites, we ensured that our web crawlers were not forbidden on these websites by checking the robots.txt files and the terms and conditions of each domain.", [["txt", "PROTEIN", 140, 143], ["scraping", "TREATMENT", 9, 17]]], ["We used the fuzzywuzzy Python module for fuzzy string matching (https://github.com/seatgeek/fuzzywuzzy).", [["fuzzywuzzy Python module", "DNA", 12, 36], ["the fuzzywuzzy Python module", "TREATMENT", 8, 36], ["fuzzy string matching", "PROBLEM", 41, 62]]], ["The module allows the estimation of differences between sequences of characters based on Levenshtein Distances.Data and methodologyManual inspection of a random sample of matches between the search queries and the list of medical terms revealed that using a sorted token approach with a partial match ratio of 0.7 resulted in a reasonably low number of false positives.", [["Manual inspection", "TEST", 131, 148], ["a sorted token approach", "TREATMENT", 256, 279], ["a partial match ratio", "TEST", 285, 306], ["false positives", "PROBLEM", 353, 368], ["false positives", "OBSERVATION", 353, 368]]], ["763 users out of the 1,656 users who used a search engine at least ones (that is, 46.07%) searched for health-related information at least once.FindingsIn this section, we present the main results of our study.Health-related internet and app use1,662 (84.84%) out of 1,959 participants in the web logs dataset visited any health-related domain.", [["participants", "SPECIES", 273, 285], ["our study", "TEST", 200, 209]]], ["Table 4 shows the five most popular subcategories of health-related domains across participants in the sample.", [["participants", "SPECIES", 83, 95], ["most popular", "OBSERVATION_MODIFIER", 23, 35]]], ["Participants seem predominantly interested in information about exercising, losing weight and food supplements, but also in alternatives to traditional medicine.", [["Participants", "SPECIES", 0, 12], ["traditional medicine", "TREATMENT", 140, 160]]], ["A comparison with Table 2 demonstrates that the subcategories with the highest numbers of unique visitors are also among those with the highest number of unique domains.", [["highest", "OBSERVATION_MODIFIER", 71, 78], ["numbers", "OBSERVATION_MODIFIER", 79, 86]]], ["494 (37.20%) out of 1,328 participants in the apps dataset used a health app at least once.", [["participants", "SPECIES", 26, 38]]], ["Using the definition of frequent health app use (see Table 3 ), we find that only 224 (16.87%) out of 1,328 participants participants frequently use health apps.", [["participants", "SPECIES", 108, 120], ["participants", "SPECIES", 121, 133]]], ["This finding is likely due to the popularity of wearables that allow, for example, the monitoring of one's heart rate.", [["heart", "ANATOMY", 107, 112], ["heart", "ORGAN", 107, 112], ["the monitoring", "TEST", 83, 97], ["one's heart rate", "TEST", 101, 117], ["is likely due to", "UNCERTAINTY", 13, 29]]], ["Similarly, many participants used an app for exercising and workout, but also apps that focus on weight loss.", [["weight loss", "DISEASE", 97, 108], ["participants", "SPECIES", 16, 28], ["weight loss", "PROBLEM", 97, 108]]], ["Furthermore, apps for women's health are popular.", [["women", "ORGANISM", 22, 27], ["women", "SPECIES", 22, 27]]], ["Manual inspection revealed that this subcategory mainly consists of period and ovulation tracker apps.", [["Manual inspection", "TEST", 0, 17], ["ovulation tracker apps", "PROBLEM", 79, 101]]], ["In addition, the popularity of apps among participants seems to match the popularity of subcategories measured by the number of unique apps in each subcategory (Table 3) .", [["participants", "SPECIES", 42, 54]]], ["Overall, however, more people seem to browse the internet rather than use apps for health-related purposes.Health-related internet and app useTo better understand who uses the internet and apps for health-related purposes, we estimate logistic regression models.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29]]], ["Columns two and three indicate that women are more likely to browse the internet for health-related purposes, while those who smoke are less likely to seek health information online.", [["women", "ORGANISM", 36, 41], ["women", "SPECIES", 36, 41]]], ["Frequent health app use decreases with age and smoking, but we also find that women are more likely to be frequent health app users.", [["women", "ORGANISM", 78, 83], ["women", "SPECIES", 78, 83]]], ["For all three models, we do not find that medical conditions (such as back problems or having a high blood pressure) play a substantial role.", [["blood", "ANATOMY", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["medical conditions", "PROBLEM", 42, 60], ["back problems", "PROBLEM", 70, 83], ["a high blood pressure)", "TREATMENT", 94, 116]]], ["The last two columns of Table 5 show results regarding the question who is most likely to search for health information using a search engine.", [["most likely", "UNCERTAINTY", 75, 86]]], ["Moreover, those who have reported a high blood pressure and depression are more likely to search information via search engines.", [["blood", "ANATOMY", 41, 46], ["depression", "DISEASE", 60, 70], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["a high blood pressure", "PROBLEM", 34, 55], ["depression", "PROBLEM", 60, 70]]], ["To account for different base levels of online and app activities, we divide each individual's overall online health activity by the same individual's overall online and app activity.", [["different base levels", "TEST", 15, 36]]], ["Moreover, those individuals who report high blood pressure spent more of their total activity with health-related activities.", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["high blood pressure", "PROBLEM", 39, 58]]], ["Similar to the results shown in Table 5 , smokers invest less time into health-related online and app activities.", [["smokers", "ORGANISM", 42, 49]]], ["Fig 1 shows the most frequently used words across participants in the search query dataset after removing stopwords.", [["participants", "SPECIES", 50, 62]]], ["Many participants searched for pharmacies.", [["participants", "SPECIES", 5, 17]]], ["Moreover, popular terms cover, for example, symptoms, pain and therapy, but also medicine and several organs or body parts (such as, skin and chest).", [["organs", "ANATOMY", 102, 108], ["body parts", "ANATOMY", 112, 122], ["skin", "ANATOMY", 133, 137], ["chest", "ANATOMY", 142, 147], ["pain", "DISEASE", 54, 58], ["organs", "ORGAN", 102, 108], ["body parts", "MULTI-TISSUE_STRUCTURE", 112, 122], ["skin", "ORGAN", 133, 137], ["chest", "ORGAN", 142, 147], ["symptoms", "PROBLEM", 44, 52], ["pain", "PROBLEM", 54, 58], ["therapy", "TREATMENT", 63, 70], ["several organs or body parts", "PROBLEM", 94, 122], ["skin", "ANATOMY", 133, 137], ["chest", "ANATOMY", 142, 147]]], ["Furthermore, women's health as well as children and babies were important topics.Health-related search queriesIn addition to single words, we also considered the most frequently used bigrams (a sequence of two adjacent words) across users (Table 7) .", [["women", "ORGANISM", 13, 18], ["children", "ORGANISM", 39, 47], ["babies", "ORGANISM", 52, 58], ["women", "SPECIES", 13, 18], ["children", "SPECIES", 39, 47]]], ["Moreover, information about specific diseases, but also about rather general health issues (dry skin) and nutrition are sought.Discussion and conclusionWe used a unique combination of records of individuals' online and app activities with sociodemographic and health information in this study.", [["skin", "ANATOMY", 96, 100], ["skin", "ORGAN", 96, 100], ["specific diseases", "PROBLEM", 28, 45], ["this study", "TEST", 282, 292], ["skin", "ANATOMY", 96, 100]]], ["This dataset provided detailed and finegrained insights into participants' internet and app use for health-related purposes.", [["participants", "SPECIES", 61, 73]]], ["In addition, we observed not only if participants used the internet and/or apps at all, but also to what extent.", [["participants", "SPECIES", 37, 49]]], ["Moreover, we also overcame limitations in sample size, while previous research often had to rely on samples limited in size.Discussion and conclusionAnalyzing health-related search queries made to search engines allowed us to study how users obtain health information on the internet.", [["size", "OBSERVATION_MODIFIER", 49, 53], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["Previous studies often had to rely on openly available, but aggregated and less detailed search query data (see, for example, [44] ).", [["Previous studies", "TEST", 0, 16]]], ["Obtaining search query data on the user level, for example from search engine providers, is difficult [40] and data, although large in size, do not come with additional information about users' sociodemographics and health.", [["large", "OBSERVATION_MODIFIER", 126, 131], ["size", "OBSERVATION_MODIFIER", 135, 139]]], ["Obtaining access to data like those used in our study, however, is relatively easy through commercial vendors.", [["our study", "TEST", 44, 53]]], ["While our data and our findings are specific to Germany, similar data are available from providers in many other countries (for example, in the U.S., U.K., Spain and France) which would allow for cross-cultural studies.Socio-demographic correlates of internet and app useOur results on usage patterns across societal groups confirm findings from previous work.", [["cross-cultural studies", "TEST", 196, 218]]], ["First, women are more likely to browse and search for health content online and spend more of their total online activities looking for health information than men.", [["women", "ORGANISM", 7, 12], ["men", "ORGANISM", 160, 163], ["women", "SPECIES", 7, 12], ["men", "SPECIES", 160, 163]]], ["Moreover, women are more likely to be frequent app users.", [["women", "ORGANISM", 10, 15], ["women", "SPECIES", 10, 15]]], ["One explanation for these findings may be that women are more often concerned with child rearing than men [52] .", [["women", "ORGANISM", 47, 52], ["men", "ORGANISM", 102, 105], ["women", "SPECIES", 47, 52], ["men", "SPECIES", 102, 105]]], ["That is, women do not only seek information for themselves, but also for their children.", [["women", "ORGANISM", 9, 14], ["children", "ORGANISM", 79, 87], ["women", "SPECIES", 9, 14], ["children", "SPECIES", 79, 87]]], ["Therefore, they spend more time as they have to seek information for more people and people with different needs.", [["people", "ORGANISM", 74, 80], ["people", "ORGANISM", 85, 91], ["people", "SPECIES", 74, 80], ["people", "SPECIES", 85, 91]]], ["AnotherPLOS ONEexplanation holds that women are more reactive to deviations from health [17] .", [["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43]]], ["Likewise, men tend to wait longer before seeking professional help with their health [53] .", [["men", "ORGANISM", 10, 13], ["men", "SPECIES", 10, 13]]], ["Regarding the finding that women are more likely to be frequent health app users, it seems that the popularity of apps for women's health (such as period trackers, ovulation diaries, and apps concerned with pregnancy) explains this finding.", [["women", "ORGANISM", 27, 32], ["women", "ORGANISM", 123, 128], ["women", "SPECIES", 27, 32], ["women", "SPECIES", 123, 128], ["ovulation diaries", "PROBLEM", 164, 181]]], ["That is, although we found that frequent health app use is rather limited, women seem to profit more than men from technological innovations in the mobile health sector.", [["women", "ORGANISM", 75, 80], ["men", "ORGANISM", 106, 109], ["women", "SPECIES", 75, 80], ["men", "SPECIES", 106, 109]]], ["Second, we found that younger people and users with a university education are more likely to use health apps and search for health information online.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["a university education", "TREATMENT", 52, 74]]], ["We believe that the effect is driven by better technology literacy among younger and people with a higher education.", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["a higher education", "TREATMENT", 97, 115]]], ["However, as the likelihood of developing (multiple) chronic health conditions increases with age, older people may actually profit more from using health apps and searching for health information on the internet [54] .", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["developing (multiple) chronic health conditions", "PROBLEM", 30, 77], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["chronic", "OBSERVATION_MODIFIER", 52, 59]]], ["Unfortunately, these results do not indicate that internet use helps reducing shortcomings in health knowledge for societal groups with low education [17] .PLOS ONEThird, our results show that smoking significantly decreases both the likelihood and the intensity of using the internet and apps for health-related purposes.", [["smoking", "CHEMICAL", 193, 200]]], ["One explanation for this finding may be that smokers are also more likely to be of lower socio-economic status (that is, lower education and lower income, for example) and more often male [55, 56] .", [["smokers", "ORGANISM", 45, 52]]], ["Thus, smokers may be less likely to engage in health-related activities due to the correlation of smoking with other determinants of health-related online activities.", [["smoking", "CHEMICAL", 98, 105]]], ["However, it is also possible that people who smoke are in general more risk tolerant and thus less concerned with their health [57] .Contents of internet and app useThe analysis of subcategories of health-related domain reveals that exercising, weight loss and nutrition are among the most popular topics.", [["weight loss", "DISEASE", 245, 256], ["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["weight loss", "PROBLEM", 245, 256]]], ["Unsurprisingly, the same categories in addition to health tracking and women's health are also popular among health apps.", [["women", "ORGANISM", 71, 76], ["women", "SPECIES", 71, 76]]], ["These results seem to speak to increasing desires for the 'quantified-self', self-optimization through tracking and the analysis of one's body using health trackers, apps and the like [58] .Contents of internet and app useAnother popular topic is mental health.", [["body", "ANATOMY", 138, 142], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["the analysis", "TEST", 116, 128]]], ["This finding is important as mental health is often associated with stigma and mental health consumers often feel discriminated [59] .", [["stigma", "PROBLEM", 68, 74]]], ["Web logs provide new ways of measuring and studying mental health that may be less affected by selfreporting bias (though we note that our measure of depression and sleeplessness rely on selfreported survey data).", [["depression", "DISEASE", 150, 160], ["sleeplessness", "DISEASE", 165, 178], ["depression", "PROBLEM", 150, 160], ["sleeplessness", "PROBLEM", 165, 178]]], ["That is, observing digital traces may offer new means for understanding who may be in need of support and how people may be reached.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["support", "TREATMENT", 94, 101]]], ["Moreover, understanding how users gather information may help inform and guide the design of targeted interventions to support those seeking professional help [60] .", [["targeted interventions", "TREATMENT", 93, 115]]], ["The popularity of the mental health category also adds to the debate about deficiencies regarding mental health support (such as insufficient availability of psychotherapy) in Germany [61] .Contents of internet and app useFurthermore, we found that alternative medicine is a popular topic among users.", [["mental health support", "TREATMENT", 98, 119], ["alternative medicine", "TREATMENT", 249, 269]]], ["Moreover, it may also supports notions of decreasing trust in evidence-based healthcare and medical experts as expressed through anti-vaccination movements, for example [18, 63] .", [["decreasing", "OBSERVATION_MODIFIER", 42, 52]]], ["Moreover, lay-people often do not have the necessary skills to evaluate the quality of medical information found online.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["While content may cover professionally or peer-reviewed information, it may also include lay-people's opinions and anecdotes that might potentially harm users [19, 64] .", [["people", "SPECIES", 93, 99]]], ["As mentioned earlier in this paper, the rise of the anti-vaccination movement and similar phenomena is facilitated through information spread through the internet [18] .", [["the anti-vaccination movement", "TREATMENT", 48, 77], ["similar phenomena", "PROBLEM", 82, 99], ["similar phenomena", "OBSERVATION", 82, 99]]], ["Using detailed records of users' online activities in combination with scraping and analyzing contents of health websites allows researchers to answer questions that were difficult to study before.Contents of internet and app useRegarding the analyses of health-related search queries, we note that users often use search engines to seek information about health professionals (such as dentists and physiotherapy) or health institutions (for example, pharmacies).", [["scraping", "TREATMENT", 71, 79]]], ["In addition, we found treatment-related terms to be among the most popular (such as treatment, therapy and surgery).", [["treatment", "TREATMENT", 22, 31], ["treatment", "TREATMENT", 84, 93], ["therapy", "TREATMENT", 95, 102], ["surgery", "TREATMENT", 107, 114]]], ["This finding is somewhat confirmed by the analysis of bigrams, which shows that users often seek information regarding pharmacies, but also about specific diseases.", [["the analysis of bigrams", "TEST", 38, 61], ["specific diseases", "PROBLEM", 146, 163]]], ["That is, users seem especially interested in obtaining information about specific health issues, but likely also information on treatment options and remedies for conditions they experience.", [["treatment options", "TREATMENT", 128, 145], ["remedies", "TREATMENT", 150, 158]]], ["Just as the popularity of health apps, the popularity of treatment-related terms demonstrates users' growing demand for understanding their body and for pro-actively surveying and managing their own health.LimitationsOur analyses of search queries in this paper could only scratch the surface of what we believe is possible with more advanced natural language processing algorithms.", [["body", "ANATOMY", 140, 144], ["surface", "ANATOMY", 285, 292], ["body", "ORGANISM_SUBDIVISION", 140, 144], ["treatment", "TREATMENT", 57, 66], ["search queries", "TEST", 233, 247]]], ["However, we also note that the automated extraction, categorization and understanding of health-related search query data is challenging, especially when it comes to inferring user intentions.", [["the automated extraction", "TREATMENT", 27, 51]]], ["For example, a person searching for \"ulcerative colitis\" may seek information about the disease because she has never heard of it, she may worry that she has the disease due to specific symptoms she experiences or she may have the disease and seek, for example, information on treatments.", [["ulcerative colitis", "DISEASE", 37, 55], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 37, 55], ["person", "SPECIES", 15, 21], ["\"ulcerative colitis", "PROBLEM", 36, 55], ["the disease", "PROBLEM", 84, 95], ["the disease", "PROBLEM", 158, 169], ["specific symptoms", "PROBLEM", 177, 194], ["the disease", "PROBLEM", 227, 238], ["treatments", "TREATMENT", 277, 287], ["ulcerative", "OBSERVATION_MODIFIER", 37, 47], ["colitis", "OBSERVATION", 48, 55]]], ["In addition, studying developments of anti-vaccination positions, for example, will likely require the observation of even longer time periods.", [["anti-vaccination positions", "TREATMENT", 38, 64]]], ["Moreover, analyzing specific health topics may also require observing larger samples as the number of observations will rapidly decrease if those topics are not widespread in the population.Future workBesides substantive interest in health research, we believe that studying health-related internet and app will prove important from a privacy perspective.", [["widespread", "OBSERVATION_MODIFIER", 161, 171]]], ["Privacy research documents that website tracking and sharing of sensitive personal information, which includes health information, is a widespread phenomenon in the online and app world [65] [66] [67] [68] [69] .", [["[65] [66] [67] [68]", "CHEMICAL", 186, 205]]], ["It is therefore crucial to understand whether third parties may be able to infer users sensitive information like their health status by observing, for example, her online activities through cookies and tracking in apps and on mobile devices [69] .Future workIn light of the current COVID-19 pandemic, it seems more important than ever to study where and how people search for health information, what kinds of websites they visit or apps they use, and critically examine the quality of information users find given that plenty of (mis) information is disseminated online.", [["people", "ORGANISM", 359, 365], ["people", "SPECIES", 359, 365], ["the current COVID", "TEST", 271, 288], ["pandemic", "PROBLEM", 292, 300]]]]}